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TC THE READERS OF THIS VOLUME: 
Provisions of the Public Health Cigarette Smoking Act of 1969 
(P.L. 91-222) require the Secretary of Health and Human Services 
to submit an annual report to the Congress on the health conse- 
quences of smoking. Attached is the 1983 report, Health Conse- 
quences of Smoking: Cardiovascular Disease. This volume is an 
indepth analysis of the scientific evidence of the relationship 
between cigarette smoking and multiple cardiovascular diseases. 
This relationship is quantitatively the most serious of the health 
consequences of smoking, but is poorly recognized by the public. 
This report represents the consolidated work of many widely- 
recognized experts known for their contribution to understanding 
cardiovascular disease. It is a scientific reference document to 
serve as a state-of-the-art source for medical and behavioral 
scientists and researchers. 
Smoking-related cardiovascular disease is estimated to account 
for more deaths than,any other smoking-related disease, including 
cancer. This report clearly establishes that cigarette smoking 
increases the risks for a number of cardiovascular diseases, partic- 
ularly coronary heart disease, the largest single cause of deaths 
in the United States. In addition, smoking +s related to an 
increased risk for stroke, atherosclerosis, and other circulatory 
diseases. 
The report clearly demonstrates that cigarette smoking is a 
major risk factor for coronary heart disease in the United States. 
There are 55 million persons who smoke, a larger population than 
those who have hypertension or elevated cholesterol, the other 
major risk factors for this disease. Smokers ’ death rates from 
coronary heart disease are 70 percent greater than those of non- 
smokers. Simply by quitting smoking, these men and women drsmati- 
tally reduce their risk of premature death from this disease. 
The economic and social toll these smoking-related deaths 
extract from the Nation’s health is immeasurable. The report ‘a 
findings re-emphasize the importance of this Department’s continued 
educational efforts to enable a fully-informed choice by indlvid- 
uals on whether to begin or to continue t.o smoke. 
In my view, this volume is a solid scientific work and a contri- 
bution to the prevention efforts of this Department. 
Heckler 
FOREWORD 
The 1983 Report is the second volume in The Health Consequences 
of Smoking series that focuses on specific diseases. The 1982 Report 
reviewed in depth the association between tobacco use and various 
cancers; the 1983 Report is a comprehensive review of the relation- 
ship between smoking and cardiovascular disease. 
The ability to draw a conclusion from the scientific evidence on the 
causal relationship between smoking and cardiovascular disease was 
reached more recently than it was from the evidence on the 
relationship between smoking and cancer. The latter relationship 
was first established scientifically 30 years ago, particularly for lung 
cancer. At the time the Advisory Committee on Smoking and Health 
was formed in 1962, the scientific evidence linking tobacco use, 
particularly cigarettes, with respiratory cancers was overwhelming. 
A causal link between cigarette use and lung cancer was both clear 
and compelling. A number of epidemiological studies on the relation- 
ship between smoking and coronary heart disease (CHD) existed at 
that time, but the Committee felt that the evidence was insufficient 
to make a judgment of a causal relationship. 
Nevertheless, the Committee found the evidence compelling 
enough to caution that even though the causal role of cigarette 
smoking in coronary heart disease was not proved, countermeasures 
were warranted, and the Committee counseled against postponing 
action until no uncertainty remained. The evidence was reviewed 
again in the 1971 Surgeon General’s Report and was, by this time, 
clearly strong enough to establish cigarette smoking as a major risk 
factor for coronary heart disease in men. By 1979, when the 15th 
year anniversary Report of the Surgeon General was published, 
there was no longer any doubt that cigarette smoking was directly 
related to coronary heart disease for both men and women in the 
United States. 
The Importance of Cardiovascular Disease 
The importance of cardiovascular disease, particularly coronary 
heart disease, to the health of the American public is evident. In 
1980 cardiovascular disease accounted for approximately half of all 
U.S. deaths-980,000 out of 1,980,OOO total deaths. Of these, slightly 
. . . 
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over 565,000 were due to coronary heart disease; that is, approxi- 
mately 30 percent of all deaths and almost 60 percent of all 
cardiovascular deaths were due to CHD. The age-adjusted CHD 
death rate peaked in 1963, and by 1980 had declined 30 percent. In 
the period between 1968 and 1978 alone, the age-adjusted rate 
declined 26.5 percent, with a greater decline noted for the younger 
age groups. 
In comparison, the total number of all cancer deaths was slightly 
over 416,000 in 1980. Thus, deaths from CHD exceeded all cancer 
deaths, and deaths from all cancers numbered less than one-half the 
total of all cardiovascular deaths. 
Last year this Department issued a report in which it was 
estimated that tobacco use, particularly cigarette smoking, was 
related to 30 percent of all cancer deaths in the United States-a 
projected 129,000 premature deaths. The findings of this year’s 
Report, however, should be considered even more alarming, in that 
the number of cardiovascular deaths that are reasonably estimated 
to be cigarette related is even higher. A number of investigators’ 
have estimated that 30 percent, or more, of CHD deaths could be 
attributed to cigarette smoking because of the higher CHD death 
rates experienced by ever-smokers compared with never-smokers. If 
30 percent of coronary heart disease deaths are attributed to 
cigarette smoking, 170,000 Americans will die prematurely of CHD 
each year. Smokers also experience increased death rates owing to 
other cardiovascular diseases such as stroke, peripheral vascular 
disease, aortic atherosclerosis, and other vascular problems. 
Findings of the 1983 Report-Coronary Heart Disease and 
Cigarette Smoking 
Each of the three major risk factors poses approximately the same 
increase in risk of CHD for the person with the risk factor, but 
cigarette smoking is far more prevalent as a risk factor for CHD in 
the American population than either hypertension or elevated 
serum cholesterol. Thus, the overall finding of this Report is clear: 
Cigarette smoking should be considered the most important of 
the known modifiable risk factors for coronary heart disease in 
the United States. 
For over 25 years, cigarette smoking has been linked epidemiologi- 
tally with an increased risk of dying from coronary heart disease. As 
early as 1954, a strong, statistically significant association between 
cigarette use and CHD was demonstrated. In the intervening years, 
additional studies have confirmed this association. An examination 
of only the major prospective studies, involving more than 20 million 
‘Report of the Royal College of Physicians. London. 1978; Sogot and Murray, Public Health Reports. 1980; 
Ganinkel, Proceedings of the Fourth World Conference on Smoking and Health, Stackbolm, 1980. See Section 3 for 
additional discussion. 
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person-years of observation, indicates that smoking has been consis- 
tently shown to elevate CHD mortality rates. Overall, smokers have 
a 70 percent greater CHD mortality than nonsmokers. Heavy 
smokers, those who consume more than two packs per day, experi- 
ence CHD mortality rates almost 200 percent greater than nonsmok- 
ers. 
In the National Pooling Project study, a unique study that 
combined data from five of the Nation’s largest incidence studies on 
heart disease, smokers of a pack or more per day were found to have 
a greater than 2.5fold increased risk of developing a major coronary 
event compared with nonsmokers. This study also found that 
smokers who have other major risk factors experience a greater 
increased risk than would be expected from the summation of the 
independent risks. Thus, cigarette smoking interacts with the other 
major risk factors in a manner that greatly increases the risk of 
CHD. 
The risk of developing and dying from CHD is directly related to 
the total dosage of cigarette smoke exposure. A dose-response 
relationship has been established for the number of cigarettes 
smoked per day, the total years of cigarette smoking, and the degree 
of inhalation; CHD risk is inversely related to the age of initiation. 
CHD mortality ratios are also greater at the younger age groups; 
thus, preventive efforts could truly have a decided impact on 
extending life-expectancy-if large numbers of smokers could be 
persuaded to quit smoking. The decrease in elevated CHD risk with 
cessation, coupled with the prevalence of smoking as a risk factor in 
the U.S. population, means that the elimination of cigarette usage 
could have a greater impact on CHD morbidity and mortality than 
any other preventive measure. 
Sudden Cardiac Death 
Smokers are at a two to four times greater risk for sudden cardiac 
death @CD) than are nonsmokers. The risk for sudden death 
increases with increasing daily exposure, as measured by the 
number of cigarettes consumed per day. 
Stroke 
The association between cigarette smoking and cerebrovascular 
disease (CVD) is largely confined to the younger age groups, with 
little evidence of an effect after age 65. The number of stroke deaths 
in 1980 totaled 170,000; even a small percentage of such deaths 
represents thousands of premature deaths. 
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Women 
For women who both smoke cigarettes and used oral contracep- 
tives, a strong association exists between their use and one form of 
stroke-subarachnoid hemorrhage. Smoking and oral contraceptive 
use appear to interact synergistically to greatly increase the risk of 
subarachnoid hemorrhage and of CHD, compared with the risk for 
those women who neither smoke nor use oral contraceptives. 
Other Cardiovascular Disease 
Cigarette smoking contributes to the development of aortic 
atherosclerosis and arteriosclerotic peripheral vascular disease 
(APVD). Ninety percent of patients with APVD are cigarette 
smokers, and the successful management of this disease includes 
complete smoking cessation by such patients. 
Changing Trends in Smoking Behavior and Coronary Heart 
Disease 
Demographers have noted a reduction in mortality rates from 
heart disease for several years. However, a sharp decline in these 
rates occurred in the late 1960s for reasons that are not entirely 
known. Significantly, declines in cigarette smoking prevalence 
among adults were first noted in 1964, the year of the first Surgeon 
General’s Report, with declines in prevalence accelerating between 
1966 and 1970. By 1980, overall adult smoking prevalence had 
declined by nearly 25 percent. While the magnitude of the impact of 
these changes in smoking behavior on the decline in CHD death 
rates is uncertain, the direction and nature of that impact is not. The 
substantial changes in smoking beh.avior that have occurred over the 
last 20 years have exerted, and will continue to exert, a substantial 
beneficial effect on the incidence of CHD in the U.S. population. 
We know from cohort mortality studies, incidence studies, and, 
more recently, intervention trials that smoking cessation results in a 
reduction in CHD mortality. 
Data from the Multiple Risk Factor Intervention Trial (MRFIT) 
have shown that those cigarette smokers who reported quitting at 
their first-year interview (after an average of 6 years of followup) 
reduced their relative risk for CHD mortality by almost half 
compared with those smokers who continued to smoke. Mortality 
from all causes was almost 30 percent lower among those who quit 
smoking compared with those who continued to smoke. These data 
correlate well with those observed in the cohort mortality studies, 
which have consistently shown a decline in CHD mortality among 
former smokers compared with continuing smokers. In some studies 
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a substantial improvement in mortality within the first few years 
after smoking cessation was demonstrated. 
Public Perception of the Scientific Link Between Cigarette 
Smoking and CHD 
A recent staff report by the Federal Trade Commission revealed 
that a substantial proportion of the American public is not aware of 
the link between cigarette smoking and heart disease. When asked 
to respond to the statement “Cigarette smoking is a major cause of 
heart disease,” 40 percent of adults responded “false” or “don’t 
know,” including almost half of the adult smokers (45 percent). This 
concurs with results from a 1980 Roper survey, which found that 53 
percent of the population and 58 percent of smokers did not know 
that smoking causes many cases of heart attack; a surprising 20 
percent were not even aware that smoking causes some cases. 
It is apparent that for a significant segment of the general public, 
a large gap exists in its understanding of the relationship between 
cigarette smoking and heart disease, a relationship that accounts for 
the largest number of excess deaths of all the diseases associated 
with cigarette smoking. 
In last year’s Report, I stated that the education of our citizens 
regarding the health hazards of smoking cannot be left solely to 
government. The findings of this Report and previous ones compel 
me again to ask for an increased commitment by the health care 
community, voluntary health agencies, schools, and other groups in 
our society to join this Department and the Public Health Service in 
our continuing efforts to reduce the premature death and disability 
associated with cigarette smoking through renewed efforts of 
education and information. 
Edward N. Brandt, Jr., M.D. 
Assistant Secretary for Health 
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PREFACE 
In 1982, the Public Health Service’s Report on the health 
consequences of smoking dealt with the relationship between 
smoking and cancer. This 1983 Report turns its attention to the 
relationship between cigarette smoking and cardiovascular disease, 
one that imposes an even greater burden of disease and premature 
death. 
In preparing this Report, the Public Health Service has reviewed a 
world literature that goes back more than 40 years and has 
examined the results of epidemiological observations covering many 
millions of person-years. This evidence permits us to affirm again 
what was said in our 1979 Report and what is the consensus of other 
scientific bodies here and across the world. Cigarette smoking is 
causally related to heart disease; it and elevated levels of serum 
cholesterol and hypertension consti.tute the major risk factors for 
contracting and dying from this disease. 
Since 1979, much additional information has accumulated to 
support this judgment. From a public health viewpoint, the most 
important is the new and further evidence presented in this volume 
that when one quits smoking, the risk of dying from heart disease 
begins to recede almost immediately and eventually becomes no 
greater than that experienced by scmeone who has never smoked at 
all. This is an encouragement to personal action and a justification 
for much greater research and program effort by government and 
voluntary agencies in helping people to quit smoking. 
As in all previous Reports, the Public Health Service has turned to 
many people and agencies within the research and clinical communi- 
ty in developing this statement. On behalf of the Service, I express 
my respect and gratitude to them. 
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Organization and Development of the 1983 Report 
The content of the Report is the work of numerous scientists and 
experts within the Department of Health and Human Services as 
well as from outside the organization. Individual manuscripts were 
written by experts nationally and internationally recognized for 
their scientific contributions to the understanding of cardiovascular 
diseases. These manuscripts were reviewed individually by other 
experts, within and outside the U.S. Public Health Service, and the 
entire Report was reviewed by a broad-based panel of distinguished 
cardiovascular scientists. The 1983 Report includes a Foreword by 
the Assistant Secretary for Health of the Department of Health and 
Human Services and a Preface by the Surgeon General of the U.S. 
Public Health Service. The body of the report consists of eight 
sections and two appendices, as follows: 
0 Section 1. Introduction, Overview, and Conclusions 
0 Section 2. Arteriosclerosis 
0 Section 3. Coronary Heart Disease 
0 Section 4. Cerebrovascular Disease 
l Section 5. Atherosclerotic Peripheral Vascular Disease and 
Aortic Aneurysm 
l Section 6. Pharmacological and Toxicological Implications of 
Smoke Constituents on Cardiovascular Disease 
0 Section 7. Changes in Cigarette Smoking Behavior in Clini- 
cal and Community Trials 
l Section 8. The Effect of Cigarette Smoking Cessation on 
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Historical Perspective 
Early reports linking smoking with a greater risk of developing 
cardiovascular disease occurred around the turn of the century. An 
early series of studies, initiated in 1904 by Erb, found a much higher 
percentage of smokers than of nonsmokers with intermittent claudi- 
cation; only 10 percent of his patients with claudication were 
nonusers of tobacco. As early as 1934, Howard made the observation 
that the increasing prevalence of coronary heart disease noted since 
the first World War might be a result of the greatly increased use of 
cigarettes. 
By the turn of the century, numerous studies had demonstrated 
clinically and experimentally that cigarette smoking or cigarette 
smoke constituents, most notably nicotine, caused an elevation in 
blood pressure and heart rate during smoking. 
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The first major prospective study results were made public in 1954 
in the United States by Hammond and Horn and found a strong 
association between cigarette use among men and coronary heart 
disease (CHD). Overall, smokers were found to carry a 70 percent 
greater risk of dying from CHD than nonsmokers; heavy smokers 
had CHD mortality rates almost two and one-half times greater than 
nonsmokers. Hammond and Horn also noted a consistent dose- 
response relationship with the number of cigarettes consumed per 
day. 
In the intervening 30 years, numerous additional epidemiological 
mortality studies were undertaken to examine this issue. These 
included studies in the United Kingdom, Canada, Sweden, Japan, 
and Switzerland in addition to the United States. In total, they 
represent more than 20 million person-years of observation. Find- 
ings from these studies have been remarkably uniform: smokers 
have much higher death rates from coronary heart disease than do 
nonsmokers, despite the fact that these studies were conducted in 
varying populations, were geographically diverse, and involved 
differing methodologies. 
The first major U.S. Public Health Service review of the relation- 
ship between smoking and heart disease was conducted by the 
Surgeon General’s Advisory Committee on Smoking and Health in 
1984. Although the Committee noted that male smokers had higher 
death rates from coronary heart disease, it was unable to conclude 
that the association had causal significance. However, it was noted 
in the report that “the causative role of these factors [risk factors 
including cigarette smoking] in coronary disease, though not proven, 
is suspected strongly enough to be a major reason for taking 
countermeasures against them. It is also more prudent to assume 
that the established association between cigarette smoking and 
coronary disease has causative meaning than to suspend judgement 
until no uncertainty remains.” 
Since the release of the original Report of the Surgeon General in 
1984, additional studies dealing with. cigarette smoking and CHD 
have been summarized in the series of annual reports of the Surgeon 
General The Health Consequences of Smoking. By 1979, the magni- 
tude of the epidemiological, pathological, clinical, and experimental 
evidence had grown to the point that the Surgeon General’s Report 
concluded: “Smoking is causally related to coronary heart disease in 
the common sense of that idea and for the purposes of preventive 
medicine.” 
Overview 
In 1980, diseases of the circulatory system were responsible for 
approximately one-half of the total U.S. mortality. CHD was the 
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single most important cause of death, accounting for approximately 
30 percent of all U.S. deaths. 
Cigarette smoking is one of the three major independent CHD risk 
factors. The magnitude of the risk associated with cigarette smoking 
is similar to that associated with the other two major CHD risk 
factors, hypertension and hypercholesterolemia; however, because 
cigarette smoking is present in a larger percentage of the U.S. 
population than either hypertension or hypercholesterolemia, ciga- 
rette smoking ranks as the largest preventable cause of CHD in the 
United States. Cigarette smoking also acts synergistically with the 
other major risk factors to greatly increase the risk for CHD. 
Arteriosclerosis is the predominant underlying cause of cardiovas- 
cular disease, and atherosclerosis is the form of arteriosclerosis that 
most frequently causes clinically significant disease, including CHD, 
atherothrombotic brain infarction, atherosclerotic aortic disease, 
and atherosclerotic peripheral vascular disease. Cigarette smoking 
contributes both to the development of atherosclerotic lesions and to 
the clinical manifestations of atherosclerotic vascular disease, in- 
cluding sudden death. Although the precise pathophysiologic basis of 
these clinical manifestations is not understood, it may be related to 
several deleterious cardiovascular effects of cigarette smoking, 
including production of an imbalance between myocardial oxygen 
supply and demand, a decrease in the threshold for ventricular 
fibrillation, and an increase in platelet aggregation. Nicotine and 
carbon monoxide are the tobacco smoke constituents most closely 
associated with these adverse effects; other cigarette smoke constitu- 
ents such as hydrogen cyanide, oxides of nitrogen, and carbon 
disulfide are being studied for possible pathogenic cardiovascular 
effects. 
Cigarette smoking is the most important risk factor for atheroscle- 
rotic peripheral vascular disease, which usually involves the lower 
extremities. Smoking cessation is probably the single most impor- 
tant intervention in the management of this disorder. The effect of 
cigarette smoking to aggravate and accelerate the development of 
atherosclerosis is more striking in the aorta than in any other 
vessels. Cigarette smoking is associated with an increased risk for 
cerebrovascular disease, especially in younger age groups, but this 
effect is less marked than for atherosclerotic disease at other sites. 
Women cigarette smokers experience an increased risk for subarach- 
noid hemorrhage; the use of both cigarettes and oral contraceptives 
greatly increases this risk. 
Smoking cessation is associated with decreased mortality and 
morbidity from atherosclerotic vascular disease. Prospective epide- 
miologic studies have shown that former cigarette smokers reduce 
their CHD death risk from that of current smokers to that of 
nonsmokers over approximately a 15-year period after stopping 
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smoking. The beneficial effects of quitting are not explained by 
differences in baseline characteristics between quitters and continu- 
ing smokers. CHD intervention trials have successfully demon- 
strated the feasibility of reducing cigarette consumption; these trials 
also documented a significant reduction in CHD mortality. 
Conclusions of the 1983 Report 
The purpose of this Report is to review in depth the many sources 
of scientific evidence relating cigarette smoking to individual 
cardiovascular disease entities. Listed below are the major findings 
of this review. 
Arteriosclerosis 
1. A preponderance of evidence both from prospective studies 
with autopsy followup and from autopsy studies with retrospec- 
tive smoking data indicates that cigarette smoking has a 
significant positive association with atherosclerosis. This evi- 
dence suggests that cigarette smoking has the effect of 
aggravating and accelerating the development of atherosclerot- 
ic lesions in the artery wall and that its effect is not limited to 
those events related to the occlusive episode. The effects are 
most striking for aortic atherosclerosis; a significant positive 
relationship also exists between cigarette smoking and athero 
sclerotic lesions in the coronary arteries, at least for most high 
risk populations. Cigarette smoking could also be associated 
with other factors that precipitate thrombosis, hemorrhage, or 
vasoconstriction leading to occlusion and ischemia. 
2. Some evidence exists that cigarette smoke alters total serum 
cholesterol concentrations and lipoprotein composition in ways 
that would be expected to increase the development of athero 
sclerosis. Recent studies of the effects of smoking on the 
hemostatic system indicate effects on platelet function. 
3. Although the specific mechanisms by which tobacco smoke 
affects arteriosclerosis have not been clearly delineated, the 
effects of cigarette smoking on the atherosclerotic lesions that 
underlie cardiovascular disease seem well established. 
Coronary Heart Disease 
1. Cigarette smoking is a major cause of coronary heart disease in 
the United States for both men and women. Because of the 
number of persons in the population who smoke and the 
increased risk that cigarette smoking represents, it should be 
considered the most important of the known modifiable risk 
factors for CHD. 
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2. Overall, cigarette smokers experience a 70 percent greater 
CHD death rate than do nonsmokers. Heavy smokers, those 
who consume two or more packs per day, have CHD death rates 
between two and three times greater than nonsmokers. 
3. The risk of developing CHD increases with increasing exposure 
to cigarette smoke, as measured by the number of cigarettes 
smoked daily, the total number of years one has smoked, and 
the degree of inhalation, and with an early age of initiation. 
4. Cigarette smokers have a twofold greater incidence of CHD 
than do nonsmokers, and heavy smokers have an almost 
fourfold greater incidence. 
5. Cigarette smoking is a major independent risk factor for CHD, 
and it acts synergistically with other risk factors (most notably, 
elevated serum cholesterol and hypertension) to greatly in- 
crease the risk of CHD. 
6. Women have lower rates for CHD than do men. In particular, 
CHD rates for women are lower prior to the menopause. A part 
of this difference is due to the lower prevalence of smoking in 
women, and for those women who do smoke, to the tendency to 
smoke fewer cigarettes per day and to inhale less deeply. 
Among those women who have smoking patterns comparable 
to male smoking patterns, the increments in CHD death rates 
are similar for the two sexes. 
7. Women who use oral contraceptives and who smoke increase 
their risk of a myocardial infarction by an approximately 
tenfold factor, compared with women who neither use oral 
contraceptives nor smoke. 
8. Cigarette smoking has been found to significantly elevate the 
risk of sudden death. Overall, smokers experience a two to four 
times greater risk of sudden death than nonsmokers. The risk 
appears to increase with increasing dosage as measured by the 
number of cigarettes smoked per day and diminishes with 
cessation of smoking. 
9. The CHD mortality ratio for smokers compared with nonsmok- 
ers is greater for the younger age groups than for the older age 
groups. Although the smoker-to-nonsmoker mortality ratio 
narrows with increasing age, smokers continue to experience 
greater CHD death rates at all ages. 
10. Cigarette smoking has been estimated to be responsible for up 
to 30 percent of all CHD deaths in the United States each year. 
During the period 1965 to 1980 there were over 3 million 
premature deaths from heart disease among Americans attrib 
uted to cigarette smoking. Unless smoking habits of the 
American population change, perhaps 10 percent of all persons 
now alive may die prematurely of heart disease attributable to 
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their smoking behavior. The total number of such premature 
deaths may exceed 24 million. 
11. Cessation of smoking results in a substantial reduction in CHD 
death rates compared with those of persons who continue to 
smoke. Mortality from CHD declines rapidly after cessation. 
Approximately 10 years following cessation the CHD death 
rate for those ex-smokers who consumed less than a pack of 
cigarettes daily is virtually identical to that of lifelong non- 
smokers. For ex-smokers who had smoked more than one pack 
per day, the residual risk of CHD mortality is proportional to 
the total lifetime exposure to cigarette smoke. 
12. Epidemiologic evidence concerning reduced tar and nicotine or 
filter cigarettes and their effect on CHD rates is conflicting. No 
scientific evidence is available concerning the impact on CHD 
death rates of cigarettes with very low levels of tar and 
nicotine. 
13. Smokers who have used only pipes or cigars do not appear to 
experience substantially greater CHD risks than nonsmokers. 
Cerebrovascular Disease 
1. Data from numerous prospective mortality studies have shown 
an association between cigarette smoking and cerebrovascular 
disease. This risk is most evident in the younger age groups, 
and the effect diminishes with increasing age, with little or no 
effect noted after age 65. No consistent dose-response effect 
has been demonstrated. 
2. Women cigarette smokers experience an increased risk for 
subarachnoid hemorrhage. However, the use of both cigarettes 
and oral contraceptives greatly increases the risk for subarach- 
noid hemorrhage among women. 
Atherosclerotic Peripheral Vascular Disease and Aortic 
Aneurysm 
1. Cigarette smoking is the most powerful risk factor predisposing 
to atherosclerotic peripheral arterial disease. 
2. Smoking cessation plays an important role in the medical and 
surgical management of atherosclerotic peripheral vascular 
disease. 
3. Death from rupture of an atherosclerotic abdominal aneurysm 
is more common in cigarette smokers than in nonsmokers. 
Pharmacological and Toxicological Implications of Smoke 
Constituents on Cardiovascular Disease 
1. Over 4,000 different compounds have been identified in tobacco 
smoke. 
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2. Nicotine exerts an effect on ganglionic cells, producing tran- 
sient excitation. The pharmacological effects are small, but are 
reinforced several times daily in habitual smokers. The exact 
mechanisms whereby nicotine might influence cardiovascular 
events are unknown, but a lowering of the ventricular fibrilla- 
tion threshold is dose related to nicotine levels. 
3. Carbon monoxide may act to precipitate cardiac symptomatolo- 
gy or ischemic episodes in individuals already compromised by 
coronary disease. In addition, carbon monoxide binds to 
hemoproteins, potentially inhibiting their functions. 
4. Several studies have shown that smokers may alter their 
smoking behavior when they switch to low-yield cigarettes. 
This compensatory behavior may lead to the increased uptake 
of gas phase constituents including carbon monoxide, hydrogen 
cyanide, and nitrous oxides. 
5. It is unlikely that a “safe cigarette” can be developed that will 
reduce cardiovascular risk. 
Changes in Cigarette Smoking Behavior in Clinical and 
Community Trials 
1. Smokers involved in intervention programs demonstrate high- 
er smoking cessation rates than those in control groups. 
2. In general, the success of smoking intervention programs is 
related to the amount of intervention provided. 
The Effect of Cigarette Smoking Cessation on Coronary 
Heart Disease 
1. In the four intervention trials involving mortality followup of 
individual men for 5 to 10 years, the intervention groups had a 
combined total of 10 percent fewer CHD deaths than did the 
comparable control groups. Differences for other causes of 
death or for total deaths were not significant. 
2. In these trials, the amount of cigarette smoking has been 
reduced 10 to 50 percent more in the intervention group than 
in the control group, demonstrating that intervention can alter 
smoking behavior. 
3. In the two trials involving morbidity followup, the intervention 
groups had 4 and 45 percent lower total CHD incidence than 
did the respective control groups. 
4. The relative reductions in CHD mortality in each of the four 
intervention studies involving individual followup are reason- 
ably consistent with the reduction in CHD risk factors, and for 
a combination of all four studies, the reduction is statistically 
significant. 
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5. Numerous studies ha-.-e shown that those who quit cigarette 
smoking experience a substantial decrease in CHD mortality 
and an improvement in life expectancy. 
6. A number of prospective epidemiological studies indicate that 
former cigarette smokers substantially reduce their CHD and 
total death rates from that of current smokers. 
Trends in Cardiovascular Diseases 
The evidence supports the conclusion that changes in smoking 
habits have contributed to substantial improvement in mortality 
rates from the cardiovascular diseases in the United States. 
Trends in U.S. Cigarette Use, 19651980 
1. The proportion of current regular smokers declined steadily 
between 1965 and 1980. The decline was steeper among males 
(from 52.1 to 37.9 percent) than among females (from 34.2 to 
29.8 percent). 
2. The proportion of never smokers increased steadily from 1965 
to 1980 among males (27.6 to 31.6 percent), except those 45 
years old and older. Among females, only 20- to 34-year-ok% 
showed an increase in proportion of never smokers. 
3. The mean number of cigarettes smoked per day by current 
smokers increased slightly from 1970 to 1980 (from 20 to 21.7 
cigarettes). 
4. Males smoked a higher mean number of cigarettes throughout 
the 1970-1980 period, but the number for males and females 
increased about the same amount. 
5. Heaviest daily consumption was in the middle-aged group (35- 
65 years). The greatest mean increase was observed among 
women aged 35 to 44. 
6. The proportion of current smokers who smoked less than 20 
cigarettes per day decreased between 1970 and 1980 (39.8 to 
33.8 percent); the proportion smoking one pack exactly (20 
cigarettes) remained constant (34.9 to 34.8 percent); the propor- 
tion smoking from 21 to 39 cigarettes increased slightly (13.7 to 
14.5 percent); and the proportion smoking two or more packs 
per day increased from 11.4 to 16.8 percent. 
7. The proportion of current smokers who attempted to quit three 
or more times decreased slightly from 1966 to 1980 (41.2 to 38.7 
percent). 
8. The proportion of former smokers having made three or more 
attempts to quit increased sharply (36 to 53.2 percent) from 
1966 to 1975. 
9. The proportion of current smokers who had attempted to quit 
during the past year increased from 1966 to 1980 (26.0 to 36.7 
percent). 
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10. Among current smokers, younger persons and females were 
more likely than older persons and males to have attempted to 
quit during the previous 12 months. 
11. The proportion of former smokers who had attempted to quit 
during the previous 12 months decreased from 1966 to 1975 
(13.8 to 9.8 percent). 
12. Among former smokers, younger persons and females were 
more likely than older persons and males to have quit during 
the previous 12 months. 
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SECTION 2. ARTERIOSCLEROSIS 
Introduction and Definition of Terms 
Arteriosclerosis is the predominant underlying cause of cardiovas- 
cular diseases, including coronary heart disease (CHD), cerebral 
infarction, arteriosclerotic peripheral vascular disease, and athero- 
sclerotic aortic aneurysm. The specific relationships of tobacco use 
and these conditions, as well as an overview of known and suspected 
risk factors for cardiovascular disease, are reviewed in other 
sections. 
Because arteriosclerosis is sometimes used in a broad sense to 
cover a variety of arterial lesions, the nomenclature and terminology 
used in this section will be defined. 
Arteriosclerosis is a generic term that includes practically any 
arterial disease that leads to thickening and hardening of arteries of 
any size. 
Atherosclerosis is a specific form of arteriosclerosis. Its most 
distinctive feature is the accumulation of lipid in the intima of large 
elastic arteries (aorta) and medium-sized muscular arteries (coro- 
nary, femoral, carotid, and others). In addition to lipid, cells, 
connective tissue fibers, and various blood components accumulate 
in the lesions. A number of complications, including thrombosis, 
hemorrhage into a plaque, and ulceration, can also occur in or upon 
the lesions. The hallmarks of atherosclerosis are its intimal location 
during the initial stage, the involvement of large- and medium-sized 
arteries, and the accumulation of fat in the lesion. Atherosclerosis is 
the form of arteriosclerosis that most frequently causes clinically 
significant disease. 
Mbnckeberg’s medial calcific sclerosis, characterized by calcifica- 
tion of the medial layer of muscular arteries, and arteriolosclerosis, 
characterized by thickening, fibrosis, hyalinization, and narrowing 
of arterioles, are other types of arteriosclerosis quite distinct from 
atherosclerosis. They are beyond the scope of this section. Medial 
and arteriolar lesions have sometimes caused confusion in interpret- 
ing experimental studies, principally those in which rabbits and rats 
have been used. Only the intimal lesions that contain lipid and 
connective tissue elements in large elastic and medium-sized muscu- 
lar arteries are models of human atherosclerosis. 
The term atheroma has been used in several different ways, 
sometimes to refer to the entire process of atherosclerosis and 
sometimes to describe a specific lesion. Some pathologists use the 
word to mean a large atherosclerotic plaque containing a pool of 
necrotic cells, lipid, and connective tissue. Atheroma has also been 
used to refer to any lesion of atherosclerosis, including fatty streaks, 
fibrous plaques, or complicated or calcified lesions. 
The following working definitions are offered for different types of 
atherosclerotic lesions detectable grossly after staining vessels with 
Sudan IV or other fat stains. 
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A fatty streak is a fatty intimal lesion that is stained distinctly by 
Sudan IV and shows no other underlying change. Fatty streaks are 
flat or only slightly elevated in opened fresh or immersion fmed 
vessels. They do not significantly narrow the lumina of blood vessels. 
A fibrous plaque is a firm, elevated intimal lesion that in the fresh 
state is usually gray-white, glistening, and translucent. Human 
fibrous plaques characteristically contain fat. A thick fibrous 
connective tissue cap containing varying amounts of lipid covers a 
more concentrated “core” of lipid. If a lesion also contains hemor- 
rhage, thrombosis, ulceration, or calcification, that lesion is classi- 
fied according to one of the next two categories. 
A complicated lesion is an intimal plaque in which there is 
hemorrhage, ulceration, or thrombosis with or without calcification. 
A calcified lesion is an intimal plaque in which insoluble mineral 
salts of calcium are visible or palpable without overlying hemor- 
rhage, ulceration, or thrombosis. 
The term raised atherosclerotic Lesion is sometimes used as a 
measure of atherosclerosis to include the sum of fibrous plaques, 
complicated lesions, and calcified lesions. Raised lesions are contrast- 
ed with fatty streaks, which typically show little or no elevation 
above the surrounding intimal surface. 
Although this classification scheme implies a pathogenetic se- 
quence, it can be used for descriptive purposes regardless of the 
theoretical pathogenetic interrelationships among the lesions. 
Certain other intimal lesions are sometimes considered as sub- 
types of atherosclerosis or as lesions predisposing to atherosclerosis. 
These include musculoelastic or fibromuscular intimal thickening, 
gelatinous or edematous lesions, and organizing mural thrombi on 
an otherwise normal intima. The pathogenetic relationship of 
atherosclerosis and its clinical manifestations is less well established 
for these lesions, and quantitative information related to the natural 
history, topography, and geographic pathology is not available. 
“Rhythmic” or periodic wrinkling of the intimal surface of the aortas 
of children and adolescents is another change whose relationship to 
atherosclerosis has not been established. 
Clinical Significance of Atherosclerosis 
Atherosclerosis is the underlying cause of coronary heart disease 
(coronary occlusion, coronary thrombosis, myocardial infarction, and 
angina pectoris) and of one major type of stroke (cerebral thrombosis 
with infarction). Atherosclerosis also causes aortic aneurysms by 
weakening the aortic media via encroachment from primarily 
intimal lesions. Atherosclerosis also sets the stage for arteriosclerot- 
ic peripheral vascular disease by occlusive-thrombotic disease of the 
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distal aorta and by atherosclerotic lesions in the iliac-femoral 
vessels. 
Previous Literature Reviews 
The history of our knowledge about atherosclerosis was reviewed 
by Long (39). The morphology and pathogenesis of human atheroscle- 
rotic lesions were reviewed in detail by Duff and McMillan (201, and 
the gross and microscopic features of typical coronary and aortic 
human lesions at various ages were illustrated by McGill et al. (44). 
Data on the worldwide distribution of atherosclerotic lesions among 
different human populations were published in 1968 (41). Strong et 
al. (72, 73) reviewed the development of atherosclerosis by age, sex, 
and race, by the geographic variation in prevalence and extent of 
atherosclerosis, and by the relationship of atherosclerotic lesions to 
risk factors for coronary heart disease. A monograph on arterial 
smooth muscle cells by Geer and Haust (22) contains an extensive 
review of publications on the nature of cells in atherosclerotic 
lesions, descriptions of the histologic and ultrastructural features of 
arterial lesions, and electron micrographs illustrating atherosclerot- 
ic lesions. The published proceedings of international symposia on 
atherosclerosis (25, 34, 63, 64, 65, 86) contain review articles and 
reports of investigative work in atherosclerosis. 
Natural History and Topography 
Atherosclerosis begins in childhood, but does not usually become 
clinically manifest through its ischemic complications until later in 
life. The simple fatty streak is considered to represent the earliest 
lesion of atherosclerosis that can be easily recognized either grossly 
or histologically. The fatty streak is gradually converted into a 
fibrous plaque in which there is abundant connective tissue as well 
as lipid. These more advanced intimal lesions with increased 
amounts of mesenchymal tissue may enlarge to cause progressive 
stenosis of the vascular lumen. These lesions may undergo sufficient 
enlargement by accumulated lipid and connective tissue or superim- 
nosed mural thrombus to further narrow the lumen, or the lesions 
may become vascular&d and undergo intramural hemorrhage or 
may become ulcerated and covered by thrombus. In these last 
instances, rapid occlusion of the artery may result. Under certain 
circumstances and in certain arterial segments, the lesion may so 
weaken the underlying media that an aneurysm is produced, or the 
lesion may become calcified-a change that may represent a healing 
process, but nevertheless reflects an advanced stage of the athero 
sclerotic process. 
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The strong association between cigarette smoking and the clinical 
manifestations of atherosclerosis is examined in other sections of 
this Report. This section examines the relationship between ciga- 
rette smoking and the development of atherosclerotic lesions and 
other stages of occlusive arterial disease. 
A brief description of the topographic distribution of atherosclero- 
sis in different arterial segments provides additional background 
information for this section. The topographic distribution of athero- 
sclerotic lesions was reviewed by Duff and McMillan (20) and by 
Glagov and Ozoa (23). Schwartz and Mitchell (68) described selective 
involvement of some arteries and areas of localization of arterial 
plaques in their necropsy survey. Those studies were generally 
consistent, finding that lesions occur earliest and most extensively in 
the aorta. Pathologically demonstrable lesions usually develop later 
and less extensively in the coronary and cerebral arteries; the renal, 
mesenteric, and pulmonary arteries are the least susceptible to 
atherosclerotic lesions. A diagrammatic representation of the usual 
localization of arterial involvement by atherosclerosis is depicted in 
Figure 1, taken from the National Heart and Lung Institute (NHLI) 
task force report on arteriosclerosis (79). 
Studies in the International Atherosclerosis Project (IAP) led to 
the following conclusions concerning atherosclerosis in the aorta and 
in the coronary, carotid, vertebral, and intracranial arteries (43). 
The severity of atherosclerosis in one artery does not predict the 
severity in another artery for an individual case. On a cross-cultural 
basis, however, the average predilection of a population to raised 
lesions in one artery is correlated with the predilection in other 
arteries. The rank order of location-race groups in the IAP is 
approximately the same regardless of whether the ranking is based 
on raised lesions in the coronary arteries, the thoracic aorta, the 
abdominal aorta, or the cerebral arteries. This finding is consistent 
with the hypothesis that environmental conditions predominantly 
determine the severity of atherosclerosis in a population, despite 
large differences in susceptibility to lesions among individuals or 
among different anatomic loci within the arteries of each person. 
In general, the development of atherosclerosis follows a definite 
sequence. The aorta is involved first, beginning in infancy with fatty 
streaks that increase rapidly during puberty; fibrous plaques begin 
in the aorta in the third decade. Fatty streaks begin in the coronary 
arteries during puberty. They begin to increase significantly and 
become converted into fibrous plaques in the third decade of life in 
high risk populations. The carotid arteries begin to be involved with 
fatty streaks at approximately the same age as does the aorta. The 
other cerebral arteries begin to be involved at approximately the 
same age as do the coronary arteries. Raised lesions develop in the 
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FIGURE l.-Common sites of atherosclerotic lesions 
SOURCE: U.S. Public Health Service (79). 
carotid arteries at roughly the same age as in the aorta, but do not 
develop in the vertebral and intracranial arteries until much later. 
Hypotheses of Atherogenesis 
A succinct review of the major hypotheses concerning the athero 
sclerotic process (47) summarized various theories of atherogenesis 
with emphasis on the two major hypotheses-the lipid hypothesis, 
and the hypothesis that regards atherogenesis as a process involving 
the conversion of arterial mural thrombi into atherosclerotic 
plaques. 
The lipid hypothesis is based on the frequent occurrence of 
excessive amounts of cholesterol and lipid in lesions, the positive 
association between elevated serum lipids and atherogenesis in man 
and in animals, the association of dietary saturated fats and 
cholesterol with atherogenesis in man and in experimental animals, 
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and the association between specific diseases and genetic disorders 
that affect lipid metabolism and atherogenesis. 
The hypothesis concerning the conversion of mural thrombi into 
atherosclerotic plaques through tissue organization of the mural 
thrombi (the Duguid-Rokitansky concept) is based largely on patho- 
logical observations in man that show morphological evidence 
compatible with this view of atherogenesis. Such evidence is most 
convincing in relation to the middle or late development of plaques 
rather than to their early stages. Many investigators of atherosclero- 
sis have accepted this theory as a basis for plaque progression or 
complication rather than as a theory of plaque initiation. The 
demonstration that platelets are capable of interacting with intimal 
smooth muscle cells to stimulate them to proliferate has now 
extended this theory to encompass the initiation of atherogenesis 
without necessarily invoking the classical sequence of thrombosis 
(59). 
McMillan (47) pointed out that there has been a tendency for the 
proponents of one or the other of these theories to emphasize the 
rather exclusive importance of one hypothesis when considering 
various factors that are thought to be of particular importance for 
atherogenesis (such as cigarette smoking, hypertension, diabetes 
mellitus, or hyperlipoproteinemia). That is, the atherogenic factors 
often have been relegated to one or the other theory as independent 
factors that promote either lipid or thrombotic atherogenesis. 
Nevertheless, as McMillan (47) indicates, the two major theories are 
not mutually exclusive, but may complement one another in the 
initiation and progression of atherogenesis. 
There is much support for the view that atherosclerosis is best 
accounted for by the known facts if it is regarded as a multifactorial 
disease and, in the words of McMillan, “polyetiologic and polypatho 
genetic.” 
The finding that some individual fibrous plaques are uniform for 
one or other of the sex-linked isoenzymes of 6-GPD (12, 13, 14) 
suggests that each mature plaque derives from a single cell and is 
the basis for a new theory of atherogenesis, the monoclonal 
hypothesis. This theory suggests that plaques may result from the 
transformation, genetic or otherwise, of individual cells of the vessel 
wall into a cell that will react to stimulation and form a plaque. 
Other observations that fatty streaks are not monotypic (55) and that 
thin plaques tend to be heterotypic, while thicker ones from the 
same aorta tend to be monotypic (76), suggest that the phenomenon 
of cell adaptation and selection rather than that of transformation 
may be the basis for plaque monotypism. 
The arterial endothelium obviously has a key role in both the lipid 
and the thrombotic theories. In the lipid theory, the lipoprotein 
molecules traverse the endothelium in some fashion prior to being 
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accumulated in a plaque. The thrombotic theory also includes 
endothelial participation as an essential phenomenon. Endothelial 
damage or loss may be manifest either as increased permeability to 
macromolecules or as a focus for platelet adhesion, aggregation, and 
release; thus, these changes may be atherogenic stimuli. Exposure of 
the intima to lipoproteins and platelets may be mitogenic for smooth 
muscle cells, and can affect the arterial lesion by modulating the 
cellular production of collagen and glycosaminoglycans. This se- 
quence of events indicates how the lipid and thrombotic theories can 
interrelate in early atherogenesis. 
The most popular hypothesis to account for the accumulation of 
lipid in plaques involves the introduction of excessive amounts of 
plasma lipoproteins through the endothelial barrier to the intima. 
The lipoproteins, particularly low density lipoproteins (LDL), are 
internalized by smooth muscle and other connective tissue cells and 
are not metabolized rapidly; therefore, the lipid components accumu- 
late in the cells. The sterols that are liberated in the cell lysosomes of 
arterial cells may become so excessive that high density lipoproteins 
(HDL) are unable to remove them from the cells and from the 
intima. With progressive cellular lipid accumulation, cellular necro- 
sis may occur, causing lipid to be dispersed into the extracellular 
portions of the arterial wall. Thus, lipid may accumulate both 
intracellularly and extracellularly and may act as a local cause of 
injury. 
When weighing the evidence linking tobacco usage with the 
development of atherosclerotic lesions, one should consider these 
theories of atherogenesis as well as the natural history of atheroscle- 
rosis presented earlier in order to make judgments about possible 
mechanisms and the stages at which the process might be affected. 
Epidemiological Evidence Linking Cigarette Smoking With 
Atherosclerosis 
Cigarette smoking is a major risk factor for coronary heart disease, 
peripheral vascular disease, and other clinically significant sequelae 
of atherosclerosis. A key question is whether cigarette smoking has 
an effect on the development of the arterial lesions, the terminal 
occlusive events, or both. Until the recent past, few investigators 
specifically designed studies to answer questions dealing with the 
association between cigarette smoking habits and the development 
of atherosclerotic lesions in the aorta and coronary arteries. 
In the 1971 Report of the Surgeon General The Health Conse- 
quences of Smoking (801, reports of such studies were reviewed and 
summarized. Since that time, a number of additional reports have 
been published dealing with the relationship between cigarette 
smoking and atherosclerosis of the coronary arteries, aorta and 
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peripheral arteries, arterioles within the myocardium, and cerebral 
vessels. The evidence relating cigarette smoking and autopsy evi- 
dence of atherosclerotic disease in each of these areas is reviewed 
separately and summarized in individual tables in this section. 
coronary Arteries 
Table 1 summarizes the studies that have examined the relation- 
ship between cigarette smoking and autopsy evidence of atheroscle- 
rosis in the coronary arteries. Auerbach et al. (6) found more 
coronary atherosclerosis in smokers than in nonsmokers and a 
concomitant increase in the amount of atherosclerosis with the 
amount of cigarette smoking. An interim report by Strong et al. (75) 
concluded that atherosclerotic involvement of aortas and coronary 
arteries was greatest in heavy smokers and least in nonsmokers 
among autopsied men in New Orleans. A report by Vie1 et al. (81) on 
accidental deaths in Chile stated that there was no relationship 
between atherosclerotic lesions and the use of tobacco; however, 
examination of the data indicated that heavy smokers in the 50- to 
54year and 55- to 59-year age groups exhibited higher percentages of 
the left anterior descending coronary intima involved by atheroscle- 
rotic lesions than did nonsmokers. Apparently these differences were 
not statistically significant. 
A detailed study of smoking and atherosclerosis in deceased men 
in New Orleans has been conducted. Several reports based on the 
findings of that study, as well as various interpretations of those 
findings, have been published. Strong and Richards (74) reported the 
basic findings on the association of cigarette smoking and atheroscle- 
rosis in 1,320 autopsied men in New Orleans, 25 to 64 years of age. 
Coronary lesions were evaluated visually in coded specimens and 
objectively by analysis of post mortem radiographs. Using schedules 
that had been tested on pairs of living persons (49, interviewers 
obtained estimates of cigarette smoking habits of the deceased men 
from surviving relatives. Data were compared for black men and 
white men and also were analyzed in groups according to the 
presence or absence of diseases thought to be associated with 
smoking or with coronary heart disease (emphysema, lung cancer, 
myocardial infarction, hypertension, diabetes mellitus, stroke, etc.). 
Atherosclerotic involvement of the coronary arteries was greatest in 
heavy smokers and least in nonsmokers for both races in the total 
sample and in the basal group (those cases least influenced by the 
bias of autopsy selection). The data for these groups are presented in 
Table 1. 
The study by Strong and Richards (74) included approximately the 
same number of autopsied subjects from New Orleans as had the 
previously reviewed study by Auerbach et al. (6) in East Orange, 
New Jersey. Even though the methods of evaluation of arterial 
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TABLE l.-Autopsy studies of atherosclerosis involving the coronary arteries 
Data collection Measure of 
Study Population method atherosclerosis Resulta 
Smoking No atherosclerosis * Moderate Advanced 
Auerbach et al. 1,372 autopsies of Interview with Visual protocol None 5.6 57.3 21.8 15.3 
(6) men who did not relatives (20 2.6 30.9 37.3 29.2 
die of CND 20-34 .8 19.7 42.1 37.4 
40+ .6 18.1 35.4 45.9 
Avtandilov 259 males and Not specified Not specified Comparative size of mean area of atherosclerotic lesions in inner coat of coronary arteries 
(8) 141 female 
autopsies Right coronary artery Left coronary artery 
Smoker Nonsmoker Smoker Nonsmokers 
3lL39 15.5 (30)’ 1.3 (32) 6.3 ’ 2.2 
40-49 23.6 (34) 11.5 (27) 15.8 ’ 4.4 
50-59 36.3 (39)’ 14.6 (39) 27.9 ’ 9.9 
60-69 31.9 (321’ 23.6 (36) 26.5 ’ 22.5 
70-79 41.9 (16) 31.7 (36) 26.1 35.8 
NOTE The results concerning aortrc athercscleroels are gwen in form of ligure Presentation Of 
rid&analysis. 
Vie1 et al. 
(81) 
1,150 males and 290 Interview with 




Graphic data presentation only. but no association noted 
E TABLE l.-Continued. 
Study Population 
Data collection Measure of 
method atherosclerosis ReSUlta 





747 New Orleans 
males 20-64 years 
of age at death 
1,320 autopsies of 
males aged 25-64 
Interviews wth IAP protocol. 
next of kin visual grading, 
within 8 weeks and optical 
of death scanning 
Interview with Visual grading Mean percent of coronary artery intimal surface involved with raised lesions for total 
next of kin and optical sample, males 
scanning 
Average number cigarettes smoked per day 




























Data collection Measure of 
Study Population method atherosclerosis Results 
Auerbach et al. 1,056 autopsies of Interview with Visual and Distribution (in percentages) of degrees of fibrous thickening, of atheroma, and of cal- 
(4 male veterans relatives micrcacopic cification by smoking habits standardized for age (microscopic coronary study) 
evaluation 
Current cigarette smokers 
Never EX- 
Degree of smoked < pack l-2 packs 2+ pa& Cigar/ cigarette 
findings regularly per day per day per day pipe smokers 
Fibrous thickening 
None 50.1 3.9 0.6 0.4 4.5 5.0 
Slight 20.1 26.5 8.0 5.1 24.4 30.6 
Moderate 29.0 59.1 72.6 72.3 54.8 57.4 
Advanced 0.8 10.5 18.6 22.2 16.3 7.0 
-4theroma 
None 82.5 74.5 69.9 66.1 68.2 12.0 
Slight 4.1 4.0 3.7 3.1 4.5 3.9 
Moderate 13.1 19.2 20.6 20.8 23.4 21.5 
Advanced 0.3 2.3 5.8 10.0 3.9 1.6 
Calcification 
None 85.8 81.5 7A.l 73.5 75.5 79.2 
Slight 4.5 4.1 3.8 4.3 6.2 4.3 
Moderate a.4 10.3 11.1 11.2 13.4 12.7 







Distribution by percentage of degree of atherosclerosis by smoking habits standardized 
for age (macroscopic study) 




smoked < pack l-2 packs 2+ packs Cigar/ cigarette 
regularly per day per day per day pipe smoker 
Lif&.ic 
(371 
894 autopsies of 
males 20-79 at 




None or minimal 59.8 45.2 36.6 32.6 36.3 50.9 
Slight 24.7 26.9 27.9 21.5 28.4 25.5 
Moderate 10.2 16.2 16.0 16.5 21.0 12.6 
Advanced 5.3 ii.7 lY.5 23.4 14.3 11.0 
Total 100.0 loo.0 loo.0 1OQ.O 1Oil.o loo.0 
Ratio of the extent of atherosclerotic lesions in the average coronary artery between 
nonsmokers and smokers 
Total Compli- 
athero- Fatty Fibrous cated Calcified Raised 





1.0 1.1 1.0 1.5 0.6 1.0 
1.0 1.1 1.1 1.0 0.6 1.0 
TABLE l.-Continued. 
Data collection Measure of 
Study Population method atherosclerosis Results 
Schettler Autopsies of 89 Interview with Visual grading Stenosis 
et al. males aged 60-94 relatives 
(63) at death in Tokyo Smoking No Yes Total 
No 6 8 14 
Yes, daily 8 67 75 
Total 14 75 89 
Rhoads et al. 109 sutop&s of Interview with AHA panel Mean coronary atherosclerosis grade versus selected attributes 
(56) Japanese American subject 
male8 born 1900- Regression coefficients 
1919 who parti- 
cipated in Honolulu Examination variables Simple Multiple ’ 
heart study 
Relative weight 1%) 0.031 J 0.025O 
Cigarettes/day 0.022* 0.024 3 
Cholesterol(mg/dl) 0.011 3 0.0093 
Triglycerides(mg/dlI o.Oo22 NS’ 
Glucose(mg/dl) 0.004 2 NS’ 
Hematirit 1%~ o.069z NS ’ 
‘Multiple regreaxon was done by B stepw.ee ehmmatmn procedure begmnmg wth the set 
of vanables shown: coefficwnts are for the final step. Multiple correlation (final step1~0.46 
IN- 108l 
~Slgnlficant at on5 level 
~S1gmficant at 0 01 level 








35-44 X 4.4 a.4 x 32.2 32.1 X 60.3 62.1 2 8 12 
45-54 X 5.5 0.4 x 25.1 31.4 x 65.7 70.4 2 25 12 
55-64 a.1 47 7.2 31.4 31.1 20.8 60.3 57.4 62.4 11 15 9 
’ ATL as percent surface fatty streaks (F) plus raised lesions (Rl: FaF=F - (100 - R%E in percentage units 
explained in the text; X indicates subgroups having fewer than five members 
Holme et al. 
(29) 
129 autopsies from Interview with Visual grading Correlation coefficient between number of cigarettes and raised lesions in the coronary 
16,2CGC males aged subject arteries = ,039, not significant. 





60 autopaiea of 703 Interview with Visual grading Smoking and stenosis or atherosclerosis in the left anterior descending coronary artery 
males in CHD subject 
study in Malmo. LAD Coronary 
SW&n Smoking category Number rased lesions artery stenosis 
Non 3 68 33 
Ex 8 52 38 
Light 18 45 39 







Sorlie et al. 
( 70) 
139 autopsies of Interview with Visual grading Association of atherosclerosis in coronary arteries with antemortem characteristics: 
9,824 Puerto Rican sub@ simple correlation coefficients (Puerto Rico heart health program) 
males aged 35-79 m 
a prospective study Correlation coefficients 
Characteristics 







Systolic blood pressure 
Diastolic blood pressure 
Serum cholesterol 








Calories (24.hour recall) 
Starch (24.hour recall) 
Alcohol (24.hour recall) 




0.22 0.07 0.30 
0.26 0.09 0.30 
0.42 0.59 0.38 
0.01 0.32 4.08 
0.21 JJ.15 0.25 
-0.18 0.06 -0.22 
0.20 4.04 0.21 
0.14 0.36 0.12 
0.14 a.40 0.24 
0.16 4 17 0.16 
4.16 xl.05 xl.22 
a.14 a.43 407 
-0.17 -0.29 -0.09 
a.10 -9.10 a.13 
-0.04 xl.53 0.03 
0.23 0.49 0.19 
0.13 0.20 0.08 
-0.19 a.13 4.16 
lesions were not identical, the findings from both of these large 
studies of autopsied men in the United States were remarkably 
similar. Both studies reported more extensive coronary atherosclero- 
sis among the cigarette smokers than among the nonsmokers, and 
for the major comparisons, with only rare exceptions, there was an 
orderly progression of least extensive lesions in nonsmokers, inter- 
mediate extent of lesions in light or moderate smokers, and most 
extensive lesions in heavy smokers. 
In the New Orleans study (741, lesions were measured not only by 
visual evaluation, but also by optical electronic scanning of radio- 
graphic images of the flattened arteries. The measurements of 
lesions from radiographs-relative mean coronary wall thickness 
and percentage of the coronary artery intima involved with calcifica- 
tion-were consistently greater for the heavy smokers than for the 
nonsmokers. A variety of statistical analyses on smoking measures 
and atherosclerotic lesions were performed to determine the signifi- 
cance of the various differences and trends. These analyses con- 
firmed that the major differences between the heavy smokers and 
the nonsmokers in extent of raised atherosclerotic lesions (the sum of 
fibrous plaques, complicated lesions, and calcified lesions) were 
significant. A one-way multivariate analysis of nine atherosclerotic 
variables clearly indicated that there were statistically significant 
differences among the three categories of smokers (heavy, light to 
moderate, and nonsmokers) for mean coronary wall thickness, raised 
lesions in the coronary arteries, percentage of cases positive for 
fibrous plaques, percentage of cases positive for complicated lesions, 
and percentage of cases positive for calcified lesions, with lower 
values in nonsmokers and higher values in the heavy smokers. 
Pate1 et al. (53) evaluated this same data on smoking and 
atherosclerotic lesions to examine further the interrelationships 
with measures of obesity. The confounding effects of diseases such as 
hypertension and diabetes mellitus were controlled by excluding 
such cases from the analysis. The confounding effects of age and 
measures of smoking habits on the association between atherosclero- 
sis and obesity were controlled by multivariate regression analysis. 
This analysis disclosed an inverse relationship between smoking 
habits and obesity. There was also a weak positive association- 
when age and smoking were controlled for-between measures of 
obesity and mean coronary wall thickness and raised lesions in the 
coronary arteries among whites, but not among blacks. In the black 
men, again with age and smoking controlled in the analysis, a weak 
association between fatty streaks in the coronary arteries and 
obesity was found. This analysis confirmed the previously reported 
relationships between smoking habits and atherosclerosis, as mea- 
sured by mean coronary wall thickness, coronary calcifications, and 
raised lesions in the coronary arteries. 
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Since their first report in X65, Auerbach and his associates have 
investigated the relationship of cigarette smoking to microscopic 
findings in the coronary arteries (4). This study indicated that lesions 
were most extensive in cigarette smokers and confirmed earlier 
studies by Auerbach et al. (6) and Strong and Richards (74). The 
microscopic portion of the Auerbach et al. study (4) showed that 
fibrous thickening, atheroma, and calcifications of the coronary 
arteries all increased with increasing number of cigarettes smoked 
per day. They also found that the fibrous thickening of arteries 
increased in relation to the number of cigarettes smoked per day as 
the size of the artery decreased; i.e., it was least in the coronary 
arteries and greatest in the myocardial arteries. 
Lifsic (37) reported on the relationship of cigarette smoking to 
coronary atherosclerotic lesions based on the Yalta sample from the 
World Health Organization (87) autopsy study of five cities in 
Europe. Information on cigarette smoking was obtained by means of 
interviews with the subjects’ near relatives. The prevalence and 
extent of atherosclerotic lesions were evaluated in autopsies of 865 
men, aged 20 to 79 years, out of the 1,220 deaths occurring in Yalta 
residents of this age and sex group during the period of study. There 
was a positive association of smoking with the extent of coronary 
calcification; however, the author explained this association as being 
related to coexisting alcohol consumption and stated that smoking 
alone tended to be negatively associated with coronary calcification. 
The following paragraph from Lifiic’s discussion provides additional, 
information from this report. 
There was little significant difference between smokers and nonsmok- 
ers in the prevalence and extent of atherosclerotic lesions in the 
coronary arteries. Thus, of the total of 210 comparisons of different 
indices of the prevalence and extent of atherosclerotic lesions between 
subgroups X and W, significant differences positively correlated with 
smoking were found in only 20. The tendency toward a positive 
correlation of coronary atherosclerosis with smoking was found mainly 
in subjects up to the age of 50, but after 60 the opposite tendency 
prevailed. These age peculiarities agreed with data from other studies 
showing that differences in the degree of atherosclerosis between 
smokers and nonsmokers. . . are more distinct below age 60. 
The author also mentioned a positive association between smoking 
and coronary calcification in “strenuous workers.” A note added in 
proof to LifGic’s article states, “Additional study of this material by 
individually matched case-control analyses revealed a marked trend 
toward a positive association between smoking and atherosclerotic 
raised lesions in the coronary arteries” (82). Thus, while the author’s 
abstract does not indicate an important relationship of smoking and 
coronary atherosclerosis, there are findings in the study that do 
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indicate significant relationships between smoking and coronary 
atherosclerosis, especially in the younger subjects. 
A subsequent study by Vikhert et al. (83) on material from five 
cities in the U.S.S.R. evaluated the effect of nutritional status and 
tobacco smoking on atherosclerotic changes in the coronary arteries 
as measured by a visual planimetric method. This material was also 
utilized for a WHO-sponsored epidemiological study of atherosclero- 
sis (87). The vessels examined were from 430 men 40 to 69 years of 
age. The major analyses concerning tobacco smoking were made 
from 313 male heavy smokers and 82 nonsmokers. The investigators 
studied both manual workers and white-collar workers and found 
that tobacco smoking in combination with overnourishment had a 
much more positive effect on the development of coronary athero- 
sclerosis in white-collar workers than in the manual workers. 
Prospective epidemiologic studies of cardiovascular disease with 
autopsy followup provide additional information concerning the 
relationship of smoking to atherosclerotic lesions in the artery wall. 
The epidemiological studies in Oslo, Puerto Rico, and Honolulu are 
characterized by careful documentation of selected major risk 
factors, including cigarette smoking habits during life, and by 
standardized evaluation of atherosclerotic lesions at autopsy (29, 56, 
70). Each of these three studies reported findings on the relationship 
of CHD risk factors to atherosclerotic lesions in more than 100 
autopsies of deceased men who had been part of larger cohorts that 
had been examined and followed during life. In addition, a smaller 
study from Malmo, Sweden, had some of the same features as these 
larger studies (71). The Oslo, Malmo, and Puerto Rico studies used 
identical methods for grading the extent of atherosclerotic lesions. 
These prospective epidemiologic studies with autopsy followup are in 
general agreement concerning the relationship of serum cholesterol 
levels and blood pressure to the extent of atherosclerotic lesions in 
the coronary vasculature. The findings concerning the relationship 
of cigarette smoking to the extent of coronary atherosclerosis are not 
uniform. The Honolulu study (56) showed a significant relationship 
between smoking habits and extent of coronary atherosclerosis. The 
Oslo study (29) did not show a significant relationship between 
cigarette smoking and coronary atherosclerosis. The Puerto Rico 
study (70) also did not show a significant relationship between 
smoking and the extent of coronary athersclerosis. A somewhat 
similar study from Japan by Hatano and Matsuzaki (26) indicated a 
significant relationship between cigarette smoking and coronary 
artery stenosis. Thus, there is some inconsistency concerning the 
association between cigarette smoking habits and coronary athero- 
sclerosis in the prospective epidemiologic studies with autopsy 
followup. 
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In considering this entire body of evidence, however, the prepon- 
derance of evidence suggests that cigarette smoking has an effect on 
the development of atherosclerotic lesions in the coronary artery 
wall in the U.S. population, and that its effect is not limited to those 
events immediately surrounding the occlusive episode. 
Small Arteries in the Myocardium 
Table 2 reviews those studies that. have examined the relationship 
between cigarette smoking and lesions of the arterioles within the 
myocardium. Auerbach et al. (7) found a relationship between 
smoking habits and thickening of the walls of the arterioles and 
small arteries of the myocardium. Auerbach et al. (4) also performed 
a microscopic study of coronary artery lesions in autopsied men in 
relation to previous smoking histories. In the microscopic portion of 
this study, fibrous thickening, atheroma, and calcification increased 
with an increased number of cigarettes smoked per day. Moderate to 
advanced hyaline thickening of the arterioles in the myocardium 
was strongly related to smoking. It was found in 98.6 percent of the 
autopsied subjects with a two pack per day smoking habit and not 
found in the group of subjects who never smoked regularly. Naeye 
and Truong (51) reported essentially similar alterations in the 
intramyocardial arteries, which developed more rapidly in cigarette 
smokers than in nonsmokers. 
The Aorta 
Those studies that provide autopsy and other evidence for the 
relationship between cigarette smoking and atherosclerosis of the 
aorta are summarized in Table 3. 
Wilens and Plair (85) found significantly more severe sclerosis of 
the aorta in cigarette smokers than in nonsmokers. Sackett and 
Winkelstein (61) reported that elderly cigarette smokers had signifi- 
cantly higher rates of aortic calcification, detected on chest X-ray, 
than did nonsmokers. Sackett et al (601, in an autopsy study, found a 
significant relationship between the use of cigarettes and the 
severity of aortic atherosclerosis. An interim report by Strong et al. 
(75) concluded that atherosclerotic involvement of aortas was 
greatest in heavy smokers and least in nonsmokers among autopsied 
men in New Orleans. 
Most of these studies, reviewed in the 1971 Report of the Surgeon 
General The Health Consequences of Smoking (801, indicate that 
differences between heavy cigarette smokers and nonsmokers are 
particularly great in young individuals, and that heavy smokers 
have increased surface involvement with fibrous plaques or more 
advanced atherosclerotic lesions. 
Since the 1971 review, a study of smoking and atherosclerosis in 
deceased men in New Orleans has been completed. Several reports 
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1,164 males Records and Biopsy of Grade of thickness of walls of arterioles’ 
autopsied family myocardium 
at VA Number of men Percentage of men 
Grade Grade Grade Grade Grade Grade 









































19 1 loo.0 
1 3 100.0 
31 18 lc0.0 
35 46 100.0 
10 19 loo.0 
12 2 loo.0 
8 5 lc0.0 
17 16 loo.0 
35 64 loo.0 
11 39 1Oc.o 
36 16 loo.0 
22 13 loo.0 
44 4.3 100.0 
58 135 1WJ.O 
21 66 loo.0 
18 12 100.0 
19 21 loo.0 
12 18 1lx.o 
12 34 100.0 
3 6 loo.0 
9.1 66.4 4.5 
25.0* 75.0’ 
2.0 62.0 36.0 
4.7 41.2 54.1 
- 34.5 65.5 
6.7 80.0 13.3 
61.5 38.5 
- 51.5 48.5 
- 35.4 64.6 
22.0 78.0 
7.1 64.3 26.6 
- 629 37.1 
47.0 52.2 
- 30.1 69.9 
- 24.1 75.9 
6.3 56.2 37.5 
47.5 52.5 
- 40.0 60.0 
- 26.1 73.9 
- 33.3’ 66.71 
‘In the right ventrmdar wall of 1,020 men by age and smoking habits 
‘Percentage8 baeed on less than 10 cases 

















Distribution by percentage of degree of fibrous thickening of myocardial arteries, subepicardial arteries. 
and hyaline thickening of myocardial arterioles (microscopic myocardial study), by smoking habit 
standardized by age 






~1 pack 1-2 packs z+packB Cigar/ cigarette 
regularly per day per day per day pipe smokers - 
Myocardial arteries 
















74.7 17.5 2.4 1.4 
24.9 56.8 35.1 32.7 
0.4 19.0 28.8 23.8 
- 6.7 33.7 42.1 
loo.0 100.0 100.0 100.0 
2.9 1.1 22.0 32.0 
37.1 29.6 70.6 63.2 
39.0 45.0 6.7 4.2 
21.0 24.3 0.7 0.6 












92.0 2.1 - - - 3.2 
8.0 28.7 2.2 1.4 39.6 40.8 
- 20.8 9.6 7.9 19.6 19.1 
- 40.4 68.2 90.7 40.8 36.9 
100.0 100.0 loo.0 loo.0 loo.0 100.0 
TABLE 3.-Autopsy studies of atherosclerosis involving the aorta 
Study 
Smoking data Measure of 







at NY VA 
hospital 
Patient chart Visual grading Percent of subjects by smoking status and atherosclerosis 
Severity of Non- Pipe/ 
sclerosis smoker Heavy Moderate Light cigar Other 
Number 161 199 288 152 70 119 
Percent above average 9.9 25.1 26.4 19.1 10 10.9 
Percent average 60.2 61.3 62.5 63.2 60 63.0 




1,320 Interview Visual grading Mean percent of intimal surface of abdominal aorta involved with raised lesions 
autopsies with relatives 
of males Average number of cigarettes smoked per day 
aged 25-64 











1 7 7 
14 33 44 
33 52 56 
46 63 71 
4 7 9 
6 20 28 
14 37 45 
26 51 56 
g TABLE $-Continued. 
Study 
Smoking data Measure of 
Population source atherosclerosis Results 
Sackett and 590 







Patient Chest X-ray The relationship between smoking and calcification of the thoracic aorta 
questionnaire for calcification 
in thoracic aorta Nonsmokers Smokers 
Percent with Percent with Probability 
Age group Number calcification Number calcification value 1 Totals 
50-59 61 13 131 11 0.4 192 
60-69 90 16 124 26 0.2 214 
70 and over 116 37 63 54 0.02 164 
Totals 267 25 323 26 - 590 
Age-adjusted percent - 22 - 30 - - 
‘Chi-square of independence, twotcded. 




70 and over 
Totals 
Nonsmokers Light smokers Heavy smokers 
Percent with Percent with Percent with 
Number calcification Number calcification Number calcification Totals 
61 13 104 9 27 22 192 
90 16 107 24 17 35 214 
116 37 63 56 5 40 164 
267 26 274 29 49 27 590 
Age-adjusted percent - 22 - 29 - 32 - 
TABLE S.-Continued. 
Study 
Smoking data Measure of 




1,019 Standardized Visual grading Mean ag?+adjusted atherosclerosis ridits versus gr aded use of cigarettes and alcohol 
consecutive interview with on a numerical 
autopsies of patient on scale Alcohol Cigarettes 
white admiwion 
patienta &/day None 1 :! pack 1’2 pack+ 
None ,351 ,466 ,498 
0.5-1.5 ,424 ,570 .56l3 
1.6+ ,426 ,526 ,589 
Strong et al. Autopies Interview Visual grading Mean percentage of intimal surface of aorta involved with raised lesions by age, race, and average rate 
(75) of 741 with relativea and optical of cigarette smoking in the last 10 years of life 
males 20-64 Bcanning 
year8 at 
death 
Cigarettes pe r day 









0 l-24 25+ 
16 35 49 
29 52 54 
48 66 70 
3 22 24 
12 38 50 
21 50 49 
$ TABLE 3 -4‘ontinued. 
Study 
Smoking data Measure of 







Visual gradmg Prevalence of atherosclerotic lesions in the abdominal aorta in different subgroups (percentage) 
of males 
aged 2&79 


















































Smoking data Measure of 

















Correlation coefficients among selected autopsy and examination variables’ 
Aorta (N = 124). atherosclerosis grade 
Age at death 
Examination variables 
Height (cm) 




Uric acid (mg/dl) 
Glucose (mg/dl) 
Hematocrit (%I 
Vital capacity (liters) 
Alcohol (pm, 
Systolic pressure (mm Hg) 
Diastolic pressure (mm Hgl 
















I N= number of specimens. 
sS~gniiicant at 0.05 level 
a Significant at 0.01 level. 
‘When a correlation coeffXent is based on less than 95 percent of the ~pecmwns available (because of missing 
data), the number of observations is indicated in parentheses. There were 96 autopsies with both aorta and 
coronary vesel grades available. 13 wth coronary only. and 28 with aorta only 
TABLE 3.-Continued. 
Study 
Smoking data Measure of 
Population SO”FX? atherosclerosis ReSUlta 
Auerbach 1,412 males Family Visual grading Percentage of selected findings by smoking habits 
and Garfinkel autopsied 
(5) at VA hos- Percentage of cases’ 
pita1 
“Current” cigarette smokers 
Findings 
Never smoked 1 pack l-2 pack3 2+ packs Cigar Excigarette 
regularlv per day per day per day or pipe smoker 
Thoracic aorta 
Many or diffuse 
distribution of plaques 
Moderate or advanced 
ulceration 




Many or diffuse 
distribution of plaques 
Moderate or advanced 
ulceration 
Moderate or advanced 
calcification 
Thrombus present 
16 26 41 37 27 29 
4 6 14 12 10 8 
56 63 74 74 53 67 
4 7 14 11 11 9 
28 54 68 79 46 53 
7 19 27 27 13 22 
63 76 84 88 74 81 
7 23 23 31 14 23 
lPercentages are adjusted to distribution by age group of all men in study. 
TABLE 3.-Continued. 
Study 
Smoking data Measure of 
Population source atherosclerosis Results 
Sternby 
(71) 
60 Interview Visual grading Smoking and atherosclerosis of the aorta 
autopsies with subject 
from 703 Raised lesions in the 
males enrol- Smoking category Number abdominal aorta 
led in a 
CHD study Non 3 26 
in Malmo. ET. 8 43 
Sweden Light 18 53 
Heaw 7 83 
Smoking and atherosclerosis m peripheral arteries 
Femoral artery Lower leg artery 
Smoking 
Iliac artery 
Raised Sterosis RalSed Stenosis 
category N Raised lesions lesions (701 lesions (70) 
Non 3 17 20 0 2 0 
EX 8 18 43 33 18 22 
Light 18 29 29 6 3 11 
Heavy 17 50 50 35 12 41 
g TABLE S.-Continued. 
Study Population 
Smoking data Measure of 
source atherosclerosis Results 
Tracy et al. Autopsies Interview Visual exam Means of observed minus expected raised-among-lesions GE), fatty streaks among flat surfaces (FaF), 
(77) of 1.380 with relatives all types of lesions tATL1, and number of cases (N) by age, race, and cause of death according to 
white and smoking category I, abdominal aorta 
black males 
aged 2564 O-E Faf ATL 
at death 





















-3.7 3.9 0.6 25.3 32.1 36.6 26.4 36.6 34.7 
-7.3 5.0 12.7 22.8 30.8 35.5 27.9 48.1 64.7 
77 6.1 3.6 21.3 28.9 31.4 47.3 57.3 65.8 
-0.6 3.0 6.7 33.7 33.1 35.5 56.5 68.6 76.2 
X X X X X X X x x 
-18.7 15.3 6.8 43.2 28.2 39.2 55.3 67.9 68.0 
8.0 3.6 1.3 25.7 40.8 33.1 500 81.4 73.4 
4.5 5.4 2.2 44.3 37.7 40.1 77.7 82.8 83.7 
5.3 -3.5 -3.8 28.6 32.8 36.8 30.7 34.9 38.6 
-16.9 -3.1 -3.9 26.5 31.8 33.0 27.8 43.9 45.6 
-15.7 -7.3 -5.4 25.0 32.7 37.4 33.8 47.2 60.0 
-9.5 a.3 -2.8 29.7 31.6 32.1 43.9 61.6 55.5 
X 6.3 X X 39.7 X X 44.6 X 
X -2.7 9.3 X 28.0 29.9 X 55.1 61.8 
X 4.6 4.8 X 34.2 386 X 72.4 73.0 
-14.4 -2.8 2.5 41.9 35.8 40.7 62.5 66.2 81.4 
’ ATL as % fatty streaks (F) plus raised lesions (RI; FaF=F : (100 - R); O-E in percentage units explained in 
TABLE 3.-Continued. 
Study 
Smoking data Measure of 
Population 8oUrC.2 athercscleroeie ReSUlts 








with subject evaluation 
Awxiation of atherosclerosis in aorta with antemortem characteristics. simple correlation coefficients 




aged 35-79 Characteristics 







Systolic blood pressure 
Diastolic blood pressure 
Serum cholesterol 








Calories (24.hour recall) 
Starch (24-hour recall) 
Alcohol (24.hour recall) 




0.25 0.27 0.24 
0.19 0.29 0.16 
0.29 0.38 0.28 
0.31 0.39 0.29 
4.08 -0.22 4.06 
-0.18 -lx21 -0.14 
0.14 0.05 0.17 
0.23 0.33 0.21 
-0.08 a.23 a.03 
0.01 -0.01 4.01 
032 0.37 0.31 
-0.24 -0‘5.5 4 12 
-0.19 a.45 -0.07 
-0.18 4.39 AI 18 
-0.19 4.49 a.11 
0.11 0.53 0.04 
0.07 0.11 0.05 
-0.29 -0.28 -0.29 
based on the findings in that study, as well as various interpretations 
of those findings, have been published. Strong and Richards (74) 
reported the basic findings on the association of cigarette smoking 
and aortic atherosclerosis in 1,320 autopsied men in New Orleans, 25 
to 64 years of age. Aortic lesions were evaluated visually in coded 
specimens and objectively by analysis of radiographs. Interviewers 
obtained estimates of cigarette smoking habits of the deceased men 
from surviving relatives. Data were compared for black men and 
white men, and also were analyzed in groups according to the 
presence or absence of diseases thought to be associated with 
smoking or with coronary heart disease (emphysema, lung cancer, 
myocardial infarction, hypertension, diabetes mellitus, stroke, etc.). 
Atherosclerotic involvement of the aorta was greatest in heavy 
smokers and least in nonsmokers for both races in the total sample, 
as well as in the basal group (those cases least influenced by the bias 
of autopsy selection). The lesions were measured not only by visual 
evaluation, but also by optical electronic scanning of radiographic 
images of flattened arteries. Atherosclerotic lesions in the abdominal 
aorta were more extensive in the heavy smokers than in the 
nonsmokers, and there was an orderly trend of increased lesions 
with increased smoking. In general, the magnitude of difference in 
extent of lesions between nonsmokers and heavy smokers was 
greater in the abdominal aorta than in the coronary arteries. A 
variety of statistical analyses of smoking measures and atheroscle- 
rotic lesions was applied to determine the significance of the various 
differences and trends. All of the analyses confirmed that the 
differences between the heavy smokers and the nonsmokers in 
extent of raised atherosclerotic lesions were significant. A one-way 
multivariate analysis of nine atherosclerotic variables indicated that 
there were statistically significant differences among the three 
categories of smokers (heavy, light to moderate, and nonsmokers) for 
lesions in the abdominal aorta. 
Following the initial report of Strong and Richards (74), there were 
three additional publications from this study. Two of these were 
directed toward interpretation of findings in regard to the effect of 
cigarette smoking on fatty streaks (the earliest grossly visible lesions 
of atherosclerosis) and raised atherosclerotic lesions (the more 
advanced stage of the atherosclerotic process). The other study was 
directed toward the interrelations of obesity, smoking, and athero- 
sclerotic lesions in these same cases. 
The original report by Strong and Richards (74) indicated that 
raised lesions, the more advanced lesions, were greater in heavy 
smokers than in nonsmokers. They also reported statistically 
significant differences for fatty streaks in the abdominal aorta and 
for fatty streaks in the coronary arteries, with the highest values in 
the nonsmokers and lowest values in the heavy smokers. The well- 
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recognized problem of evaluating fatty streaks when more advanced 
lesions of atherosclerosis are present made it difficult to interpret 
the findings on fatty streaks. Pate1 et al. (54) approached this 
problem by using a simple two-parameter model of fatty streaks 
arising from a normal intimal surface at a constant rate and with 
subsequent conversion to raised lesions at a constant rate. They 
concluded that in the abdominal aorta, smoking enhances the 
formation of fatty streaks as well as the subsequent conversions to 
more advanced lesions, and in the coronary arteries, smoking seems 
only to enhance the conversion of fatty streaks to fibrous plaques. 
Tracy et al. (77) evaluated the same data from the New Orleans 
study on smoking and atherosclerotic lesions. They approached the 
problem using a different model: N = F -+ R, where N denotes 
normal intima, F denotes fatty streaks, and R denotes raised lesions. 
In this model, class A causes are viewed as promoting the process 
from beginning to end, while class B agents act at the first or the 
second step, but not at both. Their analysis and interpretation 
suggest that cigarette smoking has a large class B effect. They 
concluded that the target tissue of smoking is the fatty streak, and 
the slowly progressing or regressing fatty streak (formed alike in 
smokers and nonsmokers) is caused to progress more rapidly or to 
cease to regress by smoking. Both of these studies, Pate1 et al. (54) 
and Tracy et al. (73, agree that smoking has a role in the progr&ion 
of fatty streaks to a more advanced stage of the atherosclerq$c 
process. 
Auerbach and Garfinkel in 1980 (5) published findings on smoking 
habits and atherosclerotic lesions in over 1,400 aortas collected at 
autopsy from male patients. The extent of atherosclerotic lesions 
(plaques, ulcerations, and calcification) increased with number of 
cigarettes smoked, and was also greater in excigarette smokers and 
pipe smokers than in nonsmokers. The findings were more striking 
in the abdominal aorta than in the thoracic aorta. Aortic aneurysms 
were found eight times more frequently among those who smoked 
one to two packs of cigarettes per day than in nonsmokers. 
LifSc (37) reported on the relationship of cigarette smoking to 
aortic lesions based on the Yalta sample from the World Health 
Organization (WHO) autopsy study of five cities in Europe (87). 
Information on cigarette smoking was obtained by means of inter- 
views with the subjects’ near relatives. The prevalence and extent of 
atherosclerotic lesions were evaluated in autopsies of 865 men, aged 
20 to 79 years, out of 1,220 deaths occurring in Yalta residents of this 
age and sex group during the period of study. There were significant 
positive relationships between smoking and the extent of fibrous 
plaques, complicated lesions, and calcified lesions in the abdominal 
aorta. 
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Aortic atherosclerosis has also been evaluated using autopsy 
followup of prospective epidemiologic studies of cardiovascular 
disease. Epidemiological studies in Puerto Rico and Honolulu 
documented selected risk factors, including cigarette smoking habits, 
during life and had standardized evaluation of atherosclerotic 
lesions at autopsy (56, 70). Each of these studies reported findings on 
the relationship of risk factors and aortic atherosclerotic lesions in 
more than 100 deceased men from large cohorts that had been 
examined and followed during life. A smaller study from Malmo, 
Sweden, had some of the same features as these larger studies (71). 
All of these studies found a significant positive relationship between 
cigarette smoking and aortic atherosclerosis. 
The prospective epidemiologic studies with autopsy followup 
confirmed the relationship between smoking and atherosclerotic 
aortic lesions found in earlier autopsy studies. The preponderance of 
evidence suggests that cigarette smoking aggravates or accelerates 
aortic atherosclerosis, and this effect on atherosclerosis may be more 
pronounced in the aorta than in the coronary arteries. 
Cerebral Vasculature 
The relationship between cigarette smoking and atherosclerosis in 
the cerebral vasculature has not been extensively evaluated. Two 
studies that have examined this question are summarized in Table 4. 
Sternby (71) reported that cigarette smokers had more extensive 
raised lesions in the basilar artery than had nonsmokers. This study 
was based on 60 autopsy subjects from 703 men born in 1914 who 
participated in a study of cardiovascular disease in Malmo, Sweden. 
Holme et al. (29) reported a positive correlation coefficient between 
raised lesions in the cerebral vessels and the number of cigarettes 
smoked; this relationship was not statistically significant, however. 
The limited amount of information available on the relationship 
between cigarette smoking and atherosclerosis in the cerebral 
vasculature does not allow a clear conclusion to be drawn at this 
time. 
Pathophysiologic Mechanisms of Tobacco Smoke 
Studies of Components of Tobacco Smoke 
The possible pathophysiologic mechanisms for the atherogenic 
influence of cigarette smoking were reviewed in the 1971 Report of 
the Surgeon General The Health Consequences of Smoking (80). The 
major components of cigarette smoke considered in that review were 
nicotine and carbon monoxide. Numerous investigators have studied 
the effect of nicotine administration, either subcutaneously or 
intravenously, upon experimentally induced changes in the aorta 
and coronary arteries of animals. When administered alone, nicotine 
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Smoking and atherosclerosis m the basilar arteries 
Smoking 
category Number Basilar artery raised lesions 
Non 3 1 
EX 8 6 
Light 18 3 
Heavy 17 7 
Holme et al. 
(29) 
129 autopsies 







Visual grading Correlation coefticlent between raised lesions in the cere- 
bra1 vessels and number of cigarettes smoked per day is 
0.090 (not statistically signifxantl. 
induces certain degenerative or necrotic changes in the arterial wall, 
but these are characteristically medial changes rather than the 
intimal changes that characterize atherosclerosis. When nicotine is 
administered in combination with a high cholesterol diet, it seems to 
aggravate arterial damage, according to a preponderance of studies. 
Some studies, however, do not report this synergism between 
cholesterol feeding and nicotine (16, 84). 
Schievelbein and associates (66) reported the effect of long-term 
nicotine exposure on the development of arteriosclerosis in rabbits. 
They administered nicotine to rabbits not being fed an atherogenic 
diet. All animals had arteriosclerotic lesions in the aorta and 
coronary arteries at the end of the experiment, but there was no 
difference between the control group and the experimental animals 
administered nicotine. They reviewed the experiments of several 
authors who studied nicotine and their own animal experiments and 
concluded that the evidence did not establish a causative role for 
nicotine in the etiology of arteriosclerosis. 
A recent report by Liu et al. (38) on experimental arterial lesions 
in rhesus monkeys with various combinations of dietary hypercho- 
lesterolemia, hypervitaminosis D(2), and nicotine indicated that the 
combination of these three factors produced high scores for various 
measures of arteriosclerotic changes in aorta, coronary, and limb 
arteries of the monkeys. When the factors were administered singly, 
however, very little arterial disease was demonstrated over the 
period of the experiment. The group with all three factors was the 
only group with significant coronary arteriosclerosis as well as 
complicated lesions of the arteries of extremities. 
Dooyse et al. (15) reported the effects of chronic oral consumption 
of nicotine on the rabbit aortic endothelium. They found that fasting 
serum levels of glucose, triglyceride, total cholesterol, and LDL 
cholesterol were elevated in nicotine-treated rabbits as compared 
with controls. They found no significant differences between the 
experimental group and the controls for leukocyte, erythrocyte, and 
platelet counts, or for hematocrit and hemoglobin. Endothelial cells 
from the aortic arch of the nicotine-treated animals showed exten- 
sive changes, such as increased cytoplasmic silver deposition, in- 
creased formation of microvilli, and numerous focal areas of 
“ruffled” endothelium. The authors concluded that nicotine adminis- 
tered orally to rabbits has a demonstrable morphologic effect on 
endothelial cells in the aortic arch. 
While the evidence for and against a primary role for nicotine in 
the development or acceleration of atherosclerosis is not conclusive, 
nicotine is certainly one of the components of tobacco smoke for 
which there are both some supporting data and a rational conceptu- 
alization for a role in the pathogenesis of atherosclerotic lesions. 
There is little doubt that nicotine alone or in combination with other 
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factors, such as hypercholesterolemia or excessive doses of vitamin 
D, can damage the arterial wall, and arterial injury is widely 
accepted as one mechanism for predisposing to or accelerating 
lesions in animal models of atherosclerosis. 
Carbon monoxide is another major component of cigarette smoke 
for which there are some data supporting a possible atherogenic role; 
however, a review of recent literature on the role of carbon monoxide 
in arterial injury and atherogenesis leads to no consensus. Early 
studies by Astrup and coworkers (3) on the effect of carbon monoxide 
in rabbits suggested the theory that carbon monoxide causes 
endothelial damage, which might promote atherogenesis. Later 
studies by Astrup’s group (2, 32) indicated that the duration of 
exposure of rabbits to carbon monoxide did not influence the intimal 
morphology of the coronary arteries or the aorta. They felt that 
these new data contradicted the theory of carbon-monoxide-mediated 
endothelial damage as a cause of atherosclerosis. 
Recent experimental studies have produced a variety of results 
regarding the effects of carbon monoxide on the development of 
arterial lesions. Malinow et al. (40) exposed cynomolgus monkeys, 
fed a standard laboratory diet or a semipurified high cholesterol diet, 
to carbon monoxide or to room air for 14 months. None of the 
animals developed a myocardial infarction, and there was no 
difference in plasma cholesterol levels or in aortic or coronary 
atherosclerosis attributable to carbon monoxide exposure. Davies et 
al. (17) studied the effect of intermittent carbon monoxide exposure 
on experimental atherosclerosis in the rabbit and found there was an 
increase in coronary artery atherosclerosis in the carbon-monoxide- 
exposed animals, but they did not find significant differences in the 
lipid content of the aortas. Armitage et al. (1) studied the effect of 
carbon monoxide on the development of atherosclerosis in the White 
Carneau pigeon and found that the severity of coronary atherosclero- 
sis was significantly greater in birds exposed to carbon monoxide 
than in nonexposed birds after 52 weeks of exposure, but not after 84 
weeks. The severity of atherosclerosis was related to the degree of 
hypercholesterolemia. They suggested that in the White Carneau 
pigeon, exposure to carbon monoxide elevates plasma cholesterol 
levels, and thereby increases the extent of experimentally induced 
atherosclerotic lesions. They further suggested that compensatory 
mechanisms may reduce the effect of carbon monoxide exposure on 
hypercholesterolemia over time. 
Two reviews in 1979 came to different conclusions concerning the 
relationship of carbon monoxide and arteriosclerosis. Astrup and 
Kjeldsen (2) surveyed the cardiovascular effects of exposure of 
animals to carbon monoxide and concluded that carbon monoxide 
produces myocardial effects that can lead to decreased myocardial 
oxygen tension with compensatory increases in coronary blood flow. 
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They stated that their previous findings of arterial intimal changes 
had not been confirmed. Turner (78) reviewed studies involving 
carbon monoxide, tobacco smoking, and the pathogenesis of athero- 
sclerosis, and concluded that carbon monoxide exposure enhances 
the extent of coronary atherosclerosis in pigeons that have been 
made hypercholesterolemic by adding dietary cholesterol. Carbon 
monoxide was without effect on normocholesterolemic birds. They 
indicated that the level of carbon monoxide exposure, the duration of 
exposure, and the level of dietary cholesterol are critically interde- 
pendent factors that can influence the pathogenesis of the disease. 
Studies by Sarma et al. (62) on the effect of carbon monoxide on 
lipid metabolism of human coronary arteries provide some support 
for the idea that carbon monoxide increases endothelial permeabili- 
ty. They perfused human coronary arteries under sterile conditions 
in vitro with blood containing high and low concentrations of carbon 
monoxide. They found no effect of carbon monoxide on lipid 
synthesis in the arterial wall; however, the arteries that were 
exposed to carbon monoxide showed a higher uptake of cholesterol 
from the perfusate as compared with their corresponding controls. 
Thus, the results of Sarma et al. (62) were in agreement with those of 
other investigators who have found that carbon monoxide signifi- 
cantly increases the permeability of endothelial membranes. 
Schneiderman and Goldstick (67) used a computer simulation of 
the oxygen transport system of the arterial wall to evaluate the 
extent of carbon-monoxide-induced hypoxia of the arterial wall 
under various conditions; the results suggested that the moderate to 
high carboxyhemoglobin levels found in some smokers may result in 
a significant reduction in the oxygen tension of the arterial wall. 
Hugod (31) reported no morphological change in the coronary 
arteries and aortas of rabbits exposed to low doses of hydrogen 
cyanide, alone or in combination with 200 ppm carbon monoxide, 
and nitric oxide for 2 weeks. 
McMillan (46) reviewed the many substances that may enter the 
body from tobacco smoke and that have been conjectured as having a 
role in cardiovascular disease. He concentrated on those substances 
other than carbon monoxide and nicotine, such as cadmium, zinc, 
chromium, carbon disulfide, carbon dioxide, tobacco antigens, hydro- 
gen cyanide, nitric oxide, and polonium-210. He concluded that these 
substances provide interesting ground for speculation as to their 
possible role in cardiovascular disease, but that only carbon monox- 
ide and nicotine offer both data and a rational conceptualization for 
a role in cardiovascular disease. 
Studies of Whole Tobacco Smoke 
McGill (42) reviewed potential mechanisms for the augmentation 
of atherosclerosis and atherosclerotic disease by cigarette smoking. 
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On the basis of his review of the evidence concerning smoking and 
serum lipid and lipoprotein concentrations, he suggested that 
cigarette smoking often causes a slight to moderate elevation of total 
serum cholesterol concentration, and that smoking may depress 
HDL concentrations and elevate LDL concentrations. These changes 
might have the effect of increasing atherosclerosis because increased 
levels of LDL and decreased levels of HDL have been shown to be 
related to increased amounts of atherosclerosis as well as to an 
increased risk of coronary heart disease. 
Hojnacki et al. (28) studied the effect of acute inhalation of 
cigarette smoke and consumption of dietary cholesterol on plasma 
lipoprotein composition in atherosclerosis-susceptible White Car- 
neau pigeons. They concluded that cigarette smoking can mediate 
alterations in lipoprotein composition independent of changes in- 
duced by dietary cholesterol and saturated fat. 
Sieffert et al. (69) demonstrated endothelial damage and focal 
platelet aggregation after exposing Sprague-Dawley rats to tobacco 
smoke for l&minute periods three times a day for 6 and 12 weeks. 
Scanning electron microscopic examination of perfusion-fixed the 
racic aortas disclosed elongation of endothelial cells, uplifting of 
endothelial cells from the basement membrane, areas of endothelial 
loss, pitting, crater formation, and white blood cell invasion of the 
underlying intima. They also found platelet aggregation on damaged 
intima. They did not indicate which one of the constituents of 
tobacco smoke they suspected as being the cause of these changes. 
Rogers et al. (58) recently completed an investigation of cigarette 
smoking, diet-induced hyperlipidemia, and experimental atheroscle- 
rosis in baboons. The design of the study and interim results are 
contained in a report by Rogers et al. (57). The baboons in this 
controlled experiment consumed a diet enriched in cholesterol and 
saturated fat for 3.3 years and puffed on lighted cigarettes or shams 
for 2.8 years. The study was designed to determine whether cigarette 
smoking interacts with diet-induced hyperlipidemia to accelerate the 
development of atherosclerosis. This hypothesis was based on a 
report by Keys (35), who found that populations with high total 
serum cholesterol concentrations and a high incidence of atheroscle- 
rotic disease have a dose-related relationship between cigarette 
smoking and the incidence of atherosclerotic disease. However, in 
populations with low total serum cholesterol levels and a low 
incidence of atherosclerotic disease, cigarette smoking is not associ- 
ated with the incidence of atherosclerotic disease. Thus, cigarette 
smoking might augment atherosclerosis cnly when it interacts with 
an atherogenic diet. The investigation by Rogers et al. (57, 581, used 
nonhuman primates-baboons-as experimental animals, and the 
animals were trained by operant conditiuning techniques to smoke 
cigarettes in a human-like manner. The diet induced a moderate 
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hypercholesterolemia, which attained a peak of 235 mg/dl 5 months 
after initiation and declined thereafter to 160 mg/dl at termination. 
The early report of Rogers et al. (57) disclosed no significant 
differences in serum lipids or lipoproteins between smokers and 
shams after 1.6 years of smoking; however, there were some 
differences that would be expected to accompany the augmentation 
of atherosclerosis, namely higher LDL/HDL ratios in smokers than 
in shams. At the completion of the experiment, these trends of 
differences in lipoprotein concentrations were not present, and the 
mean serum total cholesterol, serum triglyceride, LDL cholesterol, 
and HDL cholesterol concentrations of smokers and shams were not 
significantly different. The LDL/HDL cholesterol ratios of smokers 
and shams were almost identical. Their observations on LDL/HDL 
cholesterol ratios in the midcourse of the experiment and again at 
the end suggested that cigarette smoking either increases the 
LDL/HDL cholesterol ratio only during hypercholesterolemia or 
increases the LDL/HDL ratio only in some animals. 
At autopsy of these baboons, the mean extent of fatty streaks was 
not significantly different for smokers versus shams in the aorta, 
femoral, iliac, and innominate arteries. The mean extent of fatty 
streaks in smokers was significantly greater than in shams for the 
carotid arteries. The variability in extent of lesions was greater in 
smokers than in shams, suggesting the possibility that a subset of 
smokers may have responded positively to smoking by developing 
increased lesions. This difference in variability of lesions was 
statistically significant for the thoracic aorta, carotid, and innomi- 
nate arteries. The authors suggest that the “compensatory” decline 
in mean serum cholesterol concentration that occurred in the latter 
part of the experiment could have led to regression of experimental- 
ly induced lesions. 
The authors indicate that their results do not support the 
hypothesis that cigarette smoking, at a level approximately equiva- 
lent to that of the average human cigarette smoker, augments 
experimental atherosclerosis in the presence of a moderate level of 
diet-induced hypercholesterolemia. They did, however, find a signifi- 
cantly greater extent of fatty streaks in the carotid arteries for the 
smokers and significantly more variability in the extent of lesions in 
the smokers. Also, among the small number of animals that died 
during the course of the experiment, the smoking animals had more 
extensive involvement with lesions than did the shams. Neverthe- 
less, there were no dramatic, clear-cut, across-the-board differences 
between the smoking and nonsmoking animals. The authors con- 
clude that this experiment cannot be regarded as a conclusive test of 
the hypothesis that cigarette smoking can augment the formation of 
fatty streaks associated with dietary-induced hyperlipidemia. 
54 
McGill’s review (42) indicated that smokers have slightly increased 
erythrocyte counts, hematocrit, and hemoglobin concentrations, but 
he doubted that the slight changes observed would increase the risk 
of atherosclerosis. In the experiments with baboons, smokers also 
had elevated leukocyte counts owing to both increased polymorpho- 
nuclear leukocytes and increased lymphocytes. These changes might 
be one manifestation of an altered immune system that might 
deserve attention as a possible mechanism for accelerating athero- 
genesis. The smoking baboons had slightly elevated blood glucose 
levels; it is not known if this change would contribute to atheroscle- 
rosis. Body weight and blood pressure are slightly lower in smokers 
than in nonsmokers, and this response to smoking is in the opposite 
direction with regard to risk of atherosclerotic disease. 
Smoking and the Hemostatic System 
McGill indicated that the limited number of recent studies of the 
effects of smoking on the hemostatic system show little or no effect 
on clotting action, but marked effects on platelets. Platelet counts 
are not different in smokers and nonsmokers, but smokers have a 
decrease in survival time and an increase in platelet turnover (50), 
increased adhesiveness (49), and increased tendency for aggregation 
(24,27,36). 
Ogston et al. (52) found that chronic smoking led to an increased 
plasma fibrinogen concentration, but acute smoking did not. Janzon 
and Nilsson (33) found that chronic smoking was associated with 
increased librinolytic activity of the blood. 
Davis and Davis (18) studied the effect of cigarette smoking on 
circulating platelet aggregates as detected by the platelet-aggregate 
ratio in volunteer subjects. The platelet-aggregate ratios were lower 
in the smokers, indicating increased circulating platelet aggregates. 
The authors indicated that the decrease in platelet-aggregate ratio 
was not mediated through the elevation of plasma nonesterified 
fatty acid concentration. 
Fuster et al. (21) found a shortened platelet survival half-life in 
apparently normal persons who smoked and in persons with a strong 
family history of coronary disease. Their study suggested a possible 
relationship among cigarette smoking, strong family history of 
coronary disease, and platelet activation in the process of coronary 
atherogenesis in the young adult. 
Smoking and the Immune System 
McGill (42) suggested that the leukocytosis observed in smokers 
may represent in part a manifestation of an immune disorder. 
Immune complex disease markedly aggravates atherogenesis in 
rabbits (48) and in baboons (30). Becker and Dubin (10) and Becker et 
al. (II) have identified a low molecular weight glycoprotein in 
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tobacco smoke that is highly antigenic in man. McGill (42) suggests 
that differences in sensitivity to antigenic materials could account 
for the great variation in response to cigarette smoking. He also 
suggests endothelial injury and increased endothelial permeability 
as a mechanism for cigarette smoking effects on cardiovascular 
disease. Becker (9), in summarizing a workshop on immunologic 
injury and the thrombotic process in atherogenesis, postulated that 
the capacity of tobacco glycoprotein to activate the intrinsic pathway 
of coagulation might contribute to the growth of arteriosclerotic 
plaques and to more lethal complications by initiating thrombus 
formation. Denburg et al. (19) studied the reactivity of 164 patients 
with peripheral vascular disease to purified tobacco glycoprotein; 
they suggested that reactivity to tobacco glycoprotein may he 
causally related to the development of atherosclerotic vascular 
disease. 
Conclusions 
1. A preponderance of evidence both from prospective studies with 
autopsy followup and from autopsy studies with retrospective 
smoking data indicates that cigarette smoking has a significant 
positive association with atherosclerosis. This evidence suggests 
that cigarette smoking has the effect of aggravating and 
accelerating the development of atherosclerotic lesions in the 
artery wall and that its effect is not limited to those events 
related to the occlusive episode. The effects are most striking for 
aortic atherosclerosis; a significant positive relationship also 
exists between cigarette smoking and atherosclerotic lesions in 
the coronary arteries, at least for most high risk populations. 
Cigarette smoking could also be associated with other factors 
that precipitate thrombosis, hemorrhage, or vasoconstriction 
leading to occlusion and &hernia. 
2. Some evidence exists that cigarette smoke alters total serum 
cholesterol concentrations and lipoprotein composition in ways 
that would be expected to increase the development of athero- 
sclerosis. Recent studies of the effects of smoking on the 
hemostatic system indicate effects of smoking on platelet 
function. 
3. Although the specific mechanisms by which tobacco smoke 
affects arteriosclerosis have not been clearly delineated, the 
effects of cigarette smoking on the atherosclerotic lesions that 
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Higher rates of disease and earlier mortality in cigarette smokers 
than in nonsmokers have been documented in a large number of 
investigations. Of the several disease manifestations that account for 
the excess disability and death in cigarette smokers, coronary heart 
disease (CHD) is the leading cause in North America and northern 
Europe (18, 40,43,45, 67, 94,96, 134, 143, 189,214,224,257). CHD is 
related to several risk factors, including cigarette smoking. Esti- 
mates indicate that up to 30 percent of all CHD deaths in the United 
States are attributable to the cigarette smoking habit (189). 
Three of the major prospective studies have reported estimates of 
cigarette-related CHD mortality based on the number of observed 
versus expected CHD deaths in smokers and nonsmokers. In the ACS 
25State study, involving more than 1 million men and women, 
Garfinkel(73) estimated that of the 12,724 CHD deaths that occurred 
among all males followed prospectively for 6 years, 5,358 (46 percent) 
would not have occurred if all male cigarette smokers had the same 
CHD death rates as did nonsmoking males. Among females, a similar 
percentage of excess deaths (40 percent) attributed to smoking was 
noted; however the total number of CHD deaths was not large. Rogot 
and Murray (224) followed 290,000 U.S. veterans over a period of 16 
years. During this time 13,845 CHD deaths were observed among 
cigarette smokers, whereas only 8,787 were expected. This repre- 
sents an approximately 40 percent greater observed-toexpected 
ratio. In the British physicians study, in which 34,000 male British 
physicians were followed for 22 years, it was reported that cardiovas- 
cular disease accounted for 52 percent of all excess deaths in 
smokers, including 31 percent arising from CHD. By contrast, lung 
cancer was responsible for 19 percent of the cigarette-related excess 
deaths (232). 
Whyte (277), using the “attributable fraction” method as advocat- 
ed by Miettinan (179), reanalyzed data from the Pooling Project 
study and estimated that 24 percent of first major coronary events 
were cigarette related and independent of other risk factors. When 
all three major risk factors were considered together, the proportion 
of attributable risk increased to 70 percent. 
Both Lute and Schweitzer (163, 164) and Boden (21) attributed 25 
percent of all circulatory diseases to smoking. Both used data derived 
from estimates provided by the NIH Task Force Report on Preven- 
tive Medicine (63). These estimates are in close agreement with that 
published by Richter and Gori (219) that attributed 30 percent of 
heart disease to smoking; they also estimated that 33 percent of all 
arteriosclerosis was cigarette related. The latter estimate is identical 
to those published by the National Cancer Institute and the National 
Heart, Lung, and Blood Institute in the final report on the program 
to reduce the risk of disease in smokers (189). 
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In young people-including young women who are otherwise at 
very low risk for CHD-as many as threequarters of the cases may 
be attributable to the cigarette smoking habit (244, 257). During the 
period 1965-1977, there were an estimated 2.8 million premature 
deaths from heart disease, primarily CHD, in American men and 
women attributable to the use of tobacco. Furthermore, unless 
smoking habits of Americans change, over 10 percent of all those 
now alive may die prematurely of heart disease that will be 
attributable to the use of tobacco. The number of such deaths may 
exceed 24 million (189). 
Annually during recent years, more than one and a quarter 
million Americans have suffered fatal or nonfatal heart attacks (2, 
101, 198). The deaths from CHD have numbered over 500,000 and 
have exceeded the deaths from any other cause; half or more of these 
deaths are sudden (139). In addition to these acute manifestations of 
CHD, more than 5 million Americans are under treatment for 
chronic manifestations of CHD (2, 198). Millions of others have 
significant CHD that is undiagnosed. Of those currently undiag- 
nosed, approximately one-quarter will manifest sudden, unantici- 
pated death as the first clinical indication of CHD (110, 137, 153). 
Scientific Investigation of the Relationship Between Coronary 
Heart Disease and Smoking: Objectives of the Present Review 
The scientific basis for the judgment that cigarette smoking is a 
major contributor to CHD in Americans has been presented in the 
Reports of the Surgeon General beginning in 1971 (264l and 
emphasized recently in the Reports of 1979 (263) and 1980 (261). A 
large number of epidemiologic, clinical, and experimental studies 
using a variety of methods and research designs have accumulated 
overwhelming evidence of the strong relationship between cigarette 
smoking and CHD. The possibilities of sample selection bias or 
confounding of this association by other factors as explanation for 
this association have been examined exhaustively and do not explain 
the relationship between cigarette smoking and CHD. 
In this section, emphasis is placed on critical examination of the 
relationship between cigarette smoking and CHD incidence and 
mortality. The independence of cigarette smoking as a predictor of 
CHD is considered in the context of those other risk factors that also 
predict the occurrence of CHD. This includes evaluation of the 
consistency of the relationships between risk factors and subsequent 
CHD, including those mathematical models for prediction of CHD 
that have been applied widely among diverse population groups. The 
examination takes into account sample size, effects of multiple risk 
factors acting simultaneously, and secular trends in risk factor 
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prevalence. Areas of opportunity for expansion of knowledge are 
discussed. 
Mortality studies are summarized with respect to the relationship 
of smoking and CHD. The large prospective mortality studies provide 
evidence of the influence of cigarette smoking in large and varied 
populations, and they provide sufficient numbers of cases for 
detailed analyses of the influence of smoking intensity and duration, 
age, sex, race, and smoking cessation on CHD. 
Coronary Heart Disease Manifestations 
The major clinical manifestations of CHD are myocardial infarc- 
tion (MI), which may be fatal or nonfatal; other death from CHD, 
which may be sudden or not; and angina pectoris, which is the first 
clinical manifestation in about one-third of new cases (40). 
In most cases, obstruction to blood flow in the coronary arteries is 
caused by arteriosclerotic narrowing (34, 39). Some cases are 
associated with coronary artery spasm with or occasionally without 
atherosclerotic change in the coronary arteries (39, 87, 174, 202). 
When there is thrombosis superimposed on the coronary narrowing, 
myocardial infarction typically results (34). The aggregation of 
platelets and formation of fibrin thrombi are related tc the acute 
clinical manifestations of coronary heart disease, and may also play 
a role in the development of coronary atherosclerosis (187, 230). 
Several autopsy studies in the United States and elsewhere have 
shown that atherosclerosis of the coronary arteries is more common 
in cigarette smokers than in nonsmokers (3, 7, 8, 9, 220, 245, 247). 
This topic is discussed elsewhere in this Report. 
Clinical Manifestations and Epidemiologic Criteria for Coronary 
Heart Disease Events 
Myocardial Infarction 
Myocardial infarction (MI) denotes necrosis of a discrete volume of 
heart muscle resulting from prolonged, severe ischemia following 
interruption of coronary blood flow. The characteristic symptom is 
unremitting chest pain that may be associated with sweating, 
nausea, shortness of breath, dizziness, or loss of consciousness. The 
role of coronary thrombosis in the evolution of acute myocardial 
infarction (AMI) has been debated in the past; recently, coronary 
angiography has been performed in large numbers of patients with 
AMI. In the majority, coronary thrombosis has been found to be 
superimposed upon preexisting arteriosclerotic narrowing. In a 
small proportion of cases, but more commonly in young men and 
women, MI has been observed in patients with little or no coronary 
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atherosclerosis who have had coronary artery spasm or coronary 
thrombosis or both (I). 
Loss of consciousness in acute myocardial infarction is an ominous 
sign because it often reflects inadequate pumping action of the heart 
owing either to catastrophically abnormal cardiac rhythm or to 
severe deterioration of cardiac muscle function. A broad range of 
cardiac rhythm disturbances may occur, but the most characteristic 
catastrophic one accompanying myocardial infarction is a chaotic 
irregularity of muscle fiber contraction (ventricular fibrillation) that 
results in a cessation of effective pumping by the heart. In such 
instances, death occurs within several minutes after cessation of 
blood flow to the brain if the rhythm disturbance is not reversed. 
In patients who survive long enough to be admitted to the hospital, 
the diagnosis of AM1 may be made from changes in the electrocardio- 
gram and increases in serum enzymes (I). In comprehensive clinical 
epidemiologic studies, the criteria for identifying cases of MI include 
specific presenting symptoms, electrocardiographic changes, and 
serum enzyme elevations (40,214). 
Death from CHD 
In fatal cases, evidence of CHD may be provided by clinical or 
autopsy information (40, 214). In the absence of adequate clinical or 
autopsy evidence, diagnosis of death from CHD is based on documen- 
tation of a sufficiently short interval from onset of symptoms until 
death and the absence of another potentially lethal condition (153). 
Sudden Cardiac Death 
A large proportion of deaths certified as due to CHD have been 
sudden, and a significant fraction of these sudden cardiac deaths 
@CD) have occurred in persons with no prior history of CHD (68, 109, 
139, 152, 154, 220). The incidence of SCD increases with age, and it is 
substantially more frequent in men than in women; in women the 
incidence of SCD lags behind that of men by 20 years (139). 
Epidemiologic investigations have shown that the majority of 
deaths in ambulatory adults that are sudden and unanticipated are 
associated with severe CHD. In the Baltimore study by Kuller et al. 
(1531, 71 percent of the deaths (excluding trauma) that occurred 
within 24 hours of the onset of terminal illness in individuals who 
had been able to function in the community were from CHD. In those 
with other causes, more than half were associated with fatty liver. 
Alcohol consumption appears to have a complex relationship to 
CHD, and heavy alcohol consumption has been identified as a factor 
in sudden death in several studies. This relationship has been shown 
to be independent of the relationship with cigarette smoking (38, 64, 
148, 158, 173, 188, 209, 216). Although some difficulty may arise in 
appropriate designation of unwitnessed deaths, the less frequent and 
rare conditions are usually differentiated easily from SCD. 
Criteria for SCD have varied in different studies. Among ambula- 
tory adults considered to be well who die suddenly, the probability of 
severe CHD has been shown to be very high both by autopsy data 
and by clinical data (40, 109, 139, 157, 200, 248). In large population 
studies, however, information for some cases is often not available to 
determine the exact interval from onset of symptoms until death; 
therefore, criteria for sudden death have often included intervals up 
to 24 hours (153, 156, 200). In a high proportion of such cases, severe 
CHD has been observed by autopsy examination (10, 12, 50, 68, 109, 
153, 160, 200, 208). 
The physiologic disorders responsible for sudden collapse and 
cardiac arrest in ambulatory adults have been well documented. In 
the overwhelming fraction, ventricular fibrillation is the terminal 
ventricular rhythm disorder; however, profound cardiac bradycardia 
or cardiac standstill can be the mechanism as well. Ventricular 
fibrillation may further degenerate into cardiac standstill (33, 47,55, 
56, 145, 202). Among patients resuscitated following cardiac arrest, 
AM1 has been documented during the subsequent hospital course in 
one-quarter toone-half of the cases; in the others, severe, multivessel 
coronary atherosclerosis, with or without old MI, has been observed 
by coronary angiography in three-quarters or more (33, 56,273). 
Ascertainment of CHD From Death Certificates 
In large-scale mortality studies the underlying cause of death on 
death certificates has usually been used to identify the deaths from 
coronary heart disease. [In recent editions of the International 
Classification of Diseases, the term ischemic heart disease is 
preferred over the older term coronary heart disease. Some authors 
prefer the term arteriosclerotic heart disease. For uniformity, 
coronary heart disease (CHD) is used throughout this section 
regardless of the usage in the publications reviewed.] The accuracy of 
death certificate data has been evaluated through review of avail- 
able clinical data and retrospective analyses and from available 
pathological data. Coronary heart disease has been confirmed as 
probable or likely in the vast majority of cases (183, 184, 236, 284). 
In a random sample of 1,362 U.S. death certificates in 1960, 
pertinent clinical and pathological information to determine the 
cause of death was investigated by Moriyama et al. (182). In the 87 
percent of cases for which responses from medical certifiers were 
obtained, only 7 percent of those certified to be CHD were judged to 
be incorrect or probably incorrect. The information for diagnosis of 
CHD was judged to be reasonable or well established in 74 percent 
and inadequate to determine the cause of death in 19 percent. 
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In recent years, cardiac evaluation has become more prevalent 
with widespread use of objective diagnostic tests. This should result 
in even greater accuracy of CHD case ascertainment from death 
certificates. 
Angina Pfxtoria 
Angina pectoris is the first clinical manifestation in about one- 
third of the new cases of CHD (1331. In the typical form, observed in 
about 90 percent of clinically diagnosed patients, chest pain or 
tightness occurs with exertion or excitement and is relieved prompt- 
ly by rest or nitroglycerin. Such patients usually have fixed 
obstruction to blood flow due to arteriosclerosis in one or more of the 
coronary arteries (34, 174,237). Patients with typical angina pectoris 
are at increased risk for the more serious manifestations of CHD, 
myocardial infarction, and death from CHD (34, 133, 174, 175, 241). 
In the atypical form, chest discomfort usually occurs at rest, 
although it may also occur with exertion, and it is usually relieved 
by nitroglycerin (87, 174, 175,237,241). This atypical or variant form 
of angina pectoris has been shown to result from coronary artery 
spasm that occurs at the site of atherosclerosis in many cases, but in 
otherwise normal-appearing coronary arteries in others (87, 175, 
202). Sudden death is a rather common complication of variant 
angina (39, 110, 175,202, 241). 
Conditions other than CHD may cause symptoms that mimic 
angina pectoris, and definitive diagnosis may require clinical obser- 
vation over time and the performance of ancillary diagnostic 
procedures (34, 40). However, in large-scale epidemiologic studies, 
complete diagnostic evaluation is usually not feasible, and the 
proportion of cases with underlying severe coronary atherosclerosis 
has probably varied among the different studies (40, 121, 273). 
In addition to those in the population who have symptoms of CHD, 
there are many with significant coronary atherosclerotic obstruction 
who are undiagnosed. The frequency of clinically silent but physic 
logically significant coronary artery disease is unknown; it is 
estimated that in one-quarter of the cases with a new myocardial 
infarction, the infarction is silent and detected only on followup by 
electrocardiographic (ECG) examination (I 72). 
In prospective epidemiologic studies with clinical followup, cases 
may be classified only by the most severe CHD manifestation, in this 
order: death from CHD, nonfatal myocardial infarction, and angina 
pectoris. Thus, the cases classified as angina pectcris are those 
remaining who have not experienced a more serious CHD event, and 
as noted above, this diagnosis may lack sensitivity and specificity for 
coronary atherosclerotic disease. Variation in the strength of 
association between smoking and angina pectoris may be influenced 
by these methodological considerations (48,49, 121, 135,229). 
70 
A number of well-documented, clinical series of patients with 
angina pectoris and severe CHD confirmed by coronary angiography, 
surgery, or post-mortem examination have been reported (4, II, 32, 
42, 97, 98, 118, 171, 201, 253, 268, 272). These studies provide 
important information for clinical management and add insights 
into relationships with risk factors. However, causal inferences must 
be made with caution when measurements of risk factors have been 
made after the onset of clinical disease and data from appropriate 
comparison groups are not available. 
Epidemic CHD and the Application of Epidemiologic 
Methodology 
CHD was thought to be uncommon in the early part of this century 
when most deaths were caused by infectious disease. Before the mid- 
century, however, CHD had become the leading cause of death, and 
year to year increases were large (101, 159). Neither the cause of 
CHD nor the reasons for the rising epidemic could be explained. 
Nevertheless, pioneering efforts in cardiovascular epidemiology 
revealed that certain characteristics were observed more often in 
CHD cases, and epidemiologic investigations were begun to obtain 
data with which to make causal inferences (4486, 143). 
Prospective Cohort Studies: Intensive Population Studies of 
Risk Factors and CHD 
In several early investigations, cigarette smoking and several 
other characteristics were observed to be strongly associated with 
CHD (60, 136, 276). To clarify the nature of these relationships, 
defined population samples were examined for personal characteris- 
tics that could be related to CHD. Intensive observation for 
subsequent incidence of CHD through reexamination and surveil- 
lance activities in members of population samples that were free of 
disease at the baseline examination provided a substantial part of 
the data from which causal inferences relating to smoking and CHD 
were made. A number of these are briefly described in the following 
pages. In each study, smokers were found more likely to develop 
CHD than nonsmokers. 
studies in U.S. whites 
Within the U.S. population, CHD mortality has been highest in 
white men, and they were investigated most intensively in the early 
prospective studies. To provide a sufficiently large number of cases 
for detailed analyses of the relationship of CHD to cigarette smoking 
and other risk factors, several of the long-term epidemiologic studies 
agreed to pool their data in the National Cooperative Pooling Project 
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sponsored by the Council on Epidemiology of the American Heart 
Association and supported by the American Heart Association and 
the National Heart Institute, now designated the National Heart, 
Lung, and Blood Institute (168, 214). Five of the studies participating 
in this effort had used comparable methodology in data collection so 
that the data from each of these five cohorts could be pooled for 
analysis. In Table 1, analyses for the pooled data are referred to as 
“Pool 5.” The five cohort studies contributing to the pooled data will 
be characterized briefly individually, and then analysis of the pooled 
data will be summarized. 
Fmmingham Heart Disease Epidemiology Study 
The Framingham study was initiated by the Public Health Service 
in 1948. The members of the prospective cohort were 2,282 men and 
2,845 women who were aged 29 through 62 and free of CHD at initial 
examination (40, 86, 133). The cohort was based on a random 
subsample of the residents of Framingham, Massachusetts; the 
response rate was 69 percent. The respondents were supplemented 
by volunteers who had similar characteristics. A standardized 
cardiovascular examination at entry included information on habits, 
physical characteristics, and blood chemistries. Reexamination has 
been carried out biennially for ascertainment of cardiovascular 
disease and changes in characteristics. Cardiovascular disease case 
ascertainment has included community and mortality surveillance 
activities (86, 136). Analyses through 24 years of followup have 
shown that cigarette smoking is strongly related to MI and death 
from CHD (40, 133, 135). In Table 1, Framingham data analysis is 
shown with that of the other cohorts participating in the National 
Cooperative Pooling Project. The excess risk of MI and death from 
CHD was found to increase progressively with the number of 
cigarettes smoked (Table 1). 
The relationship to angina pectoris has been less clear. In the 12- 
year and the 24-year followup data analyses, however, male cigarette 
smokers were observed to experience a higher incidence of angina 
pectoris than were nonsmokers (40, 135). The effect was stronger at 
younger ages; after 24 years of followup, the incidence of angina 
pectoris in those 30 to 39 years old at entry to the study was twice as 
high in smokers as in nonsmokers (Figure 1). 
Albany Cardiovascular Health Center Study 
In 1952 the New York State Health Department established at the 
Albany Medical College a prospective study of male civil servants 
working in Albany. Participation was obtained from 87 percent of 
eligible men aged 40 through 54, of whom 1,823 were free of CHD at 
initial examination. After 6 years, the incidence of MI and death 
from CHD was significantly higher in cigarette smokers in compari- 
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TABLE l.-National Cooperative Pooling Project. Analysis 
of the incidence of CHD by smoking behavior 
in five participating cohorts individually and in 
the data pooled for the five cohorts with 
comparable methodology (Pool 5). Standardized 
incidence ratio, risk ratios, number of men, 
person-years of experience, and number of first 
events 
smoking behavior Pool 5 
Standardized incidence ratio by study group 
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SOURCE: Pooling Project Raearch Group (214. 
son with nonsmokers (48). Subsequent analysis after 10 years of 
followup confirmed these findings (Table 1). 
Chicago Peoples Gcs Company Study 
Beginning in 1958, the Chicago Peoples Gas Company medical 
department examined 1,264 white men aged 40 to 59 (92 percent of 
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FIGURE l.-Twenty-four-year incidence of angina pectoris 
in men, by cigarette smoking status 
NOTE: Tbe crude rata have been mrrected to take into account those members of the population who are no 
longer at risk by reasan of having developed the disorder in question or having been lost to observation by death. 
SOURCE: Dawber (40). 
those eligible) who were free of CHD (161, 214). Analysis of the data 
obtained during an average of 8.8 years of followup revealed a higher 
incidence of MI and death from CHD in cigarette smokers than in 
nonsmokers (Table 1). 
Chicago Western Electric Company Study 
Beginning in 1957,67 percent of male Western Electric Company, 
Chicago, employees aged 40 to 55 were examined; 1,98l‘ were free of 
CHD (161, 206, 214). After an average followup of 8.3 years, the 
incidence of MI and death from CHD was higher in cigarette 
smokers than in nonsmokers (Table 1). 
Tecumseh Health Study 
The Tecumseh health study began examination of the entire 
community of Tecumseh, Michigan, in 1959; participation was 
obtained from 90 percent (61, 214). Included was a cohort of 1,240 
white men aged 40 to 59 who were free of CHD at initial 
examination. During an average followup of 8.05 years, the incidence 
of MI and death from CHD was higher in cigarette smokers than in 
nonsmokers (Table 1). 
Minnesota Business and Professional Men Study 
Selected Minnesota business and professional men were first 
examined in 1948; 284 men aged 40 to 59 years were free of CHD 
(144, 214). During an average followup of 14.1 years, those who 
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smoked cigarettes experienced a higher incidence of MI and death 
from CHD than did nonsmokers. 
Minnesota-Based Railroad Worker Study 
Among eligible railroad men working in the northwest sector of 
the United States, 65 percent participated in the Minnesota-based 
railroad worker study examinations beginning in 1958 (143, 214). Of 
these men, who were white, aged 40 to 59 years, and free of CHD at 
first examination, 2,571 were followed for an average of 4.9 years. 
Those who smoked cigarettes experienced a higher incidence of MI 
and death from CHD than did nonsmokers. 
National Coopemtive Pooling Project 
As indicated above, the data from five of the cohorts participating 
in the National Cooperative Pooling Project were pooled for those 
white men who were aged 40 to 59 years, were free of CHD at initial 
exam, had comparable baseline examinations, and were followed for 
up to 10 years with comparable case ascertainment (Table 1). The 
demographic and other characteristics of these cohorts were similar 
to the characteristics of middle-aged white men in general living in 
the United States during the same period (190-196). 
Subjects contributing to the pooled data numbered 8,422; during 
an average followup of 8.5 years (72,011 person-years), 688 cases of 
major CHD were observed (214). Major CHD was defined as nonfatal 
or fatal MI or sudden death from CHD (death in less than 3 hours 
from the onset of illness). 
Risk of CHD With Smoking 
According to the pooled data for men aged 40 to 59, those who 
smoked a pack or more of cigarettes per day at initial examination 
experienced a risk for a first major coronary event that was 2.5 times 
as great as the risk of nonsmokers (Table 1). In these analyses, 
nonsmokers included those who never smoked, cigar and pipe only 
smokers, past smokers, and those who smoked less than half a pack 
per day. Those smoking less than half a pack per day consisted 
largely of those who smoked occasionally or only two or three 
cigarettes per day. For each of the five cohorts separately, the 
relative risks varied from 2.2 to 3.3. 
The risk was greatest in those with the heaviest smoking habits in 
all age groups (Table 2), and excess incidence attributable to smoking 
more than one pack of cigarettes per day tended to increase with 
increasing age up to age 60; however, with increasing age, relative 
risk declined. This apparent paradox is due to the rapid rise of CHD 
incidence with age. The excess incidence in heavy smokers (more 
than one pack per day) was large and statistically significant for 
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TABLE 2.-National Cooperative Pooling Project. Analysis 
of the risk of CHD by smoking behavior from 
the pooled data of the five cohorts* observed 
with comparable methodology (Pool 5). Average 
annual risk of first major coronary event, 
standardized incidence ratio (SIR), risk ratio >l 
pack per day/nonsmokers, and number of first 
events, by age group 
smoking pattern 
Age @-UP 
4cM4 45-49 iti& 5.5-59 60-64 40-64 
Average annual risk (per 1,000 man-years) 
All 3.1 6.4 8.0 22.6 19.9 
Nonsmoker (1.5) 3.0 3.6 7.3 15.5 
Never smoked (1.9) (0.7) (2.5) 8.7 11.4 
Past smoker (0.9) 5.5 4.3 6.1 15.5 
<l/2 pack/day (1.7) (4.7) (5.9) (6.4) (7.5) 
Cigar and pipe only (2.1) (2.21 (2.1) 12.1 19.5 
Cigarette amokera 
About l/2 pack/day (3.1) (5.0) (6.2) 15.5 24.3 
About 1 pack/day 3.9 8.4 10.3 13.8 22.0 
>l pack/day 4.9 12.2 17.4 22.5 26.8 
Riik ratio 
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’ Approximate 95% confidence interval: 2.642. 
NOTE: ( ): bad on fewer than 10 first events. 
SOURCE: Pooling Project Research Group (2I4. 
each !5-year age group between 45 and 64, and the differences were 
progressively greater with age up to 60. For those smoking about one 
pack per day and about one-half pack per day, the excess risks were 
sizable, but of a lower magnitude. Because of the relatively smaller 
numbers, the data were not sufficient for evaluation of differences in 
risks among those who had never smoked, those who had smoked 
less than one-half pack per day, and former smokers. 
In the Pooling Project data, the risk for cigar and pipe smokers 
was not significantly different from either the nonsmoker group or 
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the half-pack per day smokers, but it was significantly lower than 
that for men who smoked a pack of cigarettes per day (Table 2). 
However, the position of cigar and pipe smokers on the continuum of 
risk could not be adequately evaluated from these data because of 
small numbers. 
In summary, detailed prospective studies of the incidence of CHD 
in white males in the U.S. population have demonstrated a clear, 
strong, dose-related relationship between cigarette smoking and 
acute myocardial infarction and death from CHD. This cigarette 
smoking effect was proportionally greater in younger populations, 
but was present in all age groups examined in these studies. 
Cigarette smokers in the Framingham study had a high incidence of 
angina pectoris among the younger age groups, but this relationship 
was not as strong as the relationship between smoking and myocar- 
dial infarction. Pipe and cigar smokers had a risk that was not 
statistically different from the risk of nonsmokers. 
Ethnic Groups in the United States With Lower Risk of 
CHD - 
CHD mortality in blacks is lower than in whites in the United 
States (75, 76, 197, 225, 236, 259). A case-control study of the 
incidence of CHD during World War II in young Army men observed 
a risk ratio of 0.61 in black men relative to white men (120). Reasons 
for lower rates in black men are not adequately understood, 
although the smoking habits of blacks have been found to differ from 
those of whites. Blacks have tended to smoke cigarettes with higher 
tar and nicotine content, but they have also tended to smoke fewer 
cigarettes (262). Hypertension is also more prevalent in blacks than 
in whites (142). On the other hand, plasma lipid levels were reported 
to be more favorable; high density lipoprotein cholesterol levels 
(HDLC) were higher and low density lipoprotein cholesterol levels 
(LDL-C) were lower in black men than in white men aged 20 to 49 
(259). HDLC has been negatively associated with CHD, and LDL-C 
has been positively associated with CHD @Q&4,21 7). 
The Evans County, Georgia, study was initiated in 1960 to 
investigate differences in coronary heart disease incidence and risk 
between blacks and whites for an entire community in a rural, 
principally agricultural setting (107). All residents of Evans County 
over age 40 and a 50 percent subsample of those aged 15 to 39 years 
were eligible; 92 percent of those eligible were examined between 
1960 and 1962. Followup examinations from 1967 through 1969 
provided a mean followup period of 7 l/4 years. Reexamination for 
evidence of new CHD was obtained in 91 percent of the 3,102 
initially examined members of the population, including 537 black 
males and 947 white males (83 percent and 93 percent, respectively, 
of those initially available). In addition, community and mortality 
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surveillance was used to ascertain the incidence cases of fatal and 
nonfatal CHD. 
During the 7 l/4 years of followup, 13.6 percent of the black males 
and 12.7 percent of the white males died. The onset of CHD was 
observed in 6 surviving and 7 decedent black men and in 40 
surviving and 32 decedent white men. The age-adjusted incidence 
rate for white men was 3.5 times the rate in black men. There were 
few cases in women, but the incidence rates in black women and in 
white women appeared to be similar. CHD incidence was higher in 
smokers than in nonsmokers for the black and the white popula- 
tions. 
Beginning in 1965, 9,824 men aged 45 to 64 years who were 
residents of four rural and three urban areas of Puerto Rico were 
examined at a clinic in San Juan. The methods used were compara- 
ble to those used by the Framingham study (85). Of the targeted 
population samples, over 80 percent attended the medical examina- 
tion, and over 90 percent of the examined cohort participated in four 
followup examinations at 2 l/2-year to Syear intervals. The average 
followup was 8 l/4 years (246). 
In comparison with men in Framingham, fewer men in Puerto 
Rico were smokers, and the Puerto Rican smokers consumed fewer 
cigarettes per day (85). After 2 l/2 years of observation, the 
incidence of CHD in Puerto Rican men was only half that observed 
in Framingham, and the difference between smokers and nonsmok- 
ers was not significant (222). However, after 8 l/4 years of 
observation and the accumulation of approximately four times as 
many cases, cigarette smokers had a significantly higher incidence of 
MI than did nonsmokers; this was true both for those living in the 
rural areas and for those in the urban areas when considered 
separately (246’). 
Japanese Americans have an incidence and mortality from CHD 
that is intermediate between the very low rates in Japan and the 
high rates in white Americans (X$222,284). The explanation for this 
gradient of CHD with migration has been investigated by the Ni- 
Han-San study centering on a cohort of Japanese Americans living 
in Hawaii (14, 222). 
The target cohort of the Honolulu heart study was all noninstitu- 
tionalized men of Japanese ancestry born between 1900 and 1919 
who were living on the Island of Oahu in 1965 (130). Initial 
examinations were conducted between 1965 and 1968, and participa- 
tion was obtained from 72 percent of the identified men who were 
eligible (7,705 men aged 45-69 years and free of CHD). CHD 
incidence was observed by followup examination (at 2 and 6 years) 
and by intensive community and mortality surveillance activities. 
The 2-year incidence of MI and death from CHD was only half of that 
observed in Framingham men, but was significantly higher in 
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cigarette smokers (85). The relative risk for those smoking 21 or 
more cigarettes per day was six times higher than for nonsmokers 
(221). At 6 years of followup, the risk of MI and death from CHD, but 
not of angina pectoris, was strongly related to cigarette smoking, and 
the risk increased in proportion to the number of cigarettes smoked 
per day (130). 
CHD death rates are lower in Great Britain than in the United 
States by about one-fourth, and those in Norway are substantially 
lower than either. In 1962 the National Heart Institute and the 
National Cancer Institute in the United States, the London School of 
Hygiene and Tropical Medicine, and the Norwegian Cancer Registry 
undertook a study to examine differences in death rates among 
migrant populations to the United States (223). Native-born Ameri- 
cans were included in the study for comparison. Approximately 
32,000 British migrants and 18,000 Norwegian migrants aged 30 to 
74, residing in 12 States, were sent questionnaires. For native-born 
Americans, similar questionnaires were sent to a subsample of 
23,CKKl white persons drawn from a 1961 National Health Survey 
sample covering the same geographic areas. A total of 7,895 CHD 
deaths occurred (3,193 British, 1,213 Norwegian, and 3,489 native- 
born deaths). Norwegian migrants exhibited the lowest CHD death 
rates. British migrants’ rates were about equal to those for native- 
born Americans. 
The decedent’s cigarette smoking status as of October 1962 was 
requested from the next of kin, Smoking status from October to the 
end of the study period (1963-1966) was presumed not to be altered. 
Mortality ratios for CHD were significantly elevated among smokers 
compared with nonsmokers, particularly at the younger ages. The 
ratios were 1.9 or greater for both males and females at age 45 to 54 
years and decreased somewhat with age. CHD death rates among 
smokers demonstrated little difference between the three groups, 
and ratios were greater for female than male smokers in all but two 
instances. Table 3 provides a summary of these mortality ratios by 
migrant class, age, and sex. 
In summary, a number of ethnic groups in the United States have 
lower rates of CHD, but even in these populations, the risk of MI and 
CHD death are significantly higher in smokers than in nonsmokers. 
Studies in Other Countries 
Cigarette smoking has been found to be related to the incidence of 
CHD in other countries where long-term followup of large, defined 
cohorts has been performed. For some cohorts, early data analyses 
with relatively few cases have not shown significant differences, but 
later followup analyses with large numbers of cases have usually 
demonstrated a positive relationship between cigarette smoking and 
CHD. 
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TABLE 3.4ronary heart disease mortality ratios (smoker 
versus nonsmoker) of British and Norwegian 
migrants to the United States and native-born 
Americans by age, sex, and cigarette smoking 
stahll3 
Aae and mortality ratio (smoker vs. nonsmoker) 
Group 45-54 55-64 65-74 
British migranb 
Malea 1.9 1.3 1.3 
Females 2.9 2.4 1.7 
Norwegian migrants 
Males 2.3 1.5 1.6 




NOTE: All nonsmoker ratice are 1.0. 
‘Les.thm 1odeaths. 
SOURCE Ra@ WZ0. 
2.3 2.7 1.4 
2.6 2.0 1.3 
An international study conducted in seven countries observed 
large differences in CHD incidence and mortality among 16 cohorts 
of men aged 40 to 59 at baseline examination in the United States, 
Europe, and Japan (143). The United States cohort was the railroad 
men described above in the Pooling Project (214). This cohort 
experienced a relative risk of CHD with cigarette smoking that was 
similar to that of other U.S. cohorts of white men (Table 1). The 
other cohorts of men were residents of Yugoslavia (Dalmatia, 
Slovenia, Velika Krsna, Zrenjanin, and Belgrade), Japan (Ushibuka 
and Tanushimaru), Finland (districts in the east and west), Italy 
(Crevalcore, Montegiorgio, and railroad men in Rome), the Nether- 
lands (Zutphen), and Greece (Crete and Corfu). In all, 12,763 men 
were examined, of whom 12,509 were free of evidence of coronary 
heart disease at baseline examination. During the 10 years of 
followup, 1,512 deaths occurred from all causes, and 413 were 
attributed to coronary heart disease. 
Ten-year CHD death rates were less than 75 per 10,000 for the 
cohorts living in Crete (Greece) and in Croatia (Yugoslavia) and for 
the two cohorts in Japan; however, for the cohorts of east and west 
Finland, the U.S. railroad men, Zutphen (the Netherlands), and 
Belgrade (Yugoslavia), the CHD death rates were 250 per 10,000 or 
higher. Although the cohorts participating in the Seven Countries 
study were not selected as representative of their countries, the CHD 
death rates of cohorts grouped by country were highly correlated 
with the CHD death rates for men of the same ages reported in the 
vital statistics of these countries. 
Cigarette smoking was strongly related to CHD mortality in those 
cohorts with both high CHD death rates and relatively large 
numbers of cases for analysis. For example, among U.S. railroad 
men, CHD death rates were about three times as high in men who 
smoked 20 or more cigarettes per day compared with men who had 
never smoked or men who had stopped smoking. Furthermore, the 
association between CHD and number of cigarettes smoked daily was 
stronger in the cohorts with high CHD mortality than in the cohorts 
with low CHD mortality. Among northern European men as well as 
United States railroad men, the lo-year age-standardized CHD death 
rates increased significantly with the level of cigarette smoking, and 
the risk for northern European men smoking 20 or more cigarettes 
per day was more than four times greater than for men who had 
never smoked (Figure 2). For the southern Europeans, however, 
differences were only twofold and not statistically significant. Age- 
standardized rates for death from all causes, respiratory tract 
cancer, and neoplasms were also more closely related to the number 
of cigarettes ‘consumed in northern Europe than in southern Europe, 
and for all deaths the differences were significant in both regions. 
The lO-year incidence date provide a larger number of cases for 
analysis, as deaths from CHD represented only about 20 percent of 
the total CHD incidence in the Japanese and European cohorts. 
Definite CHD was observed in 351 of the 9,780 men during the 
followup period. The highest rate (11 percent) was observed in east 
Finland, and the lowest (0.3 percent) was observed in Crete (Table 4). 
Rates within countries were similar in general, but in Greece the 
rates were higher in Corfu than in Crete; in Finland the rate in the 
eastern district was double that in the western district; in Yugosla- 
via, the Serbian cohorts in Belgrade and Zrenjanin were similar, but 
in the farming village of Velika Krsna the rate was only half as high. 
The Japanese cohorts were small and the incidence too low for 
evaluation of the influence of smoking. Only 19 men in the two 
Japanese cohorts were observed to develop definite coronary heart 
disease during the 10 years of followup. 
To provide greater stability in analyses, the European cohorts 
were grouped together by region: the three cohorts in Finland and 
the Netherlands, the five cohorts in Yugoslavia, and the three 
Italian cohorts with the two Greek cohorts. The lO-year CHD 
incidence in Finland and the Netherlands was significantly related 
to the number of cigarettes currently smoked, and former smokers 
had a CHD incidence that was twice that of those who had never 
smoked (Figure 3). In Yugoslavia, the CHD incidence in smokers was 
nearly twice that of those who had never smoked. Also in Yugosla- 
via, the CHD incidence was nearly three times higher for those 
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FIGURE 2.-Age-standardkd N-year death rates from all 
causes and from coronary heart disease of 
men in northern Europe (east and west 
Finland and Zutphen), classified by smoking 
habit at entry; all thee of cardiovascular 
disease at entry 
SOURCE Keys U4.9. 
smoking 20 or more cigarettes per day at entry compared with those 
who had never smoked, but no  significant differences were observed 
between former smokers and never smokers (Figure 4). In the Italian 
and the Greek cohorts, the contrasts were less marked (Figure 5). 
The incidence of CHD was significantly higher in those northern 
Europeans and Yugoslavs smoking 10 or more cigarettes per day 
compared with lighter smokers, never smokers, or ex-smokers. The 
rates were also higher in the Italian and Greek cohorts, but were not 
statistically significant. 
Observation of the Italian cohorts has continued, and 20-year 
followup data were recently reported (126). W ith the substantially 
larger number  of cases, a  significantly higher incidence of CHD was 
observed in cigarette smokers than in nonsmokers. The 20-year 
incidence of CHD increased from 90 per 1,000 in those who had never 
smoked to 159 per 1,000 in those smoking 10 to 19  cigarettes per day. 
The incidence in the highest smoking category (20+ cigarettes per 
day) was slightly lower (140 per 1,000) than the rate in those 
smoking from 10 to 19  cigarettes per day. 
A number  of prospective studies of CHD have been performed in 
the United Kingdom. Those with mortality followup-for example, 
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TABLE 4.-Ten-year incidence of coronary heart disease 
among men free of cardiovascular disease at 
entry (age-standardized rate per 10,000) 
Cohort 
Hard CHD Any CHD 
N N Rate SE N Rate SE 
JMmatia 662 13 165 52 40 629 94 
Slav&a 880 18 253 60 40 561 88 
Tanusbimaru 504 8 148 5-4 20 354 82 
East Finland 728 71 1,074 115 201 2,868 166 
West Finland 808 45 539 80 129 1,582 129 
CEValCOre 956 43 450 67 105 1,080 100 
M0hgi0rgi0 708 22 353 69 64 986 111 
Zutphen 845 45 513 76 91 1.066 106 
Ushibuka 496 11 204 63 23 458 94 
ClFk 655 2 26 20 13 210 56 
corfu 525 17 337 79 37 688 110 
Rome railroad 736 z-5 357 68 57 786 99 
Velikn Krsna 487 6 132 52 21 452 94 
Zrenjanin 476 12 239 70 37 715 118 
TOti . 9,780 351 369.9 ’ 19.1 913 943.8 ’ 29.6 
’ Mean of the cohort rate weighti by the number at rink in each cohort. 
8OlJRCE Keyn (143). 
the British physicians study and the Whitehall study-are reviewed 
below under the heading Prospective Mortality Studies. 
Morris and Kagan and associates (185) investigated differences in 
CHD in drivers and conductors working on London buses. Among 
other positive associations, those who smoked were found to have a 
higher 5year incidence of CHD than those who did not smoke. 
In 1977 Morris, Marr, and Clayton (186) reported followup on 
workers who were 30 to 67 years of age at examination. The sample 
was of 337 men living in London and in southeast England who had 
participated in a ‘I-day individual dietary survey. By 1976, 45 of 
these men had developed clinical CHD. Among the CHD cases, 
cigarette smoking was significantly more frequent than expected, 
and this was true for each occupational group: bank staff, bus 
drivers, and bus conductors. Estimated relative risks (compared with 
nonsmokers) were 3.5 for those smoking 11 to 20 cigarettes and 4.7 
for those smoking more than 20 cigarettes (88). 
The Belfast practitioner’s study was initiated in 1964, using 
experienced, self-selected practitioners to observe the operation of 
risk factors in middle-aged men who were community residents (88). 
The sample comprised all men born in the lo-year period 1909-1918 
(age 45 to 54 at the beginning of the study) who were registered in six 
cooperating group practices. Examinations were performed in 69 
percent of the designated population sample. Among the 1,202 
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FIGURE 3.-Age-standardized lo-year incidence rate of 
coronary heart disease of 2,369 men in 
northern Europe (east and west Finland and 
Zutphen), classified by smoking habit at entry 
and then free of cardiovascular disease 
SOURCE: Keys (14.3). 
during the &year period of followup. M I occurred in 55  (15 fatal), 
cardiac ischemia in 5, and angina pectoris in 49. Current tobacco 
consumption, total years of smoking, and total tobacco consumption 
were significantly higher in the cases with CHD than in the overall 
population sample. 
The Stockholm prospective study examined and followed men and 
women attending a  health survey center in 1961 and 1962 (26). This 
sample was not a  randomly selected population sample of Stockholm, 
but the incidence of myocardial infarction was similar to that of the 
Stockholm county population (27). A principal objective was to 
examine the relationships of fasting plasma triglyceride and choles- 
terol values to the future development of CHD. In analysis of g-year 
followup data for 3,168 men, the incidence of M I and death from 
CHD with all ages combined was about fourfold higher for smokers 
than for nonsmokers (26). The difference was statistically significant. 
Risk factors for M I were evaluated in 3,189 men, among whom 130 
experienced myocardial infarction during 14 years of followup; 
cigarette smokers experienced nearly three times the incidence of 
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FIGURE 4.-Age-standardized lo-year incidence rate of 
coronary heart disease of 2,797 men in 
Yugoslavia (Dahnatia, Slavonia, Velika Krsna, 
Zren@.nin, and Belgrade), classified by smoking 
habit at entry and then free of cardiovascular 
disease 
SOURCE: Keys u4.3. 
MI experienced by nonsmokers (27). In analysis of risk factors and 
death during 14.5 years of followup of 3,466 men and 2,738 women, 
death due to ischemic vascular disease (principally CHD and stroke) 
was significantly related to smoking in men and in women (22). 
The Section for Preventive Med icine at the University of Goteborg 
has observed the relationship of smoking and other risk factors to 
the incidence and the mortality from CHD in several studies of the 
G iiteborg population (278). In 1963 a  30 percent sample of men born 
in 1913 was examined (at age 50) and followed; 88  percent participa- 
tion was obtained, and 834 were found to be  free of CHD. In 1970 a  
primary prevention trial was begun for examination of 10,000 
intervention and 20,000 control subjects 47  to 54  years of age. 
The 1913 birth cohort experienced a  markedly excessive risk of M I 
with smoking during its first 4  years of observation (275); more than 
90 percent of those who had myocardial infarctions were current 
smokers in comparison with 55  percent of those who did not. 
Subsequent analyses with Byear followup have confirmed this 
strong relationship between smoking and CHD; the incidence of fatal 
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FIGURE 5.-Age-standardized IO-year incidence rate of 
coronary heart disease of 3,551 men in Italy 
and Greece (Crew&ore, Montegiorgio, Rome 
railroad, Crete, and Corfu), classified by 
smoking habit at entry and then free of 
cardiovascular disease 
SOURCE: Keys W~J. 
and nonfatal M I increased with the quantity of daily tobacco 
consumption. Pipe and cigar smokers experienced an increased risk 
similar to cigarette smokers (278). No significant difference was 
observed for angina pectoris by smoking status. 
Prospective data obtained in the Norwegian Vegetable O il workers 
study beginning in 1965 have been analyzed with respect to risk 
factors measured at the baseline examination and the incidence of 
CHD during the following year (199). The defined sample comprised 
16,608 men born between 1905 and 1916 who were emp loyed in 
industries throughout Norway. Randomization to a  control group or 
to a  group receiving linolenic acid was performed in 13,000 men 50 to 
59  years of age who were well and agreed to participate. Industrial 
physicians participated in the provision of baseline data and in the 
ascertainment of cases. 
Fewer than the expected number  of deaths occurred, but the 
number  of deaths from CHD was intermediate between that 
expected on the basis of the Oslo and the total Norwegian popula- 
tions. M I was observed in 162 men during the followup; there were 
no significant differences in CHD incidence attributable to treat- 
ment with linolenic acid. 
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TABLE 5.-First diagnosed myocardial infarction (probable 
+ possible) in relation to cigarette consumption 
Rates percentage 
5 percent sample Adjusted for age and 
MetI Infarctions 
Cigarettes MtWl at diagnmedin Weight/height Elevated sedi- 
per &Y No. choleateml risk’ otx3el-v. yr Unadjusted ratio mentation rate 
None 228 239.6 5,693 37 
l-4 40 244.1 1,094 
5-14 162 245.2 3,679 
15-24 47 240.7 1,214 
f 25+ 9 36 3 191 a 4.19 :~~~~l.% 4.15 :I~;;~..., ;f$l.m 
Unknown 126 237.0 4.304 42 96 
612 241.0 16,175 162 1.00 
’ Men with no previous infarction diagnwia 
SOURCE:Natvigetal.(199). 
The incidence of MI increased markedly with the level of cigarette 
smoking; the relative risk of MI for men smoking 25 cigarettes or 
more per day was over six times that of nonsmokers (Table 5). 
Smoking was less strongly related to angina pectoris (199). 
The Oslo study examined and followed 14,000 men aged 40 to 49 
who were free of cardiovascular disease and diabetes mellitus at 
examinations in 1972 and 1973. During 4 2/3 years of followup, 
searches of discharge records of Oslo hospitals and of death 
registration by the Oslo health department were used to identify 
nonfatal and fatal first MIS; sudden deaths without confirmation of 
MI were excluded (117). The incidence of MI in nonsmokers (never 
and ex-smokers) was only 40 percent of that in cigarette smokers 
(117). 
A ICyear prospective study of men examined in 1964 at age 50 in 
Glostrup County, Denmark, was reported by Schroll and Hagerup 
(240). Out of a total population sample of 514 men, 436 were 
examined; followup for mortality and myocardial infarction was 
obtained in virtually all patients. This population resided in a 
middleclass suburb in the western part of Copenhagen and was 
thought to reflect the change in Danish society from principally 
agricultural to industrial and to be representative of the total 
Danish population in 1964. During the l&year followup, 31 men 
developed first myocardial infarctions, an incidence of 7.1 percent. 
Fatal MI occurred in 16, and 15 experienced a nonfatal MI. A 
significantly higher risk of myocardial infarction was observed in 
those who smoked tobacco at baseline examination. The incidence 
was as follows: nonsmokers, 6 percent; smokers of 1-14 g per day, 6 
percent; smokers of 15-24 g per day, 14 percent; smokers of 25 g or 
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TABLE 6.-Seven-year incidence of fatal and nonfatal first 
myocardial infarction in 3,772 smokers by 
category of smoking habit and 440 men who 














SOURCE: GynteIberg et al. (91). 
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more per day, 19 percent. Thus, the heavy smokers experienced an 
incidence of MI that was three times that of nonsmokers. 
The incidence of fatal and nonfatal first myocardial infarctions in 
men was observed in 3,772 smokers and 1,440 nonsmokers who had 
baseline examinations in 1970 and 1971, were aged 40 to 59, and 
were employed in public and private Copenhagen combanies (91). 
The initial response rate was 87 percent. Fatal MI was ascertained 
during 7 years of followup from death certificates; nonfatal MI was 
ascertained from 5-year followup by questionnaires (79 percent 
response rate) and from hospital records. Myocardial infarction 
among t.he nonresponders was included if recorded in the Copenha- 
gen heart register, which registered all inpatient cases of myocardial 
infarction in the Copenhagen area. 
During the followup period, 41 men free of coronary heart disease 
at baseline examination died from a first myocardial infarction and 
129 men had a nonfatal first myocardial infarction. Overall, the 
relative risk of myocardial infarction was twice as high in smokers 
as in nonsmokers. The relative risk of fatal and nonfatal first MI in 
smokers compared with never smokers was as follows: cigarette 
smokers of more than 10 per day, 2.5; cigar smokers of more than 3 
per day, 2.1; cheroot smokers of more than 6 per day, 4.2; and pipe 
smokers smoking more than six times per day, 2.0 (Table 6). In this 
study heavy cheroot smokers experienced the highest risk of MI. 
Finnish men aged 50 to 53 years, insured for 10 or more years with 
a large Finnish life insurance company, were examined in 1965 and 
1966; the examined cohort (1,648 men) consisted of 40 percent of 
those respondents who had complete data (207). Risk factor data 
included serum lipids after a 1Zhour overnight fast. A smoker was a 
person who smoked cigarettes regularly every day; pipe and cigar 
smokers as well as ex-smokers were excluded from the analysis of 
smoking effects. With these criteria, 567 men were smokers and 982 
were nonsmokers. During 7 years of followup, all deaths were 
identified, and cause of death was determined from death certificate 
files. Cardiovascular deaths included those due to coronary heart 
disease, heart failure, cardiac arrhythmia, cerebrovascular acci- 
dents, and sudden deaths. Cigarette smoking was associated with 
increased cardiovascular mortality independently of other risk 
factors. 
The North Karelia, Finland, project was started in 1972 to 
mobilize community intervention for health promotion and disease 
prevention (235). Substantial risk factor data were obtained from 
random population samples of two rural counties in eastern Finland. 
Analysis showed a strong relationship between the major risk factors 
at the baseline examination (smoking, hypertension, and serum 
cholesterol) and the subsequent development of CHD. The relation- 
ship of smoking to the incidence of acute myocardial infarction was 
independent of the other risk factors (235). Eastern Finland had the 
highest incidence and mortality from CHD in the world, but the 
rates have declined substantially coincident with decreasing preva- 
lence of these risk factors (235). 
A large defined cohort of men aged 42 to 53 years, born in France 
and employed in the Paris civil service, was observed for an average 
of 4 years (range, 2-7 years) following a baseline examination for risk 
factors in 1965 (218). Those with definite Q waves on initial 
examination were excluded, leaving 7,453 men at risk. Criteria for 
CHD were based on those of the Pooling Project and the London 
Whitehall study (51,218). 
The overall incidence of CHD was 5.1 per 1,000; MI and CHD 
deaths accounted for 60 percent of the cases, while 40 percent of the 
cases were due to angina pectoris. Cigarette consumption, hyperten- 
sion, hypercholesterolemia, and clinical diabetes mellitus were 
independently related to the incidence of coronary heart disease. 
Men in their fifties had a strikingly lower incidence of CHD than 
men in the United States; this is consistent with French mortality 
statistics. In univariate analysis, the incidence of CHD was progres- 
sively higher with increasing number of cigarettes smoked per day 
among inhalers; noninhalers had an intermediate risk (Figure 6) 
(218). 
A defined cohort of 10,232 Israeli civil servants and municipal 
workers (86 percent of the defined sample) aged 40 years and above 
were first examined in 1963 and followed for fatal and nonfatal MI 
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and sudden cardiac death (177). Reexaminations were performed in 
1965 (97.5 percent reexamination rate) and again in 1968 (98 percent 
reexamination rate). After 5 years of followup, 9,794 were found to 
be free of myocardial infarction and there were 427 incidence cases 
(44 per 1,000). Of these 170 (40 percent) were unrecognized myocardi- 
al infarctions, half of which had been asymptomatic. The incidence 
of CHD was significantly related to the daily use of cigarettes, and 
the relative risk was greater at younger age (81, 176). In multivariate 
analysis the relationship of smoking to CHD became stronger when 
other variables were taken into account (81). 
In summary, there were marked differences in CHD rates for the 
populations in different countries and different geographic locations. 
The relationship between cigarette smoking and CHD was more 
pronounced in those countries with high CHD rates. However, even 
in those countries with low CHD rates the evidence increasingly 
suggests a relationship between cigarette smoking and CHD. 
Cigarette Stoking and Other Risk Factors 
The strong relationship between cigarette smoking and CHD has 
been shown to be independent of the other major risk factors in a 
number of well-designed epidemiologic studies. A number of other 
factors have also been described as having an influence on CHD risk 
(119, 124, 133, 159, 214, 251). The magnitude of excess risk observed 
with these minor risk factors has usually been small in comparison 
with the excess risk observed with the major risk factors (44 68,143, 
214). 
The independence of the relationship between cigarette smoking 
and CHD risk has been observed in a straightforward fashion. The 
excess risk of CHD in smokers compared with nonsmokers exists at 
both high and low levels of the other risk characteristics associated 
with CHD. Also, extensive experience has shown that confounding 
influences can be separated out with multiple logistic analysis (147). 
Such analyses with adjustment for potentially confounding influ- 
ences have been made for many characteristics in many of the 
studies cited in this Report. They include hypertension, elevated 
serum cholesterol, obesity, family history of CHD, diabetes mellitus, 
physical inactivity, certain personality characteristics, psychological 
stress, socioeconomic status, and intake of alcohol and coffee. When 
the data have been sufficient for adequate analysis, excess risk of 
CHD has been observed in cigarette smokers independent of the 
presence (or absence) of other CHD-risk-conferring characteristics. 
Such observations, made in a very large number of studies, indicate 
that it is the cigarette smoking habit itself that confers high risk of 
CHD rather than an associated characteristic (18, 40, 43, 45, 67, 94, 
96,143,214,244,257). 
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Behavioral characteristics other than cigarette smoking have been 
considered important in relation to CHD, but relatively few studies 
of behavioral characteristics have been conducted in the context of 
standardized examinations of defined cohorts with consideration of 
potentially confounding variables. The Western Collaborative Group 
Study (WCGS) in California met these conditions, and therefore this 
study will be considered in some detail (24, 66, 71). 
In the WCGS (229), 3,154 employed men examined in 1960-1961 
and found to be free of CHD were characterized for behavioral 
pattern by a structured interview developed for this purpose and 
administered by trained interviewers. From tape recordings of 
interviews, reviewers who had no knowledge of the subjects’ history 
or other characteristics classified the men as Type A personalities 
according to their manifestation of enhanced aggressiveness, ambi- 
tiousness, competitive drive, and chronic sense of time urgency. The 
men were classified as Type B personalities if they manifested less of 
the Type A characteristics and were more calm and relaxed. The 
Type A pattern was determined in 1,067 and the Type B pattern in 
1,182 of the subjects at risk. Previously recognized risk factors were 
also measured. Mortality surveillance was obtained, and final 
followup examinations were performed for this population in 1969. 
With an average followup of 8.5 years, there were 140 deaths; 31 
were attributed to an initial CHD event, 19 to a recurrent CHD 
event, and 90 to non-CHD causes, including 7 who had developed 
CHD prior to the onset of the non-CHD terminal illness. CHD 
incidence was observed in 257 cases. Autopsy examination was 
performed in 24 of 31 decedent cases; acute coronary thrombosis or 
acute myocardial infarction was obse~ed in 23, and severe diffuse 
coronary atherosclerosis was observed in 1 case. 
CHD death was ascertained in 34 Type A and 16 Type B subjects. 
The CHD death rate per 1,090 person-years was 2.92 for Type A and 
1.32 for Type B subjects. 
As would be expected from other studies, the CHD incidence cases 
were older, smoked more cigarettes, were heavier, and had higher 
systolic and diastolic blood pressures, higher serum cholesterol and 
triglyceride levels, and higher ratios of beta to alpha lipoproteins. 
Other positive associations were a history of diabetes mellitus, 
parental history of CHD, low level of education, and low level of 
leisure time activity. Occupational physical activity and annual 
income were not significantly related to CHD incidence. 
Cigarette smoking was significantly related to the incidence of 
CHD, and the risk was higher with increasing numbers of cigarettes 
smoked at the time of the baseline examination; the relative risk 
with smoking in older men was as great as in the younger men. 
By personality patterns, those who had been characterized as Type 
A had an incidence of CHD that was twice as high as the incidence in 
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those who had been characterized as Type B. This difference 
persisted after adjustment for the other risk factors. In both deciles 
of age at entry (3M9 and 50-59), the relative risks for current 
cigarette smokers were higher than for nonsmokers in both Type A 
and Type B personalities (Table 7) (229). 
A multiple logistic equation describing the relationships of the 
conventional risk factors to the incidence of CHD in this study was 
similar to the Framingham study equation (25). The coefficients for 
the two studies were not significantly different. Cigarette smoking, 
serum cholesterol, and systolic blood pressure were independent risk 
factors and were significantly related to the CHD incidence. The 
total number of cases and the number by decile of risk were similar, 
using the equation developed from the WCGS data and the equation 
from the Framingham study, indicating good relative agreement in 
risk prediction. In the WCGS analysis, the Type A behavior pattern 
was found to predict the incidence of CHD independently of the 
other risk factors. The additional predictive power of the Type A 
characteristic in the multiple logistic equation was related to some 
extent to higher levels of the conventional risk factors in Type A 
individuals. 
Evidence for the importance of personality characteristics was also 
observed in the Framingham cohort and in studies by the French- 
Belgian Collaborative Group (66, 104). In these studies as well, the 
effect of cigarette smoking on CHD remained independent of 
personality characteristics. 
In summary, the evidence from studies with adequate data have 
clearly demonstrated that cigarette smokers experience higher risk 
of CHD regardless of their other behavioral characteristics. 
Interaction of Cigarette Smoking and Other Risk Factors 
A number of pharmacologically active substances are present in 
tobacco smoke, and a number of direct physiologic effects have been 
observed (262) and are reviewed elsewhere in this Report. Recently, 
evidence has accumulated of an effect of smoking on lipoproteins. 
Recent population studies have demonstrated an inverse relation- 
ship between high density lipoprotein cholesterol (HDL-C) and the 
incidence of CHD (80, 84, 217). Population groups known to be at 
lower risk for CHD have been observed to have relatively high levels 
of HDL-C. Thus, HDLC levels have been higher in women in 
comparison with men, in black men in comparison with white men, 
and in men in Japan in comparison with men in the United States (5, 
106, 146, 260). An adverse influence of cigarette smoking on the 
levels of HDL-C and other plasma or serum lipoprotein components 
has been observed in a number of populations. The several classes, or 
fractions, of these lipid-protein complexes have different functions 
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$ TABLE 7.-Prospective history and findings by behavior pattern 
Age 39-49 years Age 50-59 years 
Subjects Subjects Rate of Subjects Subjects Rate of 
at risk with CHD’ CHD = at risk with CHD CHDP 
Type 5w Type Type Type Type Type Type Type Type Type Type 
A B A B A B A B A B A B 
Number of subjects 1,067 1,182 95 50 10.5 5.0 522 383 83 29 18.7 8.9 
Parental history of CHD 
YW 214 197 23 15 12.6 9.0 103 64 20 1 22.8 12.9 
No a53 935 72 35 9.9 4.2 419 319 63 22 17.7 8.1 
Smoking habits 
Never smoked 221 315 11 8 5.9 3.0 90 89 10 5 13.1 6.6 
Pipe or cigar 191 216 11 6 6.6 3.3 81 78 17 2 24.7 3.0 
Former cigarette 110 129 11 5 11.8 4.6 91 41 10 2 12.9 
Current cigarette 
5.1 
545 522 62 31 13.4 7.0 260 175 46 20 20.8 13.4 
Current cigarette usage 
None 522 660 33 19 7.4 3.4 262 208 37 9 16.6 5.1 
I-15/day 95 119 3 8 3.7 7.9 65 43 8 1 14.5 2.7 
2 16/day 450 403 59 23 15.4 11.4 195 132 33 19 22.9 16.9 
Systolic blood pressure, mm Hg 
<I20 264 328 17 4 7.6 1.4 95 80 7 4 a.7 5.9 
120-159 771 826 69 43 10.5 6.1 381 283 64 21 19.8 8.7 
2160 32 28 9. 3 33.1 12.6 46 20 12 4 30.7 23.5 
Diastolic blood pressure, mm Hg 
c95 970 1,100 81 45 9.8 4.8 448 344 64 25 16.8 8.5 
295 97 82 14 5 17.0 7.2 74 39 19 4 30.2 12.1 
TABLE 7 .-Continued. 
Age 39-49 years Age 50-59 years 
Serum cholesterol, mg/lOO ml 
< 220 486 607 24 11 5.6 2.1 211 146 20 6 11.2 4.6 
22cL259 352 376 32 20 10.7 6.3 179 142 36 10 23.7 8.3 
2260 226 195 39 19 20.3 11.5 130 90 27 13 24.4 17.0 
Fasting serum triglycerides, mg/lOfl ml 
<loo 252 346 12 I 5.6 2.4 151 99 16 5 12.5 5.9 
loo-176 500 536 48 22 11.3 4.6 236 170 37 11 18.3 7.6 
2 177 247 249 30 20 14.3 9.6 114 98 26 9 26.8 10.6 
Serum &la-lipoprotein ratio 
<2.36 733 836 57 24 9.1 3.4 323 263 43 18 15.7 8.1 
> 2.36 331 343 38 26 13.5 8.9 196 117 39 11 23.4 11.1 
I Coronary heart disease 
‘Average annual rate/l.000 subjects at risk. Difference in rates between type A and type B was tested fur significance by Mantel.Haenszel ye, wth adlustment for factors indicated For each factor, 
the adjusted asswiatwn between behavior pattern and CHD inadence is aignficant at p < .OOl. 
SOURCE: Rosenman et al. (2291. 
in lipid metabolism (41, 78, 213). Most of the cholesterol in the 
plasma is complexed in the low density lipoprotein cholesterol 
(LDLC) fraction, which appears to have atherogenic properties, 
while a lesser proportion of cholesterol is complexed with high 
density lipoprotein cholesterol (HDL-C), which appears to have 
antiatherogenic properties (82, 100, 180,230). 
The HDLC levels in the cigarette smokers in the studies cited 
above have been found to be significantly lower than in nonsmokers, 
and in some studies the concentration of HDL-C has been found to 
correlate inversely with daily cigarette consumption. This relation- 
ship does not appear to be confounded by other factors. Thus, HDGC 
is inversely correlated with indices of obesity, such as relative 
weight, and positively correlated with alcohol intake; adjustment for 
these characteristics increases the difference in HDLC between 
cigarette smokers and nonsmokers (79, 99, 105, 212). Additional 
studies are needed to investigate the complex mechanisms whereby 
cigarette smoking depresses HDL-C levels and increases the risk for 
CHD. 
Blood pressure increases transiently after smoking, mediated by 
an adrenergic mechanism (37); however, most surveys have demon- 
strated a small negative association between smoking and blood 
pressure (263). Recent investigations of this relationship have 
adjusted for the covariables of weight and alcohol. 
In an examination of the offspring of Framingham heart study 
patients and their spouses, multivariate analysis demonstrated a 
negative correlation between smoking and blood pressure, especially 
diastolic blood pressure, that was similar to the original Framing- 
ham cohort (102). A cross-sectional survey of employed men in 
Australia also demonstrated that, adjusted for weight and alcohol, 
diastolic blood pressures were slightly lower in smokers (5). In the 
cohort of the Lipid Research Clinics prevalence study, the small 
negative correlation between smoking and blood pressure was more 
apparent for systolic blood pressure (3s). In the cross-sectional and 
prospective analyses of several study populations in Chicago, how- 
ever, smoking was associated with higher blood pressure, especially 
systolic blood pressure (52, 53). Alcohol consumption was not 
included in these multivariate analyses. 
If smoking is associated with a slightly lower blood pressure, a rise 
in blood pressure might be predicted after smoking cessation, 
especially if smoking cessation is followed by weight gain, but recent 
studies have not supported this concern. In the Kaiser population, 
smoking cessation has been associated with only a small weight gain 
(70). Effects on blood pressure were also small and inconsistent 
among subgroups. In the Multiple Risk Factor Intervention Trial, 
smokers who quit lost less weight than those who did not quit (239); 
controlling for weight, there was no increase in blood pressure with 
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smoking cessation. These studies show that there is little, if any, 
adverse effect on risk factors following smoking cessation. The 
benefits of smoking cessation for health in general, and cardiovascu- 
lar health in particular, far outweigh any objectively observed 
disadvantageous effect. 
Although epidemiologic studies do not suggest that smoking 
causes high blood pressure, concern has been expressed that it may 
exacerbate the clinical course. Two casecontrol studies in Great 
Britain (20, 125) and one in New Zealand (57) compared smoking 
patterns in patients with malignant or accelerated hypertension 
with those with benign hypertension. In all three, statistically 
significant associations between smoking and the more severe 
manifestations of hypertension were demonstrated. 
A recent clinical study directly observed the blood pressure effects 
of smoking in mild hypertensives (65). When 16 habitual smokers 
abstained from cigarettes, their blood pressure was significantly 
lower than usual. Smoking two cigarettes resulted in a blood 
pressure increase of 10/8 mm Hg that lasted approximately 15 
minutes. Combining coffee drinking with smoking led to an increase 
in blood pressure to their usual levels that lasted 2 hours. 
For the most part, recent surveys have supported the traditional 
finding of a small negative association between smoking and blood 
pressure. Smoking cessation is not associated with a significant 
increase in blood pressure, especially if weight gain is avoided. 
Preliminary studies suggest that smoking increases the likelihood of 
developing malignant hypertension. Prospective and intervention 
studies are indicated to further investigate this phenomenon. 
These findings can be translated into clinical recommendations: (1) 
nonhypertensive smokers can be assured that smoking cessation will 
not lead to high blood pressure, especially if weight gain is avoided, 
and (2) hypertensive smokers should be warned that these two risk 
factors are synergistic for cardiovascular disease and that the need 
for risk reduction is increased. Smoking cessation will not complicate 
the management of high blood pressure, and may reduce hyperten- 
sive complications. Concomitant monitoring of weight during and 
after smoking cessation is indicated. 
Synergistic Effects of Cigarette Smoking When Associated 
With Other Risk Factors 
Evidence that the increase in CHD risk associated with smoking 
may be greater when other risk factors are present than when they 
are absent has been observed in several investigations. Figure 7 
presents the data from the Framingham 12-year followup. The CHD 
risk increases with increasing levels of blood pressure or serum 
cholesterol, and at each level of these two risk factors the risk in 
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smokers is greater than the risk in nonsmokers. However, the 
increment of risk with smoking is not constant, but rather increases 
with increasing levels of blood pressure or cholesterol. For example, 
in F igure 7  the increment in risk in smokers with a  systolic blood 
pressure of 80-120 mm Hg is 32  (49 m inus 17), while the increment 
for smokers with a  systolic blood pressure of 140-159 is 101 (150 
m inus 49). These data suggest that cigarette smoking interacts with 
the other two ma jor risk factors to produce a  combined risk that is 
greater than the sum of the risks that would have been produced by 
the same risk factors acting separately. 
Pooling Project data are also consistent with a  synergistic effect of 
cigarette smoking with hypertension and hypercholesterolemia 
(Figure 8) (19). Evidence of synergism has been found in other studies 
as well. In the Ni-Hon-San study, the effect of cigarette smoking on 
CHD incidence in the presence of high serum cholesterol appeared to 
be  more than additive in Japanese Americans living in Hawaii. The 
same effect was not observed in Japanese men living in Japan, who 
in general had substantially lower serum cholesterol levels (221). 
Evidence of synergism was observed in the Stockholm prospective 
study and the Goteborg studies (Figure 91(27,278). 
The synergistic interaction between the ma jor risk factors may 



















I - 1 
None SM only c or H  SMBC C&H 
of 3 only 




RISK FACTOR STATUS AT ENTRY’ 
- 
FIGURE 8.-Major risk factor combinations, N-year 
incidence of first major coronary events, men 
age 30-59 at entry, Pooling project 
’ Definitiona of the three major risk factors and their symbols: hypercholestemlemia (0. 2 250 mg/dh; elevated 
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NOTE: All rates were age adjusted by lo-year age groups to the U.S. white male population, 1980. 
SOURCE: The Pooling F’mject Reseereh Gmup (214). 
populations with low levels of serum cholesterol is substantially 
lower than the incidence predicted by the mu ltiple logistic equations 
derived from the Framingham population (85, 91, 124, 143, 146). If 
the synergistic interaction is present at low levels of the ma jor risk 
factors to the same degree as at high levels of risk factors, then the 
impact of cigarette smoking on blood pressure in a  low cholesterol 
population would he expected to be  smaller than that measured in 
high cholesterol populations such as in the United States and 
Western Europe. The mu ltiple logistic equations do not separate out 
effects that are due to synergistic interactions, and they distribute 
the synergistic effects to the separate risk factors as though there 
were no interaction among the risk factors in producing CHD. These 
equations treat the risk factors as though the effects of the risk 
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FIGURE 9.-Risk factors for disease according to 
population studies 
NOTE P = probability of nonfatal and fatal myocardial mfarction for a Sayearsld man during 13 years’ 
followup. 85.5 men bon in 1913 
SOURCE: Wdhelmsen (278) 
factors were additive. This limitation of the multiple logistic 
equation technique leads to an overprediction of the number of CHD 
cases to be expected in a population on the basis of smoking habits 
when that population has very low levels of another major risk 
factor such as serum cholesterol levels. Therefore, the very low levels 
of CHD observed in cigarette smokers from populations with very 
low serum cholesterol levels may reflect the synergistic nature of the 
interaction among the major risk factors rather than the absence of 
a CHD risk associated with cigarette smoking in those populations. 
The possibility also exists that the cigarette smokers in some of these 
populations have not been smoking for a sufficient duration or with 
a sufficient intensity to manifest an effect on coronary artery 
disease. 
Analytical and methodological refinements appear to be needed 
for better understanding of the biological significance of synergism 
(147). Nevertheless, the evidence is clear that cigarette smoking 
greatly increases the risk of CHD in individuals already at increased 
risk because of other risk factors. 
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Risk of CHD in Women 
Young and middle-aged women experience only one-fifth the 
incidence and mortality from CHD of men (16, 40, 94, 102, 139, 244, 
255, 283). These rates are steeply age dependent, and rates in young 
and middle-aged women lag behind those in men by about 10 years. 
Reasons for the sex-dependent. differences are incompletely under- 
stood, but this protective influence of female sex is partly due to 
differences in cigarette smoking and other behavioral variables (6, 
58, 103,127, 128, 150, 151, 166, 170,203,204,210,227,234,243,244, 
255, 267, 270, 280). 
During the 1950s and 196Os, when the previously reported large- 
scale investigations of smoking and CHD were conducted, relatively 
few women smoked, and on the average, those who did began at an 
older age,.smoked fewer cigarettes, and inhaled less than men (261). 
During the past two decades, women have begun to smoke cigarettes 
at younger ages, and their cigarette smoking habits have become 
more like those of men (261). Observations by a number of 
investigators have shown that the incidence of CHD in recent years 
in women who smoke cigarettes is far greater than the very low rates 
that are observed in women who do not smoke, and the incidence of 
CHD in women who smoke heavily may be similar to the incidence 
in men. 
To observe the effect of cigarette smoking in women more 
specifically, studies have been performed to take account of poten- 
tially confounding influences on the occurrence of CHD. Slone et al. 
(244) in Boston observed cases and matched controls from a large 
number of U.S. hospitals between July 1976 and December 1977. 
During this l&month period, 55 cases of nonfatal MI were identified 
in women under age 50 who had not used oral contraceptives within 
the month prior to admission and who had not been under treatment 
for heart disease or related disorders. The estimated relative risk for 
smokers compared with nonsmokers was 6.8 (p <O.OOl). In light 
smokers (1 to 14 cigarettes per day) the relative risk was 4.4, and in 
heavy smokers (more than 35 cigarettes per day) the relative risk 
was 21. The relative risk appeared as great in those who had not 
experienced menopause as in those who had experienced menopause. 
In those young women with no known risk factors other than 
cigarette smoking, the data indicated that the smoking habit 
accounted for 76 percent of the risk of nonfatal MI (244). This 
magnitude of relative and attributable risk with smoking in other- 
wise healthy young women is consistent with similar observations in 
young men. 
A subsequent report included cases observed through August 1978 
with and without the following characteristics: obesity, diabetes 
mellitus, abnormal blood lipids, hypertension, angina pectoris, 
history of preeclampsia, coffee consumption, and oral contraceptive 
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(CC) use (227). Smoking was confirmed as a singularly strong risk 
factor (Figure 10). Relative risk increased exponentially with the 
number of cigarettes smoked, and the relative risk in younger 
women was greater than in older women. A gradient of risk with 
increasing level of cigarette smoking was also observed in subjects 
who had one or more of the other risk factors. In those at the highest 
level of risk, women smoking 35 or more cigarettes per day who had 
one or more predisposing risk factors, the relative risk was 31. 
A number of investigations have been performed to observe the 
effects of OC use, and there is substantial evidence for interaction of 
the smoking effect with OC use as well as other risk factors. These 
data suggest that the biological effect of multiple risk factors, 
particularly when combined with OC use, may be multiplicative for 
the risk of CHD. Shapiro et al. (242) found that women who smoked 
more than 25 cigarettes per day but did not use OCs experienced a 
relative risk of MI of 7 in comparison with nonsmoking women who 
did not use OCs. Nonsmokers who used OCs experienced a relative 
risk of MI of 4.5. The women who combined both behaviors had a 
relative risk of MI of 39. In a case-control study of factors related to 
MI in nurses in the United States, Rosenberg et al. (226) reported 
relative risks with OC use, smoking, and hypertension of 3,5, and 8, 
respectively; however, in nurses with all three characteristics the 
relative risk was 170. 
Comparable results were observed in England by Mann, where the 
relative risk for MI in women with major cardiovascular risk factors 
(including cigarette smoking) who used OCs was up to 128 times that 
of women free of these characteristics (169). The importance of 
cigarette smoking to the incidence of MI in women has been 
confirmed by other studies in England (211, 270), Sweden (16, 2791, 
Scotland (2031, Finland (234, and elsewhere. 
In addition to the excess risk of nonfatal MI and death from CHD, 
sudden cardiac death in women has been observed to be strongly 
related to the cigarette smoking habit (249, 254). However, the 
relationship of angina pectoris to cigarette smoking is uncertain. As 
in men, some studies have shown a positive relationship with 
smoking (271), but other studies have found no significant difference 
in the occurrence of angina pectoris between female smokers and 
nonsmokers (16,40,203). 
CHD incidence and mortality in women increase remarkably after 
the menopause. Before the menopause, cases of CHD may be limited 
largely to women who smoke (15, 16, 138). Furthermore, there is 
evidence that the menopause occurs at an earlier age in women who 
smoke than in women who do not smoke (129,270). Willet et al. (282) 
observed a progressive increase in the risk of early menopause with 
an increasing level of daily use of cigarettes, and cigarette smoking 
was more closely related to early menopause than any other factor 
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considered. The evidence that a combination of cigarette smoking 
with the use of oral contraceptives potentiates (multiplies) the 
occurrence of CHD is strong, but the mechanisms are not adequately 
understood. The use of noncontraceptive estrogens was not associ- 
ated with an excess risk of MI (228). Furthermore, menopausal 
estrogen therapy has been associated with a protective effect from 
CHD death (231). There is evidence that both cigarette smoking and 
progestins in oral contraceptives depress high density lipoprotein 
cholesterol (HDL-C), and HDL-C appears to protect from CHD (13, 
23, 35, 41, 59, 62, 74, 78, 122, 123, 213, 215, 265, 266, 269, 281). Those 
with low levels of HDLC have been shown to suffer higher rates of 
CHD than those with high levels of HDGC (see Interaction of 
Cigarette Smoking and Other Risk Factors above). 
Whatever the mechanism, it must be concluded that women who 
decide to smoke assume a substantially increased risk of CHD, and 
that the risk for women who smoke heavily approaches the risk of 
CHD for men. The relative risk of cigarette smoking is greater in 
younger women than in older women, and the relative risk increases 
progressively with the number of cigarettes smoked. Women who 
smoke have been observed to experience menopause earlier than 
women who do not smoke, and this may also increase the CHD risk 
for women who smoke. A synergistic interaction between cigarette 
smoking and other risk factors for CHD has been demonstrated for 
women, particularly for oral contraceptive use. More investigation is 
required to evaluate this phenomenon; an astonishingly high rela- 
tive risk of CHD occurs in women who smoke cigarettes and also 
have other risk factors, including use of oral contraceptives. 
Risk of Sudden Cardiac Death 
The definition of sudden cardiac death @CD) is discussed in the 
introduction to this section. In a number of studies, severe CHD has 
been observed in a large proportion of the cases that have succumbed 
toSCD (10,12,139,153,154,156,157,160,162,200,208,248). 
In several epidemiologic studies, cigarette smoking has been even 
more closely related to SCD than to CHD in general. After 24 years 
of followup in the Framingham study (40, 1391, the risk of SCD in 
cigarette smokers was found to be three times that in nonsmokers, 
and a comparable relative risk was observed in the five-cohort 
Pooling Project data (124, 251). Although the relative risk in young 
men was greater than in older men, the relative risk was 2 even in 
men aged 7@ to 79 in the Framingham cohort (40). In the Pooling 
Project data, the IO-year incidence of SCD increased progressively 
with the number of cigarettes smoked per day, analogous to the 
relationships with the first major coronary event or with all CHD 
deaths (124, 251). Other studies confirming the importance of 
cigarette smoking in SCD include members of the Kaiser-Perman- 
ente health plan in the San Francisco Bay area (681, black and white 
men and women in Baltimore (156), men employed in the telephone 
industry throughout the United States (llO), and men living in 
Scandinavia (72, 220). 
Other risk factors used to predict the occurrence of SCD include 
hypertension, high relative weight, high serum cholesterol, left 
ventricular hypertrophy by electrocardiogram, and alcoholism (50, 
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64, 68, 109, 137, 139, 149, 152, 153, 156, 173, 188, 209, 216). In 
multivariate analysis of the combined Framingham and Albany data 
for men aged 45 to 64, cigarette smoking emerged with the highest 
level of statistical significance among five risk factors predicting 
SCD (137). 
Approximately half of those who experience SCD have preexisting 
clinical evidence of CHD (109, 139, 153, 154, 220). In a study by the 
Health Insurance Plan of Greater New York it was found that in 
comparison with patients who stopped smoking, those who continued 
to smoke after myocardial infarction or after the onset of angina 
pectoris experienced twice the risk of death over the subsequent 4 
l/a-year period of followup (242). Results supporting this observation 
have been observed in some other studies (69, 141,155,233,238,250). 
The results of numerous studies have consistently identified 
cigarette smoking as a leading factor in SCD. This is true for men 
and women, and the risk increases with the number of cigarettes 
smoked per day. 
Prospective Mortality Studies 
The detailed epidemiologic studies of CHD incidence described 
elsewhere in this section establish the close association between 
cigarette smoking and the subsequent development of coronary 
heart disease. The possibility that this association can be confounded 
by other characteristics with which smoking is associated has been 
intensively examined in these studies. The relationship between 
cigarette smoking and CHD has been demonstrated to exist indepen- 
dent of the presence of other risk factors. 
Studies using CHD mortality as an end point can be performed at 
a lower cost than can studies of the incidence of the disease. This 
allows the inclusion of larger numbers of individuals in order to 
examine the effects of smoking in larger segments of the population. 
It also provides sufficient numbers of cases for detailed analyses of 
the effects of dose, age, smoking cessation, and other variables of 
interest. Studies examining the relationship between cigarette 
smoking and subsequent CHD mortality are now available for a 
variety of populations and include over 20 million person-years of 
observation. In the 10 largest studies the results are remarkably 
similar. Whether in the United States, Canada, the United Kingdom, 
Scandinavia, or Japan, smokers as a group experience excess CHD 
mortality that is approximately 70 percent above that of the 
nonsmokers. 
In the following paragraphs, the major studies that have prospec- 
tively examined the relationship between cigarette smoking and 
CHD mortality are discussed. The number of individuals followed in 
these studies allows a detailed examination of the nature of this 
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relationship, including the changes in risk that occur with age, the 
relationship between dose of cigarette exposure and CHD risk, the 
effects of low tar and nicotine cigarettes, the risk of pipe and 
cigarette smoking, and the benefits of cessation. 
Overall CHD Risk for Men and Women 
A number of major prospective studies have examined the 
relationship between cigarette smoking and CHD mortality in men 
and women. Under this heading, a description of the populations 
studied and the findings for overall CHD risk in those populations 
are presented. Under subsequent headings, the questions of the 
differences in risk that occur with age, increasing dosage of cigarette 
exposure, low tar and nicotine cigarettes, pipe and cigar smoking, 
and the effects of cessation are examined on the basis of the evidence 
from these prospective studies. 
In the United States, Dorn initiated a study of U.S. veterans who 
had served in the Armed Forces between 1917 and 1940 and who had 
U.S. Government life insurance policies in force in December 1953. 
This initial cohort of 293,658 persons was mailed a questionnaire in 
1954, and the nonrespondents were followed up again in 1957. 
Responses were obtained from 248,046 veterans, with an overall 
response rate of 85 percent. Reports for 2 l/2 years (46’) and 8 l/2 
years (131) of followup were reviewed in detail in prior reports of the 
Surgeon General. The N-year followup has been completed by Rogot 
and Murray (224). Death certificates were located for 85,323 (98 
percent) of those original questionnaire respondents who died. 
Confirmation of the cause of death shown on the death certificate 
was investigated by Dorn (46). Whenever a death occurred in the 
United States, clinical confirmation concerning cause of death was 
sought from the physician who signed the death certificate. A 
response was obtained in 99 percent, and after review of the cause of 
death based on clinical data, only 6 percent of the deaths were 
reassigned to a cause different from that originally indicated on the 
death certificate. This degree of confirmation is considered good. 
Coronary heart disease mortality was 58 percent higher in cigarette 
smokers than in nonsmokers (Table 8), and CHD accounted for more 
excess deaths than any other cause of death. 
In 1952, the 9-State study by the American Cancer Society was 
initiated; 187,783 white males, aged 50 to 70, were followed for an 
average of 44 months. There were 11,870 deaths. Of these deaths, 
5,297 were due to coronary heart disease (96’). A highly significant 
excess mortality was observed in smokers as compared with non- 
smokers. The death rate for coronary heart disease was 70 percent 
higher in smokers compared with nonsmokers (Table 8). 
In late 1959 and early 1960, the American Cancer Society enrolled 
1,078,894 men and women from 25 States in a prospective study that 
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290,000 males 34,874 1.00 1.58 
188,ooo males 5,297 1.00 1.70 
122,000 males 3,351 1.00 1.71 
143.000 females 2,653 1.00 1.78 
358,@30 males 10,771 1.00 1.90-2.55 
483,000 females 4,048 1.00 l 
~78,OCKl males 3,405 1.00 
34,000 malee 3,191 1.00 
6,195 females 179 1.00 
1.60 
1.62 
27,ium males 916 1.00 1.70 
28,000 females 457 1.00 1.30 
68,cQo males 1,718 1.00 1.60 
Male data for two 
levels of smoking 
intensity, see Table 
12; ‘female data 
available by age and 
amount smoked only, 
see Tables 9 and 14 
‘Female data avail- 
able by amount 
smoked only, see 
Tables 9 and 12 
Swiss 
physicians 
3,149 males 280 1.00 xX3-2.18 Data available by 
amount smoked only, 
see Table 12 
was the largest of its kind ever conducted. All segments of the 
population were included, with the exception of groups that could 
not be easily traced. An initial demographic questionnaire recorded 
height, weight, detailed information concerning smoking (types of 
tobacco used, number of cigarettes smoked per day, inhalation, age 
at which smoking began, brand of cigarettes used), and other 
variables that might influence mortality. Hammond reported cause- 
specific mortality for the initial followup through September 1963 
(97.4 percent successfully traced) on all those aged 35 to 84 at the 
time of enrollment (93). In men, 1,639,211 person-years of experience 
were observed, and in women, 2,125,360 person-years of experience 
were observed. Death certificates were obtained in 97.9 percent of 
the 25,895 deaths. CHD mortality ratios in male cigarette smokers 
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compared with those who never smoked regularly varied from 2.81 
in men aged 45 to 54 to 1.24 in men aged 75 to 84 (Table 9). Ratios for 
women were 2.00 and 1.19 for age 45 to 54 and 75 to 84, respectively. 
In the 6year followup reported by Hammond and Garfinkel (94), 
there was a total of 28,446 deaths. Using the death rates of 
nonsmokers as the standard, over 11,590 excess deaths were 
attributable to smoking. Coronary heart disease accounted for 46 
percent of the excess deaths in men and 40.6 percent of the excess 
deaths in women. 
A study of California men in various occupations was begun in 
1954, and 68,153 men aged 35 to 64 were followed for mortality 
through December 1962 (234). Smokers included current as well as 
ex-smokers. Nonsmokers were all men who had never regularly 
smoked cigarettes for even 1 year, and pipe and cigar smokers were 
included in this group. A total of 4,706 men were identified. The 
mortality ratio for CHD was 1.6 (60 percent excess CHD mortality) in 
smokers as compared with nonsmokers. 
San Francisco longshoremen were studied by Paffenbarger et al. 
(205); 3,686 men aged 35 to 74 were examined in 1951 and followed 
for 22 years. A total of 1,270 deaths were observed during 55,635 
person-years of observation. After adjusting for difference in age, 
systolic blood pressure, and level of activity, the CHD mortality ratio 
for those smoking 20 cigarettes or more per day was 2.09 relative to 
those subjects who smoked fewer cigarettes or none. 
Gillum and Paffenbarger reported CHD mortality from followup of 
13,728 university students examined between 1939 an< 1950 (77). 
CHD morbidity followup was observed in 8,852 who had returned 
self-administered questionnaires in 1962, 1966, or 1972. Four control 
subjects were randomly assigned to each of the 98 cases of fatal CHD, 
78 cases of myocardial infarction, and 49 cases of angina pectoris. 
Fatal CHD, MI, and angina pectoris were strongly associated with 
smoking history; relative risks were near 2.5. Association with fatal 
CHD, or with MI, or both, was also apparent for a family history of 
CHD, weight, height, and systolic blood pressure. 
The Canadian Department of National Health and Welfare 
initiated a study in 1955 of smoking and health in disability 
pensioners, principally veterans of World Wars I and II. Best 
reported the results of a 6year followup in 1966 (17). The 78,000 
Canadian men were aged 30 to 90 at the onset of the study. Smoking 
habits were determined at the start of the study. Nonsmokers were 
respondents who had never smoked. Ever smokers were those who 
had smoked at least 100 cigarettes during their lifetime or 10 cigars 
or 20 pipefuls of tobacco. Current smokers were those who reported 
smoking at the start of the study. Ex-smokers were those who had 
smoked previously, but had stopped smoking at the start of the 
study. During the (i-year followup, 9,491 deaths were observed, of 
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TABLE 9.4ronary heart disease mortality ratios and 
rates, by age and smoking habit, prospective 
studies 
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Canadian veterans 55-59 60-64 6569 70-74 75-79 ~ ~ ~ - 
Nonsmoker 1.00 1.00 1.00 1.00 1.00 
CigaFettes OdY 1.90 1.61 1.36 1.79 1.45 
Swedish pmepective 16-39 40-49 50-59 6@69 
Nonsmoker 1.00 1.00 1.00 1.00 
Male smoker, cigs only - 2.60 1.70 1.70 
Female smoker - - 2.60 1.10 
Swiss physicians 35-54 5.5-G 66-74 75+ 
Nonsmoker 1.00 1.00 1.00 1.00 
Heavy smoker * 2.30 2.20 1.90 1.00 




’ Bate per 100,COO. anlam otherwIse stated. 
n Number of deaths tna small to compute a ratio. 
’ Heavy smoker: one or more path per day. 
1.00 1.00 1.00 
2.95 1.56 1.24 
which approximately 2,000 were attributed to coronary heart 
disease. Smokers experienced a death rate 68 percent higher than 
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that of nonsmokers. The excess mortality was due mainly to 
cardiovascular disease, with coronary heart disease alone accounting 
for 36 percent of the excess. The death rate due to coronary heart 
disease in smokers was 60 percent higher than the death rate in 
nonsmokers (Table 8). 
In 1951, a study of mortality in British physicians was initiated. 
The results were reported by Doll and Hill (44) and subsequently by 
Doll and Pete (45) and by Doll et al. (43). A total of 34,400 men 
responded to the questionnaire (69 percent response rate). Followup 
questionnaires were sent in 1957, 1966, and 1972. Twenty-year 
mortality through October 1971 was reported in 1976 (45). Virtually 
all of the sample had been traced, and 10,072 deaths were identified. 
Nonsmokers were defined as those who had never smoked as much 
as one cigarette per day for as long as 1 year. Smoking status was 
updated using the information from followup questionnaires. Coro- 
nary heart disease accounted for 3,191 of the deaths. Information 
from the first questionnaire was related to the deaths occurring in 
the first 7 years, information from the second questionnaire to 
deaths in the next 8 years, and information from the third 
questionnaire was related to deaths in the last 5 years of the 
followup period. The death rate for smokers of all forms of tobacco 
was 37 percent higher than the death rate for nonsmokers. 
Results of the 22-year mortality followup of female British 
physicians were reported recently (43). Among 6,194 respondents 
there were 1,094 deaths. Coronary heart disease was the underlying 
cause of death in 179. Among smokers, excess mortality was 
observed only for those smoking 15 or more cigarettes per day, but 
for these women the relative risks exceeded 2. The coronary heart 
disease mortality of all female smokers was only 35 percent of that of 
all male smokers. Those women who smoked more heavily (15 or 
more cigarettes per day) experienced CHD mortality that was 67 
percent of that of men who smoked more than 15 cigarettes per day. 
Further analyses indicated that these female smokers had a lower 
cumulative smoking exposure than the male smokers; the female 
smokers had begun smoking at later ages and smoked fewer 
cigarettes, and fewer reported inhaling cigarette smoke. The CHD 
deaths among the female smokers were too few for more detailed 
analysis of the risk at levels of smoking behavior comparable to the 
most intense male smokers. 
Examinations were given and questionnaires administered to 
18,403 British civil servants working in London (205). Blood pres- 
sure, plasma cholesterol, blood glucose, height, weight, and relevant 
data were collecfecl in a standardized fashion. During the U&year 
followup there were 1,657 deaths, of which 704 were due to coronary 
heart disease. Grade of employment was significantly related to 
death from coronary heart disease; those at the highest grades 
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(administrators and professionals) experienced the lowest rates. 
However, at each grade of employment cigarette smokers experi- 
enced higher mortality than nonsmokers. The mortality of ex- 
smokers was similar to that of nonsmokers. 
Grundy (89) reported the relationships of smoking habit and 
worksite exposure to carbon monoxide for 4,924 steelworkers in 
Ebbwvael, Wales, who were examined in 1964. After 10 years, 99 
percent of the population surveyed was traced and 740 deaths were 
recorded. The total mortality and CHD mortality were higher than 
average for England and Wales. The smokers (73 percent of the 
sample) experienced a coronary heart disease mortality that was 80 
percent higher (relative risk 1.8) than that of nonsmokers. Occupa- 
tional exposure to carbon monoxide appeared to play a negligible 
role, in comparison with the importance of cigarette smoking, for 
coronary heart disease mortality. The high smoking rate in this 
population explained a substantial part of the excess mortality of 
this population compared with the average mortality for England 
and Wales. 
In 1963, a probability sample of Swedish men and women aged 18 
to 69 was surveyed by Cederlof et al. (31), and mortality was observed 
during the subsequent 10 years through December 1972. There were 
25,444 male respondents (93 percent) and 27,342 female respondents 
(95 percent). In 1969, a followup questionnaire of a subsample 
indicated that smoking habits had not changed substantially since 
1963 in the majority of those surveyed; for example, 78 percent of 
men and 63 percent of women who reported smoking 16 or more 
cigarettes per day in 1963 reported the same cigarette habit in 1969. 
During the N-year followup, a total of 5,655 deaths were ascer- 
tained. Overall coronary heart disease mortality was 70 percent 
higher in male cigarette smokers and 30 percent higher in female 
cigarette smokers than in nonsmokers (Table 8). The possibility of 
confounding by other factors was evaluated. For univariate analysis, 
lower income and listing with the Swedish Alcohol Registry were 
associated with significantly higher CHD mortality. (In Sweden, 
violators of laws related to the use of alcohol, e.g., public drunken- 
ness, drunk driving, illegal alcohol sales, are required to be 
registered.) However, cigarette smokers in each of these groups had 
significantly higher CHD mortality than never smokers, and the 
differences were particularly marked at higher levels of cigarette 
consumption. The CHD relative risks were also significantly higher 
for cigarette smokers within the high income group, among rural 
residents, and among those not listed in the Alcohol Registry. 
In the Stockholm prospective study, risk factors for ischemic heart 
disease were evaluated in 3,486 men and 2,738 women who were first 
examined in 1961 through 1962 (22). During a 14 l/2-year followup, 
a total of 694 deaths were observed, of which 43 percent in men and 
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31 percent in women were attributed to ischemic heart disease. Of 
235 ischemic vascular deaths in men, 189 were attributed to 
myocardial infarction. In univariate and multivariate analyses, 
cigarette smoking was signiticantly and independently related to the 
risk of ischemic vascular death in both sexes. 
In 1955, a survey on the smoking habits of 3,749 Swiss physicians 
was initiated. The first reported findings (252) after 9 years of 
observation were similar to the findings in the British physicians 
study of Doll and Hill (44). More recently published data, baaed on 18 
years of followup (90), recorded 1,212 deaths among those physicians 
who completed questionnaires during the original survey and for 
whom complete information concerning cause of death was avail- 
able. A total of 280 coronary heart disease deaths (59 nonsmokers 
and 221 smokers) were reported. CHD mortality ratios increased 
with increasing number of cigarettes per day. Light smokers (10 or 
fewer cigarettes per day) had a mortality ratio of 1.33, increasing to 
2.18 with the heaviest amount smoked (35 or more cigarettes per 
day). Mortality for CHD among smokers tended to be greater in the 
younger age groups than in the older age groups. 
Hirayama has reported followup at 8,10, and 13 years for 122,261 
men and 142,857 women over 40 years of age who were residents in 
29 health districts in Japan (111-126). There was an overall 95 
percent participation rate, and ascertainment of cause of death was 
virtually 100 percent. In the 13year followup, over 3 million person- 
years of risk and 39,127 deaths (22,946 in men and 16,181 in women) 
were observed. Heart disease was certified in 3,351 men and 2,651 
women. At the time of the baseline survey, the proportion-of smokers 
was 76 percent in men and 10.5 percent in women. Mortality ratios 
for smokers were 1.7 for men and 1.8 for women. The possibility of 
confounding by other factors was evaluated through crossclassifica- 
tion of smoking by social class, consumption of meat and milk, and 
alcohol consumption. Higher coronary heart disease mortality was 
observed with higher social class and among those consuming more 
meat and milk. Alcohol intake was inversely related to coronary 
heart disease mortality. At both high and low levels of these 
characteristics, however, the risk of death from CHD among smokers 
remained higher than among nonsmokers. The proportion of coro- 
nary heart disease mortality attributed to cigarette smoking in this 
population was 34.3 percent for men and 9.5 percent for women. 
CHD mortality, as well as CHD incidence, is clearly much higher 
in cigarette smokers than in nonsmokers. This excess mortality 
occurred uniformly in each of the major prospective studies. It also 
occurred in populations of markedly different ethnic background 
and geographical location. The relationship also persisted when a 
number of other confounding variables were taken into account. The 
risk was somewhat lower for women, but in those groups of women 
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whose smoking habits approximated those of men, the CHD death 
rates were much closer to those of men. 
Impact of Cigarette Smoking on Coronary Heart Disease 
Mortality With Increasing Age 
Coronary heart disease mortality increases with increasing age in 
both cigarette smokers and nonsmokers. The question of the 
magnitude of the CHD risk due to smoking for different age groups is 
one that has important public health impact for advising individuals 
at different ages about the risks of smoking and the benefits of 
cessation. In several of the prospective mortality studies, the 
question of the magnitude of the risk of dying of coronary heart 
disease at different ages in smokers and nonsmokers has been 
examined. 
Table 9 details the coronary heart disease death rates and 
mortality ratios for different age groups of smokers and nonsmokers 
in each of the prospective studies reporting these data. As can be 
seen from this table, the CHD mortality ratios for cigarette smokers 
compared with nonsmokers decline with increasing age. However, 
the decline in the ratio is the result of the rapid rise in CHD 
mortality rates with age in nonsmokers, and the absolute difference 
between the death rates of cigarette smokers and nonsmokers 
increases with increasing age. Thus, the excess risk is actually 
numerically greater in older populations than in younger popula- 
tions, and the reduction in mortality ratio is an artifact of the fact 
that coronary heart disease is responsible for such a large part of the 
mortality of the older age groups in the United States. 
Figures 11 (men) and 12 (women) present the relationships of CHD 
mortality and age for nonsmokers and smokers of various number of 
cigarettes per day. The risk for the nonsmoker increases steadily 
with increasing age, but with each increment in number of cigarettes 
smoked per day, there is a clear increase in CHD risk prior to age 70. 
The shape of the curve with increasing age remains similar with 
increasing number of cigarettes smoked per day, and the net effect is 
consistent with cigarette smoking increasing the apparent “CHD 
risk age” of the individual by 5 to 15 years. 
The decline in the mortality ratio with increasing age found in the 
prospective mortality studies is consistent with the risk factor 
relationships found in the incidence studies. In these studies, 
cigarette smoking is responsible for a relatively larger proportion of 
the coronary heart disease occurring in younger populations and a 
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FIGURE ll.-CHD death rates (per 100,000), by age and 
number of cigarettes smoked per day, males 
SOURCE: Derived from the ACS 25-Stat.e study (93. 
Dose-Response Relationships 
The large number of deaths observed in the prospective mortality 
studies allow a detailed examination of the relationship between the 
“dose” of smoke exposure and subsequent coronary heart disease 
mortality. The simplest measure of dose is the number of cigarettes 
smoked per day; however, the dose of smoke received by a person 
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No. of cigarettes 
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YEARS 
FIGURE lZ.-CHD death rates (per lOO,OOO), by age and 
number of cigarettes smoked per day, females 
SOURCE Derived fmm the ACS %-State study WY. 
would also be increased in those persons who inhaled deeply 
compared with those individuals who did not. The duration of the 
cigarette habit is also a measure of the dose of exposure; those 
persons who began to smoke earlier in life would have a greater 
cumulative exposure to cigarette smoke at any given age than those 
persons who began to smoke later in life. Several of the major 
prospective studies have examined these questions; the data are 
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TABLE lO.-Coronary heart disease mortality ratios by 
inhalation characteristic, prospective studies 
Study sex Nonsmoker Inhalation characteristic 
Light None 
Swedish Male 1.00 1.8 1.6 1.2 
Female 1.00 1.6 1.2 1.7’ 
YeS NO 
British Male <65 1.00 2.2 1.4 
physicians >65 1.00 1.5 1.3 
None-alight Moderate-deep 
























L Number of deaths too small for statistical reliability. 
‘Number of deaths tax small to compute. 
presented in Tables 10, 11, and 1‘2. Table 13 provides data from two 
studies that examined the risk of coronary heart disease mortality 
by length of time smoked. In general, they show that the more total 
years of smoking exposure the greater the overall risk of CHD 
mortality. 
In the study of Canadian veterans, a progressive dose-response 
relationship was observed with number of cigarettes smoked per day. 
The CHD mortality ratio increased from 1.55 in those smoking 1 to 9 
cigarettes per day to 1.78 among those who reported smoking 20 or 
more cigarettes per day. A similar relationship was found in the 
American Cancer. Society 9-State study, where the excess CHD 
mortality rate varied from 29 percent in smokers of 1 to 9 cigarettes 
per day to 140 percent in smokers of 41 cigarettes or more per day. 
In the American Cancer Society 25-State study, the number of 
CHD deaths was large enough to conduct a detailed examination of 
the relationship between the dose of cigarette smoke exposure and 
the subsequent coronary heart disease mortality. The mortality 
ratios for males in the group 45 to 54 years of age increased from 
2.35 in those who smoked 1 to 9 cigarettes per day to 3.35 in those 
who smoked 40 or more cigarettes per day. In the next oldest age 
group, those 55 to 64 years of age, the mortality ratio increased from 
1.54 in those who smoked 1 to 9 cigarettes per day to 2.13 in those 
who smoked 40 or more cigarettes per day (Table 14). The mortality 
ratio also increased with depth of inhalation. In the 45- to 54-year-old 
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TABLE il.-Coronary heart disease mortality ratios by age 





Mortality ratio by age of initiation 
us. veterans 5 14 1519 W24 2% 
55-64 1.00 1.96 1.64 1.65 1.56 
65-74 1.00 2.03 1.66 1.54 1.55 
ACS 2.5State <14 15-24 2% 
Males 45-54 1.00 3.47 3.11 2.37 
55-64 1.00 2.08 1.99 1.70 
6&74 1.00 1.54 1.62 1.17 
FemallX3 45-54 1.00 -’ 2.03 2.00 
55-64 1.00 - 1.64 1.74 
65-74 1.00 - - 1.36 
Males 1.00 3.65 1.90 1.67 
Swedish 516 17-16 219 
M&9 1.00 
. Females 1.00 
’ Number of deaths tao small to calculate ratio. 
1.90 1.70 1.70 
2.00 1.10 1.30 
age group, the mortality ratio increased from 2.67 in those who 
inhaled not at all or only very slightly to 3.17 in those who inhaled 
moderately or deeply (Table 10). There was also a consistent dose- 
response relationship when the age at which the individual started 
smoking was considered. The younger the age at which regular 
smoking began, the greater the mortality ratio. In the 45-54 age 
group the mortality ratio increased from 2.37 in those who began 
smoking at age 25 or older to 3.47 in those who began smoking prior 
to age 15 (Table 11). 
For women, the excess mortality in the American Cancer Society 
25State study generally paralleled the dose-response relationship 
observed in men, but the CHD deaths were too few for evaluation of 
the risk related to the age at which smoking was begun. 
A similar relationship was demonstrated in the study of California 
men in various occupations. The mortality ratio increased from 1.39 
for those men who smoked half a pack per day to 1.74 for those who 
had smoked 1 l/2 packs or more per day. Mortality ratios increased 
with the duration of smoking from 1.05 in those who had smoked 
from 1 to 9 years to 1.77 in those who had smoked 20 years or more. 
The study of British physicians also examined the question of a 
dose-response relationship. They found a steady increase in CHD 
mortality with increasing number of cigarettes smoked per day. The 
death rate from ischemic heart disease increased from 501 per 
100,000 in those who smoked 1 to 14 cigarettes per day to 677 per 
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TABLE 12.-Coronary heart disease mortality ratios by 
amount smoked, prospective studies 
Study 
M&S Females 
cigs/bY Ratio cigs/bY Ratio 

















(For female data, 
see Table 9) 






(For female data, 
see Tables 9 and 14) 









Nonsmoker 1.00 Nonsmoker 1.00 
1-14 1.47 1-14 0.96 
15-24 1.58 1624 f 2.20 
25+ 1.92 25+ 2.12 
Nonsmoker 1.00 Nonsmoker 1.00 
1-7 1.50 l-7 1.20 
8-15 1.70 l&15 1.60 
16+ 2.20 16+ 3.00 
Nonsmoker 1.00 
about 112 pk 1.39 
about 1 pk 1.67 






100,000 in those who smoked 25 or more cigarettes per day. Depth of 
inhalation was analyzed after adjusting for age and amount smoked. 
Those responding that they did inhale experienced a 57 percent 
higher mortality rate than those responding that they did not inhale. 
A dose-response relationship was also reported in the U.S. 
veterans study, the study of mortality in northeast England, the 
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TABLE 13.-Coronary heart disease mortality ratios by 
number of years having smoked, prospective 
studies 
Study 
Number of years having smoked 
Nonsmoker < 5 5-9 lo-14 15-19 2&29 3cM9 240 
Canadian 
veterans 1.00 1.4 1.7 1.5 1.7 1.6 1.5 1.6 
l-9 lo-19 20+ 
California 
occupations 1.00 1.05 1.13 1.77 
TABLE 14.-Coronary heart disease mortality ratios, males 
and females, by age and amount smoked, ACS 
%-State study 
Number oi 
4.544 55-64 65-74 75-64 
cigarettes/day M F M F M F M F 
Nonsmoker 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
l-9 2.36 9.94 1.54 1.26 1.26 1.10 1.17 -’ 
E-19 3.09 2.00 1.92 1.64 1.61 1.42 1.39 - 
2%39 3.11 2.67 2.04 2.01 1.56 1.65 1.11 - 
40+ 3.35 - 2.13 - - - - - 
’ Number of deaths too small to wmpute. 
Swedish probability sample study, the Stockholm prospective study, 
and the study of 29 health districts in Japan. Mortality from CHD in 
the Whitehall study was higher in inhalers than in noninhalers, but 
the relative risk was reduced after adjusting for cigarette consump 
tion and tar yield. Among inhalers, the risk increased with the 
amount smoked; this trend was less evident in those not inhaling. 
Thus, in those studies that have had an adequate number of deaths 
to examine the question of a dose-response relationship between 
cigarette smoking and death from coronary heart disease, a clear 
dose-response relationship has been demonstrated for the number of 
cigarettes smoked per day, depth of inhalation, age at initiation of 
the smoking habit, and total duration of the smoking habit. The risk 
of coronary disease mortality is lower with fewer cigarettes smoked 
per day, but the evidence presented in the prospective mortality 
studies does not suggest a threshold for this effect. There is no 
evidence to suggest that any level of cigarette smoking is safe with 
regard to coronary heart disease risk. 
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Low Tar and Nicotine Cigarettes 
There has been a major change in the tar and nicotine yield of the 
cigarettes being smoked by the U.S. population over the last 30 
years. The impact of this decline in tar and nicotine yield on the risk 
of developing coronary heart disease in individuals smoking lower 
yield cigarettes has been examined in detail in the 1981 Report of the 
Surgeon General The Health Consequences of Smoking: The Chang- 
ing Cigarette (262). There are essentially no epidemiological data on 
the risk of very low yield cigarettes (those below 5 mg of tar). The 
American Cancer Society 25-State study did, however, address the 
relative risk of those who smoked cigarettes with varying yields of 
tar (95). Groups were matched for age, race, number of cigarettes 
smoked per day, age at which smoking began, place of residence, 
occupational exposures, education, and history of lung cancer or 
heart disease. CHD mortality was calculated for two 6-year periods 
(196CL1966 and 1966-1972) for those smoking low, medium, or high 
tar and nicotine cigarettes. The men and women (both in early and 
late periods) who smoked cigarettes with high tar and nicotine yield 
experienced higher CHD death rates than those who smoked low tar 
and nicotine cigarettes (Table 15). Additional analyses were per- 
formed after further matching of the groups with respect to history 
of stroke; diabetes mellitus; hypertension; usual amount of exercise; 
obesity; consumption of aspirin, tea, coffee, and alcohol; and occupa- 
tion. Although this procedure resulted in fewer matched subjects, 
the results were comparable to the analyses above; CHD mortality in 
the low tar and nicotine cigarette smokers was 86 percent of that of 
the high tar and nicotine cigarette smokers. However, this slight 
reduction in CHD mortality associated with smoking low tar and 
nicotine cigarettes disappeared if an increase in the number of 
cigarettes smoked per day occurred. Those smokers of low tar and 
nicotine cigarettes who smoke between 20 and 30 cigarettes per day 
experienced a 10 percent higher coronary heart disease mortality 
than did smokers of 1 to 19 high tar and nicotine cigarettes. In 
addition, a comparison of matched subjects who never smoked 
regularly with those who smoked low tar and nicotine cigarettes 
revealed that the low tar and nicotine cigarette smokers experienced 
a 66 percent higher coronary heart disease mortality rate. 
Data from the Framingham study on the incidence of coronary 
heart disease (30) have not shown a lower CHD risk among filter 
smokers compared with nonfilter smokers. 
Data from the Whitehall study have been published that examine 
tar yield by number of cigarettes smoked per day in inhalers and 
noninhalers for CHD mortality. This is presented in Table 16. While 
no clear pattern is evident for noninhalers, among inhalers there 
was a tendency for the highest CHD rates to be seen in those 
smoking cigarettes with the highest tar yield (108). In a recent study 
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TABLE 15.-Adjusted number of coronary heart disease 
deaths and mortality ratios during each of two 
periods of time, by sex and by tar and 
nicotine content of cigarettes usually smoked 
sex Period ’ 
High tar Medium tar Low tar 










Adjusted number of CHD deaths 
696.5 632.5 645.6 
336.0 345.6 274.2 
318.7 277.5 257.4 
265.6 228.0 215.5 
1.616.8 1,#3.3 1.392.7 
Mortality ratios 
1.00 0.91 0.93 
1.00 1.03 0.82 
1.00 0.87 0.81 
1.00 0.86 0.81 
1.00 0.92 0.86 
‘Period 1: 1960-1966; Period 2: 1966-1972 
SOURCE: Hammond et al. wh 
TABLE le.-Ten-year coronary heart disease mortality per 
hundred (and number of deaths) standardized 
for age and employment grade, according to 
cigarette consumption and tar yield, Whitehall 
study 
Inhalers Noninhalers 
l-S/day 1@19/day > m/day I-9/day 1&19/day > 2O/day 
~ ___ ___ ___ ___ ~ 
Tar (m&i@ Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. 
18-23 2.68 (14) 5.63 (71) 6.60 (101) 3.94 (14) 4.91 (17) 6.05 (20) 
24-32 3.81 (7) 6.57 00) 6.23 (36) 1.78 (3) 9.03 (10) 4.27 (6) 
2% 7.42 CD) 6.47 (37) 7.84 (10) 5.06 (4) 4.75 (4) 0.00 (0) 
Total 4.29 (44) 5.98 (138) 6.56 (147) 3.46 (21) 5.73 (31) 5.16 (26) 
NOTE: Rate for lifelong nonsmokers of cigarettes = 2.75 (70). 
SOURCE: Higgenbottam et al. (108. 
(240), tar and nicotine content of the cigarettes was documented; 
those men who smoked low yield cigarettes did not have a lower risk 
for myocardial infarction than those smoking higher yield cigarettes. 
The relative risk of developing coronary heart disease in persons 
smoking low yield cigarettes and persons smoking high yield 
cigarettes is further confounded by the possibility that those who 
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TABLE 17.-Coronary heart disease mortality ratios for 
male cigarette, pipe, cigar, and mixed pipe 
and/or cigar smokers, prospective studies 
Study Nonsmoker 
U.S. veterans’ 1.00 
Mortality ratios 
Cigarette pipe aw Mixed pips and/ 
smoker smoker smoker or cigar smoker 
1.58 1.02 1.12 
ACS 9-Stat.e 1.00 1.70 - 1.28 
Swedish 1.00 1.70 1.40 
ACS 25State’ 1.00 1.90-2.55 1.08 
British physicians 1.00 
’ Smoker group are “pure” smokers only. 
’ Age 5664 only. 
1.62 1.03 
smoke low yield cigarettes may smoke greater numbers of cigarettes 
per day or may alter the manner in which they smoke those 
cigarettes to increase the yield from the cigarette. The available data 
are conflicting concerning a possible reduction in risk of CHD for 
those smoking the lower yield cigarettes; further evidence is needed 
before this question can be definitively answered. 
Pipe and Cigar Smoking 
A number of studies have addressed the question of.the relative 
risk for CHD from smoking pipes and cigars compared with 
cigarettes. Those prospective mortality studies containing data that 
address this question are presented in Table 17. In general, the risk 
for coronary heart disease mortality of smoking pipes and cigars is 
substantially lower than the risk of smoking cigarettes. This is 
generally felt to be due to the tendency of pipe and cigar smokers not 
to inhale smoke into the lung. If this is the mechanism of this lower 
risk, then the tendency of those who switch from cigarettes to pipes 
and cigars to continue to inhale the smoke may minimize or 
eliminate the reduction in risk for coronary heart disease that might 
be expected after switching to pipes and cigars from cigarettes. 
Cessation 
Whether the excess coronary heart disease mortality that occurs 
with cigarette smoking decreases over time following cessation of 
cigarette smoking is a question of great importance for those 
individuals who are currently smoking cigarettes. Data from the 
prospective mortality studies that have examined this question are 
presented in Table 18. 
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TABLE 18.-Cessation of smoking and coronary heart 
disease mortality ratios, prospective studies 








Japanese males in 
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TABLE 19.-&essation of smoking and CHD mortality 
ratios, by length of time off cigarettes and 
number of cigarettes smoked daily, ACS 2!5- 
State study, 6year followup 
Years stopped smoking 
Amount smoked per day 
l-19 20+ 
None, current smoker 1.87 2.06 
Le3sthan1 2.00 2.13 
1-4 1.43 2.00 
5-9 1.44 1.45 
10 or more 0.99 1.35 
All ex-emokers 1.26 1.62 
In the American Cancer Society 25-Stat.e study, the mortality 
ratios in former smokers compared with continuing smokers were 
progressively lower with increasing intervals of smoking cessation. 
For those who had smoked less than 20 cigarettes per day, the CHD 
mortality after 10 years of cessation was comparable with that of 
those who had never smoked regularly. However, for those who had 
smoked 20 or more cigarettes per day, the CHD mortality rate 
remained 35 percent higher even after 10 years (Table 19). 
The British study of physicians also conducted a detailed analysis 
of the effects of cessation. The relative risk for males 30 to 54 years 
of age was 1.9 for those who had discontinued smoking for less than 5 
years, but it was 1.3 for those who had discontinued smoking for 5 or 
more years. Those who discontinued smoking for 15 years or more 
had a relative risk that remained slightly above 1. Those aged 30 to 
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“ke Nonsmoker Yeare off cigarettes comments 
<5 5-9 l&14 5+ 
British 3s54 1.00 1.9 1.3 1.4 1.3 
phyaiciam 5544 1.00 1.9 1.4 1.7 1.3 
e@yr foump) 85+ 1.00 1.0 1.3 1.2 1.1 
<IO >lO 











Smokers who consumed 
<2oo,ooo cigaretteal 
lifetime 
Smokers who consumed 
>2wloo cigarew/ 
lifetime 
64 had a relative risk of 1.3 after 15 years, while those 65 and over 
had a relative risk of 1.1 (Table 20). 
The Swedish national probability sample study examined former 
smokers who had stopped in the 10 years prior to 1963. A relative 
risk of 1.6 existed for those who had smoked 20 years or more prior to 
quitting, but the relative risk was 0.9 for those who had-smoked less 
than 20 years before quitting. Those at younger ages had greater 
residual relative risks than those in the older age groups. Among 
those who had stopped smoking 10 or more years prior to the 
beginning of the study, no significant excess risk of coronary disease 
was observed. The results in women were consistent with those in 
men, but the cases were too few for detailed analysis (Table 20). 
In the Japanese study of 26 health districts, former smokers 
exhibited relative risks that were related inversely to the time since 
smoking cessation; the residual risk was directly proportional to the 
number of cigarettes smoked prior to quitting. 
Data from the X-year followup of U.S. veterans provides informa- 
tion on CHD mortality for ex-smokers by the number of cigarettes 
smoked per day (Table 21). Those ex-smokers with the lowest 
smoking exposure levels as measured by the number of cigarettes 
consumed per day had the lowest CHD mortality ratios. When all ex- 
smokers were analyzed by the length of time since cessation (Figure 
13), ex-smokers who had been abstinent for 20 or more years had a 
CHD mortality ratio virtually identical to lifelong nonsmokers (1.00 
versus 1.05). Friedman et al. (69) found that the benefits of quitting 
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TABLE 21.~ssation of smoking and CHD mortality ratios 
of current smokers versus ex-smokers, by 
number of cigarettes smoked daily, U.S. 
veterans study, M-year followup 
No. cig/daily Current smoker Ex-smoker 
Nonsmoker 1.00 1.00 
l-9 1.24 1.02 
lo-20 1.56 1.14 
2139 1.76 1.31 
40+ 1.94 1.30 
AU smokers 1.66 1.16 
SOURCE: Begot and Murray (224). 
A 8 C D E 
FIGURE lb-Coronary heart disease mortality rates by 
number of years stopped smoking, U.S. 
veterans study, N-year followup 
NOTE: A = Btopped b than 5 years: B = stopped 5-9 years; C = stopped 10-14 years; D = tipped 15-19 
years; E = stopped 20 or more years. 
SOURCE: Begot and Murray GW. 
smoking could not be explained by differences in other risk factor 
levels between continuing smokers and quitters. 
Thus, cessation of cigarette smoking resulted in a reduction in the 
risk of CHD in each of the mortality studies that have examined the 
question. There appears to be some residual excess CHD risk in those 
ex-smokers who smoked heavily for extended periods of time prior to 
1% 
quitting, and the magnitude of this residual risk is proportional to 
the total lifetime exposure to cigarette smoke. 
Populations With Low Rates of Smoking 
Mortality has been studied in several population groups that have 
abstained from cigarette smoking for religious reasons. These 
include Seventh Day Adventists in California, Mormons living in 
Utah, members of the Reorganized Church of Jesus Christ of the 
Latter Day Saints living in Missouri, and Old Order Amish living in 
Indiana, Ohio, and Pennsylvania. 
Seventh Day Adventists in California prohibit the use of tobacco 
and alcohol and advocate a well-balanced diet that includes a 
relatively large grain and fruit content. As reported by Wynder and 
Lemon (285), the Seventh Day Adventists have experienced excep- 
tionally low coronary heart disease as well as low cancer mortality. 
Cardiovascular mortality from 1969 to 1971 in Mormons and non- 
Mormons living in Utah was studied by Lyon et al. (165). Utah has 
the lowest per capita consumption of cigarettes and alcohol of the 50 
States, and this is attributable to the Mormon Church’s position 
against the use of tobacco and alcohol. Below the age of 65, both 
Mormons and non-Mormons in Utah had significantly lower core 
nary heart disease mortality than the average for U.S. whites, but 
above the age of 65 only Mormons had significantly lower rates. 
Mormon men and women in comparison with non-Mormon men and 
women living in Utah experienced 25 percent and 29 percent fewer 
deaths, respectively, from coronary heart disease. The rates were 
lower in Mormons than in non-Mormons at all ages. Below the age of 
65, Mormon men and women experienced CHD mortality rates only 
66 percent and 51 percent, respectively, of the rates for coronary 
heart disease that were experienced by U.S. whites. 
The mortality of Missouri residents who were members of the 
Reorganized Church of Jesus Christ of Latter Day Saints (RLDS) was 
compared with the mortality of other white Missouri residents and of 
Utah residents for the period 1971-1978 (167). The RLDS advocates 
abstinence from the use of tobacco, alcohol, and hot drinks. A well- 
balanced diet is recommended, with ample whole grains, fruits, and 
vegetables but with moderate intake of meat. The total mortality 
rate for Missouri RLDS residents was 22.6 percent lower than that of 
other Missouri white residents and 14.4 percent lower than that of 
Utah residents. CHD mortality was 17.4 percent lower than CHD 
mortality for other Missouri whites. The CHD mortality of RLDS 
members appears to be intermediate between that of Mormons living 
in Utah and that of U.S. whites. 
Mortality among Old Order Amish living in Ohio (1960-1975), 
Indiana (1967-1972), and Pennsylvania (1970-1975) was reported by 
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Hamman et al. (92). This unique population group is rooted in a rural 
lifestyle reminiscent of 19th century America. Their diet has been 
incompletely characterized, but probably is relatively high in fats 
and carbohydrates. Tobacco use has been widespread among men, 
but principally limited to pipe and cigar smoking and tobacco 
chewing. Alcohol intake is thought to be limited to consumption at 
home, and excessive intake is uncommon. Mortality of the Amish 
was compared with mortality of the non-Amish residents in the 
study counties. The non-Amish residents included an unknown 
proportion of those who were former members of the Amish faith 
and members of other conservative religious groups who shared 
components of the Amish lifestyle. Amish men, but not women, 40 to 
69 years of age had significantly lower total mortality (61 percent 
and 98 percent, respectively) and cardiovascular mortality (65 
percent and 89 percent) than did the non-Amish residents living in 
the same counties. Lower cardiovascular disease mortality for the 
Amish men was highly significant in all three States. 
Conclusions 
1. Cigarette smoking is a major cause of coronary heart disease in 
the United States for both men and women. Because of the 
number of persons in the population who smoke and the 
increased risk that cigarette smoking represents, it should be 
considered the most important of the known modifiable risk 
factors for CHD. 
2. Overall, cigarette smokers experience a 70 percent greater 
CHD death rate than do nonsmokers. Heavy smokers, those 
who consume two or more packs per day, have CHD death rates 
between two and three times greater than nonsmokers. 
3. The risk of developing CHD increases with increasing exposure 
to cigarette smoke, as measured by the number of cigarettes 
smoked daily, the total number of years one has smoked, and 
the degree of inhalation, and with an early age of initiation. 
4. Cigarette smokers have a twofold greater incidence of CHD 
than do nonsmokers, and heavy smokers have an almost 
fourfold greater incidence. 
5. Cigarette smoking is a major independent risk factor for CHD, 
and it acts synergistically with other risk factors (most notably, 
elevated serum cholesterol and hypertension) to greatly in- 
crease the risk of CHD. 
6. Women have lower rates for CHD than do men. In particular, 
CHD rates for women are lower prior to the menopause. A part 
of this difference is due to the lower prevalence of smoking in 
women, and for those women who do smoke, to the tendency to 
smoke fewer cigarettes per day and to inhale less deeply. 
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Among those women who have smoking patterns comparable 
to male smoking patterns, the increments in CHD death rates 
are similar for the two sexes. 
7. Women who use oral contraceptives and who smoke increase 
their risk of a myocardial infarction by an approximately 
tenfold factor, compared with women who neither use oral 
contraceptives nor smoke. 
8. Cigarette smoking has been found to significantly elevate the 
risk of sudden death. Overall, smokers experience a two to four 
times greater risk of sudden death than nonsmokers. The risk 
appears to increase with increasing dosage as measured by the 
number of cigarettes smoked per day and diminishes with 
cessation of smoking. 
9. The CHD mortality ratio for smokers compared with nonsmok- 
ers is greater for the younger age groups than for the older age 
groups. Although the smoker-to-nonsmoker mortality ratio 
narrows with increasing age, smokers continue to experience 
greater CHD death rates at all ages. 
10. Cigarette smoking has been estimated to be responsible for up 
to 30 percent of all CHD deaths in the United States each year. 
During the period 1965 to 1930 there were over 3 million 
premature deaths from heart disease among Americans attrib 
uted to cigarette smoking. Unless smoking habits of the 
American population change, perhaps 10 percent of all persons 
now alive may die prematurely of heart disease attributable to 
their smoking behavior. The total number of such premature 
deaths may exceed 24 million. 
11. Cessation of smoking results in a substantial reduction in CHD 
death rates compared with those of persons who continue to 
smoke. Mortality from CHD declines rapidly after cessation. 
Approximately 10 years following cessation the CHD death 
rate for those ex-smokers who consumed less than a pack of 
cigarettes daily is virtually identical to that of lifelong non- 
smokers. For ex-smokers who had smoked more than one pack 
per day, the residual risk of CHD mortality is proportional to 
the total lifetime exposure to cigarette smoke. 
12. Epidemiologic evidence concerning reduced tar and nicotine or 
filter cigarettes and their effect on CHD rates is conflicting. No 
scientific evidence is available concerning the impact on CHD 
death rates of cigarettes with very low levels of tar and 
nicotine. 
13. Smokers who have used only pipes or cigars do not appear to 
experience substantially greater CHD risks than nonsmokers. 
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Appendix: Prediction of CHD 
The probability of developing CHD may be accurately predicted 
within populations that are stratified by risk scores based on daily 
use of cigarettes and the levels of the other major risk factors. This 
may be accomplished efficiently using the multiple logistic equation, 
which provides for simultaneous consideration of multiple risk 
factors (40, 80, 84, 85, 88, 91, 126, 130, 133, 135, 137, 139, 143, 159, 
168, 214, 221, 246). Furthermore, the reproducibility of the relation- 
ship between risk factors and the subsequent development of CHD 
may be tested among different population samples. As demonstrated 
in the investigations cited above, the risk of CHD in white 
populations in the United States and northern Europe has been 
shown to be predictable based on a knowledge of cigarette smoking, 
blood pressure, and serum cholesterol. In other population groups 
with lower incidences of CHD, relative risk has been predicted well, 
although the magnitude of risk has been overestimated. Such 
predictability confirms the importance of the major risk factors to 
the development of CHD. 
Pooling Project 
The relationships among a number of characteristics measured at 
baseline examinations and the subsequent development of CHD was 
studied intensively in the Pooling Project, in which the experience of 
five major prospective studies of defined cohorts were compared and 
combined. From these analyses it was concluded that the levels of 
the three major risk factors-cigarette smoking, blood pressure 
(systolic or diastolic blood pressure), and serum cholesterol-ac- 
counted for most of the risk predicted by the variables considered; 
the other variables were relative weight and ECG abnormalities. 
Furthermore, the relationships of the risk factors to CHD were 
similar among the cohorts considered. 
Ranking of Risk 
On the basis of the observed relationships among the levels of the 
major risk factors and the subsequent incidence of CHD in the pooled 
data, the men in each of the cohorts could be ranked by order of 
expected risk. With the men thus ranked in quintiles of estimated 
risk from low to high, the incidence of CHD was found to be nine 
times higher for the men in the uppermost quintile than for the men 
in the lowermost quintile. 
Genemlizability 
To test the generalizability of the relationship between these risk 
factors and the subsequent incidence of CHD (in other words, the 
prediction of future CHD events from given individual characteris- 
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tics), the multiple logistic equation describing the relationship of risk 
factors to subsequent events in the combined data from the cohorts 
contributing to the pooled data were applied to other cohorts. In the 
cohort of U.S. railroad men, there was good correspondence between 
the number of first major coronary events predicted and the 
numbers observed by quintile of risk; 45 percent of CHD events were 
observed in the highest quintile and 74 percent were observed in the 
upper two quint&s. The total number of estimated cases was 133 as 
compared with 112 actually observed in the cohort of U.S. railroad 
men (‘Table 22). 
Comparability of Framingham Study Results With the 
Results in the Other cohorts 
The mathematical relationships between the risk factors and the 
subsequent incidence of CHD for the Framingham study men were 
near the averages observed for the other four cohorts in the Pooling 
Project (Tables 23 and 24). The Framingham study results have been 
compared with the results of other cohort studies in the United 
States and elsewhere (25, 77, 85, 182); therefore, it is of interest to 
consider in some detail the closeness of agreement between the 
prediction of CHD by Framingham data and by the other cohort data 
in the Pooling Project. In univariate analyses for each study by CHD 
event and risk factor, it was found that the Framingham coefficients 
were not significantly different from those of the other cohorts, 
except for a higher coefficient for serum cholesterol in the Tecumseh 
cohort and a higher coefficient for cigarette smoking in the Chicago 
Gas Company cohort (Table 23). The Framingham coefficient for 
smoking was slightly lower than the average for the other cohorts. 
Risk Indices for Individual Use 
Multivariate risk-scoring indices for estimating the risk of CHD 
based on daily use of cigarettes and the levels of other characteristics 
have been developed for prediction of the risk of CHD in individuals. 
These include RISKO, developed by the Michigan Heart Association, 
the Framingham Risk Index, based on the Framingham study 
experience, and the Self-Scoring Risk Test, based on the experience 
of the Chicago Western Electric Company cohort (54,138,178). 
The discriminative power of RISK0 and the Framingham Risk 
Index to identify individuals who would develop CHD was evaluated 
in the experience of Los Angeles County safety personnel (256). 
Personnel who were free of symptoms (4,066 individuals) were 
examined and followed in the 1971 to 1979 time frame with a less 
than 3 percent loss to followup (256). Subsequent to initial examina- 
tion, 71 developed CHD, these symptomatic cases were characterized 
by a higher proportion of cigarette smokers (60 percent compared 
with 37 percent), higher systolic blood pressures, higher serum 
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TABLE 22.-Prediction of lo-year risk of a first event for men of two studies (Minnesota business and 
professional men and Minnesota-based railroad workers) from parameters of the 




Pool 5 Minnesota business and professional men Minnesota-based railroad workers 
(6,875 men) G!SO men) , (2,422 men) 
Predicted, Predicted, 
mrrected for corrected for 
duration of duration of 









event.9 in V 
Percentage of 
events in 
VI + v 
41.3’ 30.0’ 29 21.1 1.0 18.4 2.0 37.6 3 53.6 16.9 34.8 6.3 17.0 8 16.5 
101.1 7 2 51.8 73 5 106 71 51.6 77 1 2.2 1 6 27.9 39 6 3.3 4 5 57.0 80 9 4 7 125.0 71 4 30.6 44 2 91.3 63 2 21.7 15 0 31.0 44 7 15  31.0 12 4
145.5 106.8 164 119.3 3.1 55.3 6.3 113.0 6 107.1 64.7 133.7 31.7 65.5 33 68.2 
264.0 192.0 251 182.5 5.5 97.4 11.2 199.1 12 214.3 115.2 237.0 56.4 116.1 50 102.9 
623.1 90.6 621 90.3 13.4 47.7 27.4 97.5 32 114.3 271.5 112.1 133.0 54.9 112 46.2 
6.4 8.7 5.3 5.3 4.0 6.8 6.8 6.3 
222.7 162.0 222 161.4 4.5 79.0 9.2 161.5 9 160.7 98.3 202.2 48.1 99.1 42 36.4 
42.4 40.4 40.8 40.8 37.5 42.2 42.4 44.6 
65.7 66.8 64.0 64.0 56.3 66.3 66.3 74.1 
‘Mean durstion of followup for Pool 5 men wae sirably leee then for Minnesota bueineee end pmfasional men. Since the relationship between ege end incidence of major coronary events is 
curvilineer (exponential). not linear. a correction factor wee derived from the 1970 U.S. life table for white men startmg et ege-predicted numbers of even@ rates were multiplied by this correction 
factor-2.044--to obtain the numbera of events and rata for different duration of followup. 
‘Mean duration of followup for Pool 5 men wee sizably greeter then for Minnmota-based railroad workers. A correction factor-O. i WI--wan derived by the method deecribed in the footnote above. 
‘Number of events. 
‘Rate per Loco. 
SOURCE: Pooling Project Reaeerch Gmup W4. 
TABLE 23.-Standardized univariate logistic coefficients for 
deaths from myocardial infarction, CHD, and 
all causes, by study and risk factor 
Flnminghem Aumny Chicago Gee Chicago W.E. Tecunueh 
Myccardial infarction or CHD death 
SBP 0.3373 0.2695 0.3123 0.2511 0.5633 
DBP 0.3126 0.2645 0.3169 0.2797 0.5059 
chol~ml 0.3433 0.3614 0.2665 0.3271 0.7KIl’ 
Relative weight 0.2775 0.2365 0.1496 0.0703 40136 
Smoking 0.3115 0.1450 0.6964’ 0.3049 0.5133 
Death all cauwa 
SBP 0.4671 0.4671 
DBP 0.3664 0.4006 
ChOleetelUl 0.1155 0.1321 
Relative weight 0.0540 -0.1452 







SBP 0.4860 0.3103 0.3663 
DBP 0.4136 0.3394 0.2816 
Cholesteml 0.2872 0.2550 0.2474 
Belative weight 0.3223 0.0490 0.1967 





















’ Differs signifiaratly from Framingham (p< .cw. 
‘DiEfee eigdicmtly from Fmmi&am (p < .01X 
NOTE: The coeff~cienta here are given in leas precision for eae ofcomparim~. For each oxfikient in the atudien 
other than Fmmingham. a teat statistic was calculated ta teat whether it differed significantly from the 
compmable mefftient for Fnunii. Thaw that did were appropriately marked. The test etatidic in the 
differma between the coeficients divided by the atanderd error of the differenm. The standard error of tbe 
difference in calcul&ed by taking the quare root of the sum of the variance of the meffkienta. Under appropriate 
nolwllity aLlmmption0, tlh statietic in B standard normel deviat.e. 
SXJRCE: Mccee end Gordon w93. 
cholesterol, slightly greater prevalence of excess body fat, and less 
frequent regular exercise. The risk scores of cases in comparison 
with noncases were significantly higher with RISK0 and with the 
Framingham Risk Index. In stepwise discriminant analysis, the 
Framingham Risk Index and RISKO, separately and in combination, 
identified the group with elevated levels of risk factors that 
experienced a higher incidence of CHD than the group with low 
levels of the risk factors. 
Blacks and Whites in Evans County, Georgia 
In looking for an explanation of the large difference in CHD 
incidence rates between black and white men in the Evans County 
study (see above), the incidence at different levels of risk factors was 
evaluated (28, 107, 258). Although cigarette smoking and other risk 
factors were strongly related to the incidence, differences in baseline 
characteristics did not appear to explain the higher rates of CHD in 
white men. However, white and black sharecroppers and farm 
132 
TABLE 24.-Standardized multivariate logistic coefficients 
for deaths from myocardial infarction, CHD, 
and all causes, by study and specified set of 
risk factors 
Mb MbY Chicago Gas Chicago W.E. Tecumaeh 
Myoaudkl infarction or CHD death 
SBP 0.3432 0.2426 0.3376 0.2342 0.5524 
Cholenteml 0.2905 0.3534 0.2187 0.3056 0.7989’ 
smo!&lg 0.3374 0.4227 0.7010 ’ 0.2820 0.5509 
DBP 0.3022 0.2725 0.3694 0.2680 0.5222 
Choleateml 0.2893 0.3462 0.2176 0.2979 0.7705 ’ 
Smoking 0.3352 0.4359 0.7240 ’ 0.2934 0.5647 














0.5483 0.4254 0.4495 0.275 ’ 0.4742 
0.0209 0.0992 0.1307 0.0260 0.4617 ’ 
0.4845 0.3453 0.6033 0.3206 0.5614 
0.4306 0.3983 0.2855 0.3382 0.4971 
0.0279 0.0937 0.1339 0.0145 0.4391’ 
0.4855 0.3638 0.6012 0.3372 0.5880 
0.5292 0.2897 0.3936 0.2981 0.5720 
0.2033 0.2406 0.1661 0.2025 0.9164’ 
0.4027 0.4107 0.8076 0.2092 0.4989 
0.4200 0.3126 0.3309 0.3799 9.5752 
0.2038 0.2324 ox@3 0.1995 0.8918’ 
0.3806 0.4273 0.8200 0.2273 0.5140 
’ Differs signiicantly from Framingham (p < .06). 
‘Differs migniticantly from Framingham (p< .Ol). 
NOTE The coefficients here are given in less precision for ease of comparison. For each coeffkient in the studies 
other than Framingham, a test statistic wan calculated ta teat whether it differed significantly from the 
comparable coefkient for Framingham. Thana that did were appropriately marked. The test statistic in the 
differma, between the coeffacienta divided by the ntandanl error of the difference. The standard error of the 
difference ia calculated by taking the equare root of the sum of the variance of the coeffkients. Under appropriate 
aormatity assumptions, this stabtic is a standard Norma deviate. 
SOURCE: Mccse and Gordon wm 
laborers had similarly low incidences, but the numbers of cases were 
too few for more definitive analysis of the influence of occupation 
(29). At all levels of the major risk factors, the incidence of CHD was 
higher in white than in black men, but some differences were 
smaller in the higher ranges of the risk factors. The absolute rates 
for white men were higher than for black men whether they were 
smokers (including ex-smokers) or nonsmokers, but the relative risk 
for white male smokers compared with nonsmokers was 2, whereas 
the relative risk in black male smokers compared with nonsmokers 
was 3 (107). 
Multivariate analyses were performed to evaluate differential risk 
between the black and the white men in Evans County (146). A 
multiple logistic model for the white men was developed using as 
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explanatory variables smoking, diastolic blood pressure multiplied 
by age, abnormal electrocardiogram, and cholesterol multiplied by 
age. This predicted the total incidence and the cases by decile of risk 
quite well among the white men. When this model was applied to the 
risk factor levels of the black men ranked by decile of relative risk, 
four times as many cases were predicted as had been observed (54 
predicted, but only 13 actually observed). However, when the 
multiple logistic model was constrained by an appropriate constant, 
the number of cases fit the black data satisfactorily. This is 
consistent with the view that cigarette smoking and the other risk 
factors are as important in the blacks as in the whites, but that the 
blacks were protected by some factor that was not accounted for in 
the analysis (146). 
The Seven Countries Study 
In the Seven Countries study, the risk of CHD in U.S. railroad men 
resident in the northwest sector of the United States was compared 
with the risk of CHD in men living in contrasting environments in 
Europe and Japan. In the Pooling Project, the U.S. railroad men 
were found to have levels of risk factors comparable to the other 
principal cohorts, but the total number of cases was 16 percent lower 
than the number predicted by average parameters of the Pooling 
Project data. 
‘I’he relationships of risk factors measured at entry to the 
subsequent incidence of CHD were less uniform in those cohorts of 
the Seven Countries study with a low incidence of CHD events, and 
the absolute incidence at specified levels of the risk. factors was 
significantly different. 
With parameters developed from the data of the U.S. railroad 
cohort and using the risk factors cigarette smoking, systolic blood 
pressure, serum cholesterol, body mass index, pulse rate, and age, 
226 CHD deaths were predicted for the northern European cohorts, 
whereas 272 CHD deaths were actually observed. Although the 
predicted number of cases based on the experience of U.S. railroad 
men underestimated the number observed in the northern European 
cohorts by 20 percent, there was excellent correlation between 
predicted and observed cases by decile of risk. Furthermore, the 
absolute rate in the northern European cohorts was close to that 
predicted by average U.S. experience as observed in the Pooling 
Project. 
In contrast to the northern European cohorts, the southern 
European cohorts had substantially fewer CHD deaths than were 
predicted by the multiple logistic equation based on the experience of 
the U.S. railroad cohort. As shown in Figure 14, 66 percent more 
cases were predicted than observed; however, rank order by decile of 







Total number of cases of 
myocardlal ~niarct~on 
or coronary death 
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Observed = 151 
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X= “HARD” CASES PREDICTED IN DECILE 
FIGURE 14.-Ten-year incidence of coronary death or 
myocardial infarction (hard CHD) in northern Europe, in 
the deciles of probability estimated from the logistic 
coefficients from the data on the men in southern Europe 
and the number of such incidence cases actually observed 
in those deciles 
SOURCE: Keys (14.3. 
Predicted = 35.9 
Observed = 91 
0 2 4 6 8 10 12 14 16 16 20 
x=CHD DEATHS PREDICTED IN DECILE 
FIGURE 15.-Ten-year deaths from coronary heart disease 
in northern Europe, predicted in the deciles of probability 
estimated from the logistic coefficients from the data on 
the men in southern Europe and the number of coronary 
deaths actually found in those deciles 
8om Keya w3l. 
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multivariate equations for CHD incidence and for CHD deaths based 
on southern European experience underpredicted CHD incidence 
and death rates for the cohorts in northern Europe by a factor of 2.5 
(Figures 14 and 15). Nevertheless, by rank order of risk, correlation 
between predicted and observed events was excellent (r = 0.98). 
These detailed comparisons of the results from major epidemiolog- 
ic investigations of CHD incidence do indicate that there is excellent 
agreement in the relationships of cigarette smoking and the other 
risk factors to the subsequent development of CHD in white men 
living in the United States and northern Europe. The agreement is 
close enough so that risk of CHD may be predicted well by the level 
of the major risk factors, using equations that are largely inter- 
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Death rates from stroke have been declining in developed coun- 
tries since the 1920s (28). Between 1968 and 1975 there was a sharp 
decline in the age-adjusted mortality rates from coronary heart 
disease, cerebrovascular diseases, and all major cardiovascular 
diseases among U.S. white and nonwhite males and females (50). As 
shown in Table 1, the decrease is close to 33 percent for stroke. 
Additional major reductions in disability and death from stroke 
can come largely from preventive measures, not from further 
innovations in treatment of the completed catastrophe. Formulation 
of a preventive program is greatly aided by an understanding of the 
epidemiology of cerebrovascular disease, including the chain of 
circumstances leading to its occurrence, the identity of vulnerable 
subgroups of the population, the existence of modifiable predisposing 
factors, and the natural history of the disease. 
Magnitude of the Problem 
Cerebrovascular diseases, both ischemic and hemorrhagic, are a 
public health problem of major proportions. They constitute the 
third leading cause of death, after coronary heart disease and cancer, 
and are responsible for 9 percent of all deaths in the United States 
(33). There are about 1.8 million stroke victims in the United States, 
and about a half-million new events occur each year; there are 
approximately 200,000 deaths annually in the United States from 
strokes. In the Framingham study it was estimated that the chances 
of suffering a stroke before age 70 are 1 in 20. The incidence was 
found to double in each successive decade after age 45. Although 
stroke incidence becomes substantial only after age 65,20 percent of 
strokes occur before that age. In men, the average annual incidence 
of atherothrombotic brain infarction is only one-third that of 
myocardial infarction, with stroke incidence lagging behind myocar- 
dial infarction by more than 10 years. In women, on the other hand, 
brain infarction incidence and myocardial infarction incidence are 
virtually identical (56). The reasons that brain infarction is manifest- 
ed later in life than CHD in men and exhibits little male predomi- 
nance are unclear. In the United States, stroke mortality is higher 
among blacks than among whites, and the difference decreases with 
age. 
The Stroke Entity 
There are three major specific forms of cerebrovascular diseases: 
(1) cerebral insufficiency associated with transient blood flow 
deficiencies; (2) cerebral infarction caused either by the blocking of a 
vessel by an embolism or by thrombosis; and (3) cerebral hemor- 
rhage, including parenchymal and subarachnoid. The terms “stroke” 
TABLE l.-Percentage of change in mortality rates of 
causes of death in persons aged 35 to 74, by 
sex and color, United States, 1966-1976 
Percentage of change 







Coronary heart disease -21.0 -26.5 -30.7 -39.1 -24.3 
Cerebrovascular diseases -30.6 -30.4 -43.7 -47.1 -32.7 
Major cardiovascular diseasea -20.9 -26.1 -33.2 -40.7 -24.6 
All causes -15.3 -16.4 -24.0 -32.7 -17.3 
SOURCE: Stamler Go). 
and “cerebral vascular accident” are nonspecific; they refer to a 
variety of clinical entities and are usually used in reference to 
syndromes accompanying ischemic or hemorrhagic lesions. 
The underlying process of a stroke may be an atheroma (i.e., fatty 
deposit in the inner lining of an artery wall), thrombosis, embolism, 
a bleeding disorder, a developmental anomaly, an aneurysm, inflam- 
mation, failure of flow, or increased blood viscosity. The chief causes 
of cerebral ischemia are atherothrombosis and embolism. Intracrani- 
al hemorrhage is generally due to hypertensive intracerebral 
hemorrhage, rupture of a saccular aneurysm, or bleeding from an 
arteriovenous malformation. A cerebral embolism usually originates 
in the heart, particularly when atria1 fibrillation, rheumatic valvu- 
lar deformity, myocardial infarction with a mural thrombus, or a 
valve prosthesis is present; it may also arise from ulcerated 
atheroma in the carotid, vertebrobasilar, or middle cerebral arteries. 
The main trunk of the middle cerebral artery and its branches are 
the most common sites for the formation of intracranial thrombosis. 
The reliability of stroke diagnoses and case ascertainment in 
diverse populations has presented problems for epidemiological and 
clinical research. With the fairly recent development of new 
technology such as computer-assisted tomography, however, the 
accuracy and the quality of differential diagnosis as to type of stroke 
are improving. It is unlikely that any single etiology or set of risk 
factors applies equally to all types of stroke. Atherothrombotic brain 
infarction is the most common variety of stroke, accounting for 
about 59 percent of the total number of strokes in the Framingham 
population (56). 
Cardiovascular Risk Factors 
Since the underlying pathologic features of atherosclerosis in the 
cerebral, cardiac, and peripheral circulation are virtually identical, 
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it is not unexpected to find that they share a number of precursors. 
Although some significant differences in their impact exist, there are 
a number of modifiable risk factors common to brain and myocardial 
infarction (22). In fact, when five major cardiovascular risk factors 
(systolic blood pressure, serum cholesterol, glucose intolerance, 
cigarette smoking, and electrocardiogram-left ventricular hypertro 
phy (ECG-LVH)) are considered jointly as a cardiovascular risk 
profile, they are actually more highly predictive of brain infarction 
than of coronary heart disease (24). The top decile of multivariate 
risk using this profde identifies half the strokes evolving in the 
Framingham population, compared with only 25 percent of the 
coronary events (22). However, for cerebrovascular @isease, systolic 
blood pressure and ECG-LVH were the chief determinants of this 
multivariate predictive capacity. In addition to these risk predictors, 
various cardiac impairments such as coronary heart disease, cardiac 
failure, and atria1 fibrillation are major predisposing factors (55). 
Cigarette smoking, which is a major predictor for coronary heart 
disease, has been less consistently predictive for cerebrovascular 
disease; but nevertheless appears to play a significant role among 
men at younger ages. 
Hypertension 
A consistent finding in epidemiologic studies is that elevated blood 
pressure is the most important risk factor for stroke. This seems to 
apply for virtually all varieties of stroke (56). It is the key risk factor 
for intracerebral hemorrhage, occlusive cerebral vascular disease, 
and perhaps subarachnoid hemorrhage (28). About 50 to 60 percent 
of strokes occur in the 20 percent of the population with definite 
hypertension. Hypertension predisposes powerfully to stroke at all 
ages and in both sexes, and even mild elevations in blood pressure 
double the risk. The stroke risk for isolated systolic hypertension is 
substantial, and the exclusive use of diastolic pressure to judge the 
risk in the elderly with systolic hypertension can be misleading. No 
component of blood pressure, including the pulse pressure, mean 
arterial pressure, or diastolic pressure, is more closely related to 
stroke incidence than systolic pressure (25). Also, lability of the 
pressure has not been shown to reduce the risk, and it is not safe to 
use the lowest pressure recorded to determine whether treatment is 
indicated. 
Blood Lipids 
Lipids and their lipoprotein vehicles, closely linked to coronary 
disease incidence, are of uncertain importance for stroke. Neither 
cholesterol nor triglyceride levels have any predictive value beyond 
age 55, when strokes are common, and partition of the serum total 
cholesterol into its atherogenic low density lipoprotein (LDL) and 
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protective high density lipoprotein (HDL) components does not 
clarify the role of cholesterol in stroke as it does for coronary heart 
disease in advanced age (II). In women there is actually a paradoxi- 
cal, strong negative association of brain infarction incidence with 
LDL cholesterol. This inverse relationship to atherogenic cholesterol 
has also been noted in Japanese men and for intracerebral hemor- 
rhage (19). Hence, further clarification is needed. 
Glucose 
Atherothrombotic brain infarction incidence is increased threefold 
in diabetics. In contrast to coronary heart disease, the impact of 
impaired glucose tolerance does not diminish with advancing age 
and is not greater for women than for men. The effect of diabetes 
mellitus is independent of other risk factors, but is greatly influ- 
enced by coexistent hypertension or cardiac disease (23). 
Cardiac Disease 
Even if asymptomatic, cardiac changes such as EC!G-LVH, cardiac 
enlargement on X-ray, atrial fibrillation, coronary disease, cardiac 
failure, or rheumatic heart disease powerfully predispose to the 
occurrence of strokes. ECG-LVH is the most powerful EZG predictor. 
Atrial fibrillation, chronic as well as intermittent, increases stroke 
risk sixfold, and when accompanied by rheumatic heart disease, 
seventeenfold (55). Although each contributes independently to risk, 
coexistent hypertension further augments the risk associated with 
any cardiac impairment. 
Environmental Factors 
Few modifiable environmental contributors to stroke incidence 
have been convincingly demonstrated. The demonstrated association 
of obesity with stroke incidence appears to derive mainly from the 
higher blood pressure and glucose intolerance that it promotes. 
Physical activity is weakly and inconsistently related to stroke 
incidence (55). The apparent influence of coffee intake disappears on 
adjustment for coexistent alcohol and cigarette use. Alcohol seems to 
be associated with an increased risk of stroke in some studies, 
possibly because of higher blood pressure in alcohol users. 
Cigarette Smoking 
The contribution of cigarette smoking to the incidence of stroke 
may vary depending on the type of stroke or clinical manifestation of 
cerebrovascular disease. The evidence for such a relationship 
suggests that smoking is more strongly associated with premature 
(i.e., before age 55) and nonfatal strokes than with fatal strokes (22). 
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With 16 years of followup data on 293,000 insured U.S. veterans, 
Rogot and Murray (43) reported that 653 excess stroke deaths were 
associated with cigarette smoking, producing a mortality ratio of 
1.47. Earlier, with 8.5 years of followup, Kahn (21) had found stroke 
mortality to be 1.4 times higher in smokers and rates to increase 
with amount smoked. In the more recent study, a slight dose- 
response relationship was found for both current and ex-smokers, 
with mortality ratios lower among former smokers than among 
current smokers. Mortality ratios for stroke were near unity for 
smokers of only cigars or pipes-l.07 and 0.99, respectively (43). A 
study of 54,460 men employed in British industries revealed no 
relationship between the cigarette habit and stroke mortality over 3 
years, but demonstrated a threefold excess coronary mortality (3). 
Kuller (28), in a review of the epidemiology of stroke, concluded 
that there was no consistent evidence of a relationship of cigarette 
smoking to stroke in several population and casecontrol studies. 
Data after 24 years of followup in the Framingham study showed no 
overall statistically significant relationship between the incidence of 
atherothrombotic brain infarction (ABI) and cigarette smoking 
among males. The stroke incidence was lower in nonsmoking males 
only between the ages of 45 and 54, and no clear dose-response was 
evident (56’). In a comparison of stroke prevalencenot specified as 
to type-among Japanese in Japan, Hawaii, and California, prelimi- 
nary analyses revealed positive correlations between stroke and 
increased blood pressure, ECG-LVH, and cigarette smoking for all 
ages (20). Paffenbarger et al. (37) found no relationship between 
cigarette smoking and stroke in a 22-year followup of 3,666 long- 
shoremen. 
In an earlier study of chronic diseases among male former 
students at Harvard, Paffenbarger and Wing (38) noted a slight 
excess of nonfatal stroke among those who had smoked during 
college. They also found that hypertension, overweight, and short 
stature were predisposing characteristics for stroke in later life. The 
data must be interpreted with some caution, however, because they 
were abstracted from existing school records and the smoking 
information was not collected in a standardized manner. In a 
Canadian retrospective study (I), a relative risk of 2.4 (p < 0.001) was 
found for stroke and smoking, but these results are also subject to 
potential bias in the recording of the smoking history. 
Hammond and Horn (15) studied the relationship between smok- 
ing and disease among 187,783 white men, 50 to 69 years old, 
followed from May 1952 through October 1955. Of the 11,870 deaths 
during this period, 1,050 were from cerebral vascular lesions. A 
statistically significant mortality ratio of 1.30 was found for smokers 
and a dose-response relationship was apparent. 
TABLE 2.-Mortality ratioa for cerebrovascuhr disease 
related to smoking, United &a* 19691 
Mortality ratioa (iV=4,099), by age 










































In a large-scale prospective study of male British physicians, Doll 
and Hill (8) found that the results differed somewhat between the 
10th and 20th year of followup. A stroke mortality ratio of 1.2 was 
found for smokers at the lO-year followup, with no dose-response 
relationship evident. After 20 years of followup, a relative risk for 
cerebral thrombosis of 1.52 was found for heavy smokers and a 
strong dose-response relationship was apparent (9). 
In an analysis of the 1,094 deaths that occurred among female 
British physicians who had been followed for 22 years, Doll et al. (7) 
found no effect of smoking on mortality from cerebral thrombosis; 
however, there were only 66 such deaths. 
The American Cancer Society studied prospectively more than a 
million men and women enrolled in 1959, following them for 13 
years. With 6 years of followup, mortality ratios for cerebral 
vascular disease were found to be increased among male and female 
smokers compared with nonsmokers, with the highest ratios evident 
among the 40- to 49-year-olds (Table 2). The excess risk was not 
present in either sex past age 70. There was no significant dose- 
response relationship (13, 14). 
A study of the differences in mortality ratios by the type of 
cigarette smoked (29) and a later analysis of data from the American 
Cancer Society study indicated lower mortality ratios from stroke 
among males who smoked low tar and nicotine or filtered cigarettes 
than among smokers of higher tar and nicotine cigarettes or of 
“plain” cigarettes (6). No such differences were found among 
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females. A study conducted by the Tobacco Research Council in 
England showed mortality ratios that were lower, but not signifi- 
cantly so, among smokers of lower tar and nicotine cigarettes (s). 
In 1965, Ostfeld began a prospective study among random samples 
of the elderly in Cook County, Illinois, to determine variables 
associated with stroke. They found that stroke-prone persons can be 
identified even among the elderly. Stroke risk was higher among the 
blacks and among persons with preexisting cardiovascular disease, 
transient ischemic attacks (TIAs), diabetes mellitus, or hypertensive 
cardiovascular disease. Cigarette smoking was, however, unrelated 
to any class of stroke in the elderly, with or without preexisting 
cardiovascular precursors (36). 
Kimura (26) reviewed the results of six prospective studies of 
cardiovascular disease in Japan and found a correlation of cigarette 
smoking with myocardial infarction when accompanied by abnor- 
malities in serum cholesterol and blood pressure; no relationship of 
cigarette smoking to stroke was noted. Okada et al. (34) studied 
stroke prospectively in Japanese men 40 years old or older residing 
in two rural communities and found relative risks of intracerebral 
hemorrhage and brain infarction among nonsmokers that were not 
statistically significantly lower than those in smokers. 
In an &year prospective study of a random sample of 35- to 59- 
year-olds in two counties in eastern Finland, age, blood pressure, 
diabetes mellitus, and previous stroke were found to be predictive of 
stroke incidence in both men and women. Cigarette smoking and 
serum triglyceride levels were found to be positively associated with 
stroke among men, but not among the women (47). In an effort to 
predict coronary heart disease and other mortality rates, Menotti et 
al. (32) analyzed 14 CHD risk factors using a multiple logistic 
function model. The study included 1,524 men between 40 and 59 
from two rural areas in Italy who were measured for all 14 risk 
factors upon entry. After 15 years, 37 men had had a stroke. Of the 
14 risk factors considered, age and blood pressure were the only 
factors found to be significantly associated with stroke risk, ranking 
1 and 2, respectively. Smoking ranked third for predicting stroke, 
but was not statistically significant. 
In a retrospective study (16’) of 126 stroke patients and 212 
matched controls in Tilburg, Holland, a significantly increased risk 
of stroke associated with cigarette smoking was not found. Hyperten- 
sion was found to be related to stroke, and the risk was age 
dependent, being strongest among the younger patients. 
An investigation in Finland (10) of 128 men and 85 women under 
50 years of age with ischemic stroke revealed 1.5 times as many 
cigarette-smoking men and three times as many cigarette-smoking 
women in the stroke group as in the Finnish population of the same 
age. Hypertension, abnormal electrocardiographic findings, and oral 
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contraceptive use in women were also shown to increase risk. In a 
large prospective study (40) of women under 55 years of age in 
California who were followed for 6.5 years, cigarette smoking 
increased the risk of subarachnoid hemorrhage 5.7 times and use of 
oral contraceptives increased it 6.5 times. The relative risk was 21.9 
among women who both smoked and used the pill compared with 
nonsmoking nonusers. In a case-control study (4) involving 12 
university hospitals, 598 nonpregnant women with strokes between 
age 15 and 44 were identified. Compared with controls, current use 
of oral contraceptives was considerably higher in women with 
thrombotic strokes (ninefold) and somewhat higher in women with 
hemorrhagic strokes. It was also found that 74 percent were current 
or past smokers. In an investigation of 75 hemiplegics aged 18 to 50 
years, Steinmann (51) found that cardiac disease and hypertension 
were the predominant risk factors. In men, but not in women, heavy 
smoking was a risk factor. 
Further confirming the general impression that cigarette smoking 
is a stroke risk factor in young men are the results of three cas+ 
control studies. Among 100 male stroke patients, aged 40 to 69, Koch 
et al. (27) found a relative risk of 11.2 for smokers of more than 20 
cigarettes a day. In a study (30) of 56 male and 34 female patients 
under 66 years of age with cerebral hemorrhage or infarction, 
significantly more stroke patients than their matched controls were 
found to be smokers, and more smoked at least a pack of cigarettes a 
day. Other factors predisposing to stroke in this study population 
were high blood pressure, oral contraceptive use, and a family 
history of stroke, plus cerebral neoplasm and thrombocytopenia. In 
another study (521, among 39 male and 28 female ischemic stroke 
patients, cigarette smoking was found significantly more frequently 
among male cases than among matched controls. In the young 
females, use of oral contraceptives was the predominant risk factor. 
Haberman et al. (12) summarized mortality and incidence studies 
dealing with smoking and stroke (Tables 3 and 4). They pointed out 
that the relationship between smoking and cerebrovascular disease 
is not a uniform finding of the epidemiologic studies of this disease 
process. The authors cautioned that the studies are not strictly 
comparable because of variations in methodologies, but they suggest- 
ed that an association between smoking and stroke may exist but be 
age dependent. An age dependency is suggested by the Framingham 
and Paffenbarger studies. 
Transient Ischemic Attacks 
Some evidence connects cigarette smoking with transient ischemic 
attacks (TIA). In a 6year followup for TIA of 7,895 men aged 45 to 68 
years in the Honolulu heart study (411, prior cigarette smoking was 
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TABLE 3.-Results of stroke incidence studies 
Study Type’ Date 
Relationship between 
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associated with TIA, even in multivariate analysis taking other risks 
into account. However, Ostfeld et al. (3s) found conflicting results. 
Subarachnoid Hemorrhage 
A retrospective study (2) of patients with subarachnoid hemor- 
rhage demonstrated an association with cigarette smoking. In this 
study, smoking was estimated to increase the risk of a subarachnoid 
hemorrhage almost fourfold in both sexes. In the Walnut Creek 
contraceptive study this was confirmed, with a 5.7-fold increased risk 
compared with nonsmokers (39). Also, in a 6.5year followup of this 
cohort of 16,759 white middle-class women aged 18 to 54, cigarette 
smoking was associated with a fivefold to sevenfold relative risk of 




Controlled clinical trial data measuring the effect of smoking 
cessation on cerebrovascular disease are not available; observational 
studies have been published. In the 16year followup of 293,000 
insured veterans (43), specific causes of death were studied in 
relation to smoking status. Mortality ratios for ex-smokers were 
found to be much lower than for current smokers. For stroke, the 
mortality risk for the ex-smoker rapidly returned to the nonsmoker 
rate after the cessation of smoking. Koch et al. (27) found an 
increased risk of stroke in young patients that was not detectable in 
ex-smokers after 1 year. 
Oral Contraceptives 
Oral contraceptives (OCs) have been widely used for more than 20 
years, and many reports suggest that women who use them are at 
increased risk of stroke (4, 5, 18, 44, 53, 54). Firm, undistorted 
prospective data on the risk of cigarette smoking in women taking 
OC!s are sparse, owing to the generally low incidence of stroke in 
women of childbearing age. Reliance is placed chiefly on retrospec- 
tive data subject to unavoidable selective bias or on multicenter 
prospective data based on small numbers of events. Such data as 
exist strongly suggest a synergistic effect of smoking and oral 
contraceptives that may be related to “hemorrhagic stroke” (42, 46). 
In 1969, the Walnut Creek Contraceptive Drug Study began a long- 
term study of the effects of OC use on the health of women aged 18 to 
54 at study initiation. After 6.5 years of followup, Petitti and 
Wingerd (39) analyzed the data from 15,260 women. The authors 
found relative risks associated with OC use of 6.5 and 7.6 for 
subarachnoid hemorrhage and thromboembolism, respectively. The 
risk of subarachnoid hemorrhage for smokers was 5.7 times that for 
nonsmokers; the relative risk of subarachnoid hemorrhage for 
women who smoked and used oral contraceptives was 21.9. Among 
the small number of ex-users, past use significantly increased the 
risk of subarachnoid hemorrhage, but not of other vascular diseases 
(39). In another study, cigarette smoking in itself was evidently not a 
demonstrable risk factor for stroke among women, even at an early 
age (42). 
In a two-part review article, Stadel(48, 49) indicates that CC use 
multiplies, rather than adds to, the risk of age and other factors in 
the development of myocardial infarction (MI) and stroke. On the 
basis of a total of only 31 cases reported in two studies and 134 
reported in a third, Stadel (49) further indicates that current and 
past use of OCs appears to increase the risk of subarachnoid 
hemorrhage in women near age 35 or older (17). Stadel suggests that 
the risk of cardiovascular disease among current users of oral 
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TABLE B.-Annual death rate for oral contraceptive users 
related to age, duration of use, and smoking 
habits 
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contraceptives is related to the estrogen and progestogen content of 
the pill. 
A large prospective study in England (46,000 British women) found 
that both the incidence and the mortality rates of a variety of 
diseases, including cerebrovascular disease, were increased among 
users of oral contraceptives versus nonusers (4s). The number of 
stroke deaths in the Royal College of General Practitioners (RCGP) 
study was small; thus, risk estimates were subject to error. Women 
over 35 and women who smoked and took oral contraceptives were 
found to be at substantially higher risk than were nonsmokers and 
nonusers of GCs. 
Additional analysis of the RCGP study including followup through 
1976 showed that current or previous users of oral contraceptives 
had a standardized mortality rate for cerebrovascular disease 4.7 
times that of controls. Increases in total death rates were found 
among older women, women who had used the pill for 5 or more 
years, and women who smoked cigarettes (44) (Table 5). 
Results from a c ase-control study conducted by the Collaborative 
Group for the Study of Stroke in Young Women (5) showed that 
cigarette smoking and the use of oral contraceptives were indepen- 
dent risk factors for subarachnoid hemorrhage; the relative risk was 
2.6 for smokers and 4.1 for users of GCs. When a heavy smoker also 
took oral contraceptives, the risk increased to 6.1 or 7.6, depending 
upon the control group used for comparison. In an earlier report, the 
same group (4 reported that risk of cerebral ischemia or thrombosis 
was approximately nine times greater among women using oral 
contraceptives than among nonusing controls. They also reported 
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lower incidence rates among black women than among white women 
and that more of the cases than of the controls were or had been 
regular smokers. 
The data suggest that cigarette smokers who use oral contracep 
tion are at significantly increased risk of stroke and that this risk 
may result from a synergistic interaction between cigarette smoking 
and the use of oral contraceptives. 
Preventive Implications 
Declining trends in stroke mortality and the marked geographic 
variation suggest that cerebrovascular disease may not be an 
inevitable consequence of aging or of genetic makeup. High risk 
candidates can be identified using a general cardiovascular risk 
profile. There is as yet no conclusive evidence that intervening to 
lower lipids, reduce overweight, provide exercise, treat diabetes 
mellitus, or stop cigarette smoking will in fact reduce stroke risk. 
However, former cigarette smokers appear to have a lower risk of 
stroke than do continuing smokers. 
The key to stroke prevention is early, vigorous, sustained control 
of hypertension and the cardiac impairments that escalate the risk. 
Cigarette smoking cessation may also play a role, particularly in 
young male stroke candidates or in women using oral contraceptives. 
Summary 
A preventive approach to stroke is imperative because central 
nervous system damage often leads to an irreversible functional 
deficit. Less than a third of stroke victims have symptoms warning of 
the impending stroke. The similarity of factors predisposing to 
stroke and those increasing susceptibility to coronary heart disease 
and congestive heart failure indicates that vascular disease of the 
brain is part of a larger problem of cardiovascular disease. The 
measures indicated for prevention of stroke include those recom- 
mended for prevention of coronary heart disease, occlusive peripher- 
al arterial disease, and congestive heart failure. Hypertension is 
clearly the major contributor to stroke incidence. Cigarette smoking 
also contributes, especially in younger populations, and may be 
important because of its demonstrated relationship to coronary 
heart disease and congestive heart failure, which powerfully contrib- 
ute to stroke risk. Cigarette smoking cessation is indicated as part of 
a comprehensive program of risk factor modification to avoid 
atherosclerotic cardiovascular disease, including stroke. 
Women cigarette smokers experience an increased risk for sub- 
arachnoid hemorrhage; the use of both cigarettes and oral contracep- 
tives appears to synergistically increase this risk. 
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Conclusions 
1. Data from numerous prospective mortality studies have shown 
an association between cigarette smoking and cerebrovascular 
disease. This risk is most evident in the younger age groups, and 
the effect diminishes with increasing age, with little or no effect 
noted after age 65. No consistent dose-response effect has been 
demonstrated. 
2. Women cigarette smokers experience an increased risk for 
subarachnoid hemorrhage. However, the use of both cigarettes 
and oral contraceptives greatly increases the risk for subarach- 
noid hemorrhage among women. 
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Atherosclerotic Peripheral Vascular Disease 
Introduction 
The peripheral arteries include those branches of the aorta 
supplying the upper and lower extremities and the abdominal 
viscera. Most peripheral arterial occlusive disease is due to athero- 
sclerosis, although other conditions such as fibromuscular dysplasia, 
muscular entrapment, cystic adventitial degeneration, and arteritis 
may cause obstruction of the peripheral arteries. Symptomatic 
atherosclerotic peripheral vascular disease (ASPVD) occurs most 
often in the vessels of the lower extremities. The anatomic location 
of such disease is usually classified according to the major arterial 
segments involved, including aortoiliac, femoro-popliteal, and tibio- 
peroneal artery occlusive disease. Occlusive lesions of the origins of 
visceral arteries commonly involve the renal arteries and the 
mesenteric arteries, including the celiac and superior and inferior 
mesenteric arteries. 
With many asymptomatic patients, peripheral arterial occlusive 
disease can be detected on physical examination. Symptomatic 
patients are usually classified according to the severity of presenting 
complaints; for example, patients may be classified as suffering 
intermittent claudication (leg pain brought on by exercise and 
relieved by rest), ischemic rest pain, or, the most severe complaint, 
tissue necrosis, including gangrene or ischemic ulceration. Patients 
with renal artery occlusive disease may present with severe and 
uncontrollable hypertension, although such patients may respond to 
medical treatment for hypertension. Patients with arterial occlusive 
disease of the mesenteric arteries may present with acute ischemia 
of the intestine, due to thrombosis or embolization, or with more 
chronic symptoms of pain aggravated by eating and weight loss. 
The diagnosis of peripheral arterial occlusive disease can usually 
be made from the history and physical examination, including the 
evaluation of peripheral arterial pulsations and detection of arterial 
bruits. However, more accurate and objective diagnosis of peripheral 
arterial occlusive disease is possible with noninvasive diagnostic 
techniques, particularly Doppler ultrasound or plethysmography. 
Arteriography is reserved for patients with symptoms sufficient to 
make them candidates for surgery, and is not usually required for 
the diagnosis of peripheral arterial occlusive disease. 
The majority of patients with peripheral arterial disease may be 
candidates for medical therapy such as exercise regimens and 
reduction of known risk factors through cessation of smoking, 
control of diabetes mellitus, dietary measures to control hyperlipide 
mia and obesity, and medical management of hypertension. Inten- 
sive foot hygiene and avoidance of trauma are additional important 
medical measures for patients with lower extremity ASPVD. The 
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newly developed treatment of balloon dilatation (percutaneous 
transluminal angioplasty) may be used to restore pulsatile flow for 
severely symptomatic patients. Surgical therapy is required in only 
about 10 percent of the patients with advanced arterial occlusive 
disease. One surgical approach is arterial reconstruction, usually 
involving endarterectomy or bypass with vein or prosthetic grafts of 
diseased segments. Sympathectomy is infrequently used, but it may 
be helpful in patients with cutaneous ischemia, for whom restoration 
of pulsatile flow is not possible. Amputation of limbs with advanced 
arterial occlusive disease that cannot be remedied by surgical 
reconstruction remains in use, but it is required by only about 5 
percent of all patients presenting with peripheral arterial occlusive 
disease. 
Risk Factors for Peripheral Arterial Occlusive Disease 
The most powerful risk factor predisposing to atherosclerotic 
peripheral arterial occlusive disease is cigarette smoking (47); in fact, 
the rarity of peripheral arterial occlusive disease in patients who 
have never smoked was noted by Eastcott as early as 1962 (23). The 
epidemiologic evidence linking cigarette smoking to atherosclerotic 
peripheral arterial occlusive disease is discussed in detail below. 
Several studies have suggested hyperlipoproteinemia as a risk 
factor contributing to atherosclerotic peripheral arterial occlusive 
disease. The type of hyperlipoproteinemia and the degree of associa- 
tion with peripheral vascular disease appear to be different, how- 
ever, from the hyperlipoproteinemia associated with coronary artery 
disease. Zelis et al. (92) reported that patients with Type III 
hyperlipoproteinemia are particularly susceptible to the develop 
ment of peripheral vascular disease, and they noted objective 
improvement in the peripheral circulation with medical treatment 
of this disorder. Greenhalgh et al. (30) reported that fasting serum 
lipid concentrations were abnormally high in 44 percent of a 
consecutive series of 116 patients with proven peripheral vascular 
disease. In 39 percent of the patients the serum triglyceride level was 
raised, and in 15 percent the serum cholesterol level was increased. 
Ballantyne and Laurie (5) evaluated 353 consecutive patients with 
peripheral vascular disease and showed a predominance of Type IV 
hyperlipoproteinemia in males, but a predominance of Type IIa 
hyperlipoproteinemia in females. Patients with peripheral vascular 
disease and Type IIa or Type Ilb hyperlipoproteinemia were more 
likely to have associated coronary artery disease. Eighty-four 
percent of the patients were cigarette smokers, with the majority 
smoking more than 10 cigarettes daily. There was no relationship 
between cigarette consumption and the occurrence of hyperlipopro 
teinemia. However, Farid et al. (25) found that in 122 patients with 
angiographically proved peripheral arterial occlusive disease, heavy 
smoking seemed to be associated with an unexpectedly high propor- 
tion of an abnormal lipid pattern: 43 percent of the males exhibited 
Type IV hyperlipoproteinemia. Lawrie et al. (51) surveyed 4,477 
healthy males and females in the west of Scotland and found a high 
prevalence of hyperlipoproteinemia of Type II and Type IV. Hyperli- 
poproteinemia occurred more frequently in survivors of myocardial 
infarction, but also occurred, though to a lesser extent, in patients 
with peripheral vascular disease. 
Olsson and Eklund (57) evaluated 160 men and 123 women with 
digit plethysmoraphy and found that most atherogenic lipoprotein 
abnormalities associated with disease of the lower extremities 
involved the relatively triglyceride-rich part of the low density 
lipoprotein (LDL) fraction and the relatively cholesterol-rich part of 
the very low density lipoprotein (VLDL) fraction. These authors 
found a deleterious influence of smoking even in the preclinical 
stage of peripheral vascular disease. Davignon et al. (18) evaluated 
114 French Canadian patients with angiographically proved periph- 
eral vascular disease. The severity of atherosclerosis correlated 
positively with plasma triglyceride concentration, but cigarette 
smoking was the risk factor most frequently found in patients with 
peripheral vascular disease. In contrast, Erikson et al. (24) did not 
find a positive correlation between arteriographic changes in 30 
patients with intermittent claudication and serum concentrations of 
lipids and lipoproteins. Trayner et al. (80) compared 32 patients with 
peripheral vascular disease to control subjects. The vascular disease 
study group had a significantly higher incidence of hypertriglycerid- 
emia, more marked for the males, and had lower levels of high 
density lipoproteins (HDL) than did the control subjects. The study 
group also had a twofold higher prevalence of cigarette smoking 
than control subjects. Control patients who smoked also had lower 
levels of HDL than those who did not smoke. Phillips et al. (61) also 
established a relationship between an increase of VLDL triglyceride 
and cigarette smoking, while HDL cholesterol decreased with 
cigarette smoking. 
Hypertension is associated not only with coronary and cerebrovas- 
cular disease, but also with peripheral arterial occlusive disease (46). 
Larson et al. (50) established an interaction of hypertension and 
hypercholesterolemia in an experimental study of mongrel dogs, 
suggesting that the combination of these two risk factors produces 
alterations in lipid composition in the canine aorta that appears to 
be geometric rather than arithmetic in nature. However, Stehbens 
(74) claimed that epidemiologic studies are less conclusive than 
experimental studies in establishing the relationship of risk factors 
in atherosclerosis. He postulated that local hemodynamics associated 
with hemodynamic stress, rather than the level cf lipid intake, is the 
principal factor governing the accumulation of lipid in the vessel 
wall. 
It is clear that multiple risk factors have been associated with 
atherosclerosis not only in the coronary and cerebrovascular arterial 
beds but also in the peripheral circulation. Ftosen et al. (6.5) evaluated 
the association of risk factors in 109 patients with peripheral arterial 
occlusive disease. The arterial disease was established by clinical and 
arteriographic examination and classified into three anatomic 
groups-aortoiliac, combined aortoiliac and femoropopliteal, and 
femoropopliteal disease. Type IV hyperlipoproteinemia and glucose 
intolerance were significantly more common in patients with 
isolated femoropopliteal disease. Cigarette smoking was the most 
prominent risk factor in all groups, occurring in 90 percent of 
patients with aortoiliac or combined disease and in 75 percent of 
patients with femoropopliteal artery disease. The onset of clinical 
symptoms occurred at an average of 8 to 10 years earlier in smokers 
than in nonsmokers. Heyden et al. (35) established that smoking and 
coffee drinking interact in affecting LDL and total cholesterol, but 
coffee drinking alone did not appear to affect blood lipids. Criqui et 
al. (16’) reviewed the relationship between cigarette smoking and 
HDL cholesterol in 2,663 men and 2,553 women aged 20 to 69 years 
in 10 North American populations of the Lipid Research Clinics 
Program Prevalence Study. Cigarette smoking was associated with 
substantially lower levels of HDL cholesterol; this association was 
dose related. Hulley et al. (37) found the same association in a 
longitudinal study of 301 high-risk males 35 to 57 years of age. After 
1 year’s intervention on diet, hypertension treatment, and smoking 
counseling, both smoking frequency and serum thiocyanate were 
significantly and independently associated with the changing plasma 
HDL-cholesterol concentration. A relationship linking cigarette 
smoking and abnormal lipoprotein metabolism comes from the 
report of Topping et al. (78), which found that patients with both 
Type III hyperlipoproteinemia and cigarette smoking suffer abnor- 
malities of liver metabolism of cholesterol-rich “remnants.” Such 
impaired hepatic metabolism may result in hyperlipoproteinemia 
and subsequent peripheral vascular disease. 
Sllmmary of Epidemiologic Studies 
Because peripheral arterial occlusive disease does not pose as 
severe a mortality threat as coronary artery disease does, there have 
been fewer major epidemiologic studies of peripheral vascular 
disease. However, the underlying pathologic lesion, atherosclerosis, 
remains the same in the two conditions, and there is increasing 
evidence of an association between peripheral vascular disease and 
similar lesions in the coronary or cerebrovascular beds. Both clinical 
and angiographic correlates of peripheral arterial disease with 
concomitant coronary artery disease were suggested by the reports of 
Friedman et al. (281, Kuebler et al. (49), Silvestre et al. (72), and 
Hertzer et al. (34). These reports not only suggest a clinical 
relationship between peripheral and coronary artery occlusive 
disease, but also indicate that the perioperative and long-term risks 
of treatment for peripheral vascular disease are strongly influenced 
by the presence of concomitant coronary artery disease. 
Several publications have extensively reviewed the evidence 
associating cigarette smoking with peripheral arterial occlusive 
disease (81, 82, 83). Early studies by Juergens et al. (44), Begg (7), 
Schwartz et al. (71), and Widmer et al. (87) documented a much 
higher prevalence of cigarette smoking (usually exceeding 90 per- 
cent) in patients with peripheral arterial occlusive disease, when 
compared with control patients without vascular disease. Data from 
the Framingham study (4s) suggest that cigarette smoking is one of 
the major risk factors in the development of intermittent claudica- 
tion (Table 1). Over a X-year period of followup, a higher total 
incidence and a higher annual incidence of intermittent claudication 
were noted in smokers as compared with nonsmokers. This differ- 
ence was statistically significant for all age groups of both sexes. 
Using multivariate analysis to control for other risk factors, this 
relationship of smoking to intermittent claudication became stron- 
ger. 
Many other investigators have noted a high prevalence of ciga- 
rette smoking in patients with peripheral arterial occlusive disease. 
Tomatis et al. (77) found that 98 percent of patients with aortoiliac 
disease and 91 percent of patients with femoropopliteal disease were 
cigarette smokers. Astrup et al. (3) found a significant correlation 
between the frequency of severe intermittent claudication and the 
consumption of more than 15 cigarettes a day in nondiabetic patients 
with peripheral vascular disease. A significant difference between 
heavy smokers and other smokers was not found, however, for the 
development of gangrene. Further, the development of claudication 
did not vary with the number of years of smoking or the total 
number of cigarettes consumed in a lifetime. Weinroth and Herz- 
stein (84) noted a 50 percent greater incidence of peripheral arterial 
occlusive disease in diabetics who smoked than in those who did not, 
Juergens et al. (44) followed 520 patients with nondiabetic peripheral 
arterial occlusive disease, approximately 50 percent of whom contin- 
ued to smoke despite medical advice to quit. Of those who continued 
to smoke, approximately 10 percent eventually required amputation, 
but no amputations were necessary in patients who successfully 
stopped smoking. 
Horowitz et al. (36) reported that age was a significant factor in the 
prevalence of arterial disease, with nearly half of the cases occurring 
in patients over the age of 70. A higher percentage of patients with 
lQ!! 
TABLE L-Average annual incidence (over 16 years) of 
intermittent claudication according to cigarette 
habit at examination 
Age at examination 
and cigarettes 









Rate per 10,OQO 
Actual Smoothed * 
MY- 6290 16 15.9 7933 4 3.8 
None 2342 6 9.8 4514 3 2.4 
Under 20 903 17 13.4 1876 0 4.0 
20 1466 30 16.3 1090 9 6.5 
over 20 1523 16 24.9 422 12 10.6 
55-64 years 4484 51 51.3 5959 19 19.3 
None 2170 28 27.6 4276 19 17.5 
Under 20 743 61 43.6 1030 19 21.6 
20 a79 40 66.7 434 0 26.7 
Over 20 670 in 107.9 197 76 33.1 
65-74 years 1326 57 56.6 1924 31 31.2 
None 190 44 55.2 1541 19 23.6 
Under 20 254 98 51.3 266 94 45.3 
20 167 90 59.5 I9 0 66.5 
over20 111 0 61.7 29 172 164.2 
’ Numhen of subjecta at rislr according to cigar&em smoked do not add to tot& shown because same subjecta 
a?eintheunkn~category. 
‘The “amwthed” rates an based on the mean of the individual probabilities of development of intermittent 
ckudication in ti 2 yeam following examioa tion. where individual probability h calculated awarding to cigar&e 
we at examination using the values of the parameten atiited in Wing the logistic function to the oavmnee of 
intermittent claudication in the sex-age group. 
NOTE: The trend is aigniticantly Merent from zao at the 0.05 level for women 65 to 74 yearn of age and at the 
0.01 level for men 65 to 64. 
SOURCE lbumel and Shurtleff (481. 
arterial disease smoked than did patients without arterial disease. A 
higher percentage of males than of females had peripheral arterial 
occlusive disease. De Backer et al. (21) likewise noted an increase in 
intermittent claudication with increasing age, but also found a 
significant correlation of serum cholesterol, systolic blood pressure, 
blood glucose, and cigarette smoking in patients with intermittent 
claudication. 
Future epidemiologic studies of peripheral vascular disease must 
take into account the merits and limitations of the clinical diagnosis 
of peripheral arterial occlusive disease. Horowitz et al. (36) suggest 
that the judgment of trained paramedical personnel compares 
favorably with that of physicians in screening large numbers of 
patients for peripheral vascular disease. 
De Backer et al. (21) emphasized the importance of using ankle 
systolic blood pressure measurement with Doppler ultrasound to 
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objectively screen patients for peripheral arterial occlusive disease. 
Such useful techniques have been emphasized by Marinelli et al. (54) 
in a large epidemiologic study of vascular disease in patients with 
diabetes mellitus. 
In addition to clinical studies, several autopsy surveys have 
reported an association between smoking and peripheral atheroscle- 
rosis (59, 60, 66, 67, 75, 89). Such studies have supported a direct 
association between smoking and the formation of abdominal aortic 
fatty streaks, as well as their subsequent conversion to raised lesions. 
Most reports of peripheral vascular disease emphasize the predom- 
inant occurrence of this disorder in males (88). However, diabetes 
mellitus may predispose females to peripheral arterial occlusive 
disease in a frequency similar to that of males. Broome et al. (12) 
reported on 15 women with aortoiliac occlusive disease, all of whom 
were cigarette smokers (mean, 20 cigarettes a day), and none of 
whom had diabetes mellitus. The temporal trend toward increased 
smoking by women may significantly increase their risk of peripher- 
al arterial occlusive disease. The Framingham heart study (47) found 
that the incidence of peripheral vascular disease was increased 
among smokers and that cigarette smoking was as strong an 
independent risk factor in women as in men. Heavy smokers had a 
threefold increase in the incidence of peripheral arterial occlusive 
disease. Weiss (86) evaluated 245 women with peripheral arterial 
occlusive disease. The risk in ex-smokers who had not smoked for 5 
years or more was nearly normal, with a risk ratio of 1.06. Patients 
who had not smoked for 1 to 5 years had a risk ratio of 1.70. Patients 
who continued to smoke, but smoked less than one pack a day, had a 
risk ratio of 11.53, and those who smoked more than a pack a day 
had a risk ratio of 15.56. The risk for arterial occlusive disease was 
particularly associated with the proximal aortoiliac segment and 
was less associated with distal or femoral-popliteal artery disease. 
This study described both a dose-response effect and a benefit 
following cessation of smoking. 
There have been few studies of the association of visceral arterial 
occlusive disease and cigarette smoking. Mackay et al. (53) reported 
on the correlation of smoking and renal artery stenosis. They found 
that smoking was nearly twice as common in patients with nonma- 
lignant hypertension associated with renal artery stenosis as in 
those patients with hypertension of comparable severity without 
renal artery disease. Previous studies documented that a higher 
proportion of smokers was noted in patients with malignant 
hypertension (IO, 39). Cigarette smoking was present in 20 of 22 
patients with malignant hypertension and associated renal artery 
stenosis (53). 
Cigarette smoking appears to be the only form of tobacco 
consumption associated with an increased risk of developing periph- 
era1 arterial occlusive disease. Smith (73) reported that no cases of 
intermittent claudication were found in patients who used only 
smokeless tobacco (snuff, chewing tobacco), provided that patients 
with a history of diabetes mellitus, heavy ethanol intake, or dietary 
problems were excluded. 
Frishman (29) reviewed the effects of involuntary smoking on the 
cardiovascular system. Although levels of carbon monoxide common- 
ly found in cigarette-smoke-filled environments have been demon- 
strated to decrease exercise tolerance in patients with existing 
angina pectoris and intermittent claudication, studies are not 
available to document the role that passive smoking might play in 
the etiology of atherosclerotic cardiovascular disease (69). 
Clinical Investigations in Humans 
In several studies, the effect of cigarette smoking or the constitu- 
ents of cigarette smoke on the human peripheral vascular system 
has been investigated. Cryer et al. (17) studied the effects of cigarette 
smoking, sham smoking, and smoking with adrenergic blockade in 
10 subjects. There was a significant increase in the mean plasma 
norepinephrine and epinephrine levels associated with smoking. The 
smoking-related increase in pulse rate, blood pressure, blood glycer- 
ol, and blood lactate-pyruvate ratio was prevented by adrenergic 
blockade. These findings were attributed to local norepinephrine 
release from adrenergic axon terminals within tissues rather than to 
increments in circulating catecholamines. In experiments comparing 
cigarettes of varying nicotine content, the subjective recognition of 
different cigarette brands may influence the results of clinical 
experiments. Ossip et al. (58) have suggested that nicotine extraction 
filters be used to minimize the within-subject differences due to the 
recognition of cigarette brand. The influence of the type of beta 
blocker used in therapy of patients who are cigarette smokers was 
investigated by Trap-Jensen et al. (79). These authors found that the 
use of a nonselective beta blocker, propranolol, during smoking 
caused a marked rise in diastolic and mean blood pressure and 
forearm vascular resistance, due to the blockade of adrenaline- 
induced vasodilatation, which is mediated by beta-2 receptors in the 
resistance vessels. Selective beta-l blockade with atenolol attenuated 
the systolic blood pressure and the tachycardiac responses induced 
by cigarette smoking. 
Several studies have suggested an association between cigarette 
smoking and the level of circulating hemoglobin. Castleden et al. (14) 
evaluated 61 male nondiabetic smokers with peripheral artery 
disease and compared them with age-matched nondiabetic male 
smokers and nonsmokers admitted for routine inquinal herniorrha- 
phy. They found a significant association between smoking and 
hemoglobin levels and a highly significant correlation between 
smoking and peripheral vascular disease. In addition, the carboxy- 
hemoglobin generated by smoking was associated with increased 
platelet adhesiveness, decreased fibrinolytic activity, and increased 
plasma fibrinogen. Yamori et al. (91) suggested that the hematocrit 
was increased in proportion to the number of cigarettes smoked and 
that this may be a mechanism for increased mortality rate from 
cardiovascular diseases in smokers. 
Other hematologic effects of cigarette smoke have been observed 
in blood platelets and with fibrinolysis. Davis and Davis (19) studied 
18 volunteers to assess the effect of cigarette smoking on platelet 
aggregation. The smoking of two unfiltered tobacco cigarettes during 
a 2Cminut.e period resulted in a significant increase in the platelet 
aggregate ratio. During this time, the mean plasma nonesterified 
fatty acid concentration remained unchanged. These same authors 
(20) subsequently reported that the increase in the platelet aggregate 
ratio resulting from smoking two unfiltered cigarettes could be 
prevented with pretreatment with one aspirin tablet. Janxon and 
Nilsson (43) evaluated the fibrinolytic activity in vein walls among 
71 randomly selected heavy smokers and 41 nonsmokers from a 
population of men born in 1914 residing in Malmo, Sweden. After 12 
hours’ abstention from tobacco, the smokers were found to have the 
same fibrinolytic activity as nonsmokers. Smoking six cigarettes 
during 3 hours increased the fibrinolytic activity in the blood, 
presumably hecause of the combined effects of nicotine and carbon 
monoxide. 
Several studies of the effects of smoking on the peripheral 
circulation have involved noninvasive measurement of limb blood 
flow using plethysmographic techniques. Janzon (40) used a water- 
filled plethysmograph to study 71 randomly selected heavy smokers 
and 41 nonsmokers from the study group of men born in 1914 and 
residing in MalmS, Sweden. The smokers were found to have lower 
systolic and diastolic arm blood pressure and lower systolic blood 
pressure in the big toe with greater pressure gradients from the arm 
to the big toe compared with nonsmokers. During reactive hyper- 
emia, smokers had decreased blood flow and increased peripheral 
vascular resistance. This same author (42) studied the acute effect of 
smoking on heart rate, blood pressure, and calf blood flow in 20 
randomly selected 59-year-old male heavy smokers (more than 15 g 
of tobacco per day). After smoking two cigarettes, there was a 
significant increase in blood pressure and heart rate. Blood flow and 
resistance to blood flow in the calf did not change at rest, but during 
reactive hyperemia, the resistance to blood flow decreased and calf 
blood flow increased, an effect attributable to the peripheral 
vascular effects of nicotine. Janzon (41) evaluated 51 randomly 
selected 59-year-old heavy smokers for changes in peripheral vascu- 
lar function after smoking cessation of 8 to 9 weeks. He noted an 
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increase in blood flow during reactive hyperemia in patients who 
stopped smoking and a decrease in blood flow in patients who 
continued to smoke. Isacsson (38) performed venous occlusion 
plethysmography on the calf of 809 randomly selected 55-year-old 
men residing in Malmij, Sweden. Sixty-two percent of the total 
population examined were cigarette smokers. A history of intermit- 
tent claudication was present in 20 subjects, but arterial insufficien- 
cy could be clinically demonstrated in only 6 of the 20. Ilio-femoral 
occlusive disease was found in another eight patients. These patients 
had a higher prevalence of systolic hypertension, hypercholesterol- 
emia, hypertriglyceridemia, and lipoprotein abnormalities. The 
amount of smoking was inversely related to the magnitude of the 
arterial flow capacity in the legs and directly related to the presence 
of occlusive arterial disease. More ex-smokers had high blood flow 
capacity than had a low flow capacity. The arterial flow capacity in 
the legs was reduced in direct proportion to the tobacco consumption 
per day. Coffman (15) used plethysmographic and isotope methods to 
document cutaneous vasoconstriction, increased skeletal muscle 
blood flow, and decreased venous distensibility in human subjects 
after tobacco smoking or nicotine injection. 
Recent studies have employed Doppler ultrasound to document 
changes in blood velocity and transit time following cigarette 
smoking. Sarin et al. (68) noted a reduction in mean digital artery 
blood flow velocity of 42 plus or minus 6 percent following the 
smoking of a single cigarette in 10 male volunteers. Lusby et al. (52) 
evaluated the effects of cigarette smoking on hemodynamics in the 
large and small vessels of patients with peripheral arterial occlusive 
disease. Using Doppler probes, large vessel response to smoking was 
evaluated by measurement of pulse transit time delay. Patients with 
occlusive arterial disease had significant shortening in transit time 
delay, suggesting a stiffening in the main vessels in response to 
smoking. Such changes were not seen in control patients without 
peripheral arterial occlusive disease. A digit pulse volume recorder 
was used to measure the amplitude of digit pulsation, a measure of 
small vessel hemodynamics. The digit pulse amplitudes decreased 
significantly in response to both low and high nicotine cigarettes, 
and patients tended to self-titrate their nicotine intake. Due to this 
maintenance of nicotine level, the study failed to demonstrate a 
benefit on small vessel hemodynamics accompanying a switch from 
high to low nicotine cigarettes. 
Recent studies suggest that tobacco allergy may play a role in the 
development of the cardiovascular effects of cigarette smoking. 
Becker and Dubin (6) reported that approximately one-third of 
healthy smoking and nonsmoking volunteers exhibited immediate 
cutaneous hypersensitivity to a glycoprotein antigen purified from 
cured tobacco leaves and found in cigarette smoke. Denburg et al. 
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(22) skin-tested 164 peripheral vascular disease patients with puri- 
fied tobacco glycoprotein. The authors also performed basophil 
degranulation tests to assess in vitro reactivity to tobacco glycopro- 
tein. Immediate skin-test hypersensitivity to tobacco glycoprotein 
was found in 11 percent of patients with angiographically demon- 
strable peripheral vascular disease; a control group of normal 
patients was not skin tested. The basophil degranulation test was 
positive in 60 percent of smokers compared with 24 percent of 
nonsmokers (p < 0.01). Forty-three percent of skin-test-negative and 
91 percent of skin-test-positive patients with peripheral vascular 
disease had a positive basophil degranulation test. Only 3 percent of 
patients with negative basophil degranulation tests had a positive 
skin test. The percent of patients with positive skin tests increased in 
proportion to the severity of angiographic peripheral vascular 
disease. What role tobacco hypersensitivity may play in the develop 
ment of peripheral atherosclerosis remains to be elucidated. 
A final area of clinical epidemiologic study is the relationship of 
maternal smoking to the fetal cardiovascular system. Asmussen (2) 
studied the umbilical artery, umbilical vein, and vessels of the 
placental villi of newborn children in relation to the maternal 
smoking history. His studies documented that severe damage to 
vessel walls is associated with maternal tobacco smoking during 
pregnancy. These fetal vascular changes may lead to vascular lesions 
later in life. 
Experimental Studies in Animals 
In several experimental animal studies, the relationship between 
cigarette smoking and atherosclerotic peripheral vascular disease 
has been investigated. Birnstingl et al. (9) evaluated the effect of 
short-term exposure to carbon monoxide on platelet adhesion in 
rabbits. In rabbits exposed on several occasions to an atmosphere 
containing 400 parts per million carbon monoxide for 6 to 14 hours, 
there was a highly significant increase in platelet stickiness immedi- 
ately after exposure to carbon monoxide, followed the next day by a 
significant fall to levels below the preexposure value. 
Richardson (62) evaluated the effects of nicotine and tobacco 
smoke on capillary blood flow in the rat. Red blood cell velocity in 
single capillaries within the mesenteric tissue of anesthetized rats 
was evaluated immediately before and after either intravenous 
injection of nicotine or inhalation of tobacco smoke. Blood velocity 
changes associated with tobacco exposure were considered to be 
passive consequences of changes in systemic arterial blood pressure. 
This study did not evaluate differential effects on various vascular 
beds of cigarette smoke or nicotine. 
Fisher et al. (27) evaluated the effect of exposure of cholesterol-fed 
rabbits to the smoke of one cigarette daily over an ll- to 19month 
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period. The study failed to demonstrate quantitative or qualitative 
differences in atherosclerosis in the aorta or coronary or visceral 
arteries or significant changes in serum lipids. Rooyse et al. (II) 
administered nicotine in the drinking water of New Zealand white 
rabbits during a 25-week period. Fasting serum levels of glucose, 
triglyceride, total cholesterol, and LDL cholesterol were elevated in 
the nicotine-treated rabbits compared with the controls. However, 
there was no significant difference between nicotine-treated and 
control animals in leukocyte, erythrocyte, and platelet counts or in 
hematocrit or hemoglobin. Endothelial cells from the aortic arch of 
nicotine-treated animals showed extensive changes, including in- 
creased cytoplasmic silver deposition, increased formation of micro- 
villi, and numerous focal areas of “ruffled” endothelium (projections 
from the cell surfaces). 
Marshall et al. (55) evaluated the effects in minipigs of exposure to 
cigarette smoke or varying concentrations of carbon monoxide for l- 
to X-hour periods. Cigarette smoke and short carbon monoxide 
exposure resulted in adherence of platelets to the endothelium. After 
longer exposures, microscopic thrombi were found in the vessel 
walls. Underlying degeneration in the endothelial cells developed 
upon exposure to carbon monoxide. 
Recent investigations have involved the training of subhuman 
primates to smoke cigarettes in order to assess the effect on the 
peripheral circulation and hematologic factors. Schwartz et al. (70) 
have summarized data on experiments in baboons taught to smoke 
cigarettes. Rogers et al. (63) reported on 36 young adult male 
baboons who were fed an atherogenic diet. Twenty-eight baboons 
were randomly assigned to smoke 43 cigarettes daily, and 18 baboons 
were taught to puff air under equivalent experimental conditions. 
The cigarette-smoking baboons demonstrated significantly higher 
carbon monoxide and thiocyanate concentrations in blood and 
cotinine concentrations in the urine than did the nonsmoking 
baboons. There were no significant differences found in serum total 
cholesterol, VLDL, and LDL cholesterol or triglyceride concentra- 
tions in the smokers compared with the controls. Smoking baboons 
had significantly higher fasting glucose concentrations and lympho- 
cyte counts. Platelet counts, platelet aggregation, food and water 
intake, and body weight were not significantly different in the two 
groups. Such experimental models may provide a valuable method to 
assess the long-term effects of smoking on the peripheral vascular 
system of primates. 
Intervention Studies 
There is considerable indirect evidence that cessation of smoking 
may significantly influence the effect of medical or surgical therapy 
on peripheral arterial occlusive disease. Unfortunately, the tendency 
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of some patients with peripheral arteral occlusive disease to con- 
tinue smoking often defeats the purpose of medical intervention. 
Thiruvengadam et al. (76) evaluated the effect of diseases at different 
organ sites upon the smoking habit of chronic smokers. A significant 
reduction or cessation of smoking was observed in subjects with 
cardiovascular, pulmonary, neoplastic, or gastointestinal disease, 
diabetes mellitus, or cirrhosis of the liver. Medical advice played a 
role in the reduction for only 19 percent of the subjects. Other 
reasons for reduction or cessation of smoking were socioeconomic 
factors, aggravation of disease, or belief in a possible relationship 
between smoking and the disease. Only subjects with psychiatric 
illnesses and peripheral vascular diseases showed no significant 
reduction in the smoking habit in comparison with the controls. Of 
89 subjects with peripheral vascular disease, 12 increased their 
smoking with the advent of disease. Feinleib and Williams (26) 
emphasized that peripheral vascular disease risk is elevated only in 
cigarette smokers and not in cigar or pipe smokers. Smokers who 
quit gradually approach the lower risk of nonsmokers. Birkenstock 
et al. (8) reported on the role of cessation of smoking on the medical 
therapy of 390 patients with peripheral vascular disease who were 
either ineligible or unfit to undergo operative treatment. Conserva- 
tive management included foot hygiene, walking exercise, cessation 
of smoking, a low cholesterol diet, and vitamin E therapy. Of 277 
patients who smoked, 164 were able to stop smoking. Eighty-five 
percent of patients who stopped smoking showed improvement in 
symptoms of peripheral vascular disease on the medical regimen, in 
comparison with only 20 percent who improved among those who 
continued to smoke. The degree of improvement was greater in ex- 
smokers than in nonsmokers. No patient with diabetes mellitus who 
continued to smoke improved under medical management. 
Cessation of smoking appears to play an important role in the 
long-term success of reconstructive arterial surgery. Wray et al. (901 
recorded a significantly higher rate of late arterial occlusion in 
patients who had undergone aortofemoral bypass and who persisted 
in smoking when compared with patients who stopped smoking 
postoperatively. In 30 patients who continued to smoke, 9 late 
occlusions occurred, but no occlusions developed in 16 patients who 
ceased smoking postoperatively. Myers et al. (5s) reported a retro- 
spective study of 217 patients undergoing aortofemoral (135) or 
femoropopliteal (107) vascular reconstruction. Patients who stopped 
smoking or smoked no more than five cigarettes daily after their 
operation had late patency rates of approximately 90 percent for 
aortofemoral reconstruction and 80 percent for femoropopliteal vein 
grafts. Patients who continued to smoke more than five cigarettes 
daily had a late complication rate approximately three times greater 
after aortofemoral reconstruction and four times greater after 
femoropopliteal vein grafting, compared with examokers. The late 
patency rate was approximately inversely proportional to the 
number of cigarettes smoked per day after the operation. The 
incidence of late complications was not correlated with the number 
of cigarettes smoked prior to operation. Burgess et al. (13) noted that 
among patients whose below-knee amputation failed to heal, six of 
seven (85 percent) were cigarette smokers, whereas among those 
whose distal amputations healed, only half were smokers. 
Aortic Aneurysm 
Nature of Abdominal Aortic Aneurysm 
Abdominal aortic aneurysm refers to the dilatation or expansion 
of the aortic wall due to degenerative or inflammatory destruction of 
the components of the wall. The vast majority of abdominal aortic 
aneurysms are due to atherosclerosis, although other conditions, 
including infection, trauma, dissection, or inherited metabolic dis- 
ease (Ehlers-Danlos syndrome) may be causes. The dilatation may 
involve only a portion of the arterial wall (saccular aneurysm), but 
most often involves generalized fusiform enlargement of the artery. 
Most abdominal aortic aneurysms are located distal to the renal 
arteries and proximal to the aortic bifurcation. Abdominal aortic 
aneurysms may coexist with aneurysmal changes in the iliac, 
femoral, or popliteal arteries. Less commonly, an aneurysm may 
involve the entire aorta, including the suprarenal and descending 
thoracic aorta (thoracoabdominal aneurysm). 
Most abdominal aortic aneurysms are asymptomatic and are 
discovered incidentally during a physical examination or on X-ray 
examination of the spine or abdominal organs. Symptoms, such as 
back pain or shock, are usually associated with the complication of 
rupture and constitute the main threat of abdominal aneurysm. Less 
commonly, distal embolization may lead to acute or chronic periph- 
eral arterial occlusive disease. Although palpation of aortic enlarge- 
ment is the best clinical indicator of abdominal aneurysm, abdomi- 
nal B-mode ultrasonography is the most accurate noninvasive 
method to estimate the exact size of the aneurysm. Arteriography is 
seldom used before an operation unless there is associated occlusive 
peripheral vascular disease or a suspicion of renovascular hyperten- 
sion; this is because the arteriogram may often not depict the true 
size of the aneurysm owing to the mural thrombus contained within 
the aneurysm. Surgical repair with a prosthetic graft is recommend- 
ed for all abdominal aortic aneurysms more than 5 cm in diameter 
unless associated diseases make the operative risk greater than that 
of the prognosis of the aneurysm. The risk of rupture increases 
exponentially with the diameter of the aneurysm. 
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TABLE S.-Mortality ratios and deaths (n in parentheses)’ from nonsyphilitic aortic aneurysm related 






Data Followup Number 








187,783 white Questionnaire 
males in 9 and followup 
states, !50-69 of death 
years of age certiticate 
U.S. male Questionnaire 
veterans, and followup 






NS’ 1.00 (25) (expected) 
SM’ 2.72 (66) (p<O.o05) 
>39 . . . . . 7.26 (17) 
NS ._................ 1.00 (58) 
Current cigarettes 5.24 (234) 
l-9 cigarettes/day. 2.12 (13) 
10-20 . . . . . 5.53 (124) 
2139 ..t.. 5.95 (76) 
NS-1.00 (58) NS-1.00 (56) 
SM-1.13 (8) SM-2.06 (24) 
Hammond & 358,534 males, Questionnaire 6 337 NS .................. 1.00 Data apply 
Garfinkel 445,875 females, and followup I-9.. ................ 2.62 only to males, 
1969 40-79 years of of death lo-19 ............... 3.85 M-69 years 
(31) age at entry certificate 20-39 ............... 4.54 of age 
>40.. ............... 8.00 
Weir and 68,153 Questionnaire 5-8 51 NS .................. 1.00 SM includes 
Dunn California and followup All .................. 2.64 ex+mokers; 
1970 male workers, of death f10.. ............... 2.44 NS includes 
(85) 35-64 years of certificate 220 ................ 2.88 pipe and 
age at entry 230.. ............... 2.54 cigar smokers 
’ Unless otherwise specified, disparities between the total number of deal he and the individual categories are due to the exclusion of occasional, miscellaneous, or former smokenr. 
‘NS = nonsmokers; SM = smokers. 
Summary of Epidemiologic Data 
Several large epidemiologic studies have suggested an elevated 
incidence of death from ruptured abdominal aneurysm in smokers 
compared with nonsmokers (31,32,33,45,85) (Table 2). Anderson et 
al. (I) analyzed 344 autopsies for causes of death and relationship to 
smoking history. The male to female ratio was 1.9:l.Q with a 
smoking incidence of more than double that of the general popula- 
tion. The overall longevity of men was less than that of women. 
There was an inverse relationship between smoking and longevity. 
Five diseases that accounted for 39 percent of the deaths of smokers 
were bronchogenic carcinoma, peptic ulcer, aortic aneurysm, acute 
myocardial infarction, and centrilobular emphysema. The 15 rup 
tured abdominal aortic aneurysms were in 13 male and 2 female 
smoking patients. 
Auerbach and Garfinkel (4) evaluated atherosclerosis and aneu- 
rysm of the aorta relative to smoking habits and age. In 1,412 aortas 
collected at autopsy from 1965 to 1970 from male patients, there was 
a direct relationship between the extent of atherosclerotic lesions 
and both smoking habit and age. The aortic lesions were graded for 
formation of plaques, ulceration, and calcification. The complexity of 
the plaques increased with the number of cigarettes smoked and was 
greater in ex-cigarette smokers and pipe or cigar smokers than in 
nonsmokers. More extensive alterations were found in the abdomi- 
nal aorta than in the thoracic aorta. Aneurysms were found eight 
times more frequently among those smoking one to two packs of 
cigarettes per day than among nonsmokers. Black subjects showed 
about one-half the number of aneurysms and fewer extensive 
atherosclerotic lesions than did white subjects. At ages over 65 years, 
abdominal aortic aneurysms were found in 11 percent of all men and 
in 16 percent of the heavy smokers. 
Rogot and Murray (f%) evaluated the smoking relationship to 
causes of death among U.S. veterans. Over a X-year period, there 
was a significant reduction in mortality rate with the number of 
years of smoking cessation. Aortic aneurysm, along with bronchitis 
and emphysema and lung cancer, were among the diseases in which 
substantial excess risk remained even after 20 years’ cessation of 
cigarette smoking. 
Conclusions 
1. Cigarette smoking is the most powerful risk factor predisposing 
to atherosclerotic peripheral arterial disease. 
2. Smoking cessation plays an important role in the medical and 
surgical management of atherosclerotic peripheral vascular 
disease. 
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3. Death from rupture of an atherosclerotic abdominal aneurysm 
is more common in cigarette smokers than in nonsmokers. 
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Cardiovascular diseases are the leading causes of death in most of 
the technologically advanced countries of the Western Hemisphere, 
accounting for approximately half of all deaths annually in the 
United States (see Appendix A). The most common among these 
diseases are atherosclerosis and coronary heart disease; their 
ischemic complications result in increased morbidity and mortality. 
Coronary heart disease is the leading cause of death in the United 
States, accounting for two-thirds of all cardiovascular deaths (9s). 
It is generally acknowledged that coronary heart disease is a 
multifactorial process; that is, a variety of factors are involved in the 
development and clinical manifestations of this disease. Therefore, it 
is not a simple task to determine the etiology and time course of 
atherogenic development. In addition, the study of atherosclerosis is 
singularly difficult because no model in the experimental animal 
exactly replicates the human disease in physiological, morphological, 
and clinical detail. Investigations in human subjects are further 
limited by the inability to diagnose the disease in preischemic phases 
(44). Most studies of the pathology of cardiovascular diseases (CVD) 
have been based on autopsies by coroners or on hospital populations 
in which only a limited fraction of decedents have been examined. 
Individuals may show considerable variance in the degree of 
atherosclerosis identified at autopsy, limiting the value of retrospec- 
tive analysis (137). 
In 1971, the U.S. Government established the Task Force on 
Arteriosclerosis to assess research needs and to make recommenda- 
tions on priorities for future program plans in this area. Most of the 
recommendations of this task force have been implemented during 
the past decade, and important advances have been made in basic 
and clinical research (96’). Most important, major epidemiological 
associations of cardiovascular disease risk not only have been 
established, but also have been supported by examinations of the 
arterial wall itself, enabling an increased understanding of the basic 
mechanisms of disease processes. 
Research in cell and molecular biology has provided new informa- 
tion about the interaction of blood-borne components, such as 
cholesterol, with the arterial wall. Basic research regarding this risk 
will help to increase our understanding of the effects of other 
circulating components, such as inhaled cigarette smoke constitu- 
ents, and will elucidate the susceptibility of arterial cells to these 
effects. 
The most firmly established modifiable risk factors for atheroscle- 
rotic CVD are hypercholesterolemia, hypertension, and cigarette 
smoking. In addition to these, diabetes mellitus, lack of exercise, 
obesity, and type A behavior have all been suggested as contributors 
to the multifactorial process known as atherogenesis (82). The 
assessment of any risk factor, such as cigarette smoking, must be 
made within the constellation of other risks, i.e., susceptibility to 
disease that is predicted by multifactorial analysis (53, 82). 
In the case of cigarette smoking, we are faced with an extremely 
difficult effort in determining direct cause and effect phenomena 
that are attributable to single factors. Over 4,000 different com- 
pounds have been identified in tobacco smoke (45), and the determi- 
nation of the direct or indirect actions of each upon the arterial wall 
seems an impossible task. 
We will attempt, however, to examine the major components 
believed to be associated with increased risk for CVD and to 
remember the multiple risk factors that might be associated with the 
development of cardiovascular dysfunctions in cigarette smokers. 
The variety of possible pharmacological and toxicological implica- 
tions of smoke and its constituents-and the absence of firm proof of 
what mechanisms are precisely involved in the unequivocal cause 
and effect relationship between smoking and cardiovascular dis- 
ease--should not detract from our confidence in the epidemiological- 
ly and clinically irrefutable evidence of the cause and effect role of 
cigarette smoking in contributing importantly toward heart disease. 
Tobacco Smoke: Physical Nature and Chemical Composition 
Inside the burning cone of a cigarette, a variety of physical and 
chemical processes occur in an oxygendeficient, hydrogen-rich 
environment at temperatures up to 900°C. Two major regions for the 
smoke formation are primarily observed-the heat-producing com- 
bustion zone and the pyrolysisdistillation zone (II). The mainstream 
smoke (MS) is formed during puff drawing; the sidestream smoke 
(SS) is generated largely by the smoldering of the cigarette between 
puffs. Throughout this review, data are discussed relating to 
cigarette smoke generated by smoking machines, unless otherwise 
noted. The standard machine smoking parameters for cigarettes 
were primarily developed for comparing smoke yields obtained 
under identical conditions. Today, these smoking parameters do not 
reflect the smoking behavior of many of the cigarette smokers and 
especially not that of smokers of low-yield cigarettes who tend to 
draw puffs of greater volume more frequently (64, 68,145). 
The mainstream smoke of tobacco products represents a very 
dense aerosol. In the case of a cigarette without a filter tip, it 
contains about 5 x 10’ spherical particles per milliliter. The size of 
the particles varies between 0.1 and 1.0 pm, with an average 
diameter of 0.4 pm (12). Three to eight percent of the weight of the 
total mainstream smoke of a cigarette without a filter tip is 
attributable to the particulate matter. The remainder consists of 
vapor phase components with nitrogen (So to 70 percent), oxygen (10 
TABLE l.-Approximate number of smoke compounds 
identified in some major compound classes 
Compound class Number identified 

































to 15 percent), carbon dioxide (10 to 15 percent), and carbon 
monoxide (3 to 6 percent) as major constituents (27,106). Of the more 
than 4,060 components identified in cigarette smoke, 400 to 500 are 
present in the vapor phase (27, 45). Table 1 lists some major classes 
of smoke components as recently recorded by Dube and Green (45). 
The total number of 4,720 in the table exceeds by far the total 
number of identified compounds because of repeated listing of the 
compounds that contain multifunctional groups. The acute toxicity 
of tobacco smoke is influenced not only by the chemical composition, 
aerosol concentrations, and particle sizes of the smoke, but also by 
the smoke pH. With a pH greater than 6.2, the smoke contains 
increasing amounts of unprotonated nicotine, which is the most toxic 
form of this habituating agent (Figure 1) (26). The unprotonated 
nicotine is at least partially present in the vapor phase and thus is 
likely to be more rapidly absorbed by the smoker (5). 
The U.S. cigarette is filled with a blend of tobaccos consisting of 
Bright, Burley, and Turkish types. Its mainstream smoke pH lies 
between 5.5 and 6.1. The smoke of cigarettes and cigars made up 
entirely of Burley or dark tobacco varieties has pH values of about 
6.5 for the first puffs and up to 8.0 for the last puffs (2s). 
Sidestream smoke, which is formed between puff drawings, is 
freely emitted into the air from the smoldering tobacco products. The 
peak temperature in the burning cone of a cigarette during puff 
drawing is about 900°C and between puffs it is about 600°C (162). 
This is an important factor for the divergence of specific toxic agents 
generated in mainstream and sidestream smoke. Another major 
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FIGURE l.-Protonation of nicotine 
SNJRCJC Srunnemann and Hofimann LX9. 
difference is that the side&ream smoke leaving the site of formation 
is subjected to greater air dilution and faster temperature decline 
than is the mainstream smoke, which travels through the tobacco 
column and is then inhaled as a concentrated aerosol. These 
conditions for sidestream smoke generation favor formation of 
aerosol particles of smaller size (0.01 to 0.1 pm) than those occurring 
in the mainstream smoke (0.1 to 1.0 urn) (12). The pH of sidestream 
smoke of a U.S. blended cigarette varies between 6.7 and 7.5, 
compared with pH values of less than 6.2 for the mainstream smoke 
of the same cigarette (26). This sidestream smoke thus contains free 
nicotine, which is essentially absent in mainstream smoke. Further- 
more, during smoldering, sidestream smoke is generated in a zone 
that is even more oxygen deficient than the zones involved in 
mainstream smoke generation during puff drawing. Consequently, 
components that are primarily formed in a reducing atmosphere are 
released into the environment to a greater extent than those formed 
in mainstream smoke that is inhaled by the smoker. Table 2 lists the 
amounts of some selected toxic compounds in mainstream smoke and 
the ratios of undiluted sidestream smoke components to mainstream 
smoke components (691. 
The air dilution of sidestream smoke emitted into the atmosphere 
is, of course, a determining factor for any assessment of human 
exposure. Nonetheless, in risk assessment, consideration must also 
TABLE t.-Distribution of selected toxic compounds in 
cigarette mainstream smoke (MS) and 
sidestream smoke (SS) of nonfilter cigarettea 
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be given to the fact that nitrogen oxide (NO), emitted into the 
environment as a sidestream smoke component, is rapidly oxidized 
to the more toxic nitrogen dioxide (NOz) (27). 
Nicotine 
Chemistry 
A number of observations have supported the concept that 
nicotine is the major habituating agent in tobacco and tobacco smoke 
(90). In addition to nicotine, tobacco contains a large variety of other 
alkaloids, most of which are 3-pyridyl derivatives (Figure 2). In the 
blended U.S. cigarette, nicotine constitutes 85 to 95 percent of the 
total alkaloids. Its concentration in the leaf depends primarily on the 
tobacco type and variety, stalk position, and cultivating practices 
(140). A study on the fate of Wlabeled nicotine, added in the form of 
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a salt solution to the tobacco rod of a filter cigarette, revealed that 
14.9 percent of labeled nicotine emerged in the mainstream smoke 
and 37 percent appeared in the sidestream smoke; 18.5 percent of 
Wnicotine was deposited in the butt, and the remainder (= 30 
percent) was broken down into pyrolysis products (Table 3) (73). The 
major pyrolysis products of nicotine in MS and SS of cigarettes are 
carbon dioxide, carbon monoxide, 3-vinylpyridine, 3-methylpyridine, 
pyridine, myosmine, and 2,3’dipyridyl(130). 
In most countries, cigarettes have shown a gradual and significant 
reduction over the last three decades in the sales-weighted average 
delivery of nicotine. In the United States the sales-weighted average 
nicotine yields decreased from 2.7 mg in 1955 to 2 1.0 mg in 1982 
(146). These nicotine reductions have been achieved primarily by 
technological modifications and perhaps some agricultural changes. 
The technological methods encompass extraction, oxidation or 
transformation of nicotine into less toxic compounds (91), formula- 
tion, and whole leaf curing. Reduction of nicotine delivery may be 
achieved by lowering the transfer of the alkaloid from tobacco into 
the smoke. This is accomplished by use of expanded tobacco laminae, 
adding leaf mid-veins and stems in the form of tobacco sheets 
(reconstituted tobacco), and by modifications of cigarette paper and 
by filtration (air dilution). From an agricultural standpoint, breeding 
lines have been developed with low levels of nicotine; however, these 
are not being used in commercial varieties at present (35). 
In 1982, about 90 percent of the U.S. cigarettes sold had filter tips 
made of cellulose or cellulose acetate or combinations of these with 
charcoal. Twenty-five percent of these filter cigarettes were perforat- 
ed to allow greater air dilution of the drawn smoke puffs. More 
recent filter construction utilizes longitudinal air channels in 
addition to perforation for maximal smoke dilution by air (70, 146). 
From the machine smoking of cigarettes, using standardized 
parameters of taking one puff per minute of 2 seconds’ duration with 
a volume of 35 ml, the U.S. Federal Trade Commission reported in 
March 1983 that the nicotine values of 208 commercial brands 
ranged from ~0.05 to 2.0 mg per cigarette (146). However, many 
people who smoke these cigarettes derive very different levels of 
smoke components from them, primarily because nicotine delivery 
in the mainstream smoke influences human smoking behavior and 
causes many smokers of low-yield products to draw puffs more 
frequently, take larger puff volumes, and inhale more deeply. This 
phenomenon has been observed by determining the smoking profiles 
of individuals or by assaying nicotine and cotinine in the sera of 
smokers (64,65,127). Cigarette filter construction that allows partial 
occlusion of the perforations or air channels of the filter tip may also 
lead to delivery of higher concentrations of mainstream smoke (89). 




























FIGURE 2.-Major alkaloids in tobacco and tobacco smoke 
' Numbersri~parrntheseedenoteIrgint~wokeofoaecigarette. 
' n.d.:Nc&determined. 
today primarily quantitated by gas chromatography (151). In physio- 
logic fluids such as saliva, serum, or urine, smokers’ exposure to 
nicotine is assessed by measuring the alkaloid itself or its major 
metabolite, either by gas chromatography with a special detector (63) 
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TABLE t.-Distribution of nicotine and its pyrolysis 
products in cigarette smoke 
Smoke products 
Nicotine Nicotine pyrolyaia 
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or, for large volumes of analyses, preferably by radioimmunoassay 
(RW (92). 
Metabolism 
The quantity of nicotine absorbed by the smoker depends on a 
number of factors, such as its concentration in the smoke, the 
individual’s smoking pattern, and the smoke pH. As discussed 
earlier, pH values greater than 6.2 increase the amount of unproton- 
ated nicotine in the smoke (Figure 1) (26). In the oral cavity, nicotine 
absorption varies between 4 and 45 percent (5). In the case of cigar 
smoke, the presence of free nicotine in the vapor phase, which is 
readily absorbed, and the harsh nature of alkaline smoke appear to 
be the major reasons for the cigar smoker’s tendency to avoid 
inhalation of this smoke (144). That levels of cotinine in the serum of 
cigar smokers approximate those of cigarette smokers supports the 
concept that nicotine from cigar smoke is absorbed through the 
mucous membranes of the oral cavity. Smokers of blended cigarettes 
and of British types of cigarettes (pH < 6.2) tend to inhale the smoke. 
In general, between 15 and 25 percent of the nicotine in tobacco 
appears in cigarette mainstream smoke, from which up to 90 percent 
is absorbed (162). The extraction of nicotine from the lungs occurs 
quite efficiently (143). Nicotine enters the pulmonary capillary blood 
and reaches the brain via the arterial systems (4). 
The metabolism of nicotine occurs principally in the liver. Its main 
metabolite, cotinine, appears in the blood within a few minutes after 
inhalation, and significant amounts of other metabolites appear in 
the tissues after about 5 minutes. The kidneys and lungs may, to a 
minor extent, also be involved in the metabolism of nicotine (24,143). 
Figure 3 illustrates the pathways of the metabolism of nicotine 
(54). Cotinine is the major metabolite of nicotine. It appears within a 
few minutes in the blood of smokers and has a half-life time of 
between 20 and 30 hours (92). Cotinine has been detected in 
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concentrations up to 10 pg per milliliter in the urine of smokers and 
up to 40 ng in the urine of nonsmokers who remained in a heavily 
polluted indoor environment for a minimum of 1 hour (65, 69). 
Nicotine-N’oxide has been detected in the urine of smokers (55). In 
the oral cavity of man, nicotine-N’oxide is reduced to nicotine (78). It 
has also been found that ingested nicotine-N’-oxide is reduced to 
nicotine by the gut flora or by intestinal enzymes (54). Nornicotine 
has been observed to be formed by Ndemethylation of nicotine (54). 
y-(3-Pyridyl)-y-methylamino butyric acid has been identified in 
human urine as 3-pyridylacetic acid, the major end product of 
nicotine metabolism (54). 
Association With Cardiovascular Diseases 
The pharmacological effects of nicotine absorbed by inhalers 
might be considered small and transient, but they are repeated 
many times each day and act directly on the sympathetic and 
parasympathetic cells of the central nervous system (CNS). Nicotine 
exerts a direct effect on ganglion cells, producing transient excita- 
tion followed by depression or transmission blockade. At the level of 
the central nervous system, nicotine causes CNS stimulation fol- 
lowed by CNS depression (133). 
Nicotine, like acetylcholine, discharges adrenaline from the adre- 
nal glands and other chromaffin tissue, and releases noradrenaline 
from the hypothalamus. It also releases antidiuretic hormone from 
the pituitary (331, and by excitation of chemoreceptors in the carotid 
body, augments various reflexes (36). 
The cardiovascular responses to nicotine, in general, parallel those 
that follow stimulation of the sympathicoadrenal system. Because 
nicotine has both stimulant and depressant effects, the responses of 
the cardiovascular system represent the sum of several different 
modes of action of this compound. 
Recently, progress has been made in identifying nicotine receptor 
sites in the brains of animals (81). When microinjected into the third 
cerebral ventricle, nicotine increased cardiac and respiratory rates, 
but it did not alter these parameters when microinjected into the 
periaqueductal gray. 
Most studies have shown that in people with known coronary 
heart disease, cigarette smoking increases the incidence of angina 
pectoris, although angina directly precipitated by smoking is rare. 
With additive risk factors such as hypertension, the threshold for 
attacks of angina can be significantly lowered by daily cigarette 
smoking. A long-term followup study of part of the Framingham 
cohort demonstrated a lack of association between smoking at 
diagnosis and subsequent cardiovascular events, however (74). This 
appeared to be related to changes in habits following diagnosis, 
implying that improved prognosis could be achieved by withdrawal 
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FIGURE 3.-Pathways of nicotine metabolism 
SOURCE: US. Department of Health. Education. and Welfare (144~. 
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TABLE 4.-Effects of nicotine on the cardiovascular system 
Increases in blood pressure 
Increases in heart rate 
Electorcardicgraphic changes 
Nonapecifk ST and T-wave changes 
Increased conduction velocity, propensity toward arrhythmias 
Exacerbation of angina in coronary patients 
Diminished left ventricular performance in coronary patients 
SOURCE: Stimmel(136). 
of daily cigarette smoking. The relationship here cannot be attrib- 
uted solely to removal of nicotine; it can also be related to 
improvements in cardiovascular status such as increased oxygen 
saturation. 
The exact mechanism whereby nicotine could trigger a cardiovas- 
cular event is unknown. However, a common initial feature of 
several suggested mechanisms is a sympathetic discharge (Table 4) 
(14). This stimulation of sympathetic nerves, with consequent release 
of the neurotransmitter norepinephrine within the myocardium, has 
been shown to lower the ventricular fibrillation threshold in animals 
(38). Responses to sympathetic activity such as hemodynamic 
parameters of heart rate and systolic blood pressure generally reflect 
plasma nicotine concentrations (88, 112, 135). Increase in pulse rate 
and systolic pressure, decrease of pressure pulse transit time, and 
digital blood flow are well correlated with nicotine levels of the 
cigarettes smoked (88); the same effects can be noted with intrave- 
nous injection of varying doses of Gnicotine (150). 
In a recent study on the cardiovascular effects of infused nicotine, 
Benowitz and colleagues (18) showed that nicotine infusions could 
achieve plasma concentrations and cardiovascular effects similar to 
those induced by cigarette smoking. Heart rate increased after low 
concentrations of nicotine were administered and reached a plateau, 
beyond which increasing blood concentrations of nicotine had no 
effect. In these studies, as in those of Cryer et al. (38), elevations in 
pulse rate and blood pressure occurred promptly after the start of 
nicotine exposure and preceded the investigators’ measurement of 
increased increments of plasma epinephrine and norepinephrine 
concentrations. These hemodynamic effects of nicotine are probably 
not mediated by circulating catecholamine levels, but are due to 
local release of the sympathetic neurotransmitter norepinephrine 
from adrenergic axon terminals. 
The increase in circulating catecholamines has been demonstrated 
to be nicotine dose dependent by Hill and Wynder (66), who found an 
increase in epinephrine levels in plasma to be proportional to the 
nicotine content of the cigarette smoked. Although elevated with 
smoking, norepinephrine levels were not correlated with plasma 
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FIGURE I.-Net results of catecholamine elevations as 
mediated through nicotine stimulation 
SOURCE:Schievelb& andE%erhardtWZ?J. 
nicotine. The release of epinephrine is probably mediated through 
the adrenal medulla and chromaffm tissue. A more recent study 
showed that when the pH of the smoke is altered to favor more 
effective absorption of the alkaloid, smokers compensate to adjust 
nicotine intake, resulting in modulation of the epinephrine response 
(5% 
The net results of catecholamine elevations as mediated through 
nicotine stimulation are summarized in Figure 4. In general, the 
cardiovascular responses of increased heart rate and augmented 
contractility create a variable oxygen need; nicotine also dilates the 
coronary arteries, which exerts a measurable effect only in healthy 
individuals without coronary heart disease (129). 
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Available evidence suggests that the release of adrenergic trans- 
mitters by nicotine and other cholinergic agonists is mediated by 
nicotine receptors (159). Norepinephrine outflow from adrenergically 
innervated tissues is evoked by nicotine and the nicotinic agonist 
dimethylphenylpiperainium, but not by the muscarinic agonists 
methacholine and oxytremorine (20). Studies using a variety of 
inhibitors of nicotinic receptors have resulted in a number of 
possible and related mechanisms of action of nicotine on the central 
nervous system and the cardiovascular system: (a) prevention of 
inactivation of the adrenergic transmitter after its release, (b) 
facilitation of adrenergic transmitter release, Cc) involvement of 
histamine (311, (d) mediation of nicotine by neuronal uptake, (e) 
induction of nerve action potentials, (f) depolarization of nerve 
terminals, and (e;) exocytotic release of adrenergic transmitter. These 
mechanisms are not necessarily mutually exclusive. 
Through these mechanisms, nicotine might exert powerful effects 
on the sympathicoadrenal control of cardiovascular function. Many 
issues remain to be elucidated and understood, however, such as the 
effects of drug interactions with nicotine (421, the inter-individual 
variability in metabolism of this alkaloid (18), and tolerance (1321, as 
well as the habituating mechanisms of the cigarette smoking habit 
itself (77). 
In addition to hemodynamic perturbations, nicotine intake has 
been implicated in atherosclerotic changes in the arterial wall itself. 
Nicotine has been associated with acceleration of atherosclerotic 
disease, the initiation of which is becoming more clearly understood. 
Experimental evidence is emerging that links atherogenesis to 
tobacco smoke inhalation, possibly through mechanically induced 
intimal damage as well as through hypoxia. The pathogenesis of 
vascular injury might occur via two mechanisms. The first mecha- 
nism is accelerated by high levels of blood fat, particularly cholester- 
ol in the low density lipoprotein fraction, and it is the abnormal 
accumulation of this lipid in the lining of large arteries that leads to 
changes in cells of the arterial wall, causing a thickened intima rich 
in fat and smooth muscle cells. 
The other mechanism of atherogenesis resides in vessel injury and 
thrombosis, with the thrombus persisting and becoming organized, 
leading to vessel wall thickening (103). Plaque development may 
therefore involve damage to the intima and a complex interaction 
between intima and the circulating blood, resulting in (a) platelet 
release of mitogenic factors, (b) increased uptake of serum lipopro- 
teins, and (c) intracellular deposition of lipid (123). It has been shown 
that platelets and cells, such as macrophages, can make available at 
sites of injury a protein that will cause smooth muscle cells to 
proliferate and another that will make them migrate into the 
arterial intima (122). 
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Unfortunately, we have relatively little evidence about how the 
endothelium can be injured. Blood flow, particularly at a high shear 
rate, can damage the endothelium, and high serum lipid ‘levels can 
be associated with vessel injury (125). Immune reactions have been 
shown to damage vessels, and products from cigarette smoke 
components are suspected of causing injury to the cellular lining of 
vessels (87). 
Nicotine can be implicated in the processes of atherogenesis 
through several of its known actions on the cardiovascular system 
(47). Via catecholamine release and the subsequent increase in free 
fatty acids, nicotine affects different steps in blood coagulation 
pathways, including platelet aggregation (48, 129) and increased 
fibrinolytic activity, with possible injurious effects to the cells lining 
the arterial wall. Blood pressure and heart rate can influence the 
blood shear rate, and transitory increases in blood sugar can 
influence basic metabolic rates (42). 
A desquamating effect of nicotine on the vascular endothelium has 
been demonstrated in rabbits when nicotine was given in relatively 
low doses, as compared with those received by cigarette smoking (23). 
In a clinical assay, smoking two cigarettes increased the number of 
circulating endothelial cells by 50 percent. The interaction of 
nicotine and other cigarette smoke constituents could influence this 
increase in endothelial cells released into the bloodstream (137). 
The possible role of prostaglandins in the promotion of atherogene 
sis is tied in with the nicotine induction of altered prostaglandin 
activity (155, 157). EXdence suggests that smoking causes a throm- 
boxane (TxAz):prostacyclin (PG12) imbalance. Nicotine increases 
platelet activity in vitro, and cigarette smoking in general has been 
shown to increase this activity in humans (95) as well as to 
potentiate platelet aggregability in the presence of hyperlipidemia 
(67). Nicotine inhibits the ability of coronary arteries to synthesize 
prostacyclin-like substances in vitro, an effect that is more pro- 
nounced in vascular cultures derived from patients who smoke than 
from nonsmoking control subjects (156). This phenomenon and 
alterations in endothelial barrier functions have also been investi- 
gated in umbilical arteries derived from smoking and nonsmoking 
mothers (7). Pronounced changes were seen in the endothelium of 
the vessels derived from smoking mothers. These consisted of 
swelling of the cells with numerous blebs on the luminal membrane. 
In addition, extensive edema of the subendothelial spaces was a 
regular feature, as was an increase in basement membrane 
thickness. These changes are consistent with an increase in endothe 
lial permeability (7). 
Cigarette smoking and nicotine in particular may therefore alter 
platelet function and prostaglandin production in potentially delete- 
rious ways, suggesting that smoking may interfere with vascular 
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defense against platelet deposition, a factor in atherogenesis (124). 
Specifically, nicotine might alter the occupancy of endothelial 
receptors for &adrenergic catecholamines, increasing the intracellu- 
lar concentration of cyclic AMP and inhibiting the release of 
arachidonic acid from endothelial cell phospholipids, and thereby 
reducing prostacyclin synthesis (I). 
Nicotine has been implicated at other levels of arterial cell 
function. This alkaloid has been found to produce an exposure-time- 
and concentrationdependent effect on the lysosomes of endothelial 
cells through increases in lysosome fragility and formation of large 
acid phosphatase positive vacuoles, presumably lysosomes, in rat 
endothelial cells (158). These findings suggested that the lysosomal 
vacuolar system should be examined as a possible target for cellular 
dysfunction following chronic exposure to nicotine. 
Alterations in the levels of lysosomal enzymes in atherosclerotic 
tissue have been demonstrated in the presence of single risk factors 
including hypercholesterolemia (601, hypertension, and diabetes 
mellitus (160) in animals, as well as in diseased areas of human 
vessels (49). Inhalation experiments have shown that aortic tissue 
from animals chronically exposed to cigarette smoke exhibited 
increased levels of several lysosomal enzymes as well as cholesterol 
and cholesteryl esters (57). Studies are currently being carried out to 
determine the specific cigarette smoke constituents responsible for 
these changes. 
Cigarette smoking has been implicated in elevation of serum lipids 
and changes in lipoprotein distribution (127). Reports in the litera- 
ture run from no alteration (118) to significant changes in the 
direction of those levels promoting atherogenesis (25, 71). By 
stimulating sympathetic nervous activity and catecholamine release, 
nicotine can cause an elevation in plasma free fatty acids and 
increased secretion of very low density lipoprotein triglycerides (21). 
Kirchbaum and colleagues (84) found that the rise of free fatty acids 
in plasma produced by smoking was twice as high in patients who 
had suffered a myocardial infarction as in controls. This rise in free 
fatty acids is probably a result of catecholamine-mediated lipolysis 
and may be an important mediator in the production of endothelial 
cell injury (161). In addition, cigarette smoking in general is 
associated with a reduction in high density lipoprotein apoprotein 
components (19) and may attenuate this lipoprotein’s antiatherogen- 
ic properties by altering surface phospholipid constituents (62). 
Carbon Monoxide 
Chemistry 
The formation of carbon monoxide (CO) occurs in and close to the 
burning cone of a cigarette by thermal decomposition, by reaction of 
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tobacco with atmospheric oxygen, and by secondary reactions of 
tobacco with carbon dioxide, water, and other primary pyrolysis 
products (13, 69). Studies with labeled precursors have shown that 
CO is formed at temperatures above 460°C and that about 30 percent 
of it derives from thermal decomposition of tobacco, 36 percent from 
combustion of tobacco, and 23 percent from reduction of carbon 
dioxide (13). The yield of CO in the mainstream smoke of a cigarette 
depends on the amount of tobacco and the type of paper burned 
during puff drawing, the concentration of pyrolytic precursors, the 
temperature profile of the tobacco during puff drawing, and the 
permeability of the wrapper for the outward diffusion of CO (111). 
The CO concentration in the inhaled smoke is also a function of the 
permeability of the cigarette paper and of the physical and chemical 
properties of the filter (86,153). 
The importance of the air velocity created during puff drawing is 
demonstrated by the significant increase in the smoke with increas- 
ing puff volume (Figure 5) (69). The somewhat higher CO yields in 
the smoke of cigarettes with conventional filter tips compared with 
those from nonfilter cigarettes have been attributed to the loss of air 
dilution and to the increased smoke velocity that occurs when the 
last 15 to 25 mm of the tobacco column are replaced by a filter tip 
with a nonporous wrapper (69, 153). This concept is also reflected in 
the higher CO yield for a filter cigarette smoked with puffs of 
different volumes (Figure 5). 
In recent years, cigarettes with perforated filter tips have gained 
in market share. The air entering through the perforations in these 
filter tips dilutes the mainstream smoke and thus reduces the 
concentration of CO in the smoke (Figure 5). In addition, carbon 
monoxide is selectively reduced, most likely because of the reduced 
velocity of air entering the burning cone (86). Finally, the newly 
introduced filter cigarettes with longitudinal air channels reduce CO 
in the smoke even further (68). However, as discussed before, because 
of the compensatory changes in smoking behavior that smokers 
make in order to satisfy their need for a certain amount of nicotine 
and because of the possible obstruction of perforated filter tips or 
their air channels during puff drawing, the smokers may not fully 
benefit from the intended air dilution of the smoke (64, 65, 68, 89, 
127). 
Association With Cardiovascular Diseases 
The health effects of exposure to carbon monoxide are not fully 
known. However, research findings in selected population groups 
indicate that carbon monoxide acts as an added stress factor to 
precipitate cardiac symptomatology or ischemic episodes in individu- 
als already compromised by coronary disease (3). Additionally, 
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FIGURE 5.-Carbon monoxide, tar, and nicotine in the 
smoke of cigarettes 
NOTE: NF = Nonfilter; F = Filter; PF = Perforated Filter. 
SOURCE: Hoffmann et al. (69). 
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some investigators to impair certain perceptual and motor functions 
(104). 
Carbon monoxide is a common industrial pollutant generated by 
any burning process, It is odorless and tasteless and gives no warning 
of its presence in most circumstances, thus allowing for chronic 
exposure over extended periods of time. The early symptoms of 
carbon monoxide poisoning often resemble those of a variety of 
diseases; thus, tissue hypoxia might occur in healthy people without 
forewarning (163). 
Carbon monoxide combines with hemoglobin in large quantities. 
Its chemical affinity for hemoglobin is over 200 times greater than 
that of oxygen. The ability of carbon monoxide to cause tissue 
hypoxia stems from two effects on circulating processes: (a) a 
reduction in the total amount of oxygen carried by red cells in blood, 
which reduces delivery of oxygen to tissues, and (b) a shift to the left 
of the oxyhemoglobin dissociation curve of the blood that contains 
both oxyhemoglobin and carboxyhemoglobin. The leftward shift of 
the oxyhemoglobin dissociation curve decreases the tension at which 
oxygen molecules are dissociated from hemoglobin, and therefore 
decreases the driving pressure for diffusion of oxygen into tissues 
and cells (142). The concentration of carboxyhemoglobin reached in 
blood will depend upon the concentration of carbon monoxide in the 
inhaled gas mixture as well as on the alveolar concentration, and on 
arterial oxygen tension, duration of exposure, and ventilation 
volume (142). 
It is noteworthy that carbon monoxide binds to muscle myoglobin 
as well as to hemoglobin and may exert tissue hypoxia by interfering 
with oxygen transport to muscle mitochondria. It can also have an 
effect on other hemoproteins such as those present in the cyto- 
chrome oxidase system (35). Cytochrome P-450, a mixed-function 
oxidase, probably does not bind sufficient carbon monoxide to cause 
inhibition of drug hydroxylation, even at a carboxyhemoglobin 
saturation of 15 to 20 percent (126). However, smokers and nonsmok- 
ers differ in their clinical reactivity to drugs such as phenacetin and 
diazapam through acceleration of biotransformation processes. This 
increased drug metabolism is believed to result from an induction of 
microsomal drug-metabolizing enzymes after chronic exposure to 
tobacco smoke (148). Although smoking in general results in 
accelerated enzyme induction, carbon monoxide has been implicated 
in decreased hepatic protein synthesis, a phenomenon that can be 
duplicated by chronic cigarette smoke exposure (52). This effect 
could be due to a deleterious reaction of hepatic tissue because of 
binding of carbon monoxide to intracellular hemoproteins. 
It is possible that carbon monoxide may bind to hemoproteins 
other than cytochrome oxidase, hemoglobin, or myoglobin in suffi- 
cient amounts to inhibit their function. Tryptophan dioxygenase and 
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cat&se have high affinities for carbon monoxide, which in the first 
case, could result in increased serotonin levels in several tissues, and 
through the latter enzyme, could cause the cellular accumulation of 
hydrogen peroxide, a toxic oxidant (126). 
Cigarette smoking causes increased carboxyhemoglobin levels, 
thereby reducing the oxygencarrying capacity of the blood and 
subsequent tissue oxygenation and, possibly, cellular metabolism. 
Interpretation of the effects of carbon monoxide absorption by 
healthy people is a subject of much controversy because effective 
threshold levels have not been established. Environmental exposure 
to carbon monoxide may be without chronic consequences in healthy 
people who appear able to compensate for any acute effects at levels 
of industrial exposure. However, in patients with angina pectoris, 
exposure to carbon monoxide has reduced exercise time until the 
onset of chest pain (3). 
Atherosclerosis is a multifactorial disorder in which cigarette 
smoking and carboxyhemoglobin levels may exert varying effects, 
depending upon the other risk factors present. Carbon monoxide is 
believed to be a contributing factor to the acceleration of the disease 
process. Wald and associates (152, 153) have suggested that carboxy- 
hemoglobin levels in tobacco smokers correlate better than a 
smoking history with the development of myocardial infarction, 
angina pectoris, and intermittent claudication. However, it should be 
pointed out that in such studies, elevation in carboxyhemoglobin also 
reflects the absorption of other constituents of tobacco smoke. 
In his earlier studies, Astrup (8) found that carbon monoxide or 
decreased oxygen tension enhanced coronary atherosclerosis in 
cholesterol-fed rabbits and suggested that high carboxyhemoglobin 
levels resulting from tobacco smoking were associated with the 
development of occlusive arterial vascular disease. More recent 
experiments, conducted in a blind fashion, confirmed the presence of 
myocardial lesions, but failed to produce aortic atherosclerosis (91, 
although other researchers had noted morphological alterations in 
coronary arteries similar to those seen in the earlier experiments (8, 
40). 
Animal experiments on accelerated atherogenesis with carbon 
monoxide must be considered to be unsatisfactory, and although 
clinical trials have linked elevated carboxyhemoglobin levels with 
cardiovascular symptomatology, a cause and effect phenomenon for 
carbon monoxide and disease of the arterial wall has not been 
elucidated. 
Carbon monoxide exposure has been related to increases in 
circulating blood lipids. This was first demonstrated in rabbits in 
which carboxyhemoglobin levels were 15 to 25 percent, resulting in 
elevations of serum cholesterol for a transient 2 to 3 weeks following 
exposure (10). In an epidemiological study by Van Houte and 
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Kesteloot (147) involving 42,000 subjects, significantly higher serum 
cholesterol levels were demonstrated in male smokers than in 
nonsmokers, particularly in the 30- to 39-year age group. The early 
Framingham results also reported slightly higher serum cholesterol 
levels among smokers (41), whereas Blackbum et al. (22) report 
nonsignificant differences between smokers and nonsmokers. Many 
other epidemiological investigations have analyzed the correlation 
between smoking status, serum cholesterol levels, and lipoprotein 
distributions, but the majority of results suggest a trend rather than 
significance in support of a connection between smoking and 
elevated cholesterol (100). This relationship does not offer an 
explanation for an effect of cigarette smoking on serum lipid levels, 
but experimental evidence suggests that carbon monoxide might 
exert an effect on the metabolism of chylomicron remnants (51). 
Ascorbic acid levels could limit the conversion of cholesterol to bile 
acids (85), or carbon monoxide could diminish hepatic degradation of 
lipoprotein constituents (40). 
Carbon monoxide has also been implicated in the noted decrease in 
patency following vascular surgery and arterial reconstruction 
among continuing cigarette smokers (138). Cigarette smoking as 
measured by extrapolation from carboxyhemoglobin values had a 
definite adverse effect on the healing process and success rate of 
vascular surgery (20,56). 
Additional Contributors 
Hydrogen Cyanide 
Nitrates in tobacco serve as precursors for hydrogen cyanide 
(HCN) in the smoke (61, 79). This concept has been supported by 
studies in which ‘5N-labeled nitrates of potassium, sodium, or 
calcium, respectively, had been added to cigarette tobacco and in 
which the isolated HCN from the smoke was found to contain l5N- 
HCN (79). However, tobacco proteins appear to be the major group of 
precursors for HCN in the smoke (27, 80). This was demonstrated in 
pyrolysis studies with tobacco protein and amino acids and by 
recovery in the smoke of 15N-HCN from cigarettes spiked with l5N- 
glycine (27, 80). It has been shown that HCN is formed via N- 
heterocyclic intermediates and from pyrolidine, the decarboxylation 
product of proline (80). From these intermediates, hydrogen cyanide 
is split off in the pyrolysis-distillation zone of the burning cigarette 
under the opening of the N-containing ring (27, 80). 
Several methods have been explored for the selective reduction of 
hydrogen cyanide in cigarette smoke. Charcoal-containing filter tips 
can remove 70 to 80 percent of the HCN from cigarette mainstream 
smoke (139). With increasing smoke dilution through filter perfora- 
tion, HCN can be selectively reduced up to 80 percent, with a 70 
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percent ventilation rate (105). The extraction of protein fractions 
from cigarette tobacco leads also to a selective reduction of HCN 
(141). The smoke of one cigarette contains from 20 to 480 pg of HCN, 
the lowest values being measured in the smoke of cigarettes with 
charcoalcontaining filter tips (120). 
Although only nicotine and carbon monoxide have been incrimi- 
nated as contributors to the increased risk of cigarette smokers for 
cardiovascular disease, other gas phase constituents might also play 
roles in the pathogenic processes. Hydrogen cyanide is an inhibitor 
of several respiratory enzymes and as such can influence cellular 
metabolism in the myocardium and arterial wall. It is also a 
powerful ciliatoxic agent allowing for decreased efficiency in remov- 
al of tar constitutents from the respiratory system (16). 
The arterial effects of hydrogen cyanide, nitric oxide, and carbonyl 
sulfide were investigated by Hugod and Astrup (76) in experiments 
in which rabbits were exposed to these compounds alone or in 
combination with carbon monoxide. The duration of exposure was 
from 5 days to 12 weeks, and aortas were assessed morphologically 
for intimal damage suggestive of early atherosclerotic changes. No 
hi&toxic effect on intimal or subintimal morphology was noted, and 
a parallel experiment demonstrated no effect on the coronary 
arteries (75). The duration of exposure to these compounds must be 
considered short, however, with the possibility that prolonged 
exposure might result in morphological or enzymatic alterations. 
Nitrogen Oxides 
A number of studies have shown that nitrate is a major precursor 
for nitric oxide (NO) and traces of nitrous oxide (NzO) and nitrogen 
dioxide (NO2) found in cigarette mainstream and sidestream smoke 
(79, 134). The mainstream smoke of a cigarette contains from 6 to 
600 pg of NO per cigarette, depending primarily on the nitrate 
content of the tobacco blend and the nature of the filter tip (105). The 
correlation of nitrate content of tobacco with nitric oxide yield in the 
mainstream smoke appears to be linear (27). The smoke of cigarettes 
made with Burley tobacco and particularly those made with Burley 
stems, which are rich in nitrate, is especially high in nitric oxide (29, 
107). Tobacco proteins appear also to contribute to the NO yield in 
cigarette smoke (79). 
The concentration of nitrogen dioxide and that of methyl nitrite in 
freshly generated cigarette smoke is very minute ( < 5 w/cigarette); 
however, these agents increase rapidly as a function of the aging of 
mainstream and sidestream smoke. Within about 3 minutes, 50 
percent of NO is oxidized to NO2 (149). The best approaches toward 
reducing NO in cigarette smoke are by reduction of nitrate in 
tobacco and by dilution of smoke by air entering through the holes of 
perforated filter tips (27,105). 
Changes in cardiac function of rats acutely exposed to nitrogen 
dioxide were examined by electrocardiographic records. Bradycardia 
and arrhythmias were observed following exposure to 20 ppm for 3 
hours (76). These alterations were attributed to changes in parasym- 
pathetic nervous activity following exposure. The levels used were 
high relative to those obtained from unaged tobacco smoke. In 
addition, it has been suggested that enzyme-inhibiting effects 
associated with cigarette smoking are due to nicotine N-oxide and 
nitrogen dioxide. Because thiols are readily oxidized to disulfides by 
either nitric oxide or nitrogen dioxide, they are potent inhibitors of 
thioldependent enzymes (126). In the presence of cigarette smoke, 
scavenger cells such as macrophages may not be readily activated. In 
the respiratory system, the major histological sites of damage by 
nitrogen dioxide are the terminal and respiratory bronchioles and 
the proximal portions of the alveolar ducts. Nitrogen oxides are also 
suspected of contributing to the development of pulmonary emphyse- 
ma (43) and the acceleration of platelet aggregation (191). 
Carbon Disulfide 
Epidemiological studies have incriminated carbon disulfide (C&) 
as a factor for the increased risk of arteriosclerotic diseases in 
workers in the -rayon industry (39). The reported acute dose 
levels of CSZ during workers’ exposure were 20 ppm and higher (39). 
In cigarette mainstream smoke, carbon disulfide can amount to as 
much as 4 pg per cigarette (72, 114). It appears that the sulfur- 
containing amino acids and proteins and certain pesticides serve as 
major precursors for CSZ in tobacco smoke (15, 72). 
Cadmium 
The soil supplies tobacco with traces of cadmium (Cd), which are 
selectively retained by the plant. Depending on the soil, the Cd in the 
leaf can amount to a few parts per million (SO). The mainstream 
smoke of a blended U.S. cigarette may contain up to 0.2 pg Cd (97, 
102). In the blood of cigarette smokers, Manthey et al. (99) found 2.47 
_+ 1.72 cog per liter; Cd levels in the blood of nonsmokers were only 
0.43 +_ 0.22 pg per liter. Cd appears to accumulate in the kidney, and 
has been found in higher concentrations in the kidneys of cigarette 
smokers than of nonsmokers (115). 
The potential consequences of increased lifetime exposure to low 
levels of cadmium are not known. However, autopsy studies have 
revealed increased cadmium levels in persons with emphysema and 
hypertension (131). Cigarette smoke is known to contain traces of 
cadmium (0.1 to 0.2 cog per cigarette) (97, 102). It is chiefly 
accumulated in the liver and kidneys, and has been found in levels 
about twice as high in the kidneys of hypertensive cigarette smokers 
compared with nonsmokers in the normotensive range (113). It is 
possible that an increased body burden of cadmium may be related 
more directly to blood pressure (108), although animal studies have 
implicated genetic differences in susceptibility to cadmium-induced 
hypertension (109, 110). Furthermore, epidemiological studies may 
be confounded by failure to separate cigarette smokers from drinkers 
of soft water in determining risk of elevated blood pressure from 
cadmium intake (I 7). 
Cadmium has also been implicated in accelerated atherogenesis 
and altered lipoprotein patterns in White Carneau pigeons, a species 
often used to investigate risk factors for arterial disease (119). The 
results of these studies showed that the number and size of 
atherosclerotic plaques were increased in pigeons given drinking 
water containing cadmium or lead and that the lipoprotein profile 
was altered in an independent fashion. The possible mode of action of 
cadmium on atherogenesis is unknown, but endothelial damage is 
suggested by the work of Rohrer and colleagues (121). In their 
studies, pregnant rats received a single administration of cadmium 
(0.5 to 2.0 mg/kg), and vacuoles were observed in the endothelial 
cells of fetal brains. These vacuoles distorted the shape and 
orientation of the endothelial cells in the caudate nucleus. 
Data on the relation between cigarette smoking and cadmium 
intake remain inconclusive. Drinking water and genetic factors may 
overwhelm the effects of cadmium as a cigarette smoke constituent 
on cardiovascular disease, and more work in this area is necessary 
before a cause and effect assignment can be made. 
zinc 
The average zinc (Zn) content in commercial cigarettes varies 
between 50 and 80 ppm (140) and in the mainstream smoke of U.S. 
cigarettes between 0.05 and 0.4 pg (102). So far, Zn has been 
determined only in the urine of cigarette smokers, where it occurs in 
significantly higher concentration than it does in the urine of 
nonsmokers (46). Zinc is a metal component of many important 
enzyme systems; its availability controls the rate of synthesis of 
nucleic acids and protein (!83). In fact, zinc deficiency has been 
associated with poor growth (30), and depressed plasma zinc levels 
have been used as indicators of myocardial infarction (94). In 
general, low zinc levels have been found to be associated with 
depressed health status, and supplemental zinc has not been 
correlated with increased risk of disease development. 
Tar 
The total particulate matter (TF’M) of a cigarette, often referred to 
as tar, is defined as that portion of the smoke that is retained by a 
glass fiber filter. This definition is widely accepted and can be 
regarded as a quantitative approach, since the Cambridge glass fiber 
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filter retains 99.9 percent of particles of the mainstream smoke that 
have diameters of 20.2 u (154). Different methods of smoking 
cigarettes and of determining tar in the smoke have been applied 
throughout the world; this needs to be considered when comparing 
data on cigarette smoke yields in various countries (28). 
According to the U.S. Federal Trade Commission report of March 
1983, the tar yields of commercial U.S. cigarettes vary from ~0.5 to 
30 mg (146). All cigarettes with >20 mg tar yield are nonfilter 
cigarettes, and practically all cigarettes with tar yields < 12 mg are 
cigarettes with perforated filter tips (146). As discussed before, it has 
to be realized that the standard machine smoking method developed 
for a comparison of the smoke yields of commercial cigarettes does 
not reflect the average smoking habits of cigarette smokers, especial- 
ly of those who smoke low-nicotine cigarettes (64, 65, 89, 127). A 
person’s smoking habit is largely dependent on the smoker’s need for 
nicotine. Consumers of low-nicotine cigarettes take larger puff 
volumes and inhale more frequently than do the smokers of 
cigarettes with high nicotine yields (> 1.0 mg cigarettes) (64). At 
present, the most reliable assay for determining the uptake of 
particulate matter by an individual smoker is seen in the analysis of 
nicotine and cotinine in his or her serum (58). 
In theory, reduction of the toxic components in cigarette smoke 
should reduce the risk for neoplasms and cardiovascular diseases. 
Therefore, the introduction of filter cigarettes, which should pre 
elude the inhalation of some of the tobacco tar constituents, would be 
expected to reduce the incidence of respiratory and cardiovascular 
dysfunctions. End point analysis of the long-term followup of the 
Framingham cohort made it possible to test the hypothesis that 
those who smoke filter cigarettes would be less likely to manifest 
clinical symptoms of cardivascular disease than would those who 
smoke nonftiter cigarettes. Despite what seemed a more favorable 
smoking history, the filter cigarette smokers did not have lower 
incidence rates of cardiovascular d&eases than the nonfilter smok- 
ers. This finding was unchanged after multivariate logistic regres- 
sion analysis to adjust for age, systolic blood pressure, and serum 
cholesterol (32). The relationship of this seemingly negative finding 
to the tar component of tobacco smoke must remain imprecise 
because other smoke constituents covary with the tar fraction. 
Respiratory complications and immune hypersensitivity have 
been correlated with intake of particulate phase components of 
tobacco smoke. Cigarette smokers exhibit greatly increased risks for 
pulmonary diseases, including emphysema and chronic obstructive 
lung disease (144). Such diseases can also place increased stress on 
the cardiovascular system. Cigarette smokers demonstrate more 
frequent macroscopic and microscopic lung abnormalities than do 
nonsmokers, with a dose-response relationship being apparent in 
regard to these changes and the self-reported intensity of smoking. 
Research Needs and Priorities 
The evidence linking cigarette smoking to cardiovascular diseases 
is strong. Understanding of the mechanisms whereby cigarette 
smoking initiates or accelerates disease processes remains imprecise 
because a variety of smoke constituents exert multiple effects upon 
body systems. 
Epidemiologic studies have correlated increases in atherosclerotic 
CVD death rates with increased use of cigarettes and also have 
shown that those persons who stop smoking do in fact exhibit lower 
death rates than those who continue to smoke. Despite the demon- 
strated association of smoking with enhanced atherogenesis, risk of 
coronary death in persons who stop smoking appears to revert to 
lower levels in a relatively short period following cessation. It is 
quite likely that the precipitating events leading to thrombus 
formation and occlusion are decreased, although fibrous plaques will 
not regress so rapidly (82). 
Methods for cessation of cigarette smoking, especially among high 
risk populations, must be a priority in the research endeavor to 
reduce cardiovascular disease morbidity and mortality. Although 
termination of the habit is the ideal goal, it must be recognized that 
this is a difficult task for a number of smokers. 
Reduction of the harmful components delivered to the smoker has 
been another priority objective, aimed at those smokers who will not 
give up the habit. This task has resulted in the introduction of a 
variety of low- and ultra-low-yield cigarettes. Whether risks for 
cardiovascular diseases are truly reduced when these products are 
used remains to be demonstrated. Several recent studies have shown 
that smokers alter their smoking behavior when they switch to low- 
yield cigarettes and can receive increased smoke constituents as they 
attempt to satisfy a nicotine demand (64, 65). This compensatory 
behavior may lead to accelerated atherogenesis through increased 
uptake of smoke constituents such as carbon monoxide, hydrogen 
cyanide, and nitrous oxides. Recently it was reported that the risk of 
a nonfatal first myocardial infarction in young men was not related 
to the nicotine or carbon monoxide levels of the cigarette. This could 
be due to compensatory behavior (83). 
One should not ignore the proportion of the population that 
continues to smoke, nor should one accept unchallenged the concept 
of a “safe” cigarette. The main objective is to reduce the harmful 
constituents present in tobacco smoke. It is probable that promotion 
of ultra-low-yield products will not suffice, since compensatory 
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mechanisms may be triggered by sensory needs for taste as well as 
for nicotine. 
A cigarette considered less harmful for cancer etiology might not 
reduce the risk for coronary disease. It appears to be a formidable 
task to develop a product that satisfies the smoker and does not 
increase disease risk through exposure to carbon monoxide, hydro- 
gen cyanide, nitrous oxide, or still unknown agents. 
Of the major cardiovascular risk factors, cigarette smoking is a 
powerful, prevalent, and potentially correctable contributor that 
deserves the highest priority among preventive measures to control 
cardiovascular disease (82). 
Conclusions 
1. Over 4,000 different compounds have been identified in tobacco 
smoke. 
2. Nicotine exerts an effect on ganglionic cells, producing transient 
excitation. The pharmacological effects are small, but are 
reinforced several times daily in habitual smokers. The exact 
mechanisms whereby nicotine might influence cardiovascular 
events are unknown, but a lowering of the ventricular fibrilla- 
tion threshold is dose related to nicotine levels. 
3. Carbon monoxide may act to precipitate cardiac symptomatolo- 
gy or ischemic episodes in individuals already compromised by 
coronary disease. In addition, carbon monoxide binds to hemo- 
proteins, potentially inhibiting their functions. 
4. Several studies have shown that smokers may alter their 
smoking behavior when they switch to low-yield cigarettes. This 
compensatory behavior may lead to the increased uptake of gas 
phase constituents including carbon monoxide, hydrogen cya- 
nide, and nitrous oxides. 
5. It is unlikely that a “safe cigarette” can be developed that will 
reduce cardiovascular risk. 
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This section examines the changes in cigarette smoking behavior 
resulting from intervention strategies. The next section presents 
detailed data on CHD outcome resulting from these trials compared 
with those prospective epidemiologic studies for which cessation 
outcome information is available. 
Large-scale primary preventive trials have used both single and 
multifactorial intervention in high risk populations in an attempt to 
test the effect of the modification of major risk factors, either alone 
or in combination, on coronary heart disease (CHD) or respiratory 
disease. Several of these trials have been developed and implement- 
ed since the early 19708, and provide a valuable opportunity for 
assessing the efficacy and outcomes of smoking intervention tech- 
niques in particular high risk populations and the impact of smoking 
behavior change on disease. The objective of this section is to present 
and critically appraise the smoking intervention programs and the 
smoking cessation outcomes in the large-scale controlled preventive 
trials. 
At present there are two types of preventive trials in cardiovascu- 
lar or respiratory disease that either have been completed or are 
currently in progress. One type includes clinical investigations in 
which individuals are randomized either to an intervention group 
for a risk factor reduction program or to their usual source of 
medical care. These randomized trials are either single factor trials 
that intervene on one variable such as cigarette smoking, as in the 
London Civil Servants smoking trial (55, 60, 611, or multifactorial 
trials that generally attempt to change the alterable risk factors of 
cigarette smoking, hypercholesterolemia, and hypertension, or some 
combination of these risk factors. In this group are the Goteborg 
(Sweden) trial (78, 79, 801, the Oslo (Norway) study (16, 17), and the 
Multiple Risk Factor Intervention Trial (MRFIT) (19,43). 
The randomization of entire populations to an intervention or a no- 
intervention group comprises the second type of trial. In this group 
of community investigations are trials based on random allocation of 
factories to intervention or regular care, as in the WHO study (621, 
which involves four centers-London, Brussels/Ghent, Rome, and 
Warsaw-using a common protocol, and trials in which entire 
geographic areas are randomized, as in the North Karelia project 
(52, 53, 54, 63, 64, 65). Although the Stanford study has been 
described by its investigators as a community-based investigation 
(13, 14, 36, al>, it did not involve random allocation of communities 
and thus does not belong in this group as defined here. Although the 
Stanford group studied three different communities, individuals 
within one community were randomized to intensive or to communi- 
ty intervention only. Therefore, for the purposes of this review, the 
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Stanford study will be included with the first group of trials, 
although it somewhat overlaps both groups. 
Smoking intervention methods and smoking behavior change 
outcomes for each of these trials will be presented and critically 
evaluated. These prospective studies use experimental design meth- 
odology that maximizes comparability of treated and untreated 
groups by maintaining a high degree of quality control on all aspects 
of randomization, data collection, and evaluation; by utilizing 
unbiased statistical treatment of the data; and by detailing a priori 
specification of the intervention (38). 
A major problem in assessing outcomes of smoking intervention 
studies has been research that has often been poor in methodology, 
quality control, and design. Although preventive trials have general- 
ly conformed to the desired methodology as noted above, they too, as 
with other smoking intervention studies, have been deficient in some 
of the methods used or in the reporting of the data. The deficiencies 
of smoking intervention studies have been well reviewed in past 
investigations (5,34,45,67) and will be only briefly summarized here 
to provide a basis on which to critically review the research and 
smoking intervention designs in preventive trials. 
Problems in Smoklng lnterventlon Studies 
Lack of Objective Data to Verify Self-Reported Outcomes 
A major deficiency in smoking cessation evaluation research has 
been the use of self-reported smoking data that have not been 
validated with objective measures. These data depend on the 
subjects’ honest and accurate reporting and often lead to an 
overestimation of success, especially among participants who feel the 
pressure to stop smoking, as in an intervention program. Neaton et 
al. (46) found that when the reported quit-rate of the intervention 
group in MRFIT was adjusted using serum thiocyanate (SCN) levels, 
the overreporting ranged from 5 to 9 percent, while a much smaller 
overreporting rate was found in the usual care group not treated in 
the program. The demand characteristics of the intervention pr+ 
gram may prompt some individuals to falsely comply with the 
expectations of the interventionist (2). 
One approach to validation of self-reported data involves the use of 
serum thiocyanate (SCN) determinations as objective measures of 
smoking status, with a critical cutoff point used to differentiate 
smokers from nonsmokers (3). SCN is the metabolite of hydrogen 
cyanide, a pyrrolic product in tobacco smoke. In addition to cigarette 
smoking, SCN may be elevated by the use of pipes, cigars, or 
cigarillos. However, the interpretation of SCN concentration is 
potentially confounded by at least two factors. Certain foods, 
particularly those of the Brassica genus (cabbage, cauliflower, kale, 
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kohlrabi, broccoli, brussels sprouts, turnips, and rutabagas), as well 
as fruit pits and almonds, may elevate levels. Also, diuretics tend to 
raise SCN levels by an average of 8 pmol/liter (51). With such 
limitations in mind, the biologic half-life of SCN, approximately 14 
days (511, still makes it a measure well suited for corroboration of 
self-reports. Determinations of SCN in saliva and urine have also 
been used and are more adaptable to some settings (II, 42). 
Measurement of carbon monoxide (CO) concentrations in serum or 
expired air also can be used as a validation tool (29, 57, 76). The 
major drawback of this measure is CO’s short half-life of several 
hours (56, 72); it may also be affected by various environmental 
factors (72, 77). 
The most specific objective indicator of tobacco use is nicotine 
itself or its major metabolite cotinine, both of which can be measured 
in blood, saliva, or urine (21, 31). The extremely short half-life of 
nicotine, on the order of 30 minutes, makes it unsuitable for 
verification of cessation or for quantifying estimates of tobacco 
intake, but the 20- to 30-hour half-life of cotinine is much more 
useful for these purposes (4. 82). Unfortunately, cotinine analyses 
are rarely used in clinical trials because of the expense and the 
relative unavailability of the complex analytic technique compared 
with SCN determination. 
Lack of Comparison Groups 
Only recently have clinical assessments of smoking in intervention 
programs been more consistent in their use of an experimental 
design that includes random allocation to the experimental smoking 
cessation condition or to an appropriate comparison group. Investi- 
gators using a minimal treatment or attention-placebo comparison 
group have demonstrated that these groups produce smoking 
cessation results beyond those that no intervention would be 
expected to produce (28, 32, 37). These outcomes have been partially 
accounted for by certain “nonspecific factors” common to all 
treatment settings and cannot be attributed to a specific interven- 
tion technique. These nonspecific factors include the use of self- 
monitoring, a structured program that promotes the expectation of 
success, and a therapist’s attention (1, 5, 40). Determination of the 
effect of a proposed treatment on outcome results is not possible 
without rigorous designs that include appropriate experimental 
controls, preferably a minimal-treatment control group (37). 
Classification Differences 
Smoking control studies use variable criteria for grouping individ- 
uals; this makes it difficult to compare outcomes. For example, 
Straits’ (73) successes achieved at least an 85 percent reduction in 
smoking, whereas Keutzer’s (25) successes achieved at least a 50 
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percent reduction. Kanzler et al’s (23) “continuing successes” (3 l/2 
to 4 years after treatment) were subjects who had not recidivated at 
any time for “longer than a week,” while Ockene et al.‘s (50) 
“continuing successes’* were at zero cigarettes for at least 2 years, 
and self-reports were validated with SCN measurements. 
Similarly, in some studies a smoker is someone who smokes pipes, 
cigars, or cigarettes (e.g., Oslo study), while in other studies a subject 
is classified as a smoker on the basis of whether or not he or she 
smokes cigarettes only (e.g., MRFIT). Because of the lack of 
consistency in groups compared and criteria used, outcomes of 
studies are difficult to evaluate, and cross-validation can provide 
onflicting outcomes. In order to avoid these problems, standard 
classification categories have been suggested (69). 
Followup Differences and Deficiencies 
Experimental studies of smoking have used different followup 
points to assess outcomes and to determine predictor variables. 
These followup points have included immediately post-treatment 
(25), 2 weeks’ post-treatment (11, 3-month followup (221, 6-month 
followup (@, l-year followup (701, and 3- to 4year followup (23, 30, 
50). In most studies, cessation rates at followup points refer to 
%onsmoking prevalence” at that point in time, rather than to 
continued abstinence from immediately post-treatment onward. 
Such studies give no indication of the dynamics of cessation and 
relapse that determine the nonsmoking prevalence rate, nor do they 
indicate what is happening long term with a cohort of smokers. 
Ockene et al. (48, 49), in their analyses of the smoking data from the 
Multiple Risk Factor Intervention Trial (MRFIT), demonstrate the 
importance of following cohorts of smokers from baseline to followup 
points in addition to determining cessation rates at a single point in 
time. Careful definition of cessation rates should be given in all 
research reports so that the reader can distinguish whether a given 
rate refers to a single probe measure or to a quit status of some 
known duration. Shipley et al. (71) have discussed this problem in 
depth and offered potential standards for reporting in the smoking 
cessation literature. 
Because of the high recidivism rate in the first year of abstinence 
(20), the comparison of a study that measures cessation at immediate 
post-treatment to one that assesses cessation at l-year post-treat- 
ment will demonstrate very different outcomes. As explained above, 
the smoker reporting cessation at immediate post-treatment could 
become either a continuing success or a recidivist at l-year post- 
treatment. In effect, comparing stoppers at different points is similar 
to comparing different groups (47). The smoker’s continuing suscepti- 
bility to relapse, even after being cigarette free for more than 2 
years, needs to be reflected in smoking research and intervention by 
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the inclusion of followup and maintenance programs beyond the 
usual 6 to 12 months (49). 
Most studies also fail to note whether a followup point (e.g., 1 year) 
indicates a period of time since the entire study began or since the 
smoker entered the program. If it indicates the former, it is possible 
that there is a different length of followup for participants in the 
same study, depending on when they entered the program. Outcomes 
for these participants should not be compared unless appropriate 
analytic techniques such as life tables (7) or person-years (7) are used 
to adjust for the differing lengths of followup. 
Methods of Data Reporting 
The continuing susceptibility of the smoker to relapse, as well as 
the fact that it is long-term rather than short-term cessation that has 
an impact on disease outcomes (48, 49), needs to be reflected in the 
way data are reported in smoking cessation research, although this 
rarely occurs. Cross-sectional cessation data are generally measured 
and reported giving little indication of the dynamics of cessation and 
relapse that determine the cessation rate at any one point in time 
(49). Thus, a cessation rate of 36 percent at 2-year followup does not 
mean that 30 percent of the smokers in a study remained cigarette 
free for 2 years. Perhaps only 10 percent were nonsmokers for the 
entire 2-year period. Studies of smokers quitting both with and 
without formalized aid show that people often pass through several 
cycles of cessation and relapse before permanent cessation is 
achieved (20, G6.l. Analysis of data from cohorts of baseline smokers 
followed longitudinally provides a more complete understanding of 
smoking behavior change and “true” long-term cessation. It also 
provides relevant data for evaluating the effect of cessation on 
disease outcome. Cohort analyses are missing in all but a very few 
studies. 
The primary evaluation of treatment results should be based on 
abstinence data for several reasons, as summarized by Pechacek (75), 
including the following: abstinence is the primary goal of most 
smokers enrolled in programs; smoking behavior change followup 
data have indicated that most smokers who reduce their smoking 
without totally stopping return to baseline smoking levels; a 
clinically insignificant proportion of smokers at followup can be 
abstinent and yet analyses of rate data can show statistically 
significant treatment effects; and reports of abstinence rather than 
reduction are less susceptible to exaggeration and the demands of 
the program placed on the smoker. In spite of the importance of 
cessation data and of true long-term data, these are often missing in 
outcome reports. 
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The Use of Various Methods for the Determination of 
Treatment Outcomes 
Methods for determining treatment outcomes include telephone 
calls (231, in-person interviews (19, 70), and mailed questionnaires 
(12). The variability of the groups of smokers reached by these 
different methods and their effects changes the criterion groups and 
can be responsible for an extraneous source of variance leading to 
distortion of the comparisons. Those subjects who respond immedi- 
ately to smoking behavior assessment or followup are more often ex- 
smokers, but those reached only after repeated tries are often smokers 
(68). Therefore, the success and failure groups in a study in which 
there is a high followup response (19, 47, 70) may be quite different 
from these same groups in a study with a followup response of less 
than 50 percent (23). It would be valuable to pursue a random sample 
of nonresponders in order to be able to study and compare 
responders with nonresponders in terms of generalizability of 
outcomes. 
Lack of Information and Precautions Needed to 
Adequately Interpret Outcomes 
A smoking cessation program or trial cannot be adequately 
evaluated or interpreted without sufficient information about the 
methods used in the design and implementation of the study, the 
data included for determination of outcomes, and the methods used 
for the analysis of the outcomes (9). DerSimonian et al. (9) surveyed 
67 clinical trials reported in 4 well-respected medical journals, and 
found that only 56 percent were clearly reported with respect to 11 
important variables. The 11 variables were selected with regard to 
their importance in determining the confidence that a reader could 
place in the author’s conclusions, their ability to be discerned by the 
scientifically literate general medical reader, and their applicability 
across a variety of medical specialties. 
A related point specifically aimed at the clinical trials reviewed in 
this section is the need to specify all treatments other than smoking 
cessation (e.g., modification of other risk factors) that participants 
received. What precautions should be taken comparing smoking 
cessation results from a trial modifying only smoking behavior to a 
trial simultaneously modifying several risk factors? Specific as well 
as nonspecific treatment differences are probably operative on 
outcomes. 
In summary, a critical evaluation of any smoking intervention 
program needs to consider the deficiencies inherent in the study and 
data analysis design as well as the deficiencies manifested in the 
study report by the lack of adequate information. Precautions 
regarding comparison with other studies and generalizations should 
also be considered. In the following section, the eight major large- 
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scale preventive trials implemented since 1970 that include a 
smoking intervention component and have reported smoking cessa- 
tion outcomes will be reviewed. (Three-year followup data are 
available for most of the trials; therefore, whenever possible these 
data will be presented in addition to whatever other data are 
available and relevant for comparisons.) 
Individual Allocation Trials 
Single Factor Controlled Clinical Trials 
The London Civil Servants Smoking Trial 
The participants in the London Civil Servants smoking trial were 
drawn from the 16,016 men, aged 40 to 59, who had undergone a 
cardiorespiratory screening examination in the Whitehall study of 
London Civil Servants carried out between 1968 and 1970 (55,60,61). 
The results of the screening were used to select smokers for the trial 
who had the highest risk of CHD or chronic bronchitis or both, based 
on a risk score calculated from the multivariate combination of risk 
factors (60, 61). Men were excluded if they had heart disease, severe 
hypertension (DBP> 115 mm Hg), diabetes mellitus, or major 
concomitant disease; were taking psychotropic drugs; or had a 
history of previous inpatient psychiatric treatment. The selected 
men were randomly allocated to an intervention group (IG) or to a 
“normal care” (NC) group. The results were first sent to the 
participants’ general practitioners, who had the opportunity to 
withdraw their patients from the study. Random allocation resulted 
in an intervention group of 714 men and a control group of 731 men 
(Table 1). The two groups were well balanced on all characteristics 
measured, with a mean age of approximately 53 years and a mean 
number of cigarettes smoked of 19 in the two comparison groups. 
The smokers randomized to the intervention group were sent a 
letter inviting them to come and discuss “one or two points 
personally with a physician” (58). This session took about 15 
minutes, and the smokers were advised of the health gains of 
cessation rather than the dangers of continuation and then asked to 
decide if they wanted further help and support (58, 59, 60). Booklets 
prepared for the study were handed out at this visit. Most men 
indicated that they would like help and were seen on an average of 
three more visits in the first 10 weeks, and then at 6 months, with 
each visit taking about 15 minutes. The only other health advice 
given was on calorie restriction for those who gained weight. Close 
contact was maintained over several months, and help was available 
for those smokers who continued to need it. A special substudy was 
implemented in which a group of intervention participants were 
randomly allocated either to the usual procedure of further contact 
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Randomization methods/ Baseline age and 
study groups smoking data 




1,445 healthy males 
Aged 40-59 
High risk for CHD and/or 
chronic bronchitis based on 
risk score 
Randomized to smoking 
intervention or normal care 
Intervention (IG) = 714 males 
Normal care (NC) = 714 males 
x age = 53 
X cigs = 19 
Gdteborg (Sweden) 
Study 







Living in GMeborg 
Randomized to intervention 
for smoking, hypertension, 
hypercholesterolemia, and 
low physical activity; or to 
control group 
Intervention group (IQ = 10,000 males 
Two control groups (CG) = 20,CWl males 
X age = 51 
X cigs = ? 
65% of 7,455 screened 
in IG were smokers 
16% of IG smoked 
2 15 &s/day 
Oslo (Norway) Study 
(16, 17. 181 
(5 years) 
1,232 healthy normotensive 
males 
Agad 4&59 
Upper quartile CHD risk 
based on risk scare 
Randomized to intervention 
for smoking and cholesterol; 
or to control group 
Intervention group (1) = 604 males 
Control group (Cl = 628 males 
X age = 45 
X cigs (I) = 12.5 
X cigs (C) = 13.0 




Randomization methods/ Baseline age and 
study groups smoking data 





12.666 healthy males 
Aged 35-37 
Top lo-E% risk for CHD 
baaed on risk wore 
Randomized to intervention 
for smoking, cholesterol, 
and/or blood pressure; or 
to control group 
Special intervention (SI) = 6,428 males 
Usual care WC) = 6,428 males 
x age = 46 
X cigs = 21 
64% were smokers 
X cigs (smokers) = 34 
Stanford Three 
Community Study 
(36’ 41, 4x 
(1972-1975) 
Residents of Wataonville, 
Gilroy, and Tracy, in 
California 
Random sample of 590 
residents asweed in each 
community (ages Z&59) 
Upper quartile of CHD risk 
selected from random samples 
Communities matched, not 
randomized 
Wataonville high risk 
sample randomized: 
media only (W-R0 = 56 ppts. 
media and intensive instruction 
(W-II) = 113 ppts 
Gilroy: media only (GM01 = 136 ppts. 
Tracy: control (0 = 136 ppts 
X age (3549 
sample) = approx. 47 
X cigs (high risk 
sample) = approx. 14 
by personal consultations or to further contact by mailed personal 
responses from the physician (58, 59). 
In the initial stage of the trial no contact was made with the 
control subjects, who were at no time made aware of their high risk 
status or participation in the trial (58, 60). Intervention and control 
groups were invited in for a physical examination at 1, 3, and 9 
years. They were also sent a self-administered questionnaire on 
current smoking habits, symptoms, and recent illnesses at years 1,3, 
and 9. When the control group smokers were invited for the l-year 
examinations, they were told that their names were included in a 
“statistically chosen sample” (58). At l-year followup, 19 percent of 
the smokers in both groups did not attend, and a similar loss to 
followup rate was true for the intervention group at 9 years (59, 61). 
No objective measures were used in this trial to validate self- 
reported cigarette smoking behavior. On the basis of the self-reports, 
there was a cigarette smoking cessation rate of 51 percent for 
intervention group smokers at l-year followup (nonattendee baseline 
smokers were included as smokers) (Table 2). Only 31 percent 
reported cessation of all tobacco, as many had switched to pipes and 
cigars (58). Of all of the men who stopped smoking cigarettes by the 
end of year 1, 80 percent reported doing so immediately after the 
first interview (60). At 3 years the reported cessation rate went down 
to 36 percent, perhaps partly owing to the drop in attendance at 
examinations and in return of questionnaires (i.e., only 64 percent 
returned for assessment and nonattendees are included at baseline 
levels). 
A comparison of the intervention subgroups who were contacted 
by mail with those who had a personal consultation indicates that 
outcome was significantly poorer when the personal contact was 
omitted, with a 59 percent cessation rate at 10 weeks for the personal 
contact group and a 46 percent cessation rate for the postal contact 
group (62). 
In the normal care group, 10 percent of the total smokers reported 
cessation at year 1 and 14 percent at year 3. Only 70 percent of the 
normal care group returned for the third-year examination. At 1 
year and 3 years, respectively, there is a 41 and 22 percent net 
difference in intervention versus control group reported cigarette 
smoking cessation rates. At 9 years, the return rate for intervention 
men was 83 percent, with 55 percent reporting cessation, producing 
a 46 percent reported cessation rate for all baseline smokers (62). 
About one-third of the cigarette abstainers continued to smoke pipes 
and cigars. The final g-year smoking cessation rates have not been 
reported for the normal care group, but cessation rates reported in a 
postal survey to which 60 percent of the survivors responded 
indicated that 41 percent of the normal care respondents reported 
that they were no longer smoking. As these figures have been 
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TABLE 2,-Intervention, followup, and cessation results for five major controlled clinical trials 
Clinical trial Intervention Control group contact Foliowup 





b% 59, 60) 
Letter inviting ppt. to meet 
with MD 
Initial 15 min session 
Three more 15 min visits (with 
MD) in 10 weeks 
6 mo visit 
Additional help if needed 
Not told of high risk 
status or trial participation 
Physical exams & 
smoking & medical 
Hx questionnaire at 1. 3. 
& 9 yrs for both groups 
Missed visit rates 
Treated Control Time 
51%’ (cige) 10% (cigs) 1 Yr 
31% call 
smokmg) 
36% (cigsl 14% (cigs) 3 yrs 
IG NC Year 46% (cigs) - 9 YB 
19% 19% 1 (no objective meaeures used) 
30% 30% 3 




Smokers 2 15 g tobacco/day 
invited to antismoking clinic 
Five biweekly small group 
sessions 
2d session: ppts given 
nicotine chewing gum 
Baseline smoking & 
medical Hx questionnaxe 
sent to all ppts. in one 
CG 
2% random sample of one 
CG screened 
Physical ,exams & 
smoking & medical 
Hx questionnaire at 
4 yrs for all IG males 
&‘all males in one CC 
No missed visit rates 
noted 
31% ’ 26% 4 yrs 
(no objective meashres usedi 
Followup letters at 3, 5, 12 mo 
!E TABLE 2.-Continued. 
Extended interwntmn 
protocol 11 still smoklny SI UC’ Year 
4.x 5.Yi 1 
II)‘> loci 6 
TABLE 2.-Continued. 
Clinical trial Intervention control group contact Followup 





Media: TV, radio, posters, 
mail, phone, newspapers 
Face-t+face intervention: 
group sessions 10 wks, then 
biweekly, yr 1 
Continued intervention for 
yrs2&3 
Baseline survey (physical Surveys (physical + 
+ interview) interviews) yrs 1. 2. & 3 
lst, 2d. & 3d yr surveys High nonattendance rate 
repeated: 40 min contact each yr 
Medical results sent to Highest rate for WI1 
MD group 
Year 3 
WII: 32% cessation1 
W-RC: 0% cessation 
GMO: 11.3% cessation 
(nonattenders excluded) 
TC 14.9% cessation 
(nonattenders excluded) 
WN measured, but not used 
to adjust cessation rates) 
I P  < 0.05. 
’ Not significant. 
SP so.01. 
IG: Intervention Group; CG: Control Group; SI: Special Intervention group; UC Usual Care group; WII: Watsonv~lle Intensive Intervention group; W-RC: Watsonville m&ia+,nly group; GMO. 
Gilroy medisady group; ‘I”2 Tracy Control group. 
obtained with different means at g-year followup, they cannot be 
compared. 
During the first year of the trial, the reported number of cigarettes 
smoked fell dramatically for the intervention group from 19 
cigarettes per day to about 4 cigarettes per day, which was about 
one-quarter of the consumption of the control group. There was a 
steady decrease over the next 9 years in the number of cigarettes 
smoked by the control group, but there was a steady increase for the 
intervention group. The net apparent reduction in number of 
cigarettes smoked at 9 years was 7.6 cigarettes for the intervention 
group(62). 
Multifactor Clinical Trials 
The Giteborg CSweo!en) Primary Prevention Trial 
The GGteborg study (78, 79, 80), a Cyear multifactor clinical trial, 
began in 1970 and was designed to determine whether alteration of 
the risk factors of smoking, hypertension, hypercholesterolemia, and 
to some degree, low physical activity in men aged 47 to 54 would 
lower the incidence of CHD and stroke in a random sample (78, 79, 
80). At the time that the study began, 30,000 men aged 47 to 54 were 
living in GGteborg. One-third of them, 10,000 men, were randomized 
into an intervention group, and the other 20,000 were placed into 
two control groups (Table 1). Screening took place between 1970 and 
1973, and reexamination took place between 1974 and 1977. All men 
in the intervention group and in one control group were sent a 
questionnaire that included an assessment of smoking and symp 
toms of CHD and family history. All men in the intervention group 
were invited to a baseline health checkup; a 2 percent random 
sample of men in one control group was also screened to assure 
comparability to the intervention group. At the 4year followup, all 
intervention men and men in one control group returned for a 
physical examination and questionnaire assessment (78, 79, 80). The 
whole population will be followed for 10 years. 
Of the 10,000 men randomized to the intervention group, 7,455 (or 
75 percent) took part in the entry examination; approximately 65 
percent were smokers (78). There are no indications in the scientific 
reports that investigations were implemented to determine whether 
there were any differences in individuals who participated when 
compared with those who did not come for screening. All men who 
smoked 15 or more g of tobacco per day (equivalent to 15 cigarettes 
or 3 cigars) were invited to an antismoking clinic (78, 79). Only 2.7 
percent of the men screened smoked 25 or more cigarettes per day 
(79). Hypertension and hypercholesterolemia were given interven- 
tion priority so that men with elevated blood pressure or cholesterol 
would be referred for treatment to the relevant clinic and the clinic 
physician would also provide antismoking advice. The smokers of 
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more than 15 cigarettes per day were eventually sent to the special 
smoking clinic. The smoking clinic included about five small group 
sessions run by a physician and a psychologist (79). Very occasional- 
ly, men had an individualized session. All smokers, regardless of 
number of cigarettes smoked, were sent information about smoking 
and cessation and followup letters at 3,5, and 12 months. 
Objective measures of smoking were not used in this trial. The 
immediate rate of smoking cessation among the smokers referred to 
the antismoking clinic was 35 percent. mere is no indication 
whether this is for all smokers or just for those who attended.) After 
3 months this rate fell to 23 percent. At the 4-year rescreening visit, 
it was reported that there was no significant difference in reported 
smoking cessation between the intervention and the control groups 
(78) (Table 2). A table presented in a paper reporting the trial results 
shows cessation rates of 31 and 26 percent at 4 years for the 
intervention and control groups, respectively (781, but upon which 
smokers these results are based is not indicated; thus, interpretation 
is difficult. 
The Oslo (Norway) Study 
The Oslo study (16, 17, 181, a 5year randomized clinical trial, was 
designed to determine whether the lowering of serum lipids and 
cessation of cigarette smoking in middle-aged men would lower the 
incidence of CHD. Of the 16,202 volunteers screened, 40 to 49 years 
old, 1,232 healthy men free of overt cardiac and other chronic 
diseases but at high risk for CHD were randomized to an interven- 
tion (I) group (n. =604) or to a control (C) group (n =628) (Table 1). 
All of the men at entry were normotensive with systolic blood 
pressures less than 150 mm Hg; had serum cholesterol levels of 290 
to 380 mg/dl; and were in the upper quartile of CHD risk based on 
smoking and elevated serum cholesterol. Eighty percent were 
smokers. The two groups were very comparable on all risk factors, 
with a mean age of approximately 45 and the mean number of 
cigarettes smoked daily at 12.5 and 13 for intervention group and 
control group men, respectively (16, 17). 
The smoking intervention program for the intervention group 
started immediately after randomization when each of the smokers 
met with Hjermann for 10 to 15 minutes and were informed about 
the risk factors and strongly advised to stop smoking all forms of 
tobacco. Special emphasis was placed on the synergistic effect of 
smoking and hyperlipidemia. Participants and their wives then 
attended a group session of 30 to 40 persons, where intervention 
included motivating the wives to aid their husbands in changing 
their smoking and eating habits. Half way through the trial, those 
men who continued to smoke were invited to attend in one group a 
%-day smoking cessation program” (16). 
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The intervention group had followup examinations at the center 
every 6 months. These examinations took 20 to 30 minutes and 
included a physical examination aimed at cardiovascular symptoms, 
a resting ECG, and questions about smoking and dietary habits (16, 
17). The control group returned for a similar examination annually. 
At the 5-year examination, followup was excellent, with only 1 
percent of the men who were alive refusing to attend. 
Self-reported smoking behavior at 3 years produced a cessation 
rate of 29 percent in the intervention group and 13 percent in the 
control group (16), a difference of 16 percent. Objective measures 
were not made at this point. Pipe smokers were included as smokers, 
one pack of pipe tobacco per week equaling seven cigarettes per day. 
Self-reported smoking behavior at 5 years indicated a 31 percent 
cessation rate in the intervention group and 18 percent cessation in 
the control group, producing a difference of 13 percent. Cessation of 
all tobacco smoking was 25 percent by self-report at year 5 in the 
intervention group and 1 percent in the control group (16). Although 
serum thiocyanate (SCN) was determined at the end of the trial as a 
validation of self-reported smoking, the corrected rates have not 
been reported. The investigators have noted that when serum SCN is 
used, the difference in cessation between the intervention group and 
the control group becomes smaller and there is a greater discrepancy 
between reported and corrected rates in the intervention group (16). 
When smoking behavior is strati&d, it can be noted that about 10 
percent of the men at baseline both in the intervention group and in 
the control group were light smokers (one to nine cigarettes per day). 
This increased to about 30 percent in the intervention group by the 
end of trial. An increase in this group of light smokers was 
accompanied by a decrease in the group with heavier levels of 
smoking. This reported reduction in smoking did not occur in the 
control group. Most of the cessation in the control group occurred in 
the 10 to 19 cigarettes per day group and not in the lighter or heavier 
smokers (16,17X 
The percentage of nonsmokers continued to increase steadily in 
the control group over the duration of the trial, but the greatest 
increase in the intervention group occurred in the first year, with 
slight increases through year 4 and a slight decline in year 5; thus, a 
decrease occurred in the differences between the intervention and 
control groups during the ftih year (16). The number of cigarettes 
smoked per day decreased from 13 in both groups to about 7 in the 
intervention group and 11 in the control group, resulting in an 
almost 50 percent reported decrease in smoking in the intervention 
group (17). 
The Multiple Risk Factor Intervention Dial (MRFIT) 
The Multiple Risk Factor Intervention Trial was a randomized 
clinical prevention trial followed for an average of 7 years, designed 
to test the effect of a multifactor intervention program on coronary 
heart disease (CHD) mortality and morbidity (19, 43). There were 
12,866 high-risk men, 35 to 57 years of age distributed among 22 
clinical centers. They were randomly assigned either to a special 
intervention @I) group that received treatment for hypertension, 
cigarette smoking, and elevated blood cholesterol levels or to a usual 
care (UC) group that received their usual health care in the 
community (Table 1). Persons were designated “at increased risk” if 
their levels of the three risk factors were sufficiently high at a first 
screening visit to place them in the upper 10 to 15 percent’ of a risk 
score distribution based on data from the Framingham heart study. 
Eligibility was determined at three successive screening visits. 
Men were excluded from the trial on the basis of low risk, history of 
certain diseases, among which were CHD and diabetes mellitus 
requiring medication, expected geographic mobility, a serum choles- 
terol level of 350 mg/dl or higher, or a diastolic blood pressure of 115 
mm Hg or higher. Randomization resulted in an SI group with 6,428 
participants and a UC group with 6,438 participants. There was 
excellent agreement in prerandomixation levels of numerous risk 
factors and risk-factor-related variables (19, 43, 491, with a mean age 
of approximately 46 years and a mean number of 21 cigarettes 
smoked per day. The 64 percent of the participants who were 
smokers smoked an average of 34 cigarettes per day (19, 49). The 
proportion of men who were smokers decreased markedly as the age 
of the participants increased (19). 
Since smokers were defined by their cigarette smoking habits, an 
individual who smoked only pipes and/or cigars or cigarillos at 
baseline but not cigarettes was not included in this group. Approxi- 
mately 9 percent of the MRFIT participants smoked only pipes 
and/or cigars or cigarillos at baseline. Classification of this group as 
nonsmokers was in accord with the lack of substantial evidence 
linking this type of smoking with coronary artery disease. 
Intervention for smoking cessation began after randomization at 
the third screening visit, when the smoker met with a physician who 
noted the effects of smoking on the cardiovascular and respiratory 
systems and strongly advised him to stop smoking. At this time the 
smoker also met with a “smoking specialist” who discussed the 
smoking intervention program with him and invited him to attend 
the intensive intervention group (19). Ninety-four percent agreed to 
join the group program, and 6 percent of the men elected to be seen 
individually. Each group included about 10 men and met for 10 
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sessions. The men were encouraged to bring their spouses or friends 
to the series of weekly group discussions, which were intensive 
efforts to intervene in the three risk factors (19, 48). The smoking 
intervention program included a broad spectrum of educational, 
cognitive, and behavioral approaches for cigarette smoking cessa- 
tion; no special effort was made to alter the smoking habits of 
persons smoking only pipes or cigars. Uniformity of content and 
structure was sought by the use of common protocols and education- 
al material (19,48,49). 
After the initial intensive intervention phase, individual counsel- 
ing planned and executed by an intervention team became the 
general approach. Behavioral scientists often headed the interven- 
tion team, which also included nutritionists, nurses, physicians, and 
health counselors (19, 49). The smoking cessation program following 
the termination of the integrated intervention group was either a 
“maintenance program,” directed at participants who had success- 
fully quit cigarette smoking, or an “extended intervention program,” 
directed at those who continued to smoke cigarettes or had stopped 
and recidivated. The key item in both the maintenance and the 
extended intervention components was a specified minimum con- 
tacts schedule. The maintenance program was based on a series of 
scheduled contacts between staff and participant, with the frequency 
of contacts decreasing over time as the participant continued to 
remain a nonsmoker. Participants who maintained their nonciga- 
ret&smoking status were eventually seen by the smoking specialist 
at regular Cmonth followup visits only. 
Although similar methods, materials and protocols for schedules 
of contact and suggested sequencing of methods were used for 
smokers in the extended intervention phase, an individualized 
approach took into account individual needs and differences. Thus, 
although uniformity of content and structure was sought by the use 
of common protocols, methods, and educational materials, a single 
stepby-step procedure could not be used for smokers in this phase of 
intervention. It was not the goal of this study to treat all smokers 
alike; rather it was intended to produce the optimal treatment effect. 
On or about each anniversary of randomization, participants in 
both the SI and the UC groups returned for assessment of risk factor 
levels, status on physical examination, laboratory studies, and 
morbidity status (19, 43, 48, 49). UC participants visited the clinical 
center once a year, and the results of the examinations were sent to 
their usual source of medical care. The missed-visit rates (the 
number of men alive at the time of the specified annual visit who did 
not attend, divided by the number of men randomized) were 4.5 
percent for SI and 5.2 percent for UC men at 12 months; these 
increased only slightly each year and, although somewhat higher for 
the UC group at each visit, remained below 10 percent through 6 
years for both groups (43). 
Serum thiocyanate (SCN) and carbon monoxide (CO) levels provid- 
ed objective measures and a check on the validity of self-reported 
smoking. MRFIT used a multiple regression model, which takes 
factors affecting SCN (e.g., use of diuretics, pipes, or cigars) into 
account in order to “adjust” the reported data on cessation (46’). 
Cessation rates that have been reported from MRFIT (19, 48, 49) 
therefore include both self-report and SCN-adjusted rates. At year 6, 
43 percent of the SI smokers were reporting cessation, and 25 
percent of the UC noted that they were not smoking (Table 2) (48). 
These rates include all baseline cigarette smokers so that individuals 
who did not attend the sixth annual visit were included at their 
baseline levels of smoking. When these rates are adjusted for SCN 
levels, they are 42 percent and 24 percent for SI and UC smokers, 
respectively, producing a statistically significant difference (p < 0.01) 
between SI and UC of 17 percent. Significantly more cessation 
occurred among lighter smokers in both treatment groups than 
among heavier smokers. 
The reported cessation rate for SI smokers was relatively stable 
from year 1 to year 4-about 40 percentand then increased in 
years 5 and 6 to 41 percent and 43 percent, respectively; cessation 
rates for UC smokers increased in a linear fashion from year 1 (about 
13 percent) to year 6 (25 percent). Thus the SI-UC difference in 
reported and adjusted rates decreased each year, although always 
remaining significant. Similar to the Oslo study findings (IQ, there 
were greater discrepancies between reported and adjusted rates for 
SI smokers than for UC smokers early in the trial, although by the 
sixth year there was little discrepancy in either group. In year 3, the 
reported cessation rates were 40 and 16 percent for SI and UC 
smokers, respectively, and the adjusted rates were 35 and 15 percent 
(48). 
Cohort analyses revealed that 26 percent of all SI smokers and 6 
percent of all UC smokers stopped at year 1 and continued to report 
cessation through year 6 (48). That is, the 43 percent of the baseline 
SI smokers who reported cessation at year 6 included the 26 percent 
of the baseline smokers (or 60 percent of those smokers who initially 
stopped) who continued to report cessation each year and the 17 
percent who had stopped later in the trial at years 2 through 5 or 
had recidivated and then stopped again. At year 2, 6.9 percent of 
baseline smokers were new stoppers. The rate of new reported 
cessation ranged from 3.3 to 4.7 percent at years 3 through 6. 
Similarly, the 25 percent reported cessation rate at 6 years for the 
baseline UC smokers include the almost 7 percent of the baseline 
smokers who continued to report cessation each year to year 6 and 
the 19 percent of the baseline UC smokers who had stopped later in 
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the trial at years 2 to 6 or had stopped earlier, then recidivated and 
stopped again. At year 2, 7.5 percent of baseline UC smokers 
reported new cessation. The rate of new cessation reported at years 3 
through 6 was 4.2 to 4.8 percent. 
Among smokers who stopped early in the trial (i.e., the early 
abstainers), the SI smokers had significantly less recidivism than did 
the UC, but among the late abstainers, the UC participants 
maintained their nonsmoking status somewhat better than did the 
SI cohort. The latter finding may reflect the differences in the 
remaining pool of smokers at the end of the first year of the program, 
with the smaller group of remaining SI smokers being those who 
were more recalcitrant and who would recidivate more readily. The 
data indicate that regardless of the conditions surrounding cessation 
(i.e., amount smoked, time from entry into the study at which 
cessation occurred, assignment to either the SI or UC group), the 
recidivism rates for the second and third year after cessation are 
much lower than for the first year (49). 
Although the primary objective of the MRFIT smoking interven- 
tion program was total cessation, a program for dosage reduction 
was extended to smokers who had not been successful in their 
cessation attempts (19). It provided the trial an opportunity to 
continue working with participants who stated that they did not 
want to stop smoking completely. Reduction data that were reported 
through 4 years of the trial indicate that participants in the SI group 
who did not quit smoking reported reducing their cigarette smoking 
by approximately 10 cigarettes per day at year 1, smoking about 
three-quarters of their baseline rate (19, 49). This reduction contin- 
ued to be reported through 4 years, but was not accompanied by a 
marked decrease in SCN levels. Since SCN levels can be utilized as a 
correlate of cigarette smoke exposure, there are at least two possible 
explanations of this finding. First, underreporting of cigarette 
consumption was occurring among continuing smokers. Second, 
smokers compensated for reductions in the number of cigarettes 
smoked, increasing the intensity of smoking by modifying the 
topography of puffing (15). 
The Stanford Three-Community Study 
From 1972 to 1975, the Stanford Heart Disease Prevention 
Program (SHDPP) conducted the Stanford Three-Community study, 
a field study in three comparable Northern California communities 
(13, 14, 36, 41). The noted objective of this communitywide health 
education project was to develop successful methods for reducing 
cardiovascular risk for the adult population at large that would be 
generally applicable within communities, hoping to demonstrate 
that it was indeed possible to reduce risk in this way (36,411. In order 
to demonstrate that a community-based health education program 
can decrease the risk of CHD, the program compared changes in risk 
behaviors and in risk factors (smoking, increased serum cholesterol, 
and hypertension) for subjects in two communities, using two 
different approaches to intervention, and in a third community, used 
as a no-intervention control. 
To assess the effects of interventions on risk factor knowledge and 
behavior change, baseline and three annual followup surveys 
(medical examination and interview) were conducted for a random 
sample of approximately 500 men and women, aged 35 to 59, in each 
of three intervention groups (one community had two intervention 
groups) and in the control group (36,41,44). These exams took about 
40 minutes each. High risk samples of individuals who were in the 
top quartile of risk at baseline were selected from these groups for 
further study (41). The male to female ratios in these high risk 
samples of individuals ranged from 0.97 to 1.36 (41). 
One community, Gilroy, received a mass media program only; in a 
second community, Watsonville, a media approach was used, and in 
addition, intensive face-to-face intervention was provided for a 
randomized two-thirds of the participants who were in the top 
quartile of risk for CHD. A third community, Tracy, was selected as a 
no-treatment control community because it is geographically remote 
from the other two and does not have the media systems they share 
(36, 41) (Table 1). Followup at all three annual examinations was 
between 58 and 68 percent for each of the four groups, with the 
highest nonattendance occurring in the media plus face-to-face 
intervention groups (14, 36, 41). Of the high risk subjects, 59 to 66 
percent of those subjects seen at baseline in three communities 
attended all three annual surveys, with the greatest nonattendance 
again in the face-to-face intervention group (41). 
The media campaign consisted of spots on radio and television, 
newspaper columns, and mailings of different materials (44). The 
intensive instruction, or face-to-face counseling, took the form of 
group meetings or at-home instruction, whichever the participant 
preferred. The group, usually 12 to 15 participants, met in local 
church rooms for 10 weekly sessions and then twice a month for the 
first year. In many respects the intensive face-to-face intervention 
for the Stanford study is very similar to the MRFIT intensive 
intervention. Of the 169 subjects identified as being at high risk in 
Watsonville, 113 were randomized to treatment. Of these, 107 
started treatment, and a cohort of 77 continued until the second 
annual examination. During the third year, little intervention took 
place. 
Plasma thiocyanate (SCN) concentrations were determined at each 
annual survey to help distinguish smokers from nonsmokers. A 
concentration of greater than 100 ~mol/liter was chosen to indicate 
possible inaccurate reporting (41). The investigators reported that 
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SCN measurement indicated that about 4 percent of those reporting 
abstinence “may have given false reports” (14), but SCN data were 
not integrated with the reported cessation rates (24). Therefore, the 
reported smoking behavior change results that follow have not been 
adjusted with SCN findings. The reported findings (36, 41) are also 
based only on those individuals attending followup surveys; dropouts 
and refusals are not an integral part of the analyses. Cessation 
results have been reported for high risk participants only. 
For those individuals who attended all followup visits in the 
Watsonville intensive instruction group, a 50 percent cessation rate 
was reported (41) (Table 21. This rate becomes 32 percent when the 
13 dropouts are included. Significantly fewer subjects stopped 
smoking in the Watsonville media-only group than did in the Tracy 
control community. In fact, no smokers who attended the 3-year 
followup visit in the Watsonville media-only group reported cessa- 
tion, while 14.9 percent of the control group who attended the visit 
reported cessation. In the Gilroy mediaonly group, 11.3 percent 
reported cessation (41). For the cohort of individuals who attended 
all survey visits there was a steady increase in the number of 
smokers reporting cessation each year in the Watsonville face-to-face 
intervention group. This appeared to be true also for the control 
group. No cessation in the Watsonville media-only group was noted 
during any survey. 
With regard tc reduction in number of cigarettes smoked, there 
was a reported reduction of 51.6 percent for the smokers in the 
intensive instruction group who attended all three surveys (41). Data 
are not provided for the group of nonattendees. More reduction was 
reported in the control group (21 percent) than in the two media-only 
groups (10 and 11.8 percent, respectively). 
Deficiencies in the Clinical Trials 
In this review, the objectives, smoking control methods, and 
smoking behavior change findings of the major large-scale preven- 
tive trials have been presented. As noted in the beginning of this 
section, because of their emphasis on experimental design, preven- 
tive trials provide a valuable opportunity for scientifically assessing 
the efficacy and outcomes of smoking intervention techniques with 
special populations. Although they have greatly added to the quality 
of the available smoking-behavior-change data and the methodology 
used to assess intervention techniques and outcomes, they too are 
beset with deficiencies in some important areas. The major deficien- 
cies noted in the reviewed trials are the lack of objective data to 
verify self-reported outcomes, the use of cross-sectional analyses to 
the almost complete exclusion of cohort analyses, failure to provide 
sufficient information in scientific reports to allow adequate inter- 
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pretation of outcomes, and lack of evaluation of components of the 
intervention packages. 
The use of objective data to verify self-reported data was missing 
in two of the trials: the London Civil Servants smoking trial and the 
Goteborg study. Although SCN was reported to have been measured 
in the Stanford study and in the Oslo study, the findings were not 
used tc correct the reported data. Only one trial-MRFIT-mea- 
sured and used objective data to adjust reported cessation rates. As 
observed in the discrepancies between reported and objectively 
measured cessation data for intervention group smokers in studies 
that have used objective data for verification (e.g., MRFIT and the 
Oslo study), self-reports that have not been verified need to be 
interpreted with caution: often pressures tc stop smoking, perceived 
and real, are felt by participants in an intervention program, which 
may cause misreporting and inflated cessation rates. The same 
pressures may lead to underreporting of consumption levels among 
continuing smokers, a possible interpretation of the MRFIT data 
showing reduced reported smoking among nonstoppers but main- 
tained high SCN levels, Because of differences in the samples studied 
and in the intervention methods used, it is difficult to extrapolate 
from a study that has used objective data to a study that has not used 
these data. The very use of biochemical verification techniques of 
which subjects are aware has been shown to lower deception rates 
(II, 35). Thus, although MRFIT found a discrepancy of about 6 to 9 
percent between reported and SCN-adjustment cessation rates, 
depending at which point of followup the measurements were made 
(as), the possibility of a similar discrepancy in another study using a 
different intervention approach and making different demands on 
different populations of smokers cannot safely be suggested. 
None of the trials, with the exception of MRFIT, reported 
cessation outcomes for cohorts of smokers; they used cross-sectional 
data almost exclusively. Therefore there is very little understanding 
of the actual degree of recidivism occurring each year in either the 
intervention groups or the control groups in these trials or of the 
rate of new cessation taking place in either of the groups. A program 
that obtains an outcome of 30 percent cessation at year 2 and 
includes a large proportion of individuals who have been cigarette 
free for the 2 years is perhaps fulfilling the needs of smoking control 
programs more successfully than a program that yields a 40 percent 
cessation rate at 3 years and includes a large group of smokers who 
have gone back and forth with regard to smoking cessation. As has 
been consistently noted in the smoking literature, stopping is not the 
major problem, it is stopping and staying stopped (5,20,34). Even the 
commonly cited relapse curves (20) use cross-sectional data and do 
not give the true picture of relapse. In order to judge the effective- 
ness of a program, in addition to knowing cessation rates it is 
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important to know whether any new cessation occurs as the program 
progresses or whether all of the smokers available for cessation 
made changes early in the program. Is there a group of recalcitrant 
smokers whom the program never reaches? For example, Ockene et 
al. (48) noted with their use of cohort data that although there were 
new stoppers in the SI group each year, approximately 27 percent of 
baseline cigarette smokers never reported cessation during the next 
6 years of the trial. Thus the program never reached slightly more 
than one quarter of the smokers, a fact that would not be brought 
out by cr ass-sectional data. None of this information can be provided 
with cross-sectional data. 
The 51 percent reported cessation in the London Civil Servants 
trial (58) is impressive on first look, especially given the seemingly 
less expensive intervention approach, when compared with studies 
such as the Stanford study and the MRFIT. A major difference for 
this trial when compared with the other trials in this section is that 
the London Civil Servants trial was a one-factor trial, that is, 
smoking, and the others were multifactorial trials. This difference is 
an important one when considering intervention outcomes. In year 
3, the rate fell considerably, to 36 percent. How many of the 36 
percent of the smokers who reported cessation at year 3 in the Civil 
Servants trial also reported not smoking cigarettes at year l? It is 
possible for this rate to be made up of individuals who were, in fact, 
not part of the original 51 percent at year 1. This lack of cohort data 
coupled with a lack of objective data makes it difficult to adequately 
interpret the outcomes. The Coleborg study investigators noted that 
there was no significant difference at 4 years for the intervention 
group relative to the control group. Although the cessation rates 
may not be significantly different, there may be significant differ- 
ences in the percentage of smokers who met with long-term success 
in each group; thus, there is a possibility that the program had an 
effect on long-term outcome without differentially affecting the 
prevalence of smokers. 
The nonuse of cohort data is also part of a third deficiency in the 
preventive trial literature: a lack of adequate information in the 
scientific reports to permit proper interpretation of outcomes. Also 
included here is a lack of adequate definitions of terms or criteria. 
Investigators in the London Civil Servants study (55, 60, 61) noted 
that additional smoking intervention help was provided “if needed.” 
Likewise, the Oslo study provided a “&day smoking cessation 
program” halfway through the trial for those who “continued to 
smoke” (26). There are no indications in either case of specifically 
how smokers who received additional help were defined, what 
percentage in fact needed it, what types of intervention were 
included in these programs, or what the outcomes of these specific 
programs were. 
The lack of important data in the reports of some of the trials is 
yet another concern. In the Stanford study, 3-year cessation rates for 
each study group are provided for individuals who attended the visit, 
but rates that include nonattendees are not given for each communi- 
ty. A rate of 11.8 percent for the control community of Tracy does 
not give the full story. Likewise, the investigators in the Gijteborg 
study provided a control group in which only 2 percent were initially 
screened, but all were assessed at 4 years (78, 79, 80). Comparison of 
4-year data for the control group participants who were screened at 
baseline with those not screened would also have been useful, as a 
major problem noted for some of the trials is the possible interven- 
tion effect of screening. The Giiteborg study could provide a valuable 
opportunity to investigate this possible intervention effect. 
Another deficiency noted in the trials is the lack of evaluation of 
parts of the intervention packages. Most of the trials used ap 
proaches that combined many different behavioral, educational, and 
medical interventions, but were not able to note which components 
were most effective among all of the approaches. The data available 
at present tell us only the effects of the total intervention. The total 
package may have many components that can be delivered in 
different intensities or sequences to different subgroups of the target 
population (24). It is not possible to estimate the outcome of some 
changes in the total package, as there are too many confounding 
variables that prevent procurement of secure inferences with regard 
to the additive or interactive effectiveness of the individual compo 
nents (24). Sorting out the effectiveness of single stages or elements 
in treatment packages has been a particularly complex area of 
research, with results indicating that simpler models can be superior 
(30). Also lacking are adequate studies designed to determine which 
subgroups of smokers benefit from certain interventions and which 
smokers respond poorly to these interventions (4750). Some persons 
may not need as intensive and expensive an intervention as used in 
the Stanford study and MRFIT and may do well with approaches 
similar to the less expensive and intensive approaches of the London 
Civil Servants study or the Oslo study or with less intervention. 
Trials testing differential intervention effects for subgroups of 
smokers would be able to provide valuable information. 
Comparison of Clinical Trial Outcomes 
Although deficiencies are present in the clinical trials, there are 
also many advances that these trials have made in smoking 
intervention studies. Each trial provided randomized control and 
intervention groups, long-term followup of at least 3 years, and 
standardized points of followup. The long-term followup of control 
and intervention groups provides some valuable data with regard to 
the process of smoking behavior change, although interpretation of 
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these data remains difficult because of the deficiencies as well as 
some of the differences inherent in the trials. In spite of these 
deticiencies and differences there remains much that we can learn 
from the trials reviewed above. The major points will be summarized 
in this section. 
As noted in Table 2, the 3-year reported outcomes for all of these 
trials (except for the Goteborg study) showed a significant difference 
between the intervention groups and the control groups. The 
Gijteborg study did not have 3year data available, and the 4year 
data showed no significant difference in cessation between the 
control and the intervention groups. The control groups in the trials 
where sufficient data are available (i.e., London Civil Servants study, 
the MRFIT, and the Oslo study) generally showed a steady increase 
in cessation as the trial progressed. In each of these studies there was 
a yearly examination for the control group smokers, raising the 
possibility of an intervention effect. In spite of the steady yearly 
increase of control group cessation rates in the trials, the MRFIT 
cohort data demonstrated that a significantly smaller percent of the 
control group smokers reporting cessation each year were long-term 
stoppers compared with the intervention group participants (48). 
Although cessation occurred among nonintervention smokers, it was 
probably not as well maintained as among the intervention group 
smokers. Because of the lack of cohort data, this issue cannot be 
reasonably addressed for the trials presented. 
The range of cessation rates among the control groups at 3 years is 
13 to 16 percent (except for the Goteborg study, which will be 
discussed below), with the highest rate recorded for the MRFIT. The 
London Civil Servants study provided an annual examination for the 
control group, but did not inform the participants of their high risk 
status. This latter point does not seem to have lessened the effect on 
cessation in the comparison group. On the contrary, the nonatten- 
dance rate for the control group in the London study was high-19 
percent at year 3-which may in fact have decreased the cessation 
rate, since nonattendees were included as smokers. 
The Goteborg study control group is unusual, with a possible 
cessation rate of 26 percent at 4 years. As noted, it is difficult to 
discern the rate from the investigators’ scientific report. (Three-year 
rates were not reported.) Although the rate is slightly higher than 
what might possibly be expected at 4 years from the other control 
groups, it might be anticipated that with the steady yearly increases 
observed in the other trials, they would also have higher 4year 
rates. A cessation rate of 21 percent was reported for the MRFIT UC 
group at 4 years, and at the 6-year visit this rate was 26 percent (48). 
Where yearly data are available (i.e., London Civil Servants, 
MRFIT, Stanford study), control groups increased their cessation 
rates about 2 or 3 percent each year, and during the first year, 
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reported rates were about 10 percent. The 2 or 3 percent cessation 
rate each year is not unlike what might be expected from smoking 
cessation in the general population of smokers who stop smoking on 
their own each year without intervention (75). The greater cessation 
rate for the control group relative to the general population of 
middle-aged men at year 1 suggests that factors related to the 
trials-identification as being at high risk, the screening process, 
and the yearly examinations that include questions about smoking 
and cardiovascular fitness-may have had an intervention effect (49). 
Also, illness in this high risk group may have led to cessation. 
With regard to the possibility of the effect of being at high risk, the 
Giiteborg population is the only non-high-risk population in the 
noted trials, and they exhibited a high control group cessation rate. 
Likewise, although the London Civil Servant smokers were at high 
risk, the control group smokers were not informed of this status. 
Therefore, the increased awareness of one’s smoking behavior 
through examination and questionnaires may be enough to motivate 
some persons to stop smoking. The onset of disease is certainly 
another possible factor. More analyses of the data for the control 
group smokers, including their reasons for cessation, must be 
accomplished before the variables affecting cessation in these groups 
can be better understooci. 
The reported cessation rates for the intervention groups (Table 2) 
in the trials at 3 years range from 29 percent for the Oslo study to 40 
percent for the MRFTI’. (For the Stanford study, only the results for 
the WII group are used here for comparison, i.e., 32 percent reported 
cessation.) In many respects, the five trials reviewed are remarkably 
similar with regard to the samples studied. The smoking cessation 
results reported were for healthy middle-aged men at high risk for 
CHD, except for the Giiteborg study, which involved all middle-aged 
men, and for the Stanford study, which included an almost equal 
number of men and women in the intensive intervention group. The 
mean ages were similar in three studies (45 to 47), and in the 
Giiteborg study and the London Civil Servants study the mean ages 
were 51 and 53, respectively. The greatest number of cigarettes 
smoked was by the men in the MRFIT study who smoked an average 
of 21 cigarettes per day. (The data for the Gijteborg study are not 
clear with regard to the average number of cigarettes smoked per 
day by the smokers.) The least intensive intervention for smoking 
and the least expensive approach seemed to occur in the London 
Civil Servants smoking trial and the Oslo study, both of which used 
short initial visits with physicians and then one to three followup 
visits either individually (London study) or in a group (Oslo study). 
The fewest intervention visits were noted for the Oslo group. Both of 
these studies noted the use of additional intervention when neces- 
sary, but what this means or how much additional intervention was 
provided is not specified. The Stanford study and the MRFIT seemed 
to provide the most intensive intervention, with at least 10 weekly 
group sessions and more if necessary. The smoking intervention 
program in the Giiteborg study-small group sessions-falls between 
the two levels of intervention. In addition to the group sessions, the 
Goteborg study provided nicotine chewing gum at session two. 
Each of the trials provided some continued contact, at least every 6 
months and generally more often, for the intervention group 
smokers during the first 2 years of the trials. It appears as though 
the least maintenance contact may have been provided in the 
London Civil Servants study, although this is not entirely clear from 
the reports. Hypothetically, the more continued maintenance and 
intervention contacts provided, the greater the likelihood of new 
cessation and maintenance of cessation occurring. This possibility 
has been tested only for the MRFIT, since as noted previously, only 
cross-sectional data were available for the other studies. New 
cessation continued to occur in MRFIT each year at the rate of about 
3 to 6 percent, and by the sixth year about two-thirds of the smokers 
who stopped initially continued to maintain cessation. Relative to 
past reports, this maintenance rate is indeed very promising, and it 
would be useful to know the maintenance rates of trials that used a 
lesser frequency of contact. Because of the continued contact, it is 
difficult to assess whether the followup data are good indicators of 
the level at which intervention effects stabilize (24). 
The outcomes in the Stanford study are puzzling. At the third 
annual examination, the control community of Tracy showed the 
same rate of smoking cessation as the media-only town of Gilroy and 
significantly more cessation than the media-only intervention group 
in Watsonville:Zero percent of the Watsonville media-only group 
reported cessation, but there was a steady increase in the control 
group each year to about 15 percent. These data provide no support 
for the possibility that an intensive media blitz has an impact on 
smoking cessation that is greater than the impact of “usual” 
community intervention. Perhaps there is a “saturation point” with 
regard to the effectiveness of increased awareness, which when 
reached requires intervention to be at an intensive individual level 
before the next level of smokers can be affected. Albeit, a demon- 
strated intervention effect that is less than what is observed 
spontaneously in the general population merits investigation. 
The Oslo study has the lowest 3-year reported cessation rate for 
the intervention groups, 24 percent, and seemed to deliver the least 
intensive intervention among the trials; the MRFIT had the highest 
cessation rate at 3 years, 40 percent, and perhaps provided the most 
intensive intervention among the trials. The best outcome was 
attained with the most intensive and perhaps the most expensive 
approach of the MRFIT, which demonstrated the possibility of long- 
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term cigarette smoking cessation with large numbers of people. 
Whether the intensive approach is cost effective must be evaluated. 
Similarly, as noted previously, it is important to determine whether 
there are certain groups of smokers who may not need intensive 
intervention and others who may require even more intensive work. 
Even with the use of intensive intervention (Stanford study and 
MRFIT), a cross-sectional cessation rate of less than 50 percent was 
obtained. Is even more intensive intervention (or a different treat- 
ment package) desirable, or is this rate all that can be hoped for? 
Perhaps such intense interventions are not cost effective in terms of 
the outcome achieved, and much more attention should be devoted to 
self-help approaches. 
Community Prevention Trials 
The Heart Disease Prevention Project: World Health 
Organiza tion European Collaborative Trials 
The World Health Organization (WHO) European Collaborative 
Trials (81) were set up to evaluate the ability of a multifactoral 
intervention program to alter risk factors for CHD in industrial 
workers, aged 40 to 59, and the effect of such changes on CHD 
incidence and mortality. The allocation units were factories or other 
large occupational sites, thus permitting community health educa- 
tion as well as an individual approach. In most cases the program 
operated at the participants’ workplace. The Collaborative Group 
included four centers: the United Kingdom, Belgium, Italy, and 
Poland. Although there was organizational diversity and each trial 
was essentially autonomous and self-sufficient, the experimental 
design was the same in each center with standardization of screening 
methods, intervention objectives, and end-point criteria (81). It was 
planned that each trial would run for about 5 years. 
In each trial, factories or other occupational facilities were 
arranged in pairs and matched according to size, location, and type 
of industry, and then randomly allocated to an intervention or a 
control group. A central team visited each factory for screening. All 
men in the intervention factories between the ages of 40 and 59 and 
a random 10 percent of the men in the control factories were invited 
for a screening examination. The rest of the control men were not 
told of their participation in the trial, thus preventing a possible 
influence on risk factor change. The 10 percent of the controls who 
were initially screened were reexamined after 2 years. Random 5 
percent samples of men in the intervention factories were reexa- 
mined annually in order to monitor risk factor changes. All 
survivors were examined at the termination of the trials (81). 
Intervention was provided for hypercholesterolemia, cigarette 
smoking, sedentary activity, weight control, and hypertension. All of 
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the men in the intervention factories were exposed to mass 
intervention approaches such as posters, groups, films, and demon- 
strations and received a report of their results along with printed 
advice for change. Their personal physicians also received copies of 
the reports. Individualized intervention consultations were provided 
for the 10 to 20 percent of the men who, as a result of screening, were 
asses.& to be at the “highest risk for CHD.” The intervention 
approach used in this trial was similar in some respects to that of the 
Stanford study insofar as both used a combination of facetiface and 
mass media techniques. 
Information specific for the United Kingdom and Belgium trials 
and their results is presented below. The Rome and Warsaw trials 
have not yet reported their results. 
United Kingdom Heart Disease Prevention Project 
Recruitment for the heart disease prevention project in the United 
Kingdom occurred between 1971 and 1973. Twenty-four large 
industrial groups, generally factories, employing a total of 18,210 
men, were recruited and paired (62). One of each pair was allocated 
to the intervention group (9,734 subjects) and to the control group 
(8,476 subjects). Intervention began with the acceptance of screening 
by 86 percent of the men aged 40 to 59. A cutoff risk factor score was 
determined within each intervention factory, such that it was 
exceeded by 12 to 15 percent of the examined men who were at “high 
risk” for CHD. Differences between factories in the mean levels of 
risk factors were slight (62,811, with a mean age of approximately 50 
for both groups and a mean number of cigarettes smoked of 
approximately 8 cigarettes per day for alI men and 14.3 cigarettes 
per day for the high risk men (62,811 (Table 3). 
Intervention for all of the smokers in the intervention factories 
was initiated at the screening examination, when they were asked if 
they would like to stop smoking (62). The 40 percent who were 
interested were sent a letter of encouragement, smoking record cards 
that they were asked to return after 3 weeks, and a booklet with 
smoking cessation advice. All screened participants were sent 
general information on risk factors, and the mass health education 
intervention included posters, evening meetings to which spouses 
were invited, films, talks, and question and answer sessions. Because 
of the generally poor response to the community intervention in the 
first 2 years, more personal contact was added for men whose risk 
scores came close to the high risk scores. Annual examinations were 
also used to give personal advice on smoking and diet. In the third 
year, antismoking clinics for all smokers were held by a nurse. The 
high risk men were recalled after screening by the company 
physician, who advised and treated them individually. There was an 
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18,210 factory workers 
Aged 40-59 
24 large industrial groups 
(paired) 
Factories paired for similarities 
Random allocation of one in each pair 
to intervention or to no intervention 
Intervention group (IG) = 9,734 males 
Control group (CG) = 8,476 males 
x CigB for all 
participants = 8 
x cigs for high risk 
males = 14.3 
WHO European 
Collaborative Trial: 
Belgium (8, 26, 27) 
(5 years) 
(screening 1972-1974) 
16,222 factory workers 
Aged 40-69 
30 industrial groups (paired) 
Same randomization as above 
Intervention group (IG) = 7,398 males 
Control group (CC) = 8,240 males 
I( cigs not noted 
Y w 




study groups Baseline smoking dara 
North Karelia 
(Finland) Project 
63 54. 6.x 64. 65l 
(5 years) 
(screening 1972-1977) 
Residents of North Karelia 
M.ervention community = 10 
Residents of Kuopio 
(Control community = CC) 
Surveyed residents aged 2L59 
at start of study 
No randomization 
North Karelia had a high CVD rate 
and intervention was indicated 
Community similar to North Karelia 
was matched as a control 
IC: 50.2% males smoked 
11.7% females smoked 
CC: 50.9% males smoked 
13.1% females smoked 
X cigs (CC) = 6.9 for 
all males 
Random 6.6% sample of population aged X cigs UC) = 9.9 for 
25-59 in each community surveyed in 1972 all males 
X cigs UC) = 19 for 
all smokers Random 6.6% sample (independent of 1st 
sample) surveyed at study end in 1977 
Over 10,COO subjects studied each time 
average of about four E-minute visits per high risk smoker during 
the first year (62). 
Changes in risk factors for intervention were assessed each year 
for a new 5 percent random sample of all entrants. At year 5, half of 
all the men who had not been previously assessed were called, and at 
year 6, assessment was accomplished for the other half still 
employed. Followup of high risk men occurred at either the second 
or fourth year. A random 10 percent of the men in the control group 
were invited to an examination at entry and again at 2 years and at 
4 years. The results for the intervention group were corrected for 
corresponding changes in the control group (62). Followup visits in 
all groups ranged from 86 to 94 percent of those invited. 
Objective measures were not used to validate self-reported smok- 
ing behavior. High risk men reported the best changes in smoking 
levels, with a decrease in number of cigarettes per day from 
approximately 13 at entry to about 9 at the final examination, a 29 
percent decrease. No decrease was noted for the control group; thus, 
the corrected estimate for the effect of intervention at the final 
examination was also minus 29 percent (62). There was a net 
reduction in number of cigarettes smoked of 19 percent for all 
smokers and of 16 percent when high risk smokers were removed. 
At the end of the trial, a 12 percent cessation rate for the high risk 
men in the intervention group was reported, but no change was 
reported in the control group (Table 4). About 9 percent of all of the 
intervention smokers reported cessation by the end of the trial, 
which is about 7 percent if high risk smokers are excluded (62). 
These differences are statistically significant (p <O.OOl). A compari- 
son of risk factor levels at the final examination between the 90 
percent of the control group men who had no contact with the trial 
before the examination and the remaining 10 percent who had been 
examined showed almost identical results for smoking (62). 
The Belgium Heart Disease Prevention Project 
After a preliminary feasibility study in 1971-1972 for the Belgium 
trial, initial examination for the main trial began in 1972 and 
terminated in April 1974 (81). The trial paired 30 Belgian industries, 
with 1 member of each pair randomized to the intervention and 1 to 
the control group (8, 26, 27). Out of 19,390 male workers in the age 
group of 40 to 59, 83.7 percent agreed to be screened, yielding 7,398 
men in the intervention group and 8,821 men in the control group. 
There are no indications that investigations were implemented to 
determine whether there were differences between persons who 
were screened and a random sample of those who were not screened. 
Ten percent of the subjects in each occupational unit were randomly 
selected for an examination similar to that of the intervention group; 
the other 90 percent had a resting electrocardiogram (8, 26, 27). The 
Y TABLE I.--Intervention, followup, and cessation results for three major community prevention trials 
Community trial Intervention Control group contact Followup 






Mass media intervention for 
all factory workers 
Antismoking clinics for all ( 
smokers 
High risk smokers (top IO-15% 
risk) offered individual 
treatment (four 15 min sessions 
in year 1 with company 
physician) 
Random 10% sample invited Random 5% IG examined 
for screening yearly 
The rest of control males 
not told of their 
participation in the trial 
All survivors examined 
at end of trial 
Same random 10% CG 
screened, reexamined at 
2 yea* 
















Mass media intervention for 
all factory workers 
High risk smokers (top 21% 
risk) offered counseling and 
examination by project 
physicians twice per year 
Random 10% invited for 
screening 
Other 90% had resting 
ECG only 
Random 5% IG examined 
yearly 
All survivors examined 
at end of trial 
18.7% * 12.2% 2 Ym 
(high risk (high risk 
smokers) smokers) 
12.5% (all 12.6% (all 
smokers) smokers) 
(no objective measures used) 
TABLE 4.-Continued. 
Community trial Intervention Control group contact Followup 




(52, 53, 63) 
Comprehensive “community action” 
program against risk factors 
All forms of media used 
Special groups set up aa needed 
6.6% random sample examined 
at baseline and 5 years 
Random 6.6% of each 
community surveyed and 
examined in 1977 
Results compared to 
assess RF change 
1763 15% 5 Yn 
(male (male 
smokers) smokers) 
(SCN drawn for random 
subsamples) 
Gxrelations reported. but 




intervention subjects in the top 21 percent of the risk score 
distribution were placed in the high risk group (n= 1,601). 
All smokers in the intervention factories received the mass media 
approach previously noted for the WHO trials, and all family and 
factory physicians received regular information about the partici- 
pants’ risk factors and took part in intervention (8, 26, 27). Twice a 
year, high risk subjects were individually counseled and examined 
by two project physicians (8, 26,27) (Table 3). 
Reports of the smoking results for this trial have included 
comparisons of the results for the 5 percent random sample in the 
intervention group with the results for the 10 percent random 
sample of the control group at 2-year followup and comparisons of 
the results of the high risk subjects in the intervention group with 
the results of the high risk subjects selected from the 10 percent 
random sample of the control group screened at baseline (9, 26, 27). 
Reported smoking rates have not been validated with objective 
measures. Among the high risk smokers, 18.7 percent in the 
intervention group and 12.2 percent in the control group reported 
cessation at 2 years, producing a statistically significant difference 
(p ~0.05). For the random samples there was no difference in 
reported cessation, with approximately 12.5 percent of the smokers 
reporting cessation in both groups (26, 27). Smoking cessation rates 
for the intervention group at 1 year was 12 percent and 8 percent for 
the high risk subjects and the random sample, respectively (27), 
indicating that cessation occurred gradually over the 2-year period. 
The North Karelia (Finland) Project 
The North Karelia project was carried out in Finland during 1972- 
1977 as a comprehensive community program to study the control of 
cardiovascular disease (CVD), with special emphasis on CHD, by 
reduction of the major alterable CHD risk factors (smoking, in- 
creased serum cholesterol, and hypertension (52, 53, 54, 63, 64, 65). 
The intervention area was the county of North Karelia in eastern 
Finland, which had the highest rates of CVD in that country. The 
county of Kuopio, also in eastern Finland, was selected as the control 
area because of its similarity to North Karelia. 
Both in 1972 and in 1977 a representative random 6.6 percent 
sample of the population born between 1913 and 1947 (aged 25 to 59 
in 1972 and 30 to 74 in 1977) was drawn from the two counties by 
using the national population register (53, 54). The samples in 1972 
and in 1977 were independent of each other. Those persons surveyed 
were sent a letter explaining the study, a questionnaire assessing 
medical history, health behavior and attitudes, attempts to change 
health behavior, and stress and an invitation and date for a physical 
examination. Over 10,000 subjects were studied each time, with a 
participation rate of about 90 percent (52,53,54,63,64,65). 
The comprehensive “community action” program against risk 
factors was integrated into the health and social services of the 
county and was aimed at primary and secondary prevention, 
although primary prevention was emphasized. Public information 
was provided through newspapers, radio, leaflets, posters, health 
education meeetings, and campaigns at schools and places of work 
(53); new services were set up if needed, personnel were trained, and 
environmental changes (e.g., smoking restrictions) were implement- 
ed. The project team planned the activities, prepared the educational 
material, helped train personnel, and got the community into action 
(54). Smoking cessation group activities were available to those 
smokers who wanted them, on the basis of a 3-week model developed 
by the project (63). Approximately 55 percent of the smokers were 
willing to join the groups, and 71 percent of those who started 
completed the groups (63). Approximately 27 percent of those who 
started the group reported smoking cessation at 6 months. 
The outcomes concerning changes in smoking are based on the 
comparison of data obtained in the baseline survey and in the s-year 
terminal survey from the study community and the matched control 
community. The validity of. the self-reports of smoking behavior was 
tested on a random subsample of subjects who were given a second 
interview about smoking by trained nurses unaware of the answers 
to the survey questionnaire (53). When classified by an interval of 5 
or 10 cigarettes, the agreement between the two results was 93 and 
97 percent, respectively. The agreement was 99 percent when 
classification was smoker or nonsmoker (53). Serum thiocyanate 
(SCN) determinations made during the termination interview pro- 
vided further validation. Since it is not otherwise noted in the 
scientific reports, it is assumed that the results are based on self- 
report and are not corrected, Individuals who reported ever having 
smoked regularly or having smoked during the preceding month on 
an average of more than once a day were classified as smokers. The 
reported number of cigarettes, cigars, and pipes smoked per day was 
calculated as the amount smoked (53). 
The prevalence of smoking in the study and in the control area for 
men was 50.2 and 59.9 percent, respectively, and for women 11.7 and 
13.1 percent at the start of the study. At year 5, 17 percent of the 
baseline male smokers in North Karelia reported smoking cessation 
and 15 percent of the baseline male smokers in Kuopio reported 
cessation of smoking (52, 53) (Table 4). Thus, smoking had decreased 
considerably in both the control and the study groups, yielding a 
nonsignificant net reduction in North Karelia of 2.5 percent for the 
men and 6.1 percent for the women. With regard to amount smoked, 
North Karelian men smoked more than did the men in the control 
area in 1972 (9.9 versus 8.9 cigarettes per day), and both groups were 
smoking 8.1 cigarettes per day by the end of the study (531, producing 
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a significant net reduction among North Karelian men of 9.8 
percent. The mean number of cigarettes smoked by smokers in 
North Karelia was 19 cigarettes per day, which remained stable 
during the study (63). 
A small net reduction occurred in the prevalence of smoking 
because, even though considerable cessation was reported in North 
Karelia, smoking also decreased at a similar rate in Kuopio, the 
control area. The investigators noted several possible explanations 
for this decrease (53). There was an increase in interest in antismok- 
ing activities toward the end of the study period: the Finnish 
Parliament passed new antismoking legislation in 1976, and a new 
medical school opened in Kuopio in 1972. They also indicated on the 
basis of internal followup surveys that most of the reduction in 
smoking occurred at the beginning of intervention in North Karelia, 
after the first intensive public antismoking campaign, and that this 
lower level of smoking was maintained during the rest of the period 
(39. 63). 
Deficiencies in the Community Preventive Trials 
The major deficiencies in these community preventive trials are 
the same as those noted for the clinical trials; i.e., lack of objective 
data to verify self-reported outcomes, use of cross-sectional analyses 
to the almost complete exclusion of cohort analyses, failure to 
provide sufficient information in scientific reports to allow adequate 
interpretation of outcomes, and lack of evaluation of components of 
the intervention packages. 
Objective data to verify self-reports were not used in the United 
Kingdom and the Belgium heart disease prevention projects, and 
although SCN was measured in the North Karelia study, it was not 
used to adjust the self-reported cessation data. Data for strata of 
smokers by age were presented for the North Karelia study (74), but 
not for cohorts of smokers by smoking-behavior-change categories. 
Longitudinal data for cohorts of smokers in the other two trials were 
not presented. The value of cohort data is illustrated by a statement 
made by the North Karelia investigators in which they noted that 
even though the smoking cessation rates were similar in North 
Karelia and Kuopio, most of the cessation in North Karelia occurred 
at the beginning of the project and was maintained (63, 74). This 
information was obtained by the use of followup surveys of samples 
of residents. It was hypothesized that most of the cessation for the 
comparison community may have occurred near the termination of 
the project when antismoking legislation and other changes had 
occurred there (39, 63). Cohort data for the comparison community 
or for subgroups are not available; thus, the hypothesis cannot be 
tested. 
Use of the same subjects for baseline and termination surveys are 
likely to influence outcomes; therefore, the change may look better 
than it actually is (53, 54, 63). The use of a cohort design might 
therefore produce a net effect that is not totally a consequence of the 
intervention alone, but may also include the effect of the first survey 
as well as its interaction with the intervention (63). Thus, there is a 
possible need to examine independent cross-sectional population 
samples in the two areas under study at the start and termination of 
the project. This hypothesis is not supported by data from the North 
Karelia study, where cessation rates for 6.6 percent of the random 
sample of smokers in the baseline survey of the control community 
who were also included in the termination survey were similar to the 
rates for the rest of the smokers who were surveyed only at 
termination (63). Data from the United Kingdom heart disease 
prevention project (62) also failed to support the hypothesis of a 
possible intervention effect from screening. 
Different components of intervention were not differentially 
evaluated within any of the community trials because of the 
community orientation of the projects. Thus, conclusions about the 
relative contributions of different programs, subprograms, or chan- 
nels of action cannot be drawn (39). 
Comparison of Community Trials Outcomes 
As is noted in Table 4, the 2-year cessation data for both the 
Belgium and the United Kingdom WHO trials demonstrate that 
there were significant differences in reported cessation rates for the 
intensively intervened-with high risk smokers as compared with the 
smokers in the control factories, but there were no significant 
differences between the non-high-risk smokers in the intervention 
factories who received a media-only approach as compared with the 
non-high-risk smokers in the control factories. This outcome is 
similar to the previously noted finding in the Stanford study; i.e., 
media only had no more intervention impact than had no interven- 
tion. This lack of demonstrated impact for a media approach to 
smoking cessation in the Belgium study was in part due to the 12.5 
percent cessation rate achieved by the control group. This occur- 
rence of cessation in a control group is similar to that demonstrated 
in each of the clinical trials. Again, a saturation point may have been 
reached in groups in which there is already an increased level of 
awareness, and intensive intervention may be necessary if additional 
cessation is to be realized in the next level of smokers. It may also be, 
as previously noted, that although cessation occurred among the 
nonintervention smokers, the long-term maintenance rate among 
those in this group who stop smoking may be significantly different 
from the long-term maintenance rate for the intervention group 
smokers. Because of the lack of cohort data, this issue cannot be 
addressed. 
The range of cessation rates among the comparison groups for the 
three trials is large, 0 to 15 percent, with the lowest rate recorded for 
the United Kingdom group of the WHO collaborative study and the 
highest for the Belgium group of the same study. The 0 percent 
cessation rate for the control group in the United Kingdom trial is 
puzzling, as this is less than the spontaneous cessation rate observed 
in the general population. More in-depth analysis of the data for the 
10 percent random sample of the control group who were screened at 
baseline and reexamined at 2 years is indicated. Different protocols 
for contact with the control group were used for the United Kingdom 
from those used for the Belgium groups. The most notable difference 
was that 90 percent of the United Kingdom control group were not 
told of their participation in the trial, but 90 percent of the Belgium 
group were told of their participation and had a resting ECG. An 
additional 10 percent were told of their participation and had 
complete physical examinations. It can be hypothesized that the use 
of an ECG may have had an intervention effect for the Belgium 
control group. The 15 percent rate for the North Karelia study was 
determined at 5 years. One might hypothesixe that this rate would 
be lower at 2 years, the point at which the other two studies 
conducted followup. 
The 5year cessation rate for the United Kingdom collaborative 
trial is also low when compared with the 2-year rate for the Belgium 
collaborative trial, which utilized a similar protocol. A major 
difference for these two groups was that high risk smokers in the 
Belgium study received two examinations per year while those in the 
United Kingdom were given one. There was also a difference in the 
number of physician-intervention visits during year 1; two were used 
in the Belgium study and four were used in the United Kingdom 
trial. Perhaps the feedback provided by an examination has a 
greater intervention effect than a session with a physician intended 
for counseling only. It can also be hypothesized that cultural 
differences may have affected the differences in outcome between 
the two groups in the same trial. 
In general, the use of community programs that used only a media 
approach did not produce a greater intervention effect than was 
observed in the comparison community. The incorporation of more 
intensive intervention in groups in addition to the media approach 
was necessary before significant differences could be realized. The 
same outcomes were observed in the Stanford study. 
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Conclusions 
1. Smokers involved in intervention programs demonstrate higher 
smoking cessation rates than those in control groups. 
2. In general, the success of smoking intervention programs is 
related to the amount of intervention provided. 
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Epidemiologic Evidence Regarding Smoking Cessation and 
Coronary Heart Disease 
The epidemiologic data on smoking and coronary heart disease 
(CHD) were reviewed in detail in a preceding section, as well as in 
the Reports of the Surgeon General for 1964,1971, and 1979 (60, 61, 
62). Coronary heart disease (ICD/G and ICD/7 No. 420) before 1968 
and ischemic heart disease (ICD/8 and ICD/9 Nos. 410414) since 
1968 are considered synonymous with one another for all practical 
purposes and are abbreviated as CHD. Terminology and data on 
CHD are discussed in detail elsewhere (33, 34, 44). This discussion is 
limited to epidemiologic data on smoking cessation and CHD. 
Several prospective studies involving self-selected questionnaire 
respondents include extensive epidemiologic data on smoking cessa- 
tion and CHD mortality. The results, summar@ed in Table 1, show 
CHD death rates for former smokers relative to never smokers as a 
function of the number of years stopped smoking cigarettes, general- 
ly determined as of the time the questionnaire was completed. Data 
in this form are available only for men, generally white men. The 
studies are as follows: the British physicians study, including 10-year 
followup (10, II) and 20-year followup (12); the American Cancer 
Society S-State study (22, 23) and the American Cancer Society 25 
State cancer prevention study (20, 21); the U.S. veterans study with 
&&year followup (32) and X-year followup (49); and the Swedish 
representative sample study with l@year followup (4). Excluded 
were numerous studies that present data only on former smokers as 
a whole or have data on a few special categories of former smokers, 
such as Shapiro et al. (58) and Hirayama and Hamano (25). Much of 
these other epidemiologic data on former smokers is summarized in 
the 1979 Report of the Surgeon General on Smoking and Health (60) 
and in the preceding section of this Report on coronary heart disease. 
Numerous epidemiologic studies (10, II, 12, 14, 20, 21, 32) have 
shown a decrease in CHD mortality for ex-smokers compared with 
continuing smokers, and it has been suggested that smoking 
cessation accounts for this salutary effect. Another view (57) has 
been that continuing smokers and quitters are somehow constitu- 
tionally different and that their health experiences might also be 
different, independent of smoking status. Two prospective studies of 
current smokers, some of whom became persistent quitters during 
the course of the study, show that persistent quitters have lower 
CHD and total death rates than do continuing smokers (17, 18). 
Friedman et al. (17) examined this question in some detail in the 
Kaiser-Permanente study of over 25,000 persons. They compared 18 
baseline characteristics related to coronary disease in quitters and 
continuing smokers at a time when all were smoking. They found 
that the beneficial effects of quitting on CHD mortality could not be 
explained by differences in their baseline characteristics (Table 2). 
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F TABLE l.-Male coronary heart disease and total mortality ratios for current and former cigarette smokers relative to never smokers, as a function of years stopped smoking 










American Cancer Society 
S&ate study S 
Cigarettes only 0 1.41 (464) 1.37 (1566) 
l-4 1.05 (28) 0.96 (71) 
5-9 1.25 (61) 1.18 (204) 
10-14 1.16 (59) 1.12 G?O4) 
15+ 1.12 (40) 1.11 (153) 
NS 1.00 (113) 1.00 (436) 
Attained age Attained age 
3c-54 55-64 65+ 30-64 65+ 30+ 
Cigarettes only, 0 3.5 1.7 1.3 2.0 1.6 1.8 
at least 5 years l-4 1.9 (71 1.9 (19) 1.0 (24) 1.7 (67) 1.4 (99) 1.5 (1661 
5-9 1.3 (10) 1.4 (34) 1.3 (76) 1.6 (141) 1.4 (242) 1.5 (383, 
lo-14 1.4 (101 1.7 081 1.2 (62) 1.4 (104) 1.2 (206) 1.3 (310) 
15+ 1.3 (7) 1.3 (45) 1.1 (148) 1.1 w6) 1.1 wEa 1.1 (590) 
NS 1.0 (32) 1.0 (75) 1.0 w?2) 1.0 (326) 1.0 (611) 1.0 (9371 
Cigarettes smoked per day Cigarettes smoked per day 
l-19 2t+ 1-19 20+ 
Cigarettes only 0 1.75 @J4) 2.20 (6041 1.61 (2303) 2.02 (1326) 
<l 2.10 (23) 3.00 (18) 2.04 (51) 2.69 05) 
l-9 1.54 (80) 2.06 (64) 1.30 (159) 1.82 (135) 
lO+ 1.09 (401 1.60 (40) 1.08 (141) 1.50 (87) 
NS 1.00 (709) 1.00 (709) 1.00 (1644) 1.00 wx4) 
TABLE I.-Continued. 
Overall cohort Smoking selection 
description criteria 




American Cancer Society 
25State study’ 
Cigarettes only 
Cigarettes smoked per day 
for initial ages 40-79 
1-19 20+ 
0 1.90 (1063) 2.55 (2822) 
*. 1 1.62 (29) 1.61 (62) 
l-4 1.22 (57) 1.51 (154) 
5-9 1.26 (55) 1.16 (135) 
10-19 0.96 (52) 1.25 (133) 
201 1.08 (70) 1.05 (80) 
Cigarettes smoked per day 
for initial ages 54S74 
1-19 20+ 
1.72 I20151 1.94 (3741) 
1.61 (641 2.18 (213) 
1.44 (1441 1.98 (499) 
1.34 (1261 1.49 (416) 
1.02 (2551 1.32 (5461 
NS 1.00 (1841) 1.00 (1841) 1.00 (3512) 1.00 (3512) 
Attained age. 55-64 Attained age. 55-64 
U.S. veterans’ Cigarettes with or 0 1.66 (3064) 1.72 (6928) 
without cigars/pipes, l-l 1.34 (155) 1.56 (379) 
stopped for other 5-9 1.47 (279) 1.42 (5961 
than doctor’s orders lo-14 1.13 (161) 1.28 0651 
15+ 0.97 (342) 107 (7791 
NS 1.00 (1218) 1.M) (2617) 
Attained age, 31-99 Attained age, 31-99 
U.S. veterans’ Cigarettes with or 0 1.56 (13,645) 1.73 (36,143) 
wthout cigars/pipes, 14 1.35 uO1 -1.5 (384) 
stopped for other 5-9 1.36 (599) -1.4 (1441) 
than doctor’s orders lo-14 1.29 (997) - 1.3 (2445) 
E-19 1.21 (1101) - 1.2 (2767) 
20+ 1.05 (2418) -1.05 (6049) 








Coronary heart disease 
mortality ratio* 
All causes 







Years smoked cigarettes, initial age, 40-69 Years smoked cigarettes, initial age, 40-69 
<20 >20 Total <20 >20 L Total A 
1.7 (212) 1.4 (557) 
0.9 (71 1.6 (84J 1.5 (97) 1.0 (26) 1.4 (212) 1.3 (253) 
0.9 (40) 1.1 (46) 1.0 (86) 1.0 (1231 1.0 (117) 1.0 (241) 
1.0 (219) 1.0 (219) 1.0 (219) 1.0 (671) 1.0 (671) 1.0 (671) 
’ Years stopped smoking was measured as of beginning of followup. except for the U.S. veterans study. where the number of years stopped was increased by 1 with the passage of each calendar year 
unless death occurred 0 years stopped enotes current smoker; NS denotes never smoker. 
‘Mortality ratio is former emoker death rate relatrve to never smoker death rate, properly adjusti for age; ratio for never smokers is delined to be 1.0. Number of deaths are in parentheses. 
“Study of 34,445 men aged 201. at lOyear followup. 1951-1961. Doll end Hill (10. 11). 
.Study of 34,440 men aged 20+. et Myear followup. 1951-1971. Doll and Peta (12). 
‘Study of 187,783 men aged 5O-fj9. et 44.month followup, 1952-1955. Hammond and Horn (22,23). 
‘Study of 440,558 men aged 301, approximately at 4-yeer followup. 1959-1963. for total mortality, end 358,534 diseasefree men at Gyear followup. 1959-1965, for CHD mortality Hammond (20), 
Hammond and Carfinkel(21). 
‘Study of 248,046 men a& 31-&1. at 5.5.year or 8Syear followup. 1954-1962. Kahn (32). 
a Study of 248.045 men aged 3184. at E-year or E-year followup. 1954-1969. Royot and Murray (49). 
‘Study of 51.911 men aged 18-69. at l&year followup. 1963-1972. Cederlof et al. (4). 
People who persisted in cigarette smoking had more than twice the 
risk of dying from CHD than those who quit even after taking into 
account the other baseline differences. These studies provide stron- 
ger evidence regarding the benefits of quitting than do the studies in 
which all of the ex-smokers had stopped smoking before the 
beginning of the followup. 
Data from two “natural experiments” of smoking cessation among 
physicians in Britain (12) and in California (14) are presented in 
Table 3. Because these physicians have stopped smoking to a much 
greater extent than has the general male population, the subsequent 
CHD mortality trend in physicians as a whole relative to the general 
population constitutes a crude estimate of the overall mortality 
benefits of smoking cessation, This assumes that there have been no 
other major risk factor changes in the compared populations, but 
unfortunately, other risk factors were not measured in these two 
studies. Both studies support the earlier prospective studies with 
regard to the benefits of smoking cessation on CHD mortality. In 
addition, they show the benefit of smoking cessation among a cohort 
as a whole, including the continuing smokers with the quitters. 
The most straightforward interpretation of ex-smoker data indi- 
cating that CHD mortality rates of persons who stopped smoking are 
substantially lower than those of persons who continued smoking, is 
that smoking cessation directly results in the reduction of risk of 
heart disease mortality. Underlying this presumed CHD benefit is 
the assumption that ex-smokers are a representative sample of 
smokers, except that they have stopped smoking. If the assumption 
of representativeness is not valid and significant baseline differences 
in relevant factors exist between ex-smokers and smokers, then the 
mortality comparison of ex-smokers and continuing smokers may 
not properly describe the benefits of smoking cessation for the 
typical smoker. In the Kaiser-Permanente study (17), there were 
small differences in risk profiles and other factors between those 
who continued to smoke and those who quit, but these differences 
were not large enough to account for the differences in CHD death 
rates. 
In summary, each of the several major prospective studies of 
smoking cessation demonstrates that ex-cigarette smokers have a 
decreased risk of subsequent mortality relative to continuing smok- 
ers. The decreased risk occurs fairly quickly after cessation of 
smoking, suggesting that the effects of cigarette smoking are 
reversible. The quitters were self-selected in these observational 
studies, however, and may include cigarette smokers at lower risk of 
disease. However, the steadily decreasing risk over time after 
quitting suggests that more is going on than the simple selection of a 
lower risk group. Conversely, some smokers may quit in response to 
symptoms or diagnosis of smoking-related illness, thus possibly 
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TABLE 2.-Age-, sex-, and race-adjusted death rates according to smoking category and selected major 
causes 















Persistent smokers 9,394 70,348 9.2 (557) 8.1 (465) 3.2 (191) 0.9 (58) 4.0 (240) 2.6 (166) 
Tcamporary quitters 970 6,666 7.1 (46) 6.7 (43) 2.2 (14) 0.9 (6) 3.8 (24) 2.3 (16) 
Persistent quitters 2,856 16,798 5.3 (107) 5.0 (102) 1.9 (39) 0.3 (6) 2.2 (46) 1.4 (31) 
Never smokers 12,697 9%~ 5.1 (569) 4.8 (540) 1.8 WW 0.02 (2) 2.4 (275) 1.6 W36) 
’ Figures m parentheses denote number of deaths. 
Source: Fredmen et al. (17). 
TABLE 3.-Relative trends in cigarette smoking and 
coronary heart disease mortality among male 
physicians in Britain and California in two 
natural experiments of smoking cessation, 
where status of other risk factors is unknown 
British male physicians, 1951-71’ 
Percentage of physician current 
smokers at start of time period 
Ratio of smokers 
(physicians/British males) 
Time period 
1951-55 195660 1961-65 19671 - - - - 
41 3.3 27 21 
88 68 al 51 
Standardimd mortality ratio (physiciane/Britiah males) 





All causes, attained age 
2c-64 
65a4 
107 85 62 
120 - 103 a6 
109 100 91 
88 94 100 
82 76 70 
75 77 78 
California male physicians, 1950-79’ 
Time period 
KM-54 1955-59 1960-64 196.5-69 1970-74 1975-79 ------ 
Percentage of physician current 
smokers at start of time period 53 48 39 28 20 14 
Ratio of smokers 
(phy&iaw/U.S. males) 100 a3 66 55 44 35 
Standardized mortality ratio (phyeiciane/U.S. males) 
Cl-ID 115 97 86 80 74 69 
Allcauaea a9 80 79 78 67 67 
‘Studyof31,CIOmenagsd20+.folfor~- DollandPeto (12) 
‘Study of 10,310 mea aged 26+, followed for 30 years. En&mm (14). 
underestimating the benefits of quitting that would he expected in 
an otherwise healthy population. Other variables that may contrib 
ute to mortality may not have heen included in the analysis. 
Randomized Controlled Trials of CHD Prevention Not Involving 
Smoking Cessation 
The most rigorous way to determine the value of smoking 
cessation is the randomized controlled trial. A series of important 
experimental or clinical trials have been conducted in the United 
States and other countries over the past 25 years in order to 
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establish the effectiveness of primary prevention of CHD through 
modification of risk factors. These randomized controlled trials 
involve both primary and secondary prevention (2). The primary 
prevention trials select subjects who are free of CHD or stroke at 
entry to the study. The secondary prevention trials attempt to 
modify risk factors after a heart attack or stroke in order to reduce 
the risk of a second heart attack or death (6, 7, 8, 38, 40). Secondary 
prevention trials and nonrandomized trials are not discussed further 
here. 
Most previous primary prevention trials of CHD have been limited 
to a single risk factor such as serum cholesterol reduction. Many 
single risk factor intervention trials include a pharmacologic agent 
that lowers either serum cholesterol or blood pressure and is 
compared with a placebo. Most of these studies are further limited to 
higher risk subjects, such as subjects with serum cholesterol levels in 
the highest 10 to 15 percent of the population, or to relatively small 
sample sizes. They did not monitor or control for changes in cigarette 
smoking habits. 
The most extensive primary prevention trials involve dietary 
reduction of cholesterol; they are described in more detail elsewhere 
(2, 39). The major randomized trials are the Los Angeles veterans 
domiciliary study (9), the Helsinki, Finland, mental hospital study 
(42, 59), and a feasibility study of free-living and institutionalized 
Americans (45). Each of these studies involved about 200 to 400 men 
in the dietary intervention group and a similar number in the 
control group. 
Another set of randomized trials has involved reduction of high 
blood pressure using antihypertensive medication-the U.S. Veter- 
ans Administration cooperative study (631, the U.S. hypertension 
detection and followup program (30, 31), the Australian therapeutic 
trial (I), and the Oslo drug trial (24). These large studies followed 
three small studies-Hamilton et al. (191, Wolff and Lindeman (67), 
and the Cooperative Randomized Control Trial (CRCT) (5). These 
studies generally show that lowered blood pressure results in some 
reduction in CHD among the treated groups relative to the control 
#FouP~ 
Intervention Trials of CHD Prevention Involving Smoking 
Cessation 
The observational epidemiological studies strongly suggest that 
cigarette smoking cessation decreases the risk of heart attack and 
CHD mortality compared with the risk for continuing smokers (60, 
61, 62). All of the observational studies, however, have the limitation 
that the individuals were not experimentally assigned to smoking 
and nonsmoking status. Experimental studies such as randomized 
controlled trials offer a solution to this problem, because they test a 
smoking cessation intervention in the most rigorous way .possible 
using human subjects (2, 37, 70). However, even in such trials, those 
assigned to the no-intervention group modify their smoking habits, 
and those assigned to the intervention group have incomplete 
success in quitting. 
Ideally, each risk factor should be treated independently, but 
modification of one risk factor often results in changes in other risk 
factors. For instance, some studies have noted that cigarette smoking 
cessation can lead to a modest weight gain (3, 26, 47). In a good 
primary prevention program there would be an effort to reduce or to 
eliminate the weight gain that sometimes accompanies cessation. 
Although the multifactorial approach is less precise, it has been 
considered to be a more practical approach to the problem. There has 
been only one trial of smoking cessation per se (50, 51). 
Two types of primary prevention trials involving smoking cessa- 
tion are underway. The first type of study, exemplified by the 
Multiple Risk Factor Intervention Trial (MRFIT), selected subjects 
at high risk of CHD based on a combination of cigarette smoking 
history, elevated blood pressure, and high serum cholesterol level 
(43). Subjects were then randomized into either a special treatment 
group or a comparison group. The Whitehall study (50, 51) and the 
Oslo study (27) are also of this type. 
In the second type of study, communities or groups rather than 
individuals are randomized into a treatment or a control group. The 
WHO heart disease study randomized men according to the factory 
where they work and followed the individual factory workers (70). 
The North Karelia study randomized two separate communities in 
Finland (48). Whereas the factory workers were individually fol- 
lowed, the communities were monitored only in a cross-sectional 
manner and individuals were not followed longitudinally. 
The primary hypothesis in these studies is that reduction of the 
risk factors will reduce the incidence of and mortality from CHD. 
The first step in testing this hypothesis requires that the subjects or 
groups be successfully recruited and categorized at entry to the study 
and that a very high percentage be successfully followed for the 
duration of the study. 
The second step in testing the hypothesis requires the successful 
reduction of the major risk factors-smoking, high blood pressure, 
and high serum cholesterol. Often a selected subsample of high risk 
subjects receives more intensive individual intervention, but the rest 
of the treatment group receives only community health education. It 
is not known how large a reduction in risk factors is necessary to 
observe a decrease in CHD, except that the larger the reduction in 
risk factor the greater the chance for a decrease in CHD. Specific 
goals for reduction of risk factors can be based on the presumption 
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that such reduction would result in a statistically significant 
decrease in the incidence of and mortality from CHD according to 
the observational epidemiologic studies. The relationship between 
the reduction of this risk score and actual reduction in the frequency 
of disease is, of course, the hypothesis being tested. 
The third and most critical step depends on the first two: that is, 
the measurement of outcome-changes in the incidence of or death 
from CHD. The ability to measure the incidence requires careful and 
unbiased monitoring of the sample. The determination of total and 
cardiovascular mortality is much simpler, since it depends only on 
minimizing the number of participants lost to followup. The commu- 
nity studies attempt to compare the death rates between two or more 
communities, and the power of such a statistical test is obviously 
very weak. 
Roth the community studies and the individualized studies are 
also confounded by the uncertainty of the interval between risk 
factor change and reduction in risk of disease. Those subjects most 
likely to die or to have a heart attack in the first few years of the 
study are those with the most extensive disease at baseline. Unless 
the population is followed long enough to include both the lag period 
and the effects of the initial selection of those with advanced 
subclinical disease, a spurious interpretation of the study results is 
possible. 
Generally, studies of experimental communitywide interventions 
are unlikely to determine the efficacy of smoking cessation on 
reducing the incidence of and mortality from CHD because of the 
difficulty in determining the effects of smoking cessation on specific 
individuals in the community and in separating out the effect of 
smoking cessation from other changes in the community. In many of 
these studies the percentage of men who reported quitting smoking 
is relatively small, which reduces the power of the study at least in 
terms of smoking cessation. 
This review focuses on all intervention studies involving smoking 
cessation for which CHD mortality outcome data have been pub 
lished. In another section of this Report a detailed review on 
smoking cessation in clinical and community trials is presented. 
Discussed in detail here are data from the U.S. Multiple Risk Factor 
Intervention Trial (43), the Whitehall study in London, England (511, 
the Oslo study in Norway (27), the WHO European Collaborative 
study (691, and the North Karelia project in Finland (48). Omitted 
from this section are smoking intervention studies without published 
mortality outcome data, such as the Stanford, California, three- 
community study (16), the Stanford five-community study (15), the 
Goteborg, Sweden, study (64, 65, 66), and the Helsinki, Finland, 
study (46). 
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Essential details from each trial are described in the following 
pages and tables. The initial population characteristics and risk 
factor changes are summarized in Table 4. The mortality outcomes 
in the intervention and control groups are summarized in Table 5 for 
coronary heart disease and total mortality. Available results are also 
given for other circulatory diseases, lung cancer, and other cancer. 
The results for the four trials involving cohort mortality followup 
are combined in Table 6. Coronary heart disease incidence rates 
from the Oslo and WHO studies are presented in Table 7. A 
comparison of death rates in the MRFIT intervention and control 
groups as a function of initial smoking status and status at l-year 
followup is summarized in Table 8. Observed deaths in the MRFIT 
and Whitehall studies are compared with expected deaths based on 
general population rates in Table 9. Comparisons of reductions in 
CHD and total mortality from the observational studies and from the 
MRFIT and Whitehall studies are made in Table 10. 
Randomized Controlled Trials of Individuala 
Multiple Risk Factor Intervention Trial 
The Multiple Risk Factor Intervention Trial (MRFIT) was a 
randomized controlled trial to investigate the effect of reducing 
cardiovascular risk factors in a group of asymptomatic men at high 
risk of cardiovascular disease (43). Out of 361,662 men initially 
screened, 12,866 men aged 35 to 57 were selected for the trial 
because they were at increased risk of death from CHD, but without 
clinical evidence of CHD, and agreed to be randomized and reexa- 
mined. A series of three complex screening procedures were used to 
select the final 12,866 men, who constituted only 3.6 percent of those 
screened. Men were designated as at increased risk because their 
levels of three risk factors-cigarette smoking, serum cholesterol, 
and blood pressure (BPtwere sufficiently high at a screening visit. 
All of these men were in the upper 15 percent of a risk score 
distribution based on data from the Framingham heart study; about 
twothirds were in the upper 10 percent of risk. For example, a man 
whose diastolic BP was 90 mm Hg and who reported smoking 30 
cigarettes per day was risk eligible at the 10 percent level if his 
serum cholesterol level was at least 295 mg/dl. The study was 
restricted to men, since including women, with their substantially 
lower risk of CHD, would have necessitated a larger study popula- 
tion. 
The men were randomized into two groups of equal size and 
identical baseline characteristics from December 1973 through 
February 1976. A special intervention (SD group of 6,428 men 
received an intensive counseling program, aimed at cessation of 
cigarette smoking, weight loss, and a change of diet for a reduction of 
elevated serum cholesterol and BP levels. A usual care (UC) group of 
TABLE 4.-Basic description of smoking cessation 
intervention studies of males, including 




Imiividual intervention intervention intervention 
MRFlT whitehdl onlo WHO North Karelia 
Number in intervention (I) group 6423 




Followup period: Start date 1211973 
End date 211982 
Average leagth Gym) 7 
Riskfactor(RFlat&ut 
Cigarette smokers (%) 
Relative change ‘/end 
Belative change/whole period 
Average no./day cigarettes 
Belative change/end 
Relative change/whole period 
serum cholesterol (mg/dl) 
Relative change/end 
Relative change/whole period 
Blocd pressure6 (mm H@ 
Relative change/end 
Relative change/whole peri@ 














714 604 24,615 
731 626 25,169 
52.9 45.2 46.5 
40-5940-49 4049 
-100 -100 -100 
1968-70 1972-73 1971-76 
1979 1978 1982 














































‘Relative change = (RF, - RFcMtFc. except for North Karelia. where relative difference in determined from 
(I4 1977 and tIJ2:, 1972. 
’ Estimated fmm avaiL3ble data. 
*Not meamumd or not reported. 
l Riskfactorienot partofinteneotiml. 
‘Diastolic. except for systolic in WHO study. 
6,438 men received annual checkups including medical history, 
physical examination, and laboratory studies at the MRFIT clinics, 
but were referred to their personal physicians or other community 
medical facilities for such treatment of their risk factors as was 
considered individually appropriate. Thus, no intervention program 
was offered to them. The results of their screening and annual 
examinations were provided to their respective physicians who were 
also informed as to the scientific objectives of the study. 
The smoking intervention urged those SI participants who smoked 
cigarettes to quit, but no effort was made to alter the smoking habits 
of those who smoked only pipes and cigars (29). Dosage reduction- 
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FIGURE l.-Mean risk factor levels for cigarette smoking 
by year of followup for Mulcple Risk Factor 
Intervention Trial Research Group participants 
NOTE2 SI idicntea special intervention 
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SOUFtCI3 Multiple Rid Fwtc.r Intervention Trial Research Group (13). 
switching to cigarettes low in tar and nicotine-was recommended 
only as an intermediate step to cessation. Conventional behavior 
mod ification techniques were used throughout the trial; aversive 
techniques and hypnosis were used in selected instances. Ten-week 
group sessions at the beginning of the trial and 5day quit clinics 
during the final years were found to be  particularly successful 
intervention approaches. Further details on  the smoking interven- 
tion are provided in an  earlier section of this Report, and the serum 
cholesterol and BP interventions are described elsewhere (43). 
Statistically significant CHD risk factor reductions between the SI 
and UC groups were obtained at each annual  visit. O f particular 
interest was the reduction in number  of cigarette smokers, as shown 
in F igure 1. At the beginning of followup, 59  percent of all men  had 
reported themselves as current cigarette smokers. At the E&month 
followup, the stated quit rates were 43 percent for SI men and 14 
percent for UC men; at 72  months, the rates were 50 percent and 29 
percent, respectively. Serum thiocyanate-adjusted quit rates at 12  
months were 31 percent for SI men and 12 percent for UC men; at 72  
months they were 46 percent and 29 percent, respectively. This 
means that the SI group reduced its level of smokers 30  percent more 
than the UC group. The risk factor changes are summarized in Table 
4. 
As of February 23, 1982, after an  average period of followup of 7  
years, there were 260 deaths among the UC men, of which 124 were 
ascribed to CHD and 21 to other cardiovascular causes, as summa- 
rixed in Table 5. There were 265 deaths among the SI men, of which 
115 were ascribed to CHD and 23 to other cardiovascular causes. The 
key mortality endpoint of CHD was 7.1 percent less in the SI group 
than in the UC group, while the death rate for all causes was 2.1 
percent higher for the SI men. The approximate 90 percent 
confidence interval (CI) for the percentage change in CHD mortality 
attributable to MRFIT intervention ranges from a 25 percent 
decrease to a 15 percent increase. There were 34 lung cancer deaths 
in the SI group and 28 in the UC group and 47 other cancer deaths in 
the SI group and 41 in the UC group. 
The number of deaths in the UC group was substantially short of 
expectation for the 6 complete years of followup as well as for the 
average followup period of 7 years, as shown in Table 9. These 
mortality patterns appear to be similar to those seen in healthy 
persons selected for life insurance policies (22, 41). On the basis of 
the design risk factor change assumptions and the Framingham risk 
functions, 442 deaths (including 187 from CHD) were expected 
among the 6,438 UC men by the end of 6 years of followup, but only 
219 (including 104 from CHD) occurred (50 percent of expected); 
about 515 deaths (including 220 from CHD) were expected after 7 
years, but only 260 deaths (including 124 from CHD) occurred. 
At least three possible explanations for these results must be 
considered: (1) such an intervention program is without benefit in 
terms of substantial decreases in mortality; (2) the intervention 
program does affect CHD mortality, but the benefit was not observed 
in this study, an effect of chance; or (3) one or more constituents in 
the intervention program may have had an unfavorable effect on 
survival in some subgroups, offsetting the beneficial effects of others. 
Of these possible interpretations, a combination of favorable and 
unfavorable effects of the intervention program seems most plausi- 
ble to the MRFIT investigators. Even with the unexpected sizable 
risk factor reduction among the UC men, the lower-thanexpected 
UC mortality, and the duration of intervention averaging only 7 
years, the likelihood that these factors resulted in missing an overall 
positive effect is relatively low. The data suggest that except for 
some groups of hypertensive persons, particularly those with resting 
ECG abnormalities, the MRFIT intervention is apparently associ- 
ated with a lower CHD mortality in the SI group. 
The MRFIT data also warrant analysis as an observational study 
(Table 8). Of those who had been cigarette smokers at entry, 1,365 
reported quitting at year 1 interview (and had confirmatory blood 
SCN levels) and 6,298 did not quit. Over an average 6 years of 
further followup, those who quit smoking at year 1 had a 1.10 
percent CHD mortality rate, while those who continued smoking had 
a CHD mortality rate of 2.03 percent. This corresponds to a relative 
risk of 0.54 (1.10/2.03) or a 46 percent lower risk of CHD death for 
TABLE Ei.-Comparison of deaths (d) and death rates (r) in 
the intervention. and control groups of four 
randomized controlled trials 
Cause of death 
Intervention group Control group 
n’ dl’ rc’ dc’ 
MRFlTr ‘I-year deaths 
Coronary heart dieaee 
Other circulatory diaeaae 
Lung cancer 
other cancer 
All other causea 
All cauaea 
Whitehall: l&year de&ha 
colvnaly heart dhaae 
other circulatory dieeaae 
Lung cancer 
Other -r 
All other cawen 
All canam 
oalo: &year death8 
Cmonary heart dinease 
(Fatal Ml and 
sudden cwvnary death) 
Other cimtlatory diaeaw 
All can0e.r 
All other cawes 
Allcauaea 
WHO: 6year deaths 
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’ Death mte (r) equala deatha (d) divided by initial number in group. 
’ unloa idk?d?d with a p value. diffemm are not ti-y rigni6mt (p>O.ow. based 00 * tw&ailad teat 
for a Poiron variable. 
those who quit smoking compared with those who continued. For all- 
cause mortality, the relative risk was 0.73 or a 27 percent lower risk 
for those who quit compared with those who continued to smoke. 
As demonstrated in subsequent portions of Table 8, when these 
subjects are analyzed according to level of smoking at entry or by 
status in the SI or the UC group, those who quit smoking always 
enjoyed a substantially more favorable survival rate than those who 
didn’t quit. 
Thus, MRFIT data are entirely consistent with the numerous 
previous studies showing that those who quit cigarette smoking 
enjoy a substantially improved survival. 
In conclusion, the MRFIT study has shown that it is possible to 
apply an intensive long-term intervention program against three 
coronary risk factors with considerable success in risk factor 
changes. These results are accompanied by an apparent heterogenei- 
ty of effects among sizable subgroups, and there must be caution in 
reaching conclusions from such subgroup data. It may be relevant 
that multifactor intervention received a less than optimal test, 
owing in part to unexpected declines in risk factor levels and in part 
to lower-thanexpected mortality in the UC group. In regard to the 
former, the UC men thus constituted to a considerable extent a 
“treated” group. 
Whitehall Civil Servant8 Study 
A randomized controlled trial was set up to provide an unbiased 
estimate of the consequences of smoking cessation in middle-aged 
men (SO, 51). A total of 1,445 male cigarette smokers with an 
especially high cardiorespiratory risk were selected from 16,016 men 
aged 40 to 59 who had undergone a cardiorespiratory screening 
examination in the Whitehall study of male civil servants in London. 
Using a modification of the multivariate linear discriminant func- 
tion coefficients that were calculated for predicting coronary heart 
disease (CHD) among the Framingham men aged 30 to 62, a risk 
score was similarly calculated for each man who smoked five or more 
cigarettes a day. This score ranked the smokers according to their 
estimated risk of major illness or death from cardiorespiratory 
disease. The distribution of the score was tested early in the study, 
and a cutoff point was determined such that the scores of 10 percent 
of all men and 32 percent of smokers were eligible and exceeded this 
value, which was thereafter used to define eligibility for the trial. 
Men receiving medical care for heart disease or elevated blood 
pressure, those found to have either severe hypertension or diabetes 
mellitus, and those with major concomitant disease were excluded 
from the trial. Additionally, all men taking psychotropic drugs or 
with a record of previous psychiatric inpatient treatment were 
eliminated. If during the l-year interval between initial screening 
and trial interview they had died, moved away, or stopped smoking, 
they were then not eligible for the study. The remaining 1,445 high 
risk eligible cigarette smokers were randomly allocated to study 
groups; 714 men composed the intervention group, and 731 men were 
in the normal care group. 
Men in the intervention group were recalled for a series of 
personal interviews with the physician. First, each received a letter 
inviting him to an appointment to discuss the results of his previous 
examination. At that visit the reason for recall was presented: 
evidence in his particular case that smoking represented more than 
the average risk to his future health, not the discovery of disease. 
The scientific evidence that stopping smoking was likely to bring 
benefits was explained and illustrated by charts, with the emphasis 
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FIGURE 2.-Mean daily cigarette consumption by year of 
followup for the Whitehall intervention study 
SOURCE: Rae et al. (51). 
throughout on  the evidence for the positive benefits and practicali- 
ties of stopping rather than on the hazards of continuing to smoke. 
A full report of the screening examination results and information 
that further action was in his hands was sent to the practitioners of 
men in the normal care groups. The men were not made aware that 
they were involved in a  trial. At the l-year and 3-year points in the 
study, they were asked to return for an  examination to help 
research. Examinations were popular because most men saw them as 
beneficial checkups. The questionnaire response rates among survi- 
vors were 84 percent at 1  year and 83 percent at 9  years. Dropouts 
were ma inly retirees. The proportion of responders in the interven- 
tion group who were not smoking any cigarettes was 63 percent at 1  
year, decreasing to 55  percent at 9  years; initially, all of those in the 
study were smokers. F igure 2  shows the trends in stated numbers of 
cigarettes smoked in the intervention group. After 1  year, consump 
tion in the intervention group was one-quarter of the normal care 
group level. By 9  years, the estimate of cigarette consumption for 
intervention men was 70 percent of that for the normal care 
controls. Over the 10 years, the net apparent reduction in the 
intervention group averaged 7.6 cigarettes/day (-53 percent), com- 
pared with the control level, as shown in F igure 2  and Table 4. 
During the 10 years of followup, there were 128 deaths in the 
control group compared with about 130 deaths expected from the 
age-specific rates for England and Wa les in 1974, as shown in Table 
9. The fact that all men  entering the trial were high risk smokers 
should have increased the observed deaths, but this may have been 
offset by the “healthy worker” effect in an  occupational study group 
or by the selection process that excluded very sick men. Deaths were 
also close to national levels for coronary heart disease (111 observed, 
94  expected), lung cancer (42 observed, 35  expected), and other 
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TABLE 6.-Summary of deaths and intervention/control 
differences from coronary heart disease, all 
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115 123.6 -7.1 
49 60.6 -19.1 
6 13.3 -55.4 
367 396.4 -7.4 
537 594.1 -9.6(p=.O2) 
150 135.8 t10.5 
74 64.4 f14.9 
10 9.1 +3.1 
630 627.7 +0.4 
864 837.6 +3.2 
All cauea 
265 259.6 +2.1 
whitehau 123 125.0 -1.6 
CM0 16 23.0 -30.6 
WHO 997 1024.1 -2.7 
Unweighted total 1401 1431.7 -2.1 
’ Unlsss indicated with a p value. difYerenoes are not statistically aignifiamt (p > 0.06). bawd on a twotailed tent 
for a Poiemn variable. 
cancers (40 observed, 41 expected). Seventy-two percent of deaths 
occurred in a hospital, and in 45 percent there was an autopsy. 
Additional data were obtained from the National Cancer Register of 
cases histologically confirmed either by biopsy or at autopsy for 
deaths from other causes. 
Table 5 shows that the USyear CHD death rate was 8.5 percent (62 
deaths) for the normal care group and 6.9 percent (49 deaths) for the 
intervention group, a proportionate change of -19 percent (95 
percent confidence limit of -43 to + 18 percent). Among the 369 men 
who entered the trial with evidence of myocardial ischemia (angina 
pectoris, history of possible myocardial infarction, or positive electro- 
cardiogram) the reduction was -23 percent compared with -11 
percent in those without such evidence. The number of deaths from 
cardiovascular causes other than CHD was 12 in the normal care 
group and 13 in the intervention group. 
Mortality from all causes was initially higher (though not signifi- 
cantly so) in the intervention group, but during the last 6 years of 
the trial, the rates were higher in the normal care group. During the 
whole 10 years, 123 intervention men (17.2 percent) died, compared 
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with 128 (17.5 percent) of the normal care group-a proportionate 
change of -2 percent (95 percent confidence limits of -22 percent to 
+23 percent). Causes of death were also grouped according to 
whether or not they were smoking related. The smoking-related 
causes included coronary heart disease, chronic bronchitis, and 
cancers of the respiratory tract, esophagus, urinary tract, and 
pancreas. There were 92 such deaths in the normal care group and 
81 in the intervention group, a proportionate change of -9 percent 
(95 percent confidence levels of -31 percent to +20 percent). 
The trial was designed to test whether the total reduction in 
cardiorespiratory disease among middle-aged men was as large as 
that indicated by the observational studies of ex-smokers. Its size was 
planned in the expectation that incidence as well as mortality data 
would be available; when this proved unattainable, the resultant loss 
of power was partly offset by extending the mortality followup to 10 
years. 
At l-year followup, almost twothirds of the intervention subjects 
had given up cigarettes altogether, while others claimed to be 
smoking less than before. Unlike the MRFIT study, objective tests of 
smoking behavior were not made here. However, the authors felt 
that those who reported complete cessation were generally truthful, 
while those claiming to have cut down may have been exaggerating. 
The reports were based on questionnaires completed at home, with 
little external pressure; they were largely consistent over the 
ensuing years. The progressively narrowing gap between the two 
groups was due mainly to a gradual reduction in smoking by the 
normal care men. Although the size of the gap may have been 
overestimated, there is no doubt that throughout the earlier years of 
the trial it was large. 
Over the trial as a whole, the intervention group’s level of total 
smoking exposure was estimated as about half that of the normal 
care group, implying that the effects of complete cessation might be 
substantially more than those observed in the trial. The results for 
total mortality represented the approximate balance of a favorable 
trend for smoking-related diseases and an adverse trend for non-lung 
cancers. After an exhaustive analysis of the data, the Whitehall 
investigators think the difference in non-lung-cancer mortality in 
this trial was more likely due to chance than to an effect of 
intervention. Such evidence as there is for the latter view should be 
considered as a hypothesis for further study, not as the basis for 
conclusions or for any recommendation to smokers. 
Oslo Study 
The purpose of the Oslo study was to find out whether the 
cessation of smoking and the lowering of high levels of blood lipids by 
dietary changes, if maintained for many years, would lead to 
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reduction in the incidence of first attacks of CHD in men aged 40 to 
49 (26, 27, 28). All Oslo men aged 40 to 49 were invited for screening 
of coronary risk factors during 1972-73, and 65 percent (16,202 men) 
attended. From this cohort, healthy normotensive men were selected 
for a controlled trial if they had serum cholesterol levels (mean of 
two measurements) of 290 to 380 mg/dl, coronary risk scores (based 
on cholesterol levels, smoking habits, and blood pressure) in the 
upper quartile of the distribution, and systolic blood pressures (mean 
of two measurements) below 150 mm Hg. Those selected had normal 
ECGs at rest and were free of any cardiovascular disease, chest pain 
on exercise, clinical diabetes mellitus, fasting blood sugar levels 
above 135 mg/dl, cancer, disabling disease, psychopathological 
disease, and alcoholism. 
Men who met the selection criteria were sent a letter explaining 
the experimental design of the trial; 97 percent were found willing to 
participate. There were no significant differences between the 
intervention and control groups for subject factors such as age, 
history of CHD symptoms, cigarette consumption and smoking 
status, serum cholesterol and triglyceride, systolic blood pressure, 
and diet. After the screening examination, two reexaminations were 
made before randomization, the first of these when the subjects were 
fasting. 
Each of the men in the intervention group was individually talked 
with for 10 to 15 minutes by the investigator and introduced to the 
risk factor concept and the purpose of the study. Anti-smoking 
advice was given individually to all smokers in the intervention 
group. They were informed that cessation of smoking might be of 
special importance for those with high blood lipid levels. In addition, 
the dietitian established a diet record for each man and gave 
extensive dietary advice based on this record. Other risk factors were 
not subjected to intervention. Followup exams were made every 6 
months for intervention subjects and every 12 months for controls. 
The intervention of advice on smoking and eating habits resulted 
in changes in risk variables. Tobacco consumption, expressed as the 
number of cigarettes smoked per man per day, fell about 45 percent 
more in the intervention group than in the controls, as seen in Table 
4. Pipe smoking was included, taking one pack of pipe tobacco 
weekly to equal seven cigarettes daily. The percentage of cigarette 
smokers fell by only 16 percent more. The data were assessed by a 
questionnaire and by the thiocyanate method. The mean difference 
in serum cholesterol between the two groups during the 5 years was 
13 percent. 
As the design of the study was based on CHD evidence, events of 
myocardial infarction (MI) plus sudden death were most important. 
CHD mortality (fatal MI plus sudden coronary deaths) was 55 
percent lower in the intervention group as compared with the 
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TABLE 7.-Comparison of coronary heart disease incidence 
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control group, but the difference was not statistically significant 
(p>O.O5), as shown in Tables 5 and 7. Total CHD incidence, which 
included fatal and nonfatal MI and sudden death, was 45 percent 
lower in the intervention group than in the control group, and this 
difference was significant (p < 0.051, as shown in Table 7. This is the 
only trial to date to show a significant reduction in CHD incidence. 
All cases of sudden death satisfied the diagnostic criteria for 
coronary death except one unexplained sudden death. The total 
coronary deaths, which included fatal MI and sudden death, were 
lower, but not significantly lower in the intervention group than in 
the control group. 
An estimate was made of the proportion of the difference in total 
CHD incidence between the two groups (36 versus 19 cases) due to 
the reduction in cigarette consumption and of the proportion due to 
the reduction in serum cholesterol using logistical regression tech- 
niques (28). The percentage of the decline in incidence that was due 
to reduction in cigarette consumption was estimated to be 26 percent 
among smokers only, predicting a difference between groups of 3.9 
cases, out of a total difference of 17 CHD cases. Similar procedures 
indicated that the percentage due to cholesterol changes was 60 
percent for all men, predicting a difference in CHD incidence of 10.1 
cases. It seems, therefore, that the change in cigarette consumption 
caused about 25 percent of the difference in CHD incidence between 
the two groups and that the difference was due mainly to the 
reduction in serum cholesterol. The difference between the groups 
was 17 cases: 14 can be explained by this analysis, and the other 3 
cases may be due to unexplained intervention effects or to chance. 
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Community-Based Intervention Trials 
WHO European Collabomtive Trial 
As set out in the recent WHO report on the prevention of coronary 
heart disease (701, effective prevention must involve the population 
as a whole: A high incidence in the population reflects a mass 
elevation of risk factors, and most cases of the disease occur in the 
large number of people with moderate elevations rather than in the 
high risk minority. The first issue of public health policy, therefore, 
is to know the effect of population-based prevention, using resources 
that could reasonably be afforded. Thus, a trial of CHD prevention 
has been undertaken by collaborators in Belgium, Italy, Poland, 
Spain, and the United Kingdom (68, 69). It involved the random 
allocation of 44 factory pairs, employing 63,732 men aged 40 to 59, 
either to a cardiovascular screening and health education interven- 
tion program or to a control group. Separate analyses have been 
prepared for Belgium factories (35,36) and United Kingdom factories 
(52,531, but these subgroups are not discussed in detail here. 
Randomization of individuals in a trial of community health 
education is not feasible, so a somewhat unusual design was used 
that randomized entire communities, which in this trial were 
factories or other large industrial groups. They were arranged in 
matched pairs and randomized, one to intervention and the other to 
serve as a control. All men aged 40 to 59 in the intervention factories 
were invited to complete a questionnaire and take part in a simple 
cardiovascular screening examination during working hours; 87 
percent responded. On the basis of a multifactorial scoring system 
for risk factor levels (age, job activity, cigarettes smoked per day, 
systolic blood pressure, and serum cholesterol), 15 percent or more of 
the men in each factory were designated as high risk. A general 
campaign of risk factor modification was undertaken with posters, 
brochures, personal letters, progress charts, and group discussions 
and included advice on reducing or stopping cigarette smoking, 
losing weight, lowering serum cholesterol, and increasing leisure 
physical activity. The high risk men received more individual 
attention, in addition to the general educational program, including 
a series of personal sessions with the factory or project physician. All 
men with mild hypertension were treated with diuretics or other 
drugs in the factory or were referred to a personal physician. Drugs 
were not employed to lower serum cholesterol. Annually, a random 
sample of men was rescreened. All high risk men were seen at every 
anniversary in some centers, or in other centers, at particular 
anniversaries. All men remaining in employment at the end of the 5- 
or 6-year intervention period were offered a final examination. 
In the control factories, a 10 percent random sample of men was 
screened initially, and the same 10 percent were asked to return 
after 2 years, again at 4 years, and then at the final screening at 5 or 
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6 years, when all remaining men in the original cohort, aged 40 to 59 
at the start, were offered screening. It was therefore possible to 
compare risk factor levels at the start between all screened 
intervention men and 10 percent of controls, between a 5 percent 
random sample or more of the intervention men and the same 10 
percent of the controls at 2 years and 4 years, and between all 
remaining men in both sets of factories at the final screening. 
Numbers were reduced by death, by leaving employment, and by 
nonresponse to the invitation on the screening day. The risk factor 
score used in each intervention factory to designate high risk men 
was applied to the 10 percent of the screened men in the paired 
control factory in order to identify those who would act as high risk 
controls for purposes of measuring risk factor change. Incidence and 
mortality results are now available (69) from this controlled trial, 
involving randomization of 66 factories (49,781 men) in the United 
Kingdom, Belgium, Italy, and Poland (Cracow). Results for Poland 
(Warsaw) are not yet complete, and the results have been separately 
presented for the United Kingdom (53) and Belgium (35). Net 
average reductions in risk factors (all subjects) were 8.9 percent for 
daily cigarettes, 1.2 percent for serum cholesterol, 0.4 percent for 
weight, 2.0 percent for systolic blood pressure, and 11.1 percent for a 
combined CHD risk estimate. Greater reductions occurred in high 
risk subjects (19.4 percent for the combined CHD risk estimate). 
Tables 5 and 7 show that the net overall changes in CHD rates 
were -7.4 percent (95 percent confidence interval from -29 to +15 
percent) for deaths (722 deaths) and -3.9 percent (95 percent 
confidence interval from -10 to +2 percent) for fatal CHD plus 
nonfatal myocardial infarction (1,502 cases). Among men aged 40 to 
49 the reduction for this end-point was 15 percent; at ages 50 to 59 
there was a small net increase. Deaths from all causes after an early 
adverse trend showed a -2.7 percent change overall. There were 
large differences between centers, ranging from a 5 percent net 
increase in CHD for the United Kingdom to a decrease of 24 percent 
in Belgium. In Belgium the decrease both in CHD incidence and in 
all deaths was significant at the 5 percent level (35). The effect on 
CHD in the different centers correlated broadly with their changes 
in risk factors. The authors concluded that a reduction in major 
coronary risk factors in industrial populations is possible, but it 
depends on adequate resources. The results support the hypotheses 
that CHD risk in middle-aged men is reversible and that community 
intervention can be beneficial; however, additional followup is 
necessary to determine if there are statistically significant reduc- 
tions in CHD and total mortality commensurate with the risk factor 
changes in the entire factory population. 
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North Karelia Study 
The purpose of the North Karelia, Finland, project was to provide 
a systematic comprehensive community program to reduce the 
currently high mortality and morbidity from CHD, primarily by 
reducing the known cardiovascular risk factors of smoking, serum 
cholesterol, and blood pressure, while promoting early detection, 
treatment, and rehabilitation in people with severe CHD (48, 54,Ss). 
The focus was on middle-aged males; women were included, but are 
not discussed here. A further test was made of the feasibility and the 
effect of this approach in the control of CHD and other health 
problems on a nationwide level. 
Baseline data concerning cardiovascular diseases and their main 
risk factors in the target community of North Karelia and in the 
control area of Kuopio were studied in detail. To do this, a 
representative random 6.6 percent sample was drawn for the 1972 
population of the two communities by using the national population 
register. The sample comprised men and women born during 1913 to 
1947 (then aged 25 to 59). About 52 percent of the men in the study 
were current smokers, and each smoker consumed an average of 18 
cigarettes per day. Their mean levels of serum cholesterol and blood 
pressure were above normal, as seen in Table 4. 
Owing to the high general level of the known CHD risk factors in 
this population, a comprehensive program was integrated into the 
health and social services of the community. The program consisted 
of (1) information given to the public, especially about the practical 
activities directed toward the risk factors in the community, by 
means of media (newspapers, radio, leaflets, posters, and stickers) 
and at health information education meetings and public campaigns, 
schools, and places of work; (2) organization of services by systemati- 
cally integrating the program into existing services and creating new 
services when necessary, such as special supporting services for 
stopping smoking; (3) training personnel for the special practical 
tasks of the program; (4) environmental services to support the 
desired lifestyle, for example, with regard to smoking restrictions; 
and (5) internal information services to support registers for 
hypertension, myocardial infarction, and stroke and to help with 
followup surveys. 
No differences were found in the prevalence of smoking between 
the target area and the control area at the beginning of the study in 
1972. By 1977, there was a nonsignificant net reduction of 2.5 
percent in the prevalence of smoking among North Karelia men 
relative to the control men. But when the reported amount of 
smoking was taken into account, a net 9.8 percent reduction was 
significant. This was a result of the finding that in 1972 North 
Karelian men smoked more than did those in the control area. There 
was a highly significant 4.1 percent net reduction of mean serum 
TABLE 8.-Death rates and relative risk of death in those 
MRFIT subjects who quit at 1 year and those 
who continued smoking (average further 
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cholesterol concentrations in the North Karelia men. At the start of 
the study, the mean serum cholesterol concentrations were higher in 
people in North Karelia than in the control area. There was a highly 
significant net reduction in systolic blood pressure from baseline for 
the North Karelia men. The prevalence of raised values in 1972 was 
similar among men in the two areas, and the net reduction in the 
prevalence of raised values in North Karelia was substantial and 
highly significant. 
The estimates of CHD risk showed that in 1972 the North 
Karelians had a higher mean risk score than did the population in 
the control area. During the followup period, this difference was 
reversed among the men and there was a highly significant net 
reduction in the estimated CHD risk in North Karelia of 17.4 percent 
among the men. However, there were no significant relative 
reductions in CHD or total mortality among the North Karelia men 
compared with the control men as of 1977. However, a more recent 
analysis of mortality trends in Finland suggests that a longer period 
of followup may yield some significant relative reductions (55). 
Because of the different methodology used, the mortality results 
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TABLE 9.-Observed deaths in MRFIT and Whitehall 
studies and expected deaths based on general 
population and Framingham death rates 
Study 
Coronary heart disense All causes 
observed Expected ObeeNd Expected 
in UC group (U.S. males) SMR in UC group (U.S. males) SMR 
(1979) (1979) 
MRFIT study 



















47 17 -48 35 
100 31 -50 62 
a6 171 -223 77 
a3 41 -63 65 
a3 260 -384 68 
fl+WiWh) 
56 260 -516 50 
(U.S. male43~ 
(1979) 
94 190 -244 78 
Whitehall study (English males) (English males) 
NC group (n=731) (1974) (1974) 
Years l-10 62 -48 129 128 -130 98 
from this study have not been summarized in Tables 5 and 6, but the 
risk factor changes are shown in Table 4. 
Comparison of Resutts From Intervention Trials and 
Epidemiologic Studies 
Table 10 summarizes the expected reduction in CHD and total 
mortality for former smokers who stopped for 1 to 4 years or for 5 to 
9 years, based on the three major observational studies in Table 1 
(10, II, 20, 49). This shows that, relative to current smokers, former 
smokers who have stopped for 1 to 9 years have a CHD mortality 
rate that is 25 percent less and a total mortality rate that is 18 
percent less, in approximate terms. The cigarette smokers in the 
MRFIT and Whitehall studies have been subjected to smoking 
cessation intervention as the sole, or as a major, risk factor change. 
As seen in Table 4, smoking reduction in the intervention group 
relative to the control group was 31 percent in MRFIT and 54 
percent in the Whitehall study, for an average reduction of about 40 
percent in proportion of current smokers. This means that the 
expected reduction in mortality should be about 40 percent of that 
associated with total cessation; in other words, 10 percent for CHD 
mortality and 7 percent for total mortality. Combining the observed 
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TABLE lO.-Comparison of reductions in CHD and total mortality from observational studies of former 
smokers and from MRFIT and Whitehall intervention studies 
Coronary heart disease Total mortality 
British ACS U.S. British ACS U.S. 
physicians 25-State veterans Average physicians 25-state veterans Average 
Current smokers 
Former smokers. 14 yrs 
Former smokers, 5-9 yrs 
Average former smokers, l-9 ym 
Percentage reduction. former smokers, l-9 yrs 
Percentage reduction, -40% former smokers 
MRFIT smokers at SI (Table 7) 
Whitehall smokers (Table 5) 
Unweighted total 





































deaths from these two intervention groups shows a change in CHD 
mortality of -10 percent (95 percent CI from -26 percent to +6 
percent) and a change in total mortality of +2.7 percent (95 percent 
CI from -9 percent to +14 percent). Thus, these two trials have 
yielded a result after 5 to 10 years of followup that is in good 
agreement with the observational studies for CHD deaths, but is not 
particularly close for total mortality. Because of the fairly large 95 
percent confidence interval, the intervention results are consistent 
both with the observational studies and with no change at all. It 
must be noted that in MRFIT, other risk factor interventions took 
place on blood pressure and cholesterol, and interpretation of the 
results has raised the real possibility that an adverse effect on 
survival was associated with anti-hypertensive efforts in a specific 
subgroup of hypertensive patients, a finding which, if true, might 
mask a larger beneficial effect of smoking cessation. 
As previously noted and as shown in Table 8, an analysis of 
survival in MRFIT participants who had been smokers at entry, 
demonstrates that those who quit at year 1 of followup had a 46 
percent lower CHD mortality and a 27 percent lower allcause 
mortality than those smokers who did not quit at year 1. This is 
further powerful evidence consistent with substantial improvement 
of survival associated with the cessation of cigarette smoking. 
Conclusions 
1. In the four intervention trials involving mortality followup of 
individual men for 5 to 10 years, the intervention groups had a 
combined total of 10 percent fewer CHD deaths than did the 
comparable control groups. Differences for other causes of death 
or for total deaths were not significant. 
2. In these trials, the amount of cigarette smoking has been 
reduced 10 to 50 percent more in the intervention group than in 
the control group, demonstrating that intervention can alter 
smoking behavior. 
3. In the two trials involving morbidity followup, the intervention 
groups had 4 and 45 percent lower total CHD incidence than did 
the respective control groups. 
4. The relative reductions in CHD mortality in each of the four 
intervention studies involving individual followup are reason- 
ably consistent with the reduction in CHD risk factors, and for a 
combination of all four studies, the reduction is statistically 
significant. 
5. Numerous studies have shown that those who quit cigarette 
smoking experience a substantial decrease in CHD mortality 
and an improvement in life expectancy. 
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6. A number of prospective epidemiological studies indicate that 
former cigarette smokers substantially reduce their CHD and 
total death rates from that of current smokers. 
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Introduction and Overview 
Mortality Trends 
The cardiovascular dise -primarily heart, cerebrovascular, 
hypertensive, and peripheral vascular diseases-are widely preva- 
lent in our society and cause substantial illness and death. With the 
increasing control of infectious and parasitic diseases, especially 
during the first half of the 20th century, life expectancy has 
improved and the major cardiovascular diseases as a group have 
become the underlying cause of approximately 50 percent of all 
deaths in the United States. They are responsible for more than 
950,000 deaths each year (Table 1) (16, 27). The economic cost of 
heart disease alone was estimated in 1977 to be at least $40 billion 
annually (34), and heart disease is ranked first among causes for 
utilization of acute care hospitals (31). About 21 percent of these 
cardiovascular deaths occur prior to age 65; 45 percent occur prior to 
age 75. Until recently, as the Nation’s population became proportion- 
ately older, the crude death rate for the cardiovascular diseases had 
increased to a plateau. In contrast, the age-adjusted death rate, 
stable until 1940, has since declined (2, 17, 19, 27, 40, 41). During the 
196Os, the downward trend in the age-adjusted rate steepened 
markedly. Almost twothirds of the decline between 1950 and 1978 
occurred after 1968, a 27 percent decline (Figure 1; Table 2) (I, 18,22, 
23, 24, 27, 30). Death rates for most cardiovascular diseases declined 
over the entire period from 1950 to 1978, except for the major 
subgroup of coronary heart disease (CHD), for which there was a 
consistent rise in mortality in the 1950s and 196Os, followed by a 
dramatic decline (Figure 2) (2, 25, 27). The age-adjusted death rate 
for all cardiovascular diseases combined was lower by 63 deaths per 
100,000 population in 1967 than in 1950. This decrease reflected 
declines for cerebrovascular and hypertensive diseases that counter- 
acted the increase of 27 deaths per 100,000 population for coronary 
heart disease. In the more recent period, 1998 to 1978, the death rate 
for all cardiovascular diseases declined by 100 deaths per 100,000 
population, with declines for CHD and cerebrovascular diseases 
accounting for almost all of the decline. The reversal in mortality 
from CHD during 1968-1978 was real, although partly attributable 
to the shift in classification of deaths that brought more hyperten- 
sive disease deaths into the CHD classification (see the Technical 
Notes at the end of this appendix). It was accompanied by an 
acceleration in the rate of decline for mortality from the cerebrovas- 
cular diseases and a continuation of the percentage declines for other 
subgroups of cardiovascular diseases. 
The decline in deaths from cardiovascular diseases since 1968 was 
striking in comparison with the trends for other causes of death. As 
Figure 1 and Table 2 show, the decline since 1968 for all noncardio 
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ii! TABLE l.-Number of deaths from all causes and from the major cardiovascular diseases by age, 
United States, 1979 
Causes of death1 
(terminology used 
in this report) Total 
Under 



















Diseases of arterioles, 
capillaries (440-448 
Atherosclerosis (440) 
Aortic aneurysm (441) 
Other (442-448) 
Ml other cardio 
vascular (residual) 
All other causes 
of death (residual) 
958,282 3.214 ’ 4,209 14,108 49.830 126,410 300.520 229.510 173 







300,462 115 677 

















60.324 49.760 23 
9,567 W3 16 31,916 47 210 679 
48,264 146 173 302 
28.801 4 5 37 
14,031 43 70 127 



















45.896 37.649 37 
110,424 43,732 43,615 85,435 193.156 99.215 479 
’ Coded to the Infwna~ronal Classr/icafio~ of L&a-es. Ninth Reuision. World Health Organization (45). 




1950 1955 1960 1985 1970 IQ75 1960 
YEAR 
FIGURE l.-Age-adjusted* death rates for cardiovascular . dreams and all other causes of death, United 
states, 1950-1978 
’ Bated are age-adjuted to tba 1940 U.S. population distribution. 
souRcE: Natiod Center for Health Statiatiw G?5,27). Bureau of the Census (2~. 
vascular causes of death combined was only 13 percent. The decline 
in all cardiovascular disease deaths since 1963 translates into 
239,090 fewer deaths in 1980 than would have occurred had the 
death rate remained at its 1970 level. The large decline for CHD 
alone translates into 237,000 fewer deaths in 1980 than would have 
occurred if the rate had remained at its peak (1963) level (see the 
Technical Notes at the end of this appendix). The decline in 
cardiovascular disease mortality, therefore, represents a major 
contribution to reduced total mortality and improved average life 
expectancy flable 2; Figure 3) (19, 29). 
Percentage declines were particularly steep for younger adults, for 
women, and for the nonwhite population, but were substantial for all 
demographic groups, including the elderly (Table 3). There are some 
geographic differences in U.S. cardiovascular mortality trends, but 
all areas have experienced substantial declines (13). Moreover, the 
United States differs from other countries in this decline, for in most 
countries the death rate continues to increase, especially for CHD 
among middle-aged men (Figure 4) (46). 
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TABLE 2.-Changes in the age-adjusted death rate for all causes, cardiovascular diseases, and all 
other causes of death, United States, 1950-1967 and 1968-1978 
I Y50-I!%” I , 196X-1%X 
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(‘ause 01 death 100.01n~ pop rh;m&y lfUO~3~1 pop ct1mlLy 
All (‘:i”hCs -1 15.9 -1:ix -14x.x L’o.0 
T&II cardiovamtlat -63 0 -14 H -l(N 4 -‘27 3 
(‘omnary hcwt dlseasr * 26.6 ,144 44 I -“)1, .’ 
(‘twbrowscular dlseaaes -lY 1 -21 .,5 -26 Y -37.7 
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Othrr cardiovascular dwases -24.1 -36 H * p ‘2 -75 
AlI other c:\uses or death -12.; -52 9 -48.4 -12.Y 
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FIGURE 2.-Ag~adjusted* death rates for coronary heart 
disease, United States, 195B-1978 
l Ratea are ageadjwted to the 1940 U.S. population dietribution. 
SMRCE2 Natiad Center far Haalth StdstidpS. 27h Bureau of the Census CR. 
Methodological Considerationa 
Measurement of trends in death rates from 1950 to 1979 has been 
affected by (1) revisions of the International Classification of Disease 
in 1953, 1963, and 1979, (2) revisions of population estimates 
following census counts in 1960, 1970, and 1980, and (3) the ma jor 
influenza epidemics in 1957, 1963, and 1963, which were years of 
unusually high mortality. The Technical Notes that appear  at the 
end of this appendix discuss the International Classification of 
Diseases codes and explains certain adjustments, lim itations, and 
other points of methodology of these statistics. 
Cardiovascular and Noncardiovascular Mortality 
The recent decline in cardiovascular mortality has not been 
unique. Between 1968 and 1978, the period during which the eighth 
revision of the International Classification of Diseases was in use, 
the age-adjusted death rate in the United States declined for all 
ma jor causes of death except lung cancer and chronic obstructive 
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YEAR OF BIRTH 
FIGURE 3.-Life expectancy at birth, United States, lB4B- 
1980 
SOURCE: National Center for Health Statistics (J9,29). 
(Table 4). Excluding these two causes, mortality from the other 
causes of death declined a  total of 160 deaths per 100,000 population. 
The percentage declines in mortality apply to both m iddle-aged 
persons and those 65 years of age or older. Although the percentage 
declines in mortality from diabetes me llitus and influenza or 
pneumonia exceed those for the cardiovascular diseases, mortality 
declines for the cardiovascular diseases contributed greatly to the 
declining overall mortality, accounting for 63  percent overall and 81 
percent of the decline in mortality at age 65 and older. 
F igure 5  shows that mortality rates from influenza, pneumonia,  
and diabetes me llitus have declined since the late 1960s. After a  
long-term increase, mortality from cirrhosis of the liver has declined 
since about 1975. Thus, the decline in cardiovascular disease 
mortality is not unique, but is notable for the magn itude of the 
decline in terms of reduced numbers of deaths and the acceleration 
in the declining mortality from stroke. The percentage decline in the 
death rates from coronary heart disease between 1969 and 1978 were 
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TABLE 3.-Percent changes in death rates’ for selected 
causes of death by sex, color, and selected age 
groups, united states, l!wS1978 
cerdiova9cular dieeaew (390-458) 
color, sex, age 
cmonaty Cm-ebm 
heart vascular Other cardie All other 
All diseasea disaeea vaecular callees of 
caueea Total (410-413) wo-438) dieeaea death 
Both sexes’ -20.0 -27.3 -26.5 
2.534 -16.2 -30.8 -37.5 
3544 -25.4 -35.7 -36.9 
4h54 -18.8 -27.2 -26.7 
5564 -18.6 -n.a -27.0 
674 -19.0 -28.1 -27.8 
75-64 -19.1 -25.9 -24.4 
85+ -21.0 -24.7 -21.1 
-37.7 -16.9 -12.9 
46.9 35.2 -12.9 
a.6 -29.6 -21.0 
-38.6 -20.0 -12.6 
a.3 -15.1 -9.3 
-40.7 -11.6 -5.9 
-35.5 -16.3 -4.0 
-33.4 - -24.5 -10.1 
white melee’ -17.7 -24.7 -24.5 -37.5 -11.1 -10.3 
2534 -7.5 -34.5 -31.7 44.4 -24.2 11.6 
35-44 -22.9 -33.9 -36.4 -37.5 -19.4 -17.2 
45-54 -19.4 -26.5 -21.0 Al.2 -13.4 -12.7 
55-64 -19.9 -26.4 -27.0 41.0 -10.4 -12.4 
674 -17.1 -245.0 -24.9 40.0 -6.3 -5.8 
7&%34 -13.4 -21.8 -20.0 -34.8 -9.9 +2.5 
85+ -16.9 -22.9 -18.7 -34.7 -21.8 -1.9 
white females’ -20.4 -26.3 -27.3 -36.2 -20.7 -12.7 
25-34 -18.5 -30.5 40.9 41.7 -35.6 -15.2 
35-44 -25.8 -34.1 -35.6 -34.4 32.2 -23.4 
45-54 -16.5 -27.2 -25.1 -32.9 -26.4 -12.0 
5544 -13.5 -27.3 -27.4 35.0 -18.9 -2.9 
6674 -20.0 -30.7 -31.1 110.3 -14.0 11.4 
75-84 -22.1 -27.7 -26.0 -35.9 -29.2 4.9 
86+ -23.2 -25.9 -22.2 -33.6 -26.9 -14.2 
Nonwhite malen ’ -21.1 -n.i -24.1 -40.0 -20.8 -16.7 
2534 -30.3 -43.1 -40.6 -52.1 -39.1 -28.5 
3544 -28.9 -38.2 37.3 44.0 -35.4 -25.0 
46-54 -20.4 -27.2 -24.4 -41.6 -21.5 -15.6 
5564 -18.3 -28.0 -24.4 44.8 -20.1 -8.5 
6&74 -18.4 -28.4 -25.2 40.8 -20.7 -5.1 
75-84 -13.2 -21.7 -18.6 -33.5 -11.5 -0.1 
85+ -7.4 -15.7 -14.5 -26.6 -3.8 +a.0 
Nonwhite females’ -29.7 436.0 33.7 45.9 -28.3 -23.8 
2534 41.9 -68.1 -65.7 -68.4 -55.0 -37.4 
3!%4 42.5 43.9 -53.5 -60.9 -48.1 -36.8 
4554 -31.5 42.3 -38.1 -52.4 -39.7 -23.1 
5544 -29.6 -40.0 -39.1 -51.4 -25.3 -17.7 
65-74 -27.2 -36.1 -33.9 47.7 -23.4 -11.6 
75-64 -19.7 -26.6 -25.4 34.4 -16.4 -3.9 
85+ -13.3 -17.0 -13.9 -25.9 -12.6 -3.9 
SOURCEI National Center for Health Statics (Zn; Bureau of the Census (8. 
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PERCENT CHANGE 
FIGURE 4.-Percent of change in the death rate for 
coronary heart disease in ma les, ages 35-74, by 
country, 196!3-1978* 
’ Age-averaged tes. 
*- 1969-1977. 
*** 1969-1976. 
SOURCE: World Health Organization (46). 
similar for the United States, Australia, Japan, and Israel (Figure 4). 
These percentage declines in coronary heart disease mortality 
among m iddle-aged men were at least twice the percentage decline 
for the noncardiovascular causes of death. The same was true for 
women. Elsewhere in the world, cardiovascular mortality did not 
decline; its percentage change was not much different from changes 
for the noncardiovascular causes of death as a  group (46). 
Smoking-Related Diseases 
The substantial declines in cardiovascular mortality trends are a  
long-term pattern that can be correlated to trends in cigarette 
smoking in men. Before the 195Os, total mortality in the United 
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TABLE I.-Change in age-adjusted death rates for all ages and two age groups by cause of death, 
United States, 1968-1978 
Cause of death 
All ages Ages 2S64 Ages 65+ 
Rate/100,lMO Percent R&/100,000 Percent Rate/1O@lOO Percent 
1968 1978 Change change 1968 1978 Change change 1966 1978 Change change 
All causes 743.8 595.0 -148.6 -20.0 591.4 476.3 -115.1 -19.5 5.519.6 4.453.0 -10666 -19.3 






Influenza and pneumonia 
Diabetes mellitus 
Cirrhosis of the liver 
Accidents. poisonings, 
and violence 
241.6 177.5 X4.1 -26.5 168.5 120.6 47.9 -28.4 2.297.4 1.711.6 4858 -25.5 
71.3 44.4 -26.9 -37.7 36.3 21.7 -14.6 -40.2 760.4 483.3 -285.1 -37.1 
55.5 46.1 -9.4 -16.9 41.0 32.8 -8.2 -20.0 493.4 414.7 -7R.7 -16.0 
24.9 33.2 +a.3 + 33.3 29.0 37.0 +a.0 +27.6 152.3 214.4 162 1 t40.a 
104.3 98.4 -5.9 -5.6 103.3 94.4 -8.9 -8.6 723.4 716.4 -7.0 -1.0 
11.6 14.5 +2.9 + 25.0 8.8 9.1 +0.3 13.4 103.2 143.6 +404 +39.1 
26.9 15.1 -11.8 43.9 15.3 8.0 -7.3 -47.7 205.7 143.8 -61.9 -30.1 
14.6 10.2 -4.4 -30.1 11.6 8.1 -3.5 -30.2 126.0 88.7 -37.3 -29.6 
13.9 12.4 -1.5 -10.8 22.5 19.6 -2.9 -12.9 36.9 37.3 +0.4 fl.1 
76.5 66.7 -9.8 -12.8 84.7 73.6 -11.1 -13.1 158.6 ,111.2 47.4 -29.9 
121 other causes 102.7 76.5 -26.2 -25.5 
SOURCE: National Center for Health Statistic+ f271. Bureau of the Census (2). 
70.4 51.4 -19.0 -27.0 454.3 386.0 -66.3 -14.6 
1 Influenza and Pneumonia cungcancea ( . ..dC 
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1 Bronchitis. Emphysema, 
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YEAR 
FIGURE 5.-Age-adjusted* death rates for the leading 
causes of death, United States, 1950-1978 
’ Rateaare age-adjusted to the 1940 U.S. population distribution. 
** This break in trend is due to a revision of the International Classification of Diseases. It aiT& the 
cardiovascular diseases more than other cnwea of death. 
“’ Pnmarily hypertensive. peripheral, and rheumatic heart disease. 
SOURCE. National Center for Health Statistics (16’. 22, 23.27.30). Bureau of the Cenaue II, 2). 
States declined rapidly, as the decreased mortality from infectious 
and parasitic diseases masked an increasing mortality rate from 
diseases associated with smoking-especially CHD, lung cancer, and 
COPD. Between 1955 and 1965, the total mortality decline stopped 
for men and slowed for women, partly because the numbers of deaths 
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from the smoking-related diseases of lung cancer, chronic obstructive 
lung disease, and cardiovascular disease were increasing quite 
substantially (especially among men), cancelling the gains made in 
other causes of death. Percentage increases were greater for lung 
cancer and COPD than for CHD, but compared with rates for CHD, 
death rates for these two diseases were lower in absolute terms. 
Since the mid-1960s. the remarkable decline in the coronary death 
rate has resulted in a new decline in total mortality. Although death 
rates for lung cancer and COPD are still increasing, the rate of 
increase is slowing, and in recent years, there is a suggestion of a 
reversal in lung cancer mortality among the younger cohorts (39). 
Coronary Heart Disease Mortality 
The age-adjusted death rate for CHD increased 19 percent. from 
1950 to 1963, peaked in 1963, and then declined 30 percent from 1963 
to 1979 (Figure 2). (This assumes good comparability of cause-of- 
death assignment and classification to CHD for 1963 and 1979. See 
the Technical Notes at the end of this appendix.) The reversal of the 
trend was gradual; however, the inflection point was the mid-1960s. 
During the period between 1968 and 1978, when CHD mortality was 
classified according to the eighth revision of the International 
Classification of Diseases, the age-adjusted death rate declined 26.5 
percent (Table 3). The decline was greatest at younger ages, ranging 
from 38 percent for ages 25 to 34 to 21 percent for age 85 and older. 
Nonwhite females experienced the largest decline of any sex/color 
group-34 percent, with declines exceeding 50 percent in persons 45 
years of age or younger. The mortality trends for CHD displayed in 
Figure 6 show a striking change from the differential trends among 
the four sex/color groups prior to 1968 and remarkably similar 
downward slopes since then. Rates for white and nonwhite females 
appear to have begun their current decline in about 1964. The 
earliest that the rates for white and nonwhite males began their 
current decline was 1967, following a brief plateau. Further, age- 
specific CHD mortality trends prior to the current decline showed 
greater differences than during the current decline (Figure 7). As 
stated above, however, declines continue to be steeper for younger 
than for older persons. The decline in CHD mortality is substantial 
in every State in the country, but is less marked in Appalachia, an 
area of relatively high CHD mortality. There is also some evidence 
that for life insurance policyholders, constituting a higher socioeco- 
nomic group than the general population, declines are steeper than 
for the general population (15). 
A breakdown of CHD deaths into deaths from acute myocardial 
infarction and deaths from other types of CHD is possible, but it is 
not known to which group most sudden or out-of-hospital CHD 
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FIGURE 6.-Age-adjusted* death rates for coronary heart 
disease by sex and color, all ages, United 
States, 1956-1978 
* Batea are ageadjuated to the 1940 U.S. population distribution. 
SOURCE: National Center for Health St.&Me L25,271. Bureau of the Censw (2). 
deaths are classified (Table 1). A much steeper decline in the death 
rate for acute myocardial infarction than for other CHD occurred 
during the 1968-1978 period (Figure 8). More information is needed 
before it can be determined what significance to ascribe to this 
difference. 
O ther Cardiovascular Disease Mortality 
The leading cause of death after heart disease and cancer is stroke, 
a  cerebrovascular disease and a  ma jor component  of cardiovascular 
diseases. The underlying process for about 80  percent of all strokes is 
arteriosclerosis, and hypertension is a  ma jor contributing factor (38). 
However, the age-adjusted death rate for stroke has been declining 
since before 1930, and has shown an accelerated downward trend in 
recent years (Figure 9). In the time  period 1950-1967, the age- 
adjusted death rate for cerebrovascular disease declined almost 22  
percent; this rate of decline accelerated during the time  period 1968- 
1978 to 38  percent (Table 2). The death rate declined 1.0 percent per 
year in the 1950s and 1.8 percent per year in the 1960s. As is the case 
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FIGURE 7.-Age-adjusted* death rates for coronary heart 
disease by age, white ma les, United States, 
1950-1978 
’ Rates me agegdjusted to the 1940 U.S. population dintribution. 
SOURCE: National Center for Health Statistics L25,27), Bureau of the Census (2). 
uniformly downward for the sex/color groups, with declines being 
especially steep for nonwhites and younger adults (2, 21, 23, 27). 
The age-adjusted death rate for hypertensive disease declined an 
average of 4.9 percent per year in the 195Os, 5.0 percent between 
1960 and 1967, and 7.2 percent between 1970 and 1978. Similar to 
the trend for stroke, there is a  steepening of the long-term decline in 
mortality from hypertensive disease, with recent declines being 
steeper among nonwhites than among whites. Large declines for the 
general arteriosclerosis category and for all other cardiovascular 
diseases combined occurred throughout the 1950-1978 period, in- 
cluding a  decline in mortality rates for aortic aneurysm from 1968 to 
1978. 
Incidence and Case-Fatality 
A decline in mortality rates may reflect changes in either the 
number  of new and recurrent coronary attacks (incidence) or the 
survivorship from such attacks (case-fatality). Reliable national 
statistics of either incidence or case-fatality are not available. 
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FIGURE 8.-Age-adjusted* death rates for acute myocardial 
infarction and other CHD, United States, 1968- 
1978 
’ F&ten are age&Wed (0 1940 US. population distribution. 
SOURCE: National Center for Health Statistica (27), Bureau of the Ceruus (2). 
measures of these trends. Reliance therefore must be  placed primari- 
ly on  available community- or hospital-based studies. 
In a  study of ma le emp loyees of the DuPont company in Delaware, 
the incidence rate of acute myocardial infarction was 18 percent 
lower in the 1973-1979 period than in the 1957-1964 period (33). 
Overall 3O-day case-fatality rates and the proportion of sudden 
deaths did not change significantly. However, beginning about 1969, 
the 3O-day mortality among persons who survived 24 hours after the 
attack declined significantly. 
In the Kaiser-Permanente Med ical Care Program in the San 
Francisco area, the proportion of persons hospitalized each year 
(rate/l,000 subscribers) for acute myocardial infarction declined 27 
percent between 1971 and 1977 (5). The proportion of persons 
hospitalized for any coronary heart disease event declined 18 
percent. The decline was seen in both first and recurrent events and 
did not result from shifting to noncoronary diagnoses. No clear trend 
could be  ascertained in the proportion of persons who died from 
acute myocardial infarction of all persons hospitalized for this 
disease each year. 
In a  study of the population of Rochester, M innesota, there was no 
change in the incidence of initial man ifestations of coronary heart 
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FIGURE 9.-Age-adjusted* death rates for cerebrovascular . dxeases 9  alI ages, United States, 1950-1978 
’ Rates are age-adjusted to the 1940 U.S. population distribution. 
SOURCE: National Center for Health Statistics W, 21.27). Bureau of the Census G’J. 
disease between 1950 and 1969 (3). However, the case-fatality rate, 
based on sudden, unexpected deaths and myocardial infarction 
deaths under 30  days, was 34 percent in the 1970-1975 period, 
whereas it had been 47 percent in the 1950-1955 period. In contrast, 
during 1971-1978, ma les under 65  years of age enrolled in the 
Health Insurance Plan of Greater New York who had recovered 
from a  first myocardial infarction showed no better survival over 4.5 
years than did a  comparable group during 1961-1970 (43). 
One study provides secular trends on the severity of coronary 
atherosclerosis between 1960-1964 and 1968-1972 (36). Autopsy 
findings in this New Orleans study reveal that the extent of intimal 
surface covered by raised lesions decreased significantly between 
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1960-1964 and 1968-1972 among white males 25 to 44 years of age, 
and also decreased slightly among black males. 
In the Kaiser-Permanente study, the proportion of persons hospi- 
talized for cerebral thrombosis dropped 64 percent between 1971 and 
1977, most of the drop occurring after 1973. The decline for all 
cerebrovascular diseases combined was 15 percent. In the Rochester, 
Minnesota, population there was a 45 percent decline in the 
incidence of stroke between 1945 and 1974, with reductions more 
pronounced in the elderly (6). The Framingham study observed a 
lower incidence rate for stroke among women (but not among men) 
followed since 1962, as compared with women followed since 1950 
(10). 
Trends in national hospital discharge statistics from the National 
Center for Health Statistics are available, but difficult to interpret. 
Discharge rates for both acute myocardial infarction and stroke 
between 1970 and 1978 show no increase in incidence of acute events 
(Figure 10) (26, 37). These data, however, are not inconsistent with a 
decline in CHD incidence, because patients are increasingly being 
admitted for cardiac pacemaker insertion and replacement, for 
catheterizations, and for other diagnostic and therapeutic proce- 
dures (Table 5). Figure 11 shows annual data on hospital case-fatality 
rates. Despite annual fluctuations, the trend in case-fatality rates 
from 1970 to 1978 is clearly downward for acute myocardial 
infarction. This could result from an increased tendency to admit 
milder cases not previously hospitalized, from a real improvement in 
therapeutic efficacy, or from a mixture of both. 
Risk Factors and Treatment 
Risk Factor Reduction 
As is discussed elsewhere in this Report, three major modifiable 
risk factors-cigarette smoking, hypertension, and hypercholesterol- 
emia-are statistically significant contributors to cardiovascular 
risk for both men and women (Table 10) (14). Cigarette smoking, 
hypertension, and a high serum cholesterol each have been found to 
increase coronary heart disease risk. The nationwide efforts to 
reduce cigarette smoking, to control high blood pressure, and to 
avoid foods high in saturated fats (4) have reduced the levels of these 
risk factors during the past 15 years (Tables 6,7,8, and 9) (24,28,32). 
The reduction in each of the risk factors coincides with the observed 
decline in CHD mortality. 
Attempts have been made to estimate how much of the reduction 
in cardiovascular disease mortality can be ascribed to observed 
reductions in risk factor levels (II, 12, 35). Findings have not been 
definitive because of data limitations. It has not been possible to 
quantify or to rank the separate contributions of a reduction in any 
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FIGURE lo.-Rate of hospital discharges for ma jor 
components of cardiovascular disease, ages 
45-65, United States, 1970-1978 
SOUBCB: National Center for Health Statktica C2@. Thorn et al. GVJ. 
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TABLE S-Number of selected cardiovascular surgical 
procedw, united states, 1970, 1975, 1989 
‘lcD/6 coda 2ss; ICDKJ coda 38.1-38.3. 
=wD/a mda 292-29.4 ICDIS ada 36.1.26.2.35.99. 
*IcDIB cnda 30% IcD/9 coda 37214723. 
l ICLV8 cocka 30.4; ICD/Q co&w 37.7. 
‘ED/8 coda 24-3Q ICD/D coda 36.140.6. 
‘JIxchdmrn~~ 
SOURCE: Netiwal Center for Hdtb Statistica C2@, Them (37). 
one risk factor to the mortality decline, but one analysis concluded 
that “elimination of smoking would have the greatest impact on 
CHD death rates” (II). The extent to which changes in these risk 
factors may have contributed to the decline in mortality depends, in 
part, on their prevalence in the U.S. population, and thus, on the 
reduction in prevalence that has taken place in recent years. 
An estimated 38.3 percent of adult men and 29.2 percent. of adult 
women smoke cigarettes, that is, 50 to 55 million persons as of 1980 
(Table 6). These percentages represent large declines from the 52.4 
percent and 34.1 percent, respectively, in 1965 (28). Table 6 gives the 
age-adjusted and age-specific rates that correspond to these crude 
rates of smoking. In a 1976 to 1980 survey, an estimated 22 percent 
of persons 25 to 74 years of age, about 25 million persons, had 
hypertension, i.e., a sy&lic blood pressure of 160 mm Hg or greater, 
a diastolic blood pressure of 95 mm Hg or greater, or were on 
a&hypertensive medication (Table 8) (32). Although the prevalence 
rate in 1960-1962 was about the same (20 percent), a much larger 
proportion of persons with hypertension in the more recent period 
were aware of it (73 vs. 49 percent), were on treatment for it (56 vs. 
31 percent), and had it controlled (34 vs. 16 percent). In a survey in 
1971-1974, an estimated 21.9 percent of persons 18 to 74 years of age, 
28 million persons, had serum cholesterol levels of 260 mg/lOO ml or 
greater (24). After adjusting these crude rates to make them 
comparable by age to estimates in the 1960-1962 survey, the 
percentage of persons at that level or greater was less than in the 
MB-1962 survey, although the decline was not statistically signifi- 
cant for all age/sex groups (Table 9). As of 1979, there were about 5 
million adults with diabetes mellitus, 3 percent of the adult 
population (28). There apparently has been no reduction in preva- 
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FIGURE ll.-Hospital case-fatality rate for acute 
myocardial infarction and chronic CHD, 
United States, 1970-1978 
NOTE Fir&listed diegnads on disharge: ED/8 cc& 410 for acute Ml, and 412 for chronic CHD. 
SOURCE: National Center for Health Statistica (26). Thorn et al. (37). 
The correlation of independent risk factors to cardiovascular 
disease risk is shown in Table 10. The documented changes in risk 
factors in Tables 6-9 suggest that the decline in the prevalence of 
cigarette smoking, which affected the greatest number  of people, 
may have contributed more to the decline than did changes in the 
other risk factors. This assertion depends on the quality of data on 
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the prevalence of smoking, the changes in prevalence of smoking, 
and the relative strength of the association between smoking and 
CHD risk, as well as evidence that cessation of smoking lowers the 
risk of acute and recurrent myocardial infarction mortality. 
Impact of Improved Treatment 
Improvements have been made in recent years in the medical care 
of the coronary patient prior to, during, and after hospitalization. 
Treatment is now more aggressive and sophisticated, and the 
improved management techniques are more generally available 
throughout the country. Today’s coronary patient has a much better 
chance of arriving alive at a hospital and at an earlier stage of the 
episode than was the case a decade or two ago (7). Once hospitalized, 
the patient is monitored for arrhythmias and changes in cardiac 
function, usually in a coronary care unit. Catheterizations and 
coronary artery bypass surgery have been performed with greatly 
increased frequency in recent years (Table 5). It is likely that 
improved treatment in a hospital has reduced the case-fatality rate 
of these patients (Figure 11). The post-discharge treatment is better 
managed today. The coronary patient with angina pectoris or 
hypertension receives more aggressive and effective treatment; 
antiarrhythmic drug therapies are widely used; and many patients 
are advised to stop smoking, modify their diet, and lose weight. 
Although documentation of the occurrence in time of many of these 
treatment improvements is incomplete, most were made in the 1960s 
and 1970s. 
Trends and Associafed Factors 
The reversal of the death rate for CHD and the acceleration of the 
decline for stroke have coincided over time with increased efforts in 
primary and secondary prevention. These efforts include the anti- 
smoking campaigns since 1964, the nationwide campaign against 
hypertension since 1972, a trend away from saturated fats in the 
diet, and changes in treatment, such as expanded utilization of 
coronary care units, cardiac surgery, cardiac catheterization, and 
pacemakers (8). The public is now more aware of cardiovascular risk 
factors, especially cigarette smoking, hypertension, and elevated 
serum cholesterol. Also, when a heart attack or stroke occurs, 
today’s patient generally receives more aggressive medical manage- 
ment (7, 9). 
Trends and Smoking 
The proportion of both cigarette smokers and CHD mortality 
increased until the mid-1960s and then declined markedly. Tempo- 
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TABLE &-Percentage distribution of adult current and 
former cigarette smokers, according to sex, 
race, and age, in 1965, 1976, and 1980 
Sex, race, and age 
current Bmoker’ @wcent) 
1965 1976 19K1’ 
Former smoker (percent) 
196.5 1976 1960’ 
52.1 41.6 37.9 20.3 29.6 30.5 
59.2 45.9 39.7 9.0 12.2 12.1 
60.7 46.5 43.1 14.7 16.3 20.6 
56.2 47.6 42.6 20.6 27.3 27.6 
51.9 41.3 40.8 24.1 37.1 36.9 
28.5 23.0 17.9 2.8.1 44.4 47.4 
51.3 41.0 37.1 21.2 30.7 31.9 
58.1 46.3 39.0 9.6 13.3 12.2 
60.1 47.7 42.0 15.5 18.9 21.9 
57.3 46.8 42.4 21.5 28.9 28.8 
51.3 40.6 40.0 25.1 38.1 36.4 
27.7 22.8 16.6 28.7 45.6 50.1 
59.6 50.1 44.9 12.6 20.2 20.6 
67.4 52.8 45.5 3.8 4.1 10.6 
68.4 59.4 52.0 6.7 il.8 11.9 
67.3 58.8 44.2 12.3 13.8 21.2 
57.9 49.7 46.8 15.3 28.6 26.3 
36.4 26.4 27.9 21.5 33.0 26.6 
34.2 32.5 29.8 6.2 13.9 15.7 
41.9 34.2 32.7 7.3 10.4 11.0 
43.7 37.5 31.6 9.9 12.9 14.4 
43.7 38.2 34.9 9.6 15.8 18.9 
32.0 34.8 30.8 8.6 15.9 17.1 






30.0 8.5 14.6 16.3 
33.3 8.0 11.4 12.5 
31.6 10.3 13.7 14.7 
35.6 9.9 17.0 20.2 
30.6 8.8 16.4 17.4 
17.4 4.5 11.5 14.3 
32.7 34.7 30.6 5.9 10.2 11.6 
44.2 34.9 32.3 2.5 5.0 2.2 
47.8 42.5 34.2 6.7 8.9 11.6 
42.8 41.3 36.5 7.0 9.6 12.5 
25.7 38.1 34.3 6.6 11.9 14.1 
7.1 9.2 9.4 4.5 13.3 14.1 
’ A current mnoker hiw smoked et least 100 cigarettes and now smokes; includes occasional smokers. 
‘Find estimatea. Based on data for the last 6 months of 1960. 
aBaBe ofpemtsge excludea p.3laona with unknown making ste”LIm 
‘Includes all other racea not shown separately. 
‘Age adjusted by the direct method to the 1970 civilian rnCnatitutionalii population usin 5 age groups. 
NOTE: Percentages do not add up to 100 because of %ever smokers” in the survey population. 
SOURCE: Data from the Nationd Health Interview Survey, National Center for Health Statistics, 1965.1976, 
and 1960, based on howehold interviewa with a sample of the civilian noninstitutional&d population. 
rally, the beginning of the decline in CHD mortality closely followed 
the decline in prevalence of smoking after the issuance of the first 
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TABLE ?.-Change in percentage of current cigarette 
smokers and of those who smoke 25 or more 
cigarettes per day, by color, sex, and age, 
united states, 1966 to 1980 




Smoke 25 or 
more tz&ettm 
per day 
Whit.emen,age20+ -n.o +0.7 
20-24 -31.8 -9.2 
25-34 -30.6 -12.1 
3u4 -26.5 -21 
4544 -21.6 +18.2 
65 and older -37.5 + 14.3 
Black mea. 20+ age -35.8 -125 
20-2-4 -39.4 -11.1 
25-34 -33.1 -24.2 
3&u -37.6 -32.1 
45-64 -19.7 +22.2 
65 and older -20.6 +x6.7 
whitewomell,age2o+ -13.7 +16.2 
20-24 -21.2 +38.6 
25-34 -27.2 +16.7 
35-44 -18.9 +55.6 
45-64 -7.6 +66.0 
65 and older +76.6 +257.1 
Black women, age 20+ -14.0 +50.0 
20-24 -28.7 unknown ' 
25-34 -31.2 +26.2 
35-44 -19.6 + 15.4 ’ 
45-64 31.1 +344.4' 
65 and older +22.5 unknown' 
’ Fire does not meet standards of reliability or precision. 
SOURCE: National Center for Health Statiica &?&I 
Report of the Surgeon General on The Health Consequences of 
Smoking. The same phenomenon has been reported in other 
countries as well (37). 
The decline for CHD mortality is occurring among adults of all 
age, color, and sex groups, a pattern similar to that of the reduction 
in the proportion of the population who are cigarette smokers. The 
mortality decline is steeper among younger adult age groups, which 
is consistent with not starting to smoke or early smoking cessation. 
Since 1950 for males and 1960 for females, each succeeding sex 
cohort has experienced a lower peak prevalence of smoking (42). The 
evidence of more rapid declines in mortality for persons on a higher 
TABLE &-Prevalence, awareness, and control rates of 
hypertension, persons 2&74 yeara of age, 






Percentage of total with hypertension 
Aware, Aware, Aware,’ 
medication, medication, 
Unaware’ u&Zion no control controlled 
1960-1962 20.3 51.1 17.6 15.3 16.0 
1974-1975 22.1 36.4 29.4 14.6 19.6 
19761990 22.0 26.6 17.2 22.1 34.1 
’ Bate ageadjusted by the direct method to the population at the midpoint of the 19761990 National Health 
and Nutrition Examination Survey. 
’ Systolic blood pressure 160 mm Hg or greater, or di&.olic blood pressure 95 mm Hg or greater. or on 
antihypertensive medication. 
' Reported never told by phynician of having hypertension. 
’ Three with hypertension taking antihypstensive medication whose blood p-we wan not hypertensive. 
SOURCE: National Center for Health Statistica (32). 
TABLE O.-Percentage of adults with serum cholesterol 
levels of 269 mg/199 ml and over, by sex and 
age, United States, Health Examination Survey 
(HES) 1990-1962 and Health and Nutrition 







Total. age 16-74 17.6 22.7 14.7 17.5 
16-24 3.9 4.6 2.8 3.0 
2544 10.4 7.4 8.2 5.6 
35-44 20.2 12.9 17.1 9.6 
4a54 25.7 28.0 24.1 24.6 
5664 23.5 49.7 20.2 35.3 
65-74 21.6 51.0 20.9 40.7 
’ Age adjusted by the direct method to 1971-1974 civilian noninstitutional&d population. 
NOTE: All choleat.eml values have been a&ot.ed to approximate the values of Abel1 et al. (Abell, L.L.. Levy. 
G.B., Bralie. B.B., Kendall, F.E. A simplified method for the estimation of total cholesterol in amum. and 
demonstration of its epeciricity. Journal of Eiologiml Chemistry 196: 357-265, 19521, the common referenced 
metlmd, by reducing the 1960-1962 data by 7.6 percent and the 1971-1974 data by 4.5 percent. 
SOURCE: National Center for Health Statistics (24X 
socioeconomic level and lesser declines in poorer areas of the country 
are also consistent with a favorable impact of smoking prevention or 
cessation efforts on CHD mortality, in view of the clearly demon- 
strated inverse relationship of male income level and prevalence of 
smoking. 
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TABLE 10.-Regression coefficients, risk ratios, and 
statistical significance for the risk of 
cardiovascular disease in 8 years, men and 
women, age 36-74 years, Framingham heart 
study 
Risk ratice evaluated 
MultiDle 
regreiion 
coefficient ’ T’ 
































2.37 1.3 Smoker/nonsmoker 
2.66 1.2 46 mgldl 
-2.77 - - 
6.59 1.4 M-&l 
5.40 2.1 Preeentlatwnt 
Smoker/nonsmoker 
42 m&ll 
20 mm xig 
Present/absent 
’ Unetandardisd meffcient of the multiple risk function for cardiovascular dineme within 8 years with the 
independent variables being w-am cholasteml. &&stem1 timea age. syetolie blood premure. cigar&e smoking, 
gluame intaleran~> left ventricular hypertrophy on ECG. age, and age sguared; estimati over the age range 3& 
74 yean. 
’ Thme tik fectors are statistically significant for both men and women. The critical value of T ia 
appmxbnately equal to 2.0 at a=OM. 
’ The hypothetical risk of development of cardiovsseular diwase asawiated with the 6,.&&d difference in risk 
rector levels when other risk factors in the model are held constant. A ratio greater than 1 reprecenia pmitive 
amociation with cardiovancular d&we. For serum cholesterol and systolic blood pressure, the difference chceen 
wan one standard deviation of the measurement. 
SOURCE: McGee and Abbott Ml. 
Some questions remain unanswered regarding the contribution of 
smoking cessation to the decline in CHD mortality. The percentage 
of smokers who are heavy smokers appears to be increasing, 
although it is not known whether this represents a greater cessation 
rate among lighter smokers than among heavier smokers. The 
percentage decline in CHD mortality for women has been as large as 
for men, although proportionately fewer women than men have 
given up smoking. Assertions that preventive measures have re- 
sulted in smoking changes that caused the decline in CHD mortality 
differences by age, socioeconomic status, and geographic area are 
based on limited available data. 
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Conclusion 
The evidence supports the conclusion that changes in smoking 
habits have contributed to substantial improvement in mortality 
rates from the cardiovascular diseases in the United States. 
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Technical Notes 
International Classification of D&eases 
Tables A and B contain the code numbers of the International 
Classification of Diseases (ICD) applicable to the causes of death 
described in this report (16,20,44, 45). Between each revision of the 
ICD there are breaks in the continuity of these classifications, 
affecting some diseases more than others. For cardiovascular dis- 
ease, the most serious breaks in continuity are between the seventh 
and eighth revisions and between the eighth and ninth revisions for 
CHD and for hypertensive disease. 
The cause of death commonly referred to as coronary heart disease 
(CHD) was listed in both the sixth and seventh revisions of the ICD 
(1949-1957, 195&1967) as “Arteriosclerotic heart disease, including 
coronary heart disease,” code 420; in the eighth revision (1968-1978) 
as “Ischemic heart disease,” codes 410-413; and in the ninth revision 
(after 1978) as “Ischemic heart disease,” codes 410-414. 
Expected Minus Observed Deaths 
Multiplying the 1970 age-specific death rates Wyear age groups) 
for total cardiovascular diseases times the 1980 census gives an 
estimate of the number of cardiovascular disease deaths expected in 
1980: 1,294,564 deaths, based on the level of mortality in 1970. An 
estimate of the number of cardiovascular disease deaths observed in 
1980 is 1,005,692. This latter estimate is made by combining the 
estimated 989,000 deaths from major cardiovascular d&eases in 1980 
(ICD/S codes 390-448) and the 4,803 deaths from diseases of the 
veins in 1980 (ED/S codes 451-459) (27, 29). The difference is 
288,872 cardiovascujar disease deaths “averted” in 1980 because of a 
decline in mortality from the level in 1970. 
Multiplying the 1963 age-specific death rates W&year age groups) 
for coronary heart disease (ICD/7 code 420) times the 1979 popula- 
tion estimate gives the number of CHD deaths, 804,000, expected in 
1980, on the basis of the level of mortality in 1963 (2, 25, 27). The 
observed number of deaths from CHD in 1980 for ED/9 codes 410- 
414 was 566,000, or 238,000 fewer than expected, based on the level 
of mortality in 1963. This procedure assumes reasonably good 
comparability of ICD classification of CHD in these 2 years. 
Age-Adjusted Rates 
Age adjustment for this Report is by the direct method. Age- 
specific death rates in l@year age groups are multiplied by the 
“standard million” for 1940-the U.S. population by age as enumer- 
ated in that year. 
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TABLE A.-Codes of the 6th, 7th, 8th, and 9th revisions of the International Classification of Diseases 
for Selected Diagnoses 
Diagnosis 
1949-1967 1966-1978 1979 
6th and 7th revisions 6th revision 9th revision 
Cardiovascular diseases 330-334,400460 
Coronary heart disease 420 
Acute myocardial infarction no code for this diagnosis 
Other coronary heart disease no code for this diagnosis 
Cerebrovascular diseases 330-334 
Hypertensive disease 440-M7 
Other diseases of arteries 450-456 
Atherosclerosis 450 
Aortic aneurysm 451 
Other 452456 
All other cardiovascular disease 403-416. 421-434, 460-460 
Lung cancer 162, 163 
Other cancers 140-161, 164-205 
Diabetes mellitus 260 
Influenza and pneumonia 4so493 
Chronic obstructive pulmonary disease 500, 501, 527.1 
Cirrhosis of the liver 561 




































SOURCE: World Health Organization (44,45), National Center for Health Statistica (20). 
TABLE B.-Iutmnational classification of diseases codes for 
cardiovascular-renal diseases1 and 
cardiovascular diseases*, 1900-1979 
YearS 














47,64-a, 77-66,120, 142 
47, 64-66, 77-66, 120, 142 
51, 74, 75, 03. 87-90. 
9lb, 91c, 9%96, 129, 151 
56, 82.9&95.97-103, 
131. 132 
’ Thmugb 6th revision. 
’ After 6th revision. 
SOURCEz Moriyama et al. (16-h National Center for Health 6tatietia Cm). World Health Chgmizatior, (&)b). 
Population Estimates 
Death rates for census years and for years prior to 1961 are based 
on the resident or census population estimates that were available at 
the time the official U.S. vital statistics were prepared. Rates for 
1961 to 1969, however, are based on estimates of the resident 
population revised to reflect the 1970 census, and rates for 1971 to 
1979 are based on estimates of the resident population revised to 
reflect the 1980 census (I, 2). 
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APPENDIX B: TRENDS IN U.S. 
CIGARETTE USE, 1965 
TO 1980 
introduction 
This discussion of national trends in adult cigarette smoking over 
recent years in the United States includes data on prevalence, 
consumption, and cessation. It focuses on adult cigarette smoking 
patterns and cessation by age and sex cohorts. Data were drawn from 
an analysis of three national surveys by the National Center for 
Health Statistics (NCHS) and three other national surveys on adult 
use of tobacco conducted by the former National Clearinghouse for 
Smoking and Health over the period from 1965 through 1980 (6, 7,s). 
A brief description of the data sources is presented, followed by a 
discussion of the data. 
Surveys of Tobacco Use 
The 1999 Survey on the Use of Tobacco 
Two separate national probability sample surveys on adult usage 
of and attitudes toward tobacco conducted by the National Clearing- 
house for Smoking and Health in 1966 have been combined and are 
treated here as a single survey. 
One study design imposed a two-way stratification on all house- 
holds in the continental United States, classifying each household by 
three types of population and nine geographic areas. The other 
design divided the entire area of the United States into approximate- 
ly 1,700 primary sampling units PSUs). Weighting procedures 
resulted in the selection of 5,770 respondents. 
Within each household, the first eligible respondent (age ‘21 or 
older) was the person interviewed; all current and former smokers 
were also interviewed, but only a subsample of those who had never 
smoked was interviewed. Weighting procedures were used to bring 
the three groups into balance. 
The 1970 and 1975 Surveys on the Adult Use of Tobacco 
The 1970 and 1975 surveys sponsored by the National Clearing- 
house for Smoking and Health employed the same sampling and 
interviewing methodologies. Where possible, questions were phrased 
similarly. The questionnaires for current, former, and never smokers 
differed slightly. 
In both surveys, the sample design consisted of two parts: a 
national probability sample of telephone households and a national 
probability sample of nontelephone households. 
The respondent selection procedure was designed to produce 75 
percent of the interviews with “ever” smokers and 25 percent with 
“never” smokers. Weighting procedures were used to compensate for 
this oversampling of ever versus never smokers. Other weighting 
factors were used to adjust for age, sex, and smoker mix of the 
household. The weighted number of respondents (age 21 or older) 
was 5,875 in 1970 and 12,079 in 1975. 
Smoking Supplement to the National Health Interview 
Survey 
The National Health Interview Survey (NHIS), a continuous 
nationwide sample personal household interview survey by the 
National Center for Health Statistics, included questions on ciga- 
rette smoking in 1965,1966, 1970, 1974,1976,1977, 1978, 1979, and 
1980. Information is routinely obtained on personal and demograph- 
ic characteristics. Questions focused primarily on such characteris- 
tics as present smoking status, amount smoked daily, and in more 
recent years, attempts to quit, and on tar and nicotine levels of 
cigarettes smoked. Information was not obtained on opinions, 
attitudes, or beliefs related to smoking. 
The universe for the NHIS is the civilian noninstitutionalized 
population of the United States. The survey is based on a multistage 
probability sample of primary sampling units in about 42,000 
households containing about 85,000 persons. A one-third subsample 
of the adult respondents is interviewed for the smoking supplement 
(during 1965 and 1966 smoking data were obtained for all adults). 
Patterns of Smoking Prevalence and Cessation 
Prevalence of Cigarette Smoking 
The percentage of adults who report being current regular 
smokers, defined as persons who have smoked at least 100 cigarettes 
and who were smokers at the time of interview, has been declining 
steadily over the last _15 years (Table 1). For the total white male 
population, this decline has been from 51.3 percent in 1965 to 37.1 
percent in 1980, and for white females, from 34.5 to 30.0 percent. 
Among black adults a similar pattern was seen-for males a decline 
from 59.6 to 44.9 percent, and for females, from 32.7 to 30.6 percent. 
Conversely, the percentage of the white adult male population who 
reported being former smokers increased between 1965 to 1980 from 
21.2 to 31.9 percent, and of white females, from 8.5 to 16.3 percent by 
1980. Again, a similar trend was observed among blacks, with the 
percentage of former smokers increasing from 12.6 to 20.6 percent of 
males, and from 5.9 to 11.8 percent of females. This increase in the 
percentage of former smokers is more marked among males (20.3 to 
30.5 percent) than among females (8.2 to 15.7 percent), although the 
proportion among males increased by a factor of 1.5, while that 
among females doubled. 
In addition to this increase in percentage of former smokers over 
the E-year period, among most of the sex, race, and age groups there 
also appears to be an increase in the percentage of persons who 
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TABLE I.-Percentage distribution of adult current and 
former cigarette smokers, according to sex, 
race, and age, in 1965, 1976, and 1980 
Current smoker’ @wcent) Former smoker (percent) 























52.1 41.6 37.9 20.3 29.6 30.5 
59.2 45.9 36.7 9.0 12.2 12.1 
60.7 46.5 43.1 14.7 18.3 20.6 
58.2 47.6 42.6 20.6 27.3 27.6 
51.9 41.3 40.8 24.1 37.1 36.9 
28.5 23.0 17.9 28.1 44.4 47.4 
51.3 41.0 37.1 21.2 30.7 31.9 
56.1 46.3 39.0 9.6 13.3 12.2 
60.1 47.7 42.0 15.5 18.9 21.9 
57.3 46.8 42.4 21.5 28.9 28.8 
51.3 46.6 40.0 25.1 36.1 38.4 
27.7 22.8 16.6 26.7 45.6 50.1 
59.6 50.1 44.9 12.6 20.2 20.6 
67.4 52.8 45.5 3.8 4.1 10.6 
68.4 59.4 52.0 6.7 11.8 11.9 
67.3 59.8 44.2 12.3 13.8 21.2 
57.9 49.7 46.8 15.3 26.6 26.3 
36.4 26.4 27.9 21.5 33.0 26.6 
34.2 32.5 29.8 a.2 13.9 15.7 
41.9 34.2 32.7 7.3 10.4 11.0 
43.7 37.5 31.6 9.9 12.9 14.4 
43.7 38.2 34.9 9.6 15.6 18.9 
32.0 34.8 30.8 8.6 15.9 17.1 
9.6 12.8 16.6 4.5 11.7 14.2 
34.5 32.4 Xl.0 8.5 14.6 16.3 
41.9 34.4 33.3 8.0 11.4 12.5 
43.4 37.1 31.6 10.3 13.7 14.7 
43.9 38.1 35.6 9.9 17.0 20.2 
32.7 34.7 30.6 8.B 16.4 17.4 
9.8 13.2 17.4 4.5 11.5 14.3 
32.7 34.7 30.6 5.9 10.2 11.6 
44.2 34.9 32.3 2.5 5.0 2.2 
47.6 42.5 34.2 6.7 8.9 11.6 
42.0 41.3 36.5 7.0 9.6 12.5 
26.7 36.1 34.3 6.6 11.9 14.1 
7.1 9.2 9.4 4.5 13.3 14.1 
’ A current smoker haa amoked at kast 100 eieustta, rod now smokea; includes -ional smokers. 
‘Knalestimatas.Basedondarsforthe~Gmonthsofl~. 
J Bane of percentage excludea peraau with unknown smoking status. 
‘lnCluded all other - not ohown rpuately. 
l A@z odjuntad by the direct me&cd to the 1970 civilian noninstitutionalized population using 5 age gn~~p. 
NOTE: Percentagea do not add up to 100 because of “never smoken” in the survey population. 
SOURCE: Data from the National He&h Interview Swvey, National Center for Health Statistics. 1965.1976. 
and 1960, baaed on household interviewa with a aample oftbe civilian noninstitutiioaalized population. 
report never having smoked. In males, this is demonstrated by both 
races and by the age groups younger than 45 years of age. In females, 
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TABLE 2.-Average number of cigarettes smoked per day 
by current and former smokers, by sex, age, 
and educational level, in 1970, 1975, and 1980 
1970 ’ 1975 ’ 1980’ 
Current Former Current Former Current Former 

























20.0 22.6 21.2 24.5 21.7 25.0 
21.8 25.0 22.8 n.2 23.4 28.1 
20.8 16.2 18.9 20.8 19.4 18.7 
21.0 23.4 22.1 24.0 22.1 24.0 
23.0 27.7 23.4 28.0 25.6 28.7 
24.2 25.4 W.l 29.5 27.2 31.6 
21.6 n.7 25.0 28.1 23.3 31.3 
17.2 25.3 20.3 28.0 20.9 n.1 
17.7 17.3 19.1 18.8 19.7 19.8 
16.1 13.8 18.6 14.7 17.8 17.6 
18.1 16.7 18.5 17.7 19.4 20.3 
18.6 18.2 20.1 19.5 22.5 19.8 
18.4 19.0 20.3 20.8 20.7 22.4 
17.0 15.4 19.0 20.8 20.0 20.4 







21.7 21.7 25.9 20.5 26.2 
22.2 21.6 25.0 22.3 n.a 
22.8 20.8 24.2 21.9 24.4 
22.5 21.3 25.1 22.1 24.3 
23.2 20.6 22.1 21.1 24.0 
’ National Survey on Adult Use of Tobacco. PHS. 1970. 
‘National Health Interview Survey Smoking Supplement, PHS, 19&l. 
NOTE: Data from 1966 National Survey were not compatible with other years 
the increase in percentage of persons who report never having 
smoked is limited to the age groups younger than 35 years. 
Average Daily Consumption of Cigarettes 
Table 2 shows data on the average number of cigarettes smoked 
daily during three survey periods (1970, 1975, and 1980) for both 
current and former smokers. 
Overall, current smokers reported an increased consumption, from 
a mean of 20.0 cigarettes per day in 1970 to 21.7 cigarettes per day in 
1980. The 1970 to 1980 increase in mean number of cigarettes 
smoked daily was slightly greater for females than for males (2.0 
versus 1.2), a finding consistent with the increasingly similar 
smoking behavior in females and males. Thus, although males 
continue to smoke a greater average number of cigarettes per day 
than do females, the difference in daily consumption between the 
sexes for current smokers in 1980 was less than that observed a 
decade earlier. 
The heaviest daily consumption is observed in the middle-aged 
groups (35 to 64 years). A greater mean increase from 1970 to 1980 
was observed among women aged 35 to 64. 
Male former smokers generally reported greater daily cigarette 
consumption than did current smokers in each survey. This trend 
was not found in females. This finding is contrary to the widely held 
belief that those who smoke fewer cigarettes per day are more likely 
to quit. It may be due in part to a tendency of former smokers to 
overestimate their consumption and of current smokers to underesti- 
mate their consumption or both. 
Among former smokers of both sexes, average daily consumption 
rates increased with age, peaking at the 45- to ELI-year-old age 
~tegory. 
No trend over time is discernible by educational level in the 
overall mean daily consumption among current smokers. There was, 
however, an increase in the daily cigarette consumption of former 
smokers with 8 or fewer years of education, from 21.7 in 1970 to 26.2 
in 1980. Within each survey year, there is also no discernible trend 
between level of education and daily cigarette consumption. The 
greater reported average daily consumption by educational status 
for former smokers than for current smokers may reflect cognitive 
dissonance, or changing social pressures that result in reporting bias. 
Table 3 displays the percentage distribution of current smokers by 
grouped number of cigarettes smoked daily, over the 1965,1976, and 
1980 NHIS surveys. Cigarette smokers had a tendency to round off 
their reported number of cigarettes smoked per day (3) (Table 4). 
Approximately one-third of the smokers reported smoking exactly 20 
cigarettes (one pack) a day in each of the survey years. The 
proportion of current smokers reporting consumption levels of 21 to 
29 or 31 to 39 cigarettes per day remained relatively constant 
between 1970 and 1980. 
Although the proportion of smokers who report consumption 
levels of 20 to 39 cigarettes per day has remained fairly stable over 
the last 10 years (46.6 vs. 49.31, a clear difference is observed at the 
more extreme ends of the distribution, i.e., among those smoking 
fewer than 20 cigarettes and those smoking 40 or more cigarettes per 
hY- 
In 1970, only 11.4 percent of the respondents reported smoking 40 
or more cigarettes per day; by 1980, 16.8 percent reported smoking 
40 or more cigarettes per day. During the same period, smokers 
reporting consumption levels of less than 20 cigarettes per day 
decreased from 39.8 percent in 1970 to 33.8 percent in 1980 (Table 4). 
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TABLE 3.-Percentage distribution of adult current 
smokers’ by grouped number of cigarettes 
smoked per day by sex, race, and age, 1965, 
1976, and 1980 
Ciittea smoked rer dav 
<15 15-24 225 












































28.3 24.2 23.1 46.3 44.8 42.7 25.4 31.0 34.1 
34.9 31.6 32.0 49.1 49.9 47.8 15.4 18.5 20.2 
25.1 25.5 23.6 50.0 45.8 46.5 24.3 28.7 29.9 
23.7 19.6 15.8 44.8 41.2 42.3 31.5 39.2 41.9 
26.7 18.5 21.6 45.3 44.1 36.4 28.0 37.4 42.0 
47.1 39.1 29.2 39.0 42.7 46.1 13.8 16.2 24.7 
25.9 21.4 19.1 46.8 44.9 43.6 27.4 33.7 37.4 
32.3 27.5 27.1 50.8 62.8 50.4 16.9 19.7 22.4 
22.8 22.1 19.5 51.1 46.5 41.4 26.1 31.4 33.1 
21.3 17.2 12.8 44.6 40.4 42.1 33.9 42.5 45.1 
24.6 16.2 17.3 45.4 43.3 37.4 30.0 40.4 45.3 
44.6 37.5 26.1 40.3 42.2 46.2 15.1 20.4 27.7 
48.1 43.8 46.7 42.6 44.0 40.3 9.3 
52.7 56.9 66.6 41.9 34.2 36.7 5.3 
47.8 46.0 44.4 41.7 43.5 46.2 10.5 
42.5 38.5 45.6 45.5 44.8 41.1 12.0 
46.9 35.9 51.1 43.7 50.8 35.0 9.4 












43.6 36.5 34.2 42.2 43.8 42.0 14.2 19.6 23.7 
48.4 43.1 42.0 41.9 42.4 41.1 9.7 14.5 16.1 
41.4 34.3 33.5 43.1 45.2 41.9 15.5 20.5 24.6 
39.1 33.8 27.8 43.7 44.4 39.3 17.1 21.8 33.0 
44.4 34.3 29.8 42.0 44.2 45.9 13.6 21.5 24.2 
62.6 4t3 48.9 31.0 38.9 37.7 6.4 11.8 13.4 
41.0 33.2 30.6 43.9 45.2 4.8 15.1 21.6 25.6 
45.3 39.3 37.4 44.4 44.3 44.1 10.4 16.4 18.5 
37.9 30.6 28.6 45.4 46.8 44.9 16.7 22.6 26.5 
36.2 29.5 24.6 45.3 45.4 39.9 16.4 25.1 35.5 
42.4 32.0 26.4 43.2 45.1 47.0 14.5 23.0 25.9 
61.5 45.7 46.1 31.8 41.7 37.7 6.8 12.6 14.2 
67.7 60.0 61.1 26.4 
73.4 65.7 78.0 22.1 
66.2 58.8 61.9 25.1 
63.4 60.4 555.6 30.4 
69.4 53.2 53.8 26.9 





















’ A current smoker has smoked at least 100 cigarettes and now amokeq include occasional smokers. 
’ Based on data for the last 6 months of 1980. 
*Base of percentage excludes unknown amount smoked. 
‘Includes all -not shown seperate$. 
SOURCE: Data from the National Health Interview Survey. National Center for Health Statistics. 1965.1976, 
and 1980, based on household interviewa with a aample of the civilian noninstitutionaIized population. 
TABLE 4.-Percentage distribution of adult current 
smokers who reported smoking specific 
numbers of cigarettes per day, in 1970, 1975, 
and 1980 
Percentage of current smokers 
Number of cigarettes/day 1970 ’ 1975 ’ 1980’ 
l-9 15.8 13.5 13.1 
39.81 37,O 1 33.81 
l&19 24.0 23.5 20.7 
20 34.9 32.0 34.8 
21-29 3.1 2.8 2.3 
30 9.6 12.1 11.5 
31-39 1.0 0.8 0.7 
40 8.8 10.7 11.1 
11.41 15.2 1 16.8 1 
41+ 2.6 4.5 5.7 
’ National Survey on Adult Use of Tobecm. PHS, 1970 and 1975. 
’ Natiind Health Interview Survey Smoking Supplement, PHS W’reliminary). 1990. 
NOTE: Data from 1966 National Survey are not compatible with other yean. 
These findings may be due to several factors, including (1) 
increased smoking (possibly among those who have switched to lower 
tar cigarettes), (2) a higher cessation rate among persons smoking 
fewer cigarettes, (3) the entry of new smokers of greater numbers of 
cigarettes, or (4) some combination of these factors. 
Number of Attempts to Quit Smoking 
Survey data have shown that the majority of current smokers 
have made at least one serious but unsuccessful attempt to quit (4). 
Table 5 shows the percentage of current smokers who reported 
having made three or more attempts to quit. Similar data are shown 
for former smokers for two of the survey years. A modest downward 
trend is observed in the percentage of current smokers who reported 
making three or more attempts to quit (from 41.2 percent in 1966 to 
38.7 percent in 1980), but the proportion of former smokers reporting 
three or more attempts to quit increased from 36.0 percent to 53.2 
percent over the period from 1966 to 1975; this increase is seen in 
most of the sex, race, and age groups. 
Comparing the proportion of current smokers who had made three 
or more attempts to quit by years of education showed a general 
downward trend over time for all education levels except in the less 
than 8 years of education group, where the proportion increased 
from 38.9 percent in 1966 to 47.0 percent in 1980. Among the most 
educated current smokers, the decline was from 59.8 to 39.4 percent. 
TABLE S-Percentage of current and former smokers who 
made three or more attempts to quit, by sex, 
age, and educational level, in 1996, 1975, and 
1980 
1966’ 1975 ’ 1980’ 
Current Former’ Current Former’ Current Former’ 
smoker emoker smoker smoker smoker smoker 
All ages 221 41.2 36.0 40.5 53.2 30.7 
Male 







40.7 36.9 36.4 55.1 38.8 
35.4 21.6 39.0 50.0 31.5 
37.4 50.0 38.2 43.7 38.7 
41.8 36.6 37.1 43.8 35.0 
42.9 36.8 44.1 58.4 39.8 
44.1 34.1 45.6 63.3 42.0 









41.5 34.0 42.0 49.1 38.7 
28.6 35.3 32.3 52.9 31.3 
34.5 36.1 39.5 47.2 31.0 
43.5 33.3 45.1 42.7 42.5 
56.7 23.9 44.0 57.0 37.1 
36.6 43.6 44.7 50.9 49.2 







38.9 32.3 44.3 
42.7 30.0 40.8 
36.4 36.2 40.0 
37.7 _ 42.0 36.4 






‘National Survey on Adult Use 0fTobac.x~. PHS, 1966 and 1975. 
‘National Health Interview Survey Smoking Supplement. PIiS fl’reliminary), 19&J. 
* Inclu&a the last s-ful attempt. 
l 1980 former lunoker data not availblc. 
Recent Attempt to Quit 
Data in Table 6 show the percentage of current and former 
smokers who reported an attempt to quit in the 12 months prior to 
the interview. Although there was little change overall from 1966 to 
1975 in the percentage of current smokers who reported making an 
attempt to quit smoking in the previous year (1.5 percent), from 1975 
to 1980 there was an increase of almost 10 percent. This increase is 
shown consistently for all the sex, race, and age groups. Among those 
who had attempted to quit, proportionately more young persons 
(under 35 years) than older persons reported attempting to quit 
during the previous 12 months. 
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TABLE 6.-Percentage of current and former smokers who 
attempted to quit during the last year, by sex, 




1966’ 1975 ’ 1980’ 
Current Former Current Former Current Former’ 


























23.3 12.1 25.5 8.2 33.4 
44.0 6.7 44.0 29.2 52.5 
23.8 20.4 20.7 15.8 37.3 
19.4 11.2 19.1 6.3 26.9 
19.1 14.8 20.0 7.0 27.3 
12.2 13.1 25.3 1.9 29.9 
15.6 1.8 19.3 3.1 29.2 
29.4 17.2 30.0 12.7 40.6 
40.0 33.3 50.8 27.5 55.1 
35.7 24.2 33.0 aI. 47.1 
25.0 12.5 29.1 11.7 39.5 
25.2 13.0 19.8 9.3 30.0 
17.9 11.4 23.6 6.4 31.8 
27.8 17.9 26.2 4.2 37.0 
26.4 12.1 27.6 4.2 36.7 
25.9 15.5 28.0 9.9 38.8 
268 15.1 26.1 10.0 37.7 
25.0 10.2 29.1 13.4 31.3 
26.1 15.5 27.5 9.3 38.4 
13.8 27.5 9.8 36.7 
’ Nationni Survey on Adult Ua of Tobaax,, PEE?.. 19M aad 1976. 
*National Health Interview Survey Smoking Supplement, PISS (Reliminnry), 1980. 
* lseo former smoker da&i not .¶vaileble. 
Relationship of Tar Yields to Smoking Behavior 
In 1972, the Public Health Service classified tar as one of the 
“most likely” contributors to the health hazards posed by cigarettes, 
and studies have confirmed its carcinogenicity (4). In response to this 
finding, a major change occurred in the cigarette products manufac- 
tured and actually used. Over the last two decades, the proportion of 
domestically consumed cigarettes yielding 15 mg or less of tar has 
increased from 15 percent in 1968 to 66.9 percent in 1981(7). 
The cigarette industry has also increased its promotional activities 
in marketing brands yielding 15 mg or less tar. The percentage of 
dollars expended in the United States on advertising and promotion 
of cigarettes yielding 15 mg or less tar has increased from 19.6 
percent in 1975 to 48.1 percent in 1978. These factors may account, 
TABLE 7.-Percentage distribution of current regular 
smokers by tar level of primary brand of 
cigarettes, by sex and age, in 1975 and 1989 
Sex and age 
1975 ’ 1980’ 
Tar level Tar level 
<5 5-9 lo-14 15-19 2fJ+ <5 5-9 lo-14 15-19 20+ 
mg w mg mg mg w w me me mg 
Total 
All ages 221 0.8 0.6 9.5 67.9 20.2 6.3 13.1 26.4 44.0 10.4 
Male 
AllageE 221 0.5 0.6 9.5 63.6 25.8 4.1 10.6 22.6 49.6 13.3 
21-24 - - a.4 79.0 12.6 2.6 8.1 22.2 66.0 1.0 
25-34 0.5 0.8 10.3 70.6 17.9 3.9 10.2 23.7 50.4 3.7 
3544 1.1 0.2 8.5 65.8 24.4 3.8 10.9 25.3 45.0 14.9 
45-54 - 0.5 12.1 56.1 31.3 5.0 10.1 22.2 39.0 23.6 
55-64 1.2 1.6 8.5 50.2 38.5 5.4 11.6 19.6 39.8 23.6 
t= 0.4 0.8 6.7 49.3 42.1 3.7 15.6 16.2 38.3 26.3 
Female 
Au ages 221 1.1 0.6 11.7 73.2 13.4 8.9 15.9 28.7 39.4 7.1 
21-24 1.2 0.3 11.7 80.4 6.4 5.5 8.5 32.5 51.9 1.7 
25-34 0.6 0.4 10.9 78.4 9.7 6.7 18.9 28.9 44.5 0.9 
35-44 1.2 0.9 13.0 74.6 10.3 13.6 15.2 29.1 37.1 5.1 
4I5-54 1.5 0.3 10.8 65.6 21.9 8.1 17.8 29.9 32.5 11.7 
55-64 0.8 - 12.6 70.3 16.3 9.7 13.7 24.2 37.6 14.9 
$5 2.1 3.1 12.5 63.9 18.5 9.6 18.6 26.6 30.2 14.9 
’ National Survey on Adult Use of Tolmcco, PHS, 1975. 
’ National Health Interview Survey Smoking Supplement, PIiS (preliminary). 1980. 
in part, for the ever-in&easing use by current smokers of lower tar 
cigarettes. 
The definition of cigarettes as “lower tar” at 15 mg is arbitrary. 
Nonetheless, this breakpoint has gained general acceptance. Special 
note should be taken, however, that tar yields vary continuously, and 
groupings by relative yield measurements do not automatically 
imply differences in either the type or the magnitude of their 
biological effects. 
The percentage distribution of current regular smokers by tar 
level of their primary brand of cigarette is presented in Table 8. A 
clear trend toward increased use of lower tar products is apparent. 
The 1975 data on brands were coded to the 1975 Federal Trade 
Commission (FTC) values for tar yield, and the 1980 data were coded 
to the 1979 FTC values. As tar values have bean progressively 
declining, the 1980 data probably represent slightly higher values of 
tar yields than were actually being used at that time. 
Conclusions 
1. The proportion of current regular smokers declined steadily 
between 1965 and 1980. The decline was steeper among males 
(from 52.1 to 37.9 percent) than among females (from 34.2 to 
29.8 percent). 
2. The proportion of never smokers increased steadily from 1965 
to 1980 among males (27.6 to 31.6 percent), except those 45 
years old and older. Among females, only 20- to 34-year-olds 
showed an increase in proportion of never smokers. 
3. The mean number of cigarettes smoked per day by current 
smokers increased slightly from 1970 to 1980 (from 20 to 21.7 
cigarettes). 
4. Males smoked a higher mean number of cigarettes throughout 
the 1970-1980 period, but the number for males and females 
increased about the same amount. 
5. Heaviest daily consumption was in the middle-aged group (35- 
65 years). The greatest mean increase was observed among 
women aged 35 to 44. 
6. The proportion of current smokers who smoked less than 20 
cigarettes per day decreased between 1970 and 1980 (39.8 to 
33.8 percent); the proportion smoking one pack exactly (20 
cigarettes) remained constant (34.9 to 34.8 percent); the propor- 
tion smoking from 21 to 39 cigarettes increased slightly (13.7 to 
14.5 percent); and the proportion smoking two or more packs 
per day increased (11.4 to 16.8 percent). 
7. The proportion of current smokers who attempted to quit three 
or more times decreased slightly from 1966 to 1980 (41.2 to 38.7 
percent). 
8. The proportion of former smokers having made three or more 
attempts to quit increased sharply (36 to 53.2 percent) from 
1966 to 1975. 
9. The proportion of current smokers who had attempted to quit 
during the past year increased from 1966 to 1980 (26.0 to 36.7 
percent). 
10. Among current smokers, younger persons and females were 
more likely than older persons and males to have attempted to 
quit during the previous 12 months. 
11. The proportion of former smokers who had attempted to quit 
during the previous 12 months decreased from 1966 to 1975 
(13.8 to 9.8 percent). 
12. Among former smokers, younger persons and females were 
more likely than older persons and males to have quit during 
the previous 12 months. 
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